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A b s t r a c t
Phosphoinositide 3-kinases (PI3Ks) are signal transduction proteins that regulate a 
wide range of cellular processes. A key subset of PI3Ks are the so-called class IA 
enzymes consisting of a p85 regulatory and p110 catalytic subunit. While the biological 
activities of PI3Ks have been investigated in detail, the biochemical mechanism of their 
regulation is underexplored. We therefore strived to investigate post-translational 
modifications and absolute protein levels of class IA PI3Ks using electrophoresis and 
mass spectrometry (MS). We thereby focused on endogenous PI3K subunits and 
physiological stimulation.
Modifications including amino acid substitutions, phosphorylation and 
hydroxylation were detected in the regulatory subunit of unstimulated cells. While 
modifications in p85 were unaltered following cellular stimulation, dynamic changes in 
the tyrosine phosphorylation of the catalytic subunit p1105 were detected upon B cell 
stimulation. p1105 tyrosine phosphorylation does not appear to be critical for intrinsic 
PI3K lipid kinase activity, but might have a role in the interaction of p1105 with known 
and novel potential PI3K partners identified by MS. However, identification of modified 
amino acid residues by MS turned out to be challenging, also because p110 proteins 
could not be resolved by 2D-gel electrophoresis.
An important question in the PI3K field is whether class IA subunits can exist as 
monomers. It has been reported that p85 is present in excess over p110 and 
suggested that monomeric p85 has a negative role in the regulation of PI3K activity. 
Our analysis of class IA PI3K protein expression, amongst other by affinity and ion 
exchange chromatography, does not support this notion.
In summary, our work has revealed dynamic changes in the post-translational 
modification of the p110 (but not p85) and their interaction with partners. The ratio of 
p110 to p85, however, does not seem to be as dynamic, with equal amounts of p85 to 
p110 under all conditions investigated.
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Chapter 1
1 In tr o d u c tio n
1.1 Cell signalling
Cell signalling is the communication of a cell with its environment and the 
transmission of these signals within the cell. Multicellular organisms need to be able to 
sense changes in the environment and translate these signals into appropriate cellular 
responses. Signalling cascades have evolved to transmit extracellular signals to the 
nucleus leading to changes in proliferation, migration and/or differentiation. Two 
important features of most signalling cascades are the potential for signal amplification 
and signal modulation. Furthermore, reversibility is critical for the components of the 
pathway in order to return to the basal state after the signal has passed through the 
cascade. The major information highways are gated through receptor tyrosine (Tyr) 
kinases (RTK), G protein coupled receptors (GPCR), ion channels, and intracellular 
sterol-binding receptors. Signal transduction pathways downstream of these receptors 
include the Ras-mitogen-activated protein kinase (Ras-MAPK), the Janus kinase 
(JAK)-Stat, phospholipase C (PLC), and the phosphoinositide 3-kinase (PI3K) pathway 
(Teaching-Resources, 2005)
The focus of this work is on the PI3K signal transduction pathway which will be 
therefore described in greater detail.
1.2 Phosphoinositide 3-kinase
Phosphoinositide 3-kinases (PI3Ks) are an evolutionary conserved family of 
signal transducing enzymes first identified as a phosphoinositide kinase activity 
associated with polyoma middle T antigen, the Src Tyr kinase and growth factor 
receptors (Kaplan et al., 1987; Macara et al., 1984; Sugimoto et al., 1984; Whitman et 
al., 1985). PI3Ks catalyse the transfer of y-phosphate of ATP to the 3’-OH position of 
the inositol ring of phosphatidylinositols (Ptdlns) and phosphoinositides (Pis) thereby 
generating 3-phosphorylated Pis (Traynor-Kaplan et al., 1988; Whitman et al., 1988).
The basal levels of Pis residing in the plasma membrane are low (Funaki et al., 
2000). Following cellular stimulation, PI3Ks are activated leading to the transient 
accumulation of PI3K lipid products in cell membranes. Proteins containing 
phospholipid-binding domains such as pleckstrin homology (PH) or FYVE domains can 
interact with PI3K lipid products. Membrane recruitment of these proteins induces their 
interaction with protein binding partners and activation. A variety of biological 




Multiple isoforms of PI3Ks exist, which can be divided into 3 classes based on 
their in vitro lipid substrate specificity, primary structure and mode of regulation 
(Vanhaesebroeck et al., 1997). A fourth group of enzymes named class IV or PI3K- 
related kinases contain regions homologous to PI3Ks. These proteins do not produce 







Figure 1.1: PI3Ks catalyse the phosphorylation of phospholipids
PI3Ks by definition catalyse the phosphorylation of the 3’-OH position of Ptdlns and Pis to 
generate 3-phosphorylated PI. In this figure, the reaction performed by class I PI3K is shown 
whereby Ptdlns(4,5)P2 is phosphorylated to produce Ptdlns(3,4,5)P3, also known as PIP3.
1.2.1 Class I PI3Ks
Class I PI3Ks are heterodimeric proteins consisting of a catalytic and a regulatory 
subunit. These enzymes utilise Ptdlns, Ptdlns(4)P, and Ptdlns(4,5)P2 to generate PIP3 
in vitro, however, their preferred substrate in vivo appears to be Ptdlns(4,5)P2 (Hawkins 
et al., 1992). In addition to their lipid kinase activity, class I PI3Ks possess intrinsic 
protein kinase activity (§ 1.3.3).
Class I PI3Ks are divided into 2 subclasses, called class IA (§ 1.2.1.1) and class 
IB (§ 1.2.1.2). Class IA PI3Ks are activated by interaction of the regulatory subunit with 
phosphorylated Tyr residues in activated receptors or adaptor molecules. The single 
class IB PI3K is activated by interaction with heterotrimeric GPCRs (Stephens et al.,
1994). While the primary structure of regulatory subunits of class IA and IB do not 
share homology (§ 1.2.1.1.2 and § 1.2.1.2), comparison of the primary structure among 
members of class I PI3K catalytic subunits revealed four homology regions (HR1-4) 
(Zvelebil et al., 1996). Information obtained from the crystal structure of p110y has 
provided the following general model of class I PI3K catalytic subunit conformation 
(Pacold et al., 2000; Walker et al., 2000; Walker et al., 1999). The N-terminal region,
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which provides binding to the regulatory subunit, is followed by a Ras binding domain 
(RBD), a C2 domain, a helical (PIK) domain and a catalytic domain (Figure 1.2, Figure 
1.4). While the RBD binds the GTP-bound small GTPase Ras, the C2 domain mainly 
interacts with the helical domain and serves as membrane attachment. The helical 
domain is believed to provide a core scaffold around which the other domains lie. The 
catalytic domain is made of a small N-terminal lobe and a large C-terminal lobe typical 
for ATP-dependent protein kinases. The y-phosphate of ATP binds a conserved Lys 
residue (Lys833 in p110y) lying in the cleft between the N- and C-terminal lobe. The C- 
terminal lobe can be further divided into a catalytic and activation loop. While the 
catalytic loop is required for the execution of the catalytic mechanism, the activation 
loop is responsible for substrate recognition and specificity.
1.2.1.1 Class IA PI3Ks
In mammals, 3 catalytic subunits called p110a, p110(3, and p1105 and 5 
regulatory subunits named p85a, p85(3, p55y, p55a and p50a have been identified 
(Antonetti et al., 1996; Escobedo et al., 1991; Fruman et al., 1996; Inukai et al., 1996; 
Inukai et al., 1997; Otsu et al., 1991; Pons et al., 1995; Skolnik et al., 1991). In this 
work, the catalytic subunits will be referred to as ‘pHO’ and the regulatory subunits as 
‘p85’.
Class IA PI3K homologues have been identified in C. elegans (AGE-1), D. 
melanogaster (Dpi 10), and D. discoideum (PIK1-3) (Leevers et al., 1996; Morris et al., 
1996; Zhou et al., 1995). No class IA homologues have been detected in yeast or plant 
(Vanhaesebroeck et al., 1997). The isoforms identified show a high degree of 
conservation during evolution.
In all mammalian cell types investigated, at least one class IA PI3K isoform is 
expressed. In addition, virtually every receptor that induces Tyr kinase activity also 
leads to PI3K activation (Wymann and Pirola, 1998), emphasising the important role of 
class IA PI3Ks in cellular function.
1.2.1.1.1 Class IA PI3K catalytic subunits
The three class IA PI3K catalytic subunits p110a, p110p and p1105 are products 
of 3 separate genes, but share 42-58% amino acid sequence identity (Hiles et al., 
1992; Hu et al., 1993; Vanhaesebroeck et al., 1997).
Growing evidence indicates non-redundant functions for class IA catalytic 
subunits. The catalytic subunits share to the best of our knowledge the same substrate 
specificity, binding to any of the 5 regulatory subunits, interaction with phosphorylated 
Tyr residues in receptors or adaptors, and subcellular localisation. However, they differ 
in their tissue distribution, binding partners, and in vitro lipid and protein kinase
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activities. Furthermore, differences in the oncogenic potential of class IA isoforms were 
recently revealed: the p110a gene is selectively amplified in a number of cancer 
lineages, including ovary, cervix and lung (Kang et al., 2005) and activating mutations 
in p110a have been identified (Bader et al., 2006; Samuels and Velculescu, 2004; 
Samuels et al., 2004). No oncogenic mutations have been found in the genes for 
p110p or p1105 (Cornillet-Lefebvre et al., 2006; Kang et al., 2005), but increased 
protein expression of p110(3 and p1105 occurs in some tumours and glioblastoma 
(Benistant et al., 2000; Knobbe and Reifenberger, 2003).
Helical
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Figure 1.2: Schematic representation of the class IA PI3K catalytic subunit
Class IA PI3Ks consist of p110a, p110p and p1105 catalytic subunits. These enzymes are 
made of an N-terminal p85 binding domain, followed by a Ras-binding, C2, helical (PIK), and C- 
terminal kinase domain. More detailed information is provided in § 1.2.1.1.1. Figure adapted 
from (Deane and Fruman, 2004).
1.2.1.1.1.1 p110a
The PIK3CA gene gives rise to a ubiquitously expressed p110a protein. p110a 
has been implicated in cell growth. Thus, tissue-specific overexpression of membrane- 
targeted, mammalian p110a, which is constituitively active, leads to increased heart 
size, whereas overexpression of kinase-dead p110a results in heart reduction (Shioi et 
al., 2000). Furthermore, p110a seems to have a role in the regulation of cell division. 
Overexpressed p110a increases mitogenesis in cell culture models, and neutralisation 
of p110a by Abs blocks mitogenesis following some (PDGF, EGF, insulin, CSF-1), but 
not all (bombesin, LPA) stimuli (Roche et al., 1998; Vanhaesebroeck et al., 1999). A 
further role for p110a has been suggested in glucose uptake. Membrane-targeted 
p110a induces translocation of the glucose transporter Glut4 (Frevert and Kahn, 1997; 
Tanti et al., 1996). This translocation is abolished by the PI3K inhibitor Wortmannin 
(WM) (Kanai et al., 1993) and increased by a constitutively active Akt (Kohn et al.,
1996).
Not much information was gained by the generation of p110a KO mice. p110a 
KO embryos die between E9.5 and E10.5 due to severe proliferative defects in many 
tissues. Importantly, overexpression of the regulatory subunit was observed in p110a 
KO compared to WT cells (Bi et al., 1999). This finding hampers the analysis of the role 
of p110a in these mice, since defects could be due to p110a deletion or p85
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overexpression. Mice heterozygous for p110a show no obvious defects (Brachmann et 
al., 2005).
Generation of p110a Kl mice have revealed that p110a is a key regulator in 
metabolic signalling (Foukas et al., 2006), in contrast to previous reports (Asano et al., 
2000; Roche et al., 1998). In these p110a Kl mice, class IA PI3K subunit expression is 
unchanged. Homozygous Kl embryos die between E10 and E11, but heterozygous Kl 
mice are viable and fertile. These mice are smaller than their WT littermate and display 
defects in insulin sensitivity and glucose metabolism due to reduced signalling via 
insulin-receptor substrate proteins. It was shown that p110a protein expression in 
insulin-responsive tissue is up to 2-fold higher than p110p expression and recruitment 
to activated insulin receptor substrates was 2 to 8 times higher for p110a compared to 
p110(3 leading to 50% reduction in total class IA PI3K activity in liver, muscle and fat 
cells in p110a Kl heterozygous mice.
1.2.1.1.1.2 p110p
As for p110a, p110(3 is widely expressed. In contrast to p110a and p1105, p110(3 
was shown to interact with Gpy subunits of trimeric G proteins (Kurosu et al., 1997; 
Maier et al., 2000). Stimulation of GPCR by lysophosphatidic acid (LPA) leads to p110(3 
activation (Roche et al., 1998) and this activation can be synergystically enhanced by 
interaction with phosphorylated Tyr residues in activated receptors or adaptor 
molecules.
p110p appears to be involved in the mitogenic response induced by certain 
growth factors. Microinjection of neutralising Abs specific for p110p into fibroblasts 
inhibits DNA synthesis normally induced by insulin and LPA but hardly affects PDGF 
receptor signalling (Roche et al., 1998). p110p was further shown to have a role in 
cytoskeletal organisation (Hooshmand-Rad et al., 2000; Vanhaesebroeck et al., 1999), 
where p110p is necessary for CSF-induced modulation of actin dynamics. 
Furthermore, p110(3 has a role in exocytosis since Glut4 translocation following insulin 
stimulation in NIH-3T3 is abolished upon microinjection of p110p Abs (Asano et al., 
2000). Recently, p110p was also implicated in the regulation of adhesion. Studies 
using a small molecule inhibitor with selectivity for p110p (detailed in § 1.6.1.2) 
revealed that this catalytic subunit is involved in integrin activation and platelet 
aggregation by regulating Ca2+ flux and Gpy-dependent activation of the small GTPase 
Rap (Jackson et al., 2005).
Murine p110p gene-targeting studies did not offer great insight into potential 
p110p non-redundant function. Indeed, p110p KO embryos die during implantation and 
p110p heterozygous mice display no obvious defects (Bi et al., 2002; Brachmann et al.,
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2005). Double p110a/p110(3 KO heterozygous mice are slightly glucose intolerant and 
exhibited hyperinsulinaemia in the fasting state, attributing a role for p110a and p110f3 
in metabolism. Interestingly, in addition to reduced p110 protein expression, also p85 
protein levels are decreased by 50% in these cells, indicating instability of monomeric 
regulatory subunits (Brachmann et al., 2005).
1.2.1.1.1.3 p1105
p1105 is primarily expressed in leukocytes, but can also be detected in neurons 
and cells of melanocytic or breast origin (Sawyer et al., 2003; Vanhaesebroeck et al.,
1997). p1105 primary sequence analysis revealed a p1105 unique Src-homology-3 
(SH3) domain and a basic-region leucine zipper (bZIP) motif shared with p110(3 
(Vanhaesebroeck et al., 1997). Gene-targeting of p1108 by KO or Kl strategies have 
emphasised the important role of p1105 in leukocyte function and development.
Two research groups (Clayton et al., 2002; Jou et al., 2002) generated murine 
strains with a deletion in p1105 gene leading to ablation of p1105 protein expression. 
However, these p1105 KO mice also display reduced expression of the regulatory 
subunits p85a, p55a and p50a. The mutant mice are viable, but have reduced 
numbers of mature B cells and subsequently have smaller spleens and lymph nodes. 
Cellular signalling through the B cell antigen receptor (BCR) is affected with reduced 
PIP3 production and reduced phosphorylation of downstream effectors leading to 
reduced Ca2+ flux. Ex vivo proliferation of p1108 KO cells is also reduced in response 
to various stimuli. In contrast to the B cell phenotype, the proportion of CD4+ and CD8+ 
peripheral T cells of p1105 KO mice is similar to WT mice.
The phenotype of the p1108 Kl mice appears to be more severe (Okkenhaug et 
al., 2002). BCR-induced phosphorylation of the downstream effector Akt is ablated and 
Ca2+ flux in stimulated B cells is greatly reduced (see § 1.7.2). Ex vivo proliferation 
following BCR engagement was abrogated. The effects of p1105 inactivation on B cell 
signalling detected in Kl mice were recently confirmed by p1105 inhibitor studies 
(Bilancio et al., 2006). p1105 Kl mice also display reduced T cell numbers in the 
spleen. Akt phosphorylation and Ca2+ flux is reduced in response to T cell receptor 
(TCR) stimulation (Okkenhaug et al., 2002). Furthermore, mast cell function is affected 
in p1105 Kl mice. Akt phosphorylation downstream of IL3 and SCF receptor is reduced, 
leading to reduced DNA synthesis and degranulation of mast cells (Ali et al., 2004). 
p1105 has also been implicated in the control of neutrophil function (Ptasznik et al., 
1996; Sadhu et al., 2003) and was recently shown to be activated following p110y 
activation upon neutrophil stimulation (Condliffe et al., 2005).
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1.2.1.1.2 Class IA PI3K regulatory subunits
In mammals, 5 regulatory subunits have been identified. p85a, p85(3 and p55y
are products of separate genes. Whether p55a and p50a are mRNA splice variants of 
the p85a gene or the result of alternative promoter usage is controversial (Abell et al., 
2005).
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Figure 1.3: Schematic representation of class IA PI3K regulatory subunits
Class IA PI3K regulatory subunits are the products of 3 separate genes (PIK3R1, PIK3R2 and 
PIK3R3) giving rise to p85a, p85(3 and p55y. PIK3R1 gives further rise to p55a and p50a 
protein either by mRNA splicing or alternative promoter usage. The regulatory subunits contain 
a variety of protein-interacting domains such as the SH3 domain, which binds to proline rich 
motifs, and the SH2 domains that interact with phosphorylated Tyr residues in YxxM-motifs. A 
Rac binding domain has been shown to have binding affinity to small GTPases such as Rac1 
and Cdc42 and the p110-binding domain also called interSH2 domain facilitates binding to the 
catalytic subunit (figure taken from (Deane and Fruman, 2004)).
The regulatory subunits are composed of several protein-protein interaction 
domains. While the N-termini differ substantially between the different regulatory 
subunits, the C-termini of the various regulatory subunits are conserved. A proline-rich 
region (P2), which facilitates interactions with SH3 domain-containing proteins, is 
followed by two SH2 domains. The SH2 domains allow for binding to phospho-tyrosine 
(pTyr) residues in the sequence context pYxxM (where pY is phospho-tyrosine, x 
stands for any amino acid and M is methionine) (Songyang et al., 1993). The domain 
in-between the two SH2 domains is called interSH2 (iSH2) or p110 binding domain and 
mediates binding to the p85-binding domain of class IA catalytic subunits (§ 1.3.2.1). In 
p85a and p85(3, an N-terminal SH3 domain is followed by a proline-rich segment (P1) 
and a Breakpoint Cluster Region Homology (BH) domain, which is also called Rac- 
binding domain (Otsu et al., 1991; Musacchio et al., 1996). In the shorter versions of
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the regulatory subunits, the N-termini are unique and do not have homology to known 
domains.
In addition to its role in the regulation of p110, p85 was suggested to 
independently stimulate signalling pathways (reviewed in (Okkenhaug and 
Vanhaesebroeck, 2001)).
1.2.1.1.2.1 p85a, p55a and p50a
p85a, p55a and p50a are products of PIK3R1. These isoforms are ubiquitously
expressed and seem to bind p110a, p110p and p1108 with no specific preference. It is 
emerging, however, that regulatory subunits allow different modes of p110 activation. 
For example, the lipid kinase activity of p110a associated with p50a appears to be 
higher than that of p110a-p55a or p110a-p85a following insulin receptor stimulation 
(Inukai et al., 1997; Shepherd et al., 1997; Ueki et al., 2000). In order to elucidate the 
function of the different regulatory subunits, p85a KO mice have been generated. 
However, a very frequent confounding issue in the p85a KO mice is the concomitant 
up- or down-regulation of non-targeted class IA PI3K subunits, which makes 
interpretation of the observed phenotypes not straightforward.
Deletion of the last five exons of the PIK3R1 gene leads to deletion of p85a, 
p55a and p50a protein (referred to as p85a-full KO). p85|3 is upregulated in cells of 
these mice, whereas p110a and p110p are downregulated. Mice containing this 
mutation die shortly after birth. The animals have reduced numbers of mature B cells 
and show a defect in B cell function, with reduced ex vivo proliferation in response to 
various stimuli. Furthermore, mast cells of p85a-full KO mice display a defect in SCF 
responses, but normal IgE-driven signalling (Fruman et al., 1999; Suzuki et al., 1999), 
while T cell function appears to be normal. The p85a-full KO mice feature necrosis of 
the liver and brown fat tissue. These mice are hypoglycaemic, contain lower insulin 
levels, and have increased glucose tolerance due to upregulation of PI3K signalling. 
These findings are unexpected since PI3Ks have been implicated in positively 
regulating insulin signalling in vitro (Fruman et al., 2000). Mice heterozygous for the 
p85a-full KO also possess improved insulin signalling and glucose homeostasis 
(Mauvais-Jarvis et al., 2002).
In mice with deletion of the first exon of PIK3R1, only the expression of full-length 
p85a protein is abrogated. Countervailing upregulation of p55a and p50a protein 
expression is observed. Mice containing this mutation have a similar phenotype to 
p85a-full KO, but were viable (Suzuki et al., 1999; Terauchi et al., 1999).
Mice containing a mutation in PIK3R1 gene resulting in p55a and p50a protein 
deletion show a milder phenotype than the p85a-only KO mice. These mice are viable
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and contain normal blood glucose levels, but display lower fasting insulin levels (Chen 
et al., 2004).
1.2.1.1.2.2 p85|3
The regulatory subunit p85p is ubiquitously expressed and seems to occur in 
minor amounts than p85a in insulin-sensitive cells (Ueki et al., 2002).
p85(3 KO mice were generated and have normal class IA PI3K isoform 
expression, but display hypoinsulinaemia, hypoglycaemia, and increased insulin 
sensitivity (Ueki et al., 2002). Lymphocyte development was normal in p85(3 KO mice. 
Ex vivo proliferation of p85(3 KO B cells was similar to WT cells following various 
stimuli, but proliferation of KO T cells was found to be mildly increased. Following T cell 
stimulation, a decrease in cell death was observed in p85(3 KO cells probably due to 
reduced levels of caspase-6 mRNA and reduced caspase-6 enzyme activity (Deane et 
al., 2004). These results indicate a T-cell specific function for p85|3.
1.2.1.1.2.3 p55y
p55y has high homology to p85a in the two SH2 and iSH2 domains but lacks the 
BH and SH3 domains. p55y mRNA is expressed early during development and is 
ubiquitously expressed in adult tissues (Inukai et al., 1996). The p55y regulatory 
subunit was isolated by screening expression libraries with Tyr phosphorylated IRS-1. 
The N-terminal SH2 domain of p55y was subsequently shown to interact with pYxxM- 
motif of IRS-1 (Pons et al., 1995). No p55y KO mice have been generated to date.
1.2.1.2 Class IB PI3K
p110y, the single class IB catalytic subunit, is coupled to smaller regulatory 
subunits called p101 and p84/p87PIKAP (Suire et al., 2005; Voigt et al., 2006). p110y has 
36% protein sequence identity to p110a (Stoyanov et al., 1995), whereas p101 was 
believed to have no functional homology to any known protein (Stephens et al., 1997). 
However, an 84 kDa protein was recently discovered located beside the p101 locus 
with 30% sequence identity to p101. This p84 protein was shown to interact with p110y 
and Gpy in vitro and in vivo (Suire et al., 2005) and appears to be predominantly 
expressed in the heart (Voigt et al., 2006). Furthermore, p84 was shown to interact with 
phosphodiesterase-3B (PDE3B).
Binding of p110y to p101 and to a lesser extent to p84 increases the activation of 
p110y by Gpy subunit of trimeric G proteins, and is therefore believed to be critical for 
coupling of p110y to GPCRs. Activation of p110y by Gpy subunits does not solely 
depend on membrane recruitment since either monomeric p110y or p110y/p101 
heterodimers associate with lipid monolayers in vitro irrespectively of the presence of
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G(3y (Krugmann et al., 2002). Therefore, it seems more likely that G(3y-induced p110y 
activation is due to conformational changes induced by this interaction. Similarly, 
activation of p110y by Ras does not appear to be due to membrane recruitment. 
Comparison of the crystal structures of p110y or p110y in complex with Ras indicated 
that a change in p110y conformation might allosterically increase PI3K activity (Pacold 
et al., 2000; Walker et al., 1999).
p110y autophosphorylates Ser1101 located in the C-terminal kinase domain. This 
modification does not impact on the in vitro lipid kinase activity, however, 
autophosphorylation of Seri 101 is induced by Gpy subunits (Czupalla et al., 2003). The 
biological significance of this phosphorylation has not been investigated.
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Figure 1.4: Schematic representation of class IB PI3K
Class IB PI3K consists of a 110 kDa catalytic subunit called p110y coupled to one of two smaller 
regulatory subunits, p101 or p84. p110y contains a RBD, C2 domain, helical domain and kinase 
domain with homology to class IA PI3Ks. The N-terminal region contains a unique binding site 
for the regulatory subunits. The regulatory subunits have a sequence homology of 30% to each 
other but no functional homology to any known protein.
Class IB PI3K is expressed mainly in cells of hematopoietic origin. Analyses of 
p110y KO and kinase-dead Kl mice (Hirsch et al., 2000; Li et al., 2000; Patrucco et al., 
2004; Sasaki et al., 2000) which are viable and fertile, have shown that p110y is an 
important component of the myeloid cell compartment. This protein seems to be crucial 
for neutrophil and macrophage migration towards sites of inflammation. Furthermore, a 
lack of p110y in mast cells impairs degranulation and p110y seems to play a role in 
platelet aggregation (Sasaki et al., 2000), while B cell function is normal in p110y KO 
and Kl mice. Importantly, KO and Kl mice show phenotypic differences: While p110y 
has been implicated in the modulation of heart contractility in KO mice, this phenotype 
is not observed in p110y Kl cells (Crackower et al., 2002). The molecular mechanism 
underlying the difference between these two types of p110y mutant mice is proposed to 
be based on a scaffolding function of p110y. p110y has been shown to bind and control 
PDE3B in a manner independent of its catalytic activity. PDE3B degrades cAMP 
leading to inactivation of protein kinase A and decreased heart contractility.
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Deregulation of PDE3B induces the opposite reaction (reviewed in (Vanhaesebroeck et 
al., 2004)).
1.2.2 Class II PI3Ks
Class II PI3Ks are large enzymes of 170-210 kDa predominantly associated with 
the membrane fraction of cells (Arcaro et al., 1998; Prior and Clague, 1999). Their 
catalytic domain is 45-50% homologous to class I PI3Ks, their large N-terminal region 
shows no homology to any known protein and the C-terminal region contains homology 
to C2 domains. This C2 domain can bind to phospholipids in a Ca2+-independent 
manner in vitro (MacDougall et al., 1995).
Mammals have 3 class II PI3K isoforms called PI3K-C2a, PI3K-C20, and PI3K- 
C2y, which are the products of distinct genes. Whereas PI3K-C2a and -C2p are 
ubiquitously expressed, PI3K-C2y is restricted to liver tissues (Misawa et al., 1998). D. 
melanogaster and C. elegans both possess a single class II PI3K (MacDougall et al.,
1995), but no class II PI3K has been identified in yeast, plant or D. discoideum.
Class II PI3Ks have different in vitro substrate specificity to class I PI3Ks and 
prefer Ptdlns over Ptdlns(4)P and Ptdlns(4,5)P2 (Domin et al., 1997). It is, however, not 
clear which phospholipids are generated by class II PI3Ks in vivo. Furthermore, the 
mode of activation of class II PI3Ks inside cells is not well understood, but it was shown 
that PI3K-C2p and to a lesser extent -C2a can be activated by several receptor 
systems (Arcaro et al., 2000; Brown et al., 1999; Turner et al., 1998; Zhang et al.,
1998).
1.2.3 Class III PI3K
The single class III PI3K identified in mammalian cells is a homologue to the 
yeast vesicular protein-sorting protein Vps34p (Herman et al., 1992). Other 
homologues have been identified in D. discoideum and D. melanogaster (Linassier et 
al., 1997; Volinia et al., 1995; Zhou et al., 1995).
Vsp34p was originally identified in a screen for mutants conditionally defective in 
vacuolar protein sorting (Herman and Emr, 1990). It associates with a Ser/Thr protein 
kinase, Vsp15p, that is N-terminally myristoylated and targets Vsp34p to membranes 
(Stack etal., 1993).
Class III PI3K appears not to be activated following cellular stimulation and can 
only use Ptdlns as substrate in vitro. This enzyme is thought to be responsible for the 
production of most cellular Ptdlns(3)P, the levels of which remain relatively constant.
Vsp34p also has intrinsic protein kinase activity and has been shown to 
autophosphorylate on Ser, Thr and Tyr in vitro in the absence of lipid substrate (Stack
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and Emr, 1994). However, Vsp34p has not been shown to phosphorylate any 
exogenous protein substrate and autophosphorylation does not affect its lipid kinase 
activity. Thus, the significance of Vsp34p protein kinase activity remains unclear.
1.2.4 Class IV PI3Ks
Class IV PI3K-related kinases share a catalytic domain with homology to all 
PI3Ks. The kinase domain of these enzymes possesses Ser/Thr protein kinase activity 
rather than lipid kinase activity and no lipid substrates for these kinases have been 
identified (Brown et al., 1995; Jung et al., 1997). Members include gene products that 
regulate cell cycle progression in response to DNA damage (RAD3, MEC1, TEL1, ATM 
and ATR) as well as DNA-activated protein kinase (DNA-PK) and TOR/FRAP/RAFT1 
members.
1.3 Class IA PI3K activation and regulation
Surprisingly little is understood about the regulation of class IA PI3K activity in 
vivo. This scarce knowledge is due to various factors: First, regulation of class IA PI3K 
activity most likely occurs on many levels and is therefore per se very complex. 
Second, analysis of PI3K activity has mainly been performed with recombinant protein 
and in in vitro experiments. Third, distinction between different isoforms, which are 
likely regulated in unique ways, has been impossible or neglected.
We try below to give an overview of the various possibilities to regulate class IA 
PI3K activity. In Figure 1.5, the in vitro mechanisms to regulate the intrinsic lipid kinase 
activity (described in more detail in § 1.3.1, 1.3.2, 1.3.3, and 1.3.4) are summarised. 
The in vitro lipid kinase activity of PI3Ks after experimental manipulation is compared to 
non-activated, cytosolic heterodimer yielding positive and negative regulation 
mechanisms. Briefly, compared to the p85-p110 complex residing in the cytosol, 
monomeric p110 (A) as well as membrane-targeted PI3K (B) are thought to possess 
higher lipid kinase activities. Interaction with activated, pYxxM-containing proteins (C) 
and Ras (D) also increases PI3K activity of all p110 subunits, while p110f3 was shown 
to be further activated by interaction with G(3y subunits of trimeric G proteins (E). The 
PI3K enhancer PIKE is believed to induce lipid kinase activity of nuclear PI3K (F). In 
contrast to mechanisms positively regulating PI3K activity, Ser phosphorylation of p110 
or p85 (G) likely reduces the intrinsic PI3K lipid kinase activity and interaction of p85 
with Ruk (H) was also shown to reduce lipid kinase activity.
In addition to the regulation of intrinsic p110 lipid kinase activity, the net PI3K 
activity in vivo is thought to be further positively and negatively modulated by protein- 
protein interactions, by subcellular localisation and by expression of monomeric p85.
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Figure 1.5: The intrinsic PI3K lipid kinase activity is modulated by a variety of 
mechanisms in vitro
Compared to the PI3K activity of non-activated, cytosolic p85-p110 heterodimer, PI3K activity is 
controlled by the p85 to p110 ratio (A), by subcellular localisation (B), by interaction with protein 
partners (C, D, E, F, H), and by post-translational modifications (G). More details to each 
mechanism of regulation are provided below.
In order to simplify this challenging subject, we divided the mechanisms for class 
IA PI3K regulation into different subjects, such as subcellular localisation, interaction 
partners, protein kinase activities and post-translational modifications. However, this 
classification can only be conceptual since each subset of regulating mechanisms is 
possibly interlinked with other subsets. Thus, the subcellular localisation of a protein 
might be controlled by an interaction partner, or binding to a protein partner is due to 
post-translational modifications.
1.3.1 Subcellular localisation of class IA PI3K
Traditionally, proteins have been characterised according to their broad 
subcellular localisation as being cytosolic, membrane, nuclear etc. However, many 
proteins are constantly shuttled between different cellular compartments rendering 
strict definitions redundant. Moreover, within distinct subcellular compartments, 
microdomains made of unique concentrations of certain molecules are gaining 
increased importance potentially leading to adjustment of intracellular localisation of 
many proteins, possibly including class IA PI3Ks.
Class IA PI3Ks are found in the cytoplasm, at the plasma membrane, and in the 
nucleus. While the pool of class IA PI3Ks is believed to reside in the cytoplasm, a 
fraction of the p85-p110 complexes translocates to the membrane following cellular 
stimulation where class IA PI3Ks exert their function as lipid kinases. Membrane 
recruitment upon stimulation is achieved by interaction of the SH2 domains of the
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regulatory subunits with phosphorylated Tyr residues in proteins residing at the plasma 
membrane (more detail provided in § 1.3.2.2). The key role of membrane recruitment in 
the regulation of PI3K activity was revealed by genetic manipulation of p110a. 
Constitutive membrane targeting of p110a by fusion to the membrane-targeting domain 
of Ha-Ras (Didichenko et al., 1996) or the cytosolic domain of CD2 (Reif et al., 1996) 
led to a constitutively active enzyme.
More recent investigations into the regulation of class IA PI3K lipid kinase activity 
by phospholipid concentrations revealed that recombinant p110a is more efficient at 
high Ptdlns(4,5)P2 concentrations and recombinant p110(3 is the better lipid kinase at 
low Ptdlns(4,5)P2 concentrations due to differences in their in vitro Km towards 
Ptdlns(4,5)P2 (Beeton et al., 2000). Since plasma membrane microdomains of different 
phospholipid concentrations have been described (Liu et al., 1998), it is tempting to 
speculate that p110a might be more active than p110(3 in certain fractions of the 
plasma membrane (where higher concentrations of phosphoinositides are found).
Emerging evidence is suggesting that class I PI3Ks can also translocate to the 
nucleus upon cellular stimulation where these enzymes catalyse the phosphorylation of 
Ptdlns(4,5)P2 to PIP3 (Bavelloni et al., 1999; Kim, 1998; Marchisio et al., 1998; Neri et 
al., 1994). The regulation of nuclear PI3K activity seems to be achieved at least to 
some extent by the nuclear GTPase called PI3K Enhancer (PIKE) (Rong et al., 2003). 
However, the mechanism and biological relevance of nuclear translocation of class IA 
PI3K remains to be determined.
1.3.2 Protein-protein interactions
Biological functions involve the formation of protein-protein complexes. Protein- 
protein interactions have been shown to be critical for the activity, stability, and 
subcellular localisation of many proteins. They differ based on the composition of the 
complex, on the affinity of the components to each other and on the longevity of the 
interaction and can accordingly be divided into homo- and heterocomplexes and into 
obligate or non-obligate complexes (see Table 1.1). All protein-protein interactions are 
ultimately driven by the local concentration of the components and the free energy of 
the complex.
The regulatory and catalytic subunits of class IA PI3Ks contain a multitude of 
protein-interacting domains. Additionally, class IA PI3Ks were shown to be Ser, Thr 
and Tyr phosphorylated (more information in § 1.3.4) creating further docking sites for 
SH2-, phospho-tyrosine binding (PTB)-, C2-, Forkhead-associated (FHA)- and C- 
terminal region of BRCA-1 (BRCT)- domain containing proteins (Benes et al., 2005; 
Durocher et al., 1999; Kavanaugh and Williams, 1994; Manke et al., 2003; Sadowski et
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al., 1986). It is therefore not surprising, that class IA PI3Ks have been detected in 
complex with many different protein partners. Here, we first discuss the interaction 
between p85 and p110 and introduce evidence that suggests this complex being an 
obligate or non-obligate heterodimer. This is followed by an overview of additional class 
IA PI3K binding partners.
Table 1.1: Properties of non-obligate and obligate protein complexes
Dimeric protein complexes can be divided into non-obligate or obligate interactions depending 
on the existence of monomeric (non-obligate) or strictly heterodimeric (obligate) subunits. 
Different biophysical properties can be attributed to each protein formation. Adapted from 
(Nooren and Thornton, 2003).
non-obligate obligate
Stability Protomers are independently stable. Monomers are detectable.
Monomeric protomers are not 
found as stable structures in vivo. 




Protomers are expressed non 
simultanously.
Protomers are expressed 
simultanously.
Interaction Weak interaction between protomers
Strong interaction between 
protomers
Interface Small Large and hydrophobic
1.3.2.1 p85-p110 protein interaction
The interaction between the regulatory and catalytic subunit of class IA PI3K is 
important for at least three aspects of PI3K activity regulation which will be discussed in 
more detail below. First, interaction with p85 enables p110 being shuttled to the plasma 
membrane following cellular stimulation. This translocation allows interaction with p110 
substrates and increases the intrinsic lipid kinase activity. Second, the interaction 
increases the thermal stability of the unstable, monomeric catalytic subunit and the less 
stable, monomeric regulatory subunit. Third, binding of p85 to p110 reduces the p110 
lipid kinase activity in the basal state which can be increased by interaction of the 
complex with non-PI3K binding partners following cellular stimulation.
The interaction between the catalytic and regulatory subunit involves the 
interSH2 (iSH2, also called p110-binding) domain of p85, and the p85-binding domain 
of p110 (Dhand et al., 1994; Holtetal., 1994; Hu etal., 1993; Klippel et al., 1993; Yu et 
al., 1998). While the p85 iSH2 domain is sufficient for p110 binding, it does not inhibit 
p110 activity. The presence of the N-terminal SH2 domain coupled to iSH2 is required 
for p110 lipid kinase inhibition (Yu et al., 1998). Since inhibition of p110 activity by p85 
was shown to be released by interaction of the complex to phosphorylated Tyr residues 
in pYxxM-motif containing proteins (Rordorf-Nikolic et al., 1995; Yu et al., 1998), the N- 
terminal SH2-domain of p85 was suggested as a regulator of lipid kinase activity (Yu et
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al., 1998). Inhibition of p110 by p85 is likely due to conformational changes imposed 
onto the catalytic subunit by p85 binding, which is alleviated by interaction of p85 with 
phosphorylated Tyr residues. Which domain of p85 is involved in these conformational 
rearrangements is controversial (Chan et al., 2002; Fu et al., 2004; Panayotou et al.,
1993). In addition to p110 inhibition by the non-engaged N-terminal SH2 domain of 
p85, phosphorylation of Ser608 in the iSH2 domain of p85a further reduces p110 lipid 
kinase activity (Dhand et al., 1994). This reduction might be due to p85-p110 
dissociation (Foukas et al., 2004). Further information about phosphorylation of Ser608 
is provided in § 1.3.3.
In the traditional model of class IA PI3K regulation described above, it is 
suggested that p110 and p85 form obligate heterodimers and that regulation of PI3K 
lipid kinase activity of the obligate heterodimer is mainly steered by interaction with 
non-PI3K binding partners. This model of obligate heterodimeric class IA PI3K was 
generated on the basis of observations that revealed high binding affinities between the 
subunits (Fry et al., 1992) and instability of monomeric p110 (Yu et al., 1998).
Various reports have challenged obligate heterodimericity of class IA PI3K and its 
implications on PI3K regulation. Thus, when class I PI3Ks are purified from bovine 
thymus using various chromatographic methods, two catalytically active p110 subunits 
can be distinguished: p110 in complex with p85, and p110 in what was considered to 
be a monomeric form (Shibasaki et al., 1991). In contrast to an excess of the catalytic 
subunit observed in thymic cells, more recent data gained from analysis of p85 KO 
mice indicate a greater than 30% molar excess of p85 over p110 in WT murine 
embryonic fibroblasts (MEFs) (Ueki et al., 2002) and WT murine liver cells (Mauvais- 
Jarvis et al., 2002).
The existence of monomeric class IA PI3K subunits in vivo likely has implications 
on the regulation of the lipid kinase activity. Due to the increased activity of monomeric 
p110 observed in vitro (Shibasaki et al., 1991; Yu et al., 1998), an excess of catalytic 
subunit over regulatory subunit would probably lead to increased p110 lipid kinase 
activity. In contrast, monomeric p85 is believed to compete with heterodimeric p85- 
p110 for binding to pYxxM-motif containing proteins (Ueki et al., 2002). Since 
monomeric p85 does not possess lipid kinase activity, occupation of pTyr docking sites 
by monomeric p85 instead of active, heterodimeric PI3K would lead to a decrease in 
PI3K lipid kinase activity (Luo and Cantley, 2005).
1.3.2.2 Other class IA PI3K binding partners
Class IA PI3Ks have been implicated in a multitude of protein-protein interactions 
via the diverse protein interaction domains of the catalytic and regulatory subunits. 
Binding of protein partners can regulate PI3K activity by modulating the intrinsic
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enzymatic activity, by localising the enzyme to specific cellular compartments or by 
disrupting interaction with other binding partners.
In Table 1.2, a summary of class IA PI3K interaction partners and binding 
properties are given. While this list of proteins is by no means complete, we tried to 
consider a few examples of interacting proteins for each class IA domain, which are 
described in more detail below.
Table 1.2: Class IA PI3K interaction partners
Interaction partners of class IA PI3Ks are listed according to the interacting domain in the p85 or 
p110 subunit starting from the C-terminus. If known, the stimuli and cell type upon which the 









Androgen R Receptor p85a C-terminus Androgen Lipid kinase activity t (Sun et al., 2003)
Oestrogen R Receptor p85a SH2 Lipid kinase activity T (Simondni et al., 2000)
o-Kit R Receptor p85 SH2 Lipid kinase activity t (Lev et al., 1992; Serve et al., 
1994)
EGFR Receptor p85 C-SH2 Lipid kinase activity t (Hu et al., 1992)
PDGFR Receptor p85 C-SH2 Lipid kinase activity T (Hu et al., 1992)
IGF-1 R Receptor p85 SH2 Lipid kinase activity t (Yamamoto et al., 1992)
CD28 Adaptor p85 SH2 T cells Lipid kinase activity T (Pages etal., 1994)
CD19 Adaptor p85 SH2 B cells Lipid kinase activity T (Tuveson et al., 1993; Buhl 
and Cambier, 1999)
CD5 Adaptor p85 C-SH2
N-SH2
(Dennehy et al., 1997)
IRS-1 Adaptor p85 SH2 Insulin Lipid kinase activity T (Backer et al., 1992)
BCAP Adaptor p85 SH2 B cells (Okada et al., 2000)
Gab2 Adaptor p85 SH2 (Gu et al., 2000)
SLP-76 Adaptor p85 N-SH2 CD3/T cells (Shim et al., 2004)
She Adaptor p85 C-SH2 (Harrison-Findik etal., 1995)
Ezrin Adaptor p85 C-SH2 (Gautreau etal., 1999)
Syk Kinase p85a,
P85/S
C-SH2 (Moon et al., 2005)
IkBa Kinase p85a SH2 pV/ T cells (Beraud etal., 1999)
SHIP ®-tase p85 SH2 B cell (Gupta etal., 1999)
SHP1 ®-tase p85 C-SH2 PDGF/ MCF- 
7, TRMP
(Cuevas et al., 1999; Yu et al., 
1998)
SHP2 ®-tase p85a (Kwon et al., 2005)
Rac GTPase p85 BH Lipid kinase activity T (Zheng et al., 1994; Bokoch et 
al., 1996; Tolias etal., 1995)
Cdc42 GTPase p85 BH Lipid kinase activity t (Zheng etal., 1994)
Grb2 Adaptor p85 P1 constitutive (Wang etal., 1995)
a-actinin Adaptor p85 P1 NIH-3T3 Binding t  by PIP3 (Shibasaki et al., 1994)
Fyn Kinase p85 P1 only T cells
Thrombin/
platelets
(Mak et al., 1996; Pleiman et 
al., 1994; Prasad etal., 1993)
Lyn Kinase p85 P1 only a-IgM/ B 
cells
(Yamanashi et al., 1992; 
Pleiman etal., 1994)
Src, v-Src Kinase p85 (Fukui and Hanafusa, 1989; 
Liu etal., 1993)










Cbl-b Adaptor p85p SH3 TCR/ T cells 
EGF/ PC12 
cells
Lipid kinase activity I (Hartley et al., 1995; Soltoff 
and Cantley, 1996)
Dynamin GTPase p85 SH3 Dynamin GTPase 
activity ?
(Gout etal., 1993)
p85a Adaptor p85a SH3.P1/P2 (Kapeller and Cantley, 1994; 
Harpur etal., 1999)
a/p/y -tubulin p55a/ 
Y
N-terminus constitutive (Inukai etal., 2000)
a/3 -tubulin p85 iSH2 constitutive (Kapeller et al., 1995)
y -tubulin p85 Insulin,PDGF (Kapeller et al., 1995)
Ras GTPase p110 RBD Lipid kinase activity? (Rodriguez-Viciana et al., 
1994;Rodriguez-Viciana et al., 
1996)
Rab5 GTPase p110p Lipid kinase activity? (Christoforidis et al., 1999; 
Kurosu and Katada, 2001)
GPy subunit P110P Lipid kinase activity? (Kurosu etal., 1997)
1.3.2.2.1 p85 interaction partners
The N- and C-terminal SH2 domain of the regulatory subunits are of fundamental
importance for the enzymatic function of class IA PI3K since these domains bind to 
pTyr residues of activated growth factor receptors and adaptor molecules. In this way, 
the SH2 domains of p85 dock the p110 enzyme to the plasma membrane and 
concomitantly increase the intrinsic lipid kinase activity (more information in § 1.3.2.1). 
Both SH2 domains have high affinity for binding pYxxM, and especially pYMxM. There 
is, however, a small difference in the specificities of the N- and C-terminal SH2 
domains (Panayotou et al., 1993; Songyang et al., 1993).
In addition to the SH2 domain, also the p85 BH /Rac binding domain is involved 
in the positive regulation of PI3K activity. Interaction with small GTPases via the BH 
domain leads to PI3K activation (Tolias et al., 1995). The BH domain of p85a, which 
displays sequence homology to GTPase activating proteins (GAPs), was moreover 
shown to have GAP activity towards Rab proteins, Cdc42, and Rac1 (Chamberlain et 
al., 2004).
In contrast to SH2 and BH domain, p85 SH3 binding to the adaptor proteins Ruk 
and Cbl-b mediates negative PI3K signalling. While Ruk interaction with PI3K leads to 
the downregulation of the intrinsic lipid kinase activity, Cbl-b was shown to compete 
with CD28 binding of p85 presumably interfering with positive CD28 lipid kinase 
signalling (Fang and Liu, 2001); (Fang et al., 2001). Furthermore, the SH3 domain of 
p85 was shown to bind the proline rich motifs of p85. In line with these findings, p85a 
and p85p seem to be able to form homodimers, while p55a and p50a, which are 




Furthermore, the proline-rich motifs of p85 interact with the SH3 domain of Tyr 
kinases Src, Lyn and Fyn. As described below (see § 1.3.4.2), it is unclear whether 
interaction with and subsequent phosphorylation by Src family kinases mediates 
changes in the lipid kinase activity of PI3Ks.
An intriguing interaction partner of the regulatory subunit is tubulin. While the 
small regulatory subunits p55y and p55a were shown to constitutively interact with a-, 
(3- and y-tubulin via their unique N-termini, the large regulatory subunit p85 
constitutively interacts with a- and (3-tubulin via its iSH2 domain, but binds in an 
inducible manner to y-tubulin. Since the small regulatory subunit are evolutionary 
conserved, while the large regulatory subunits are a relatively new addition to the PI3K 
subunit pool, one can speculate that the large subunits originally devoid of the tubulin 
binding sites were under evolutionary pressure to generate tubulin interaction 
sequences. This anticipation would highlight the importance of the PI3K-tubulin 
interaction.
1.3.2.2.2 p110 interaction partners
Three main interaction partners of the catalytic subunit have been described. All
class IA catalytic subunits contain a Ras-binding domain that shows binding affinity to 
GTP-bound Ras. Following Ras binding, the C2 domain and catalytic domain undergo 
molecular rearrangement that affects the conformation of the lipid substrate binding site 
(Walker et al., 1999). In line with this, interaction of p110 with Ras increases the lipid 
kinase activity of PI3K (Kodaki et al., 1994). Importantly, Ras binding was also shown 
to increase lipid kinase activity in previously pTyr-stimulated PI3K, suggesting that Ras- 
and concomitant pTyr-binding is necessary for full activation of PI3K (Jimenez et al.,
2002). Furthermore, Ras was determined as a substrate for p110a protein kinase 
activity (Foukas and Shepherd, 2004). p110(3 also interacts with a GTPase called 
Rab5. The binding of p110p to Rab5 is dependent on sequences only existent in this 
catalytic subunit isoform. As for Ras-binding, this interaction is dependent on the 
activity state of the GTPase and increases PI3K activity (Christoforidis et al., 1999; 
Kurosu and Katada, 2001).
As described above (see § 1.2.1.1.1.2), p110|3 also uniquely binds G|3y subunits 
of trimeric G proteins. This interaction increases its lipid kinase activity synergystically 
to the binding of pYxxM-motif containing proteins (Kurosu et al., 1997).
1.3.3 Protein kinase activity of PI3K
The protein kinase activity of class IA PI3K plays an important role in the negative 
regulation of its lipid kinase activity.
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p110a and to a lesser extent p110(3 phosphorylate p85a on Ser608 leading to an 
80% decrease in PI3K lipid kinase activity in vitro (Carpenter et al., 1993; Dhand et al., 
1994; Foukas et al., 2004). Ser608, which is part of the iSH2 domain of p85a, was 
shown to be an important residue in the interaction with the catalytic subunit, since its 
mutation causes a decrease in p110 binding (Foukas et al., 2004). Dissociation of p85 
from p110 provides a basis for regulation of PI3K lipid kinase activity by Ser608 
phosphorylation. In addition to p85a, also p85p is phosphorylated by p110a in vitro, its 
phosphorylation sites remain to be discovered (reviewed in (Vanhaesebroeck and 
Waterfield, 1999)).
p110(3 and p1105 both autophosphorylate Ser residues in their C-termini 
(Ser1070 in p110(3 and Ser1039 in p1105, respectively) (Czupalla et al., 2003; Czupalla 
et al., 2003; Vanhaesebroeck et al., 1999). As for Ser608 phosphorylation of p85a by 
p110a, Ser autophosphorylation of recombinant p110(3 and p1108 mediates the 
downregulation of PI3K lipid kinase activity. Further analysis revealed that p110(3 
autophosphorylation is not enhanced by binding to pYxxM-containing peptides or Gpy 
complexes. While p110p autophosphorylation has only been investigated in vitro, the 
role of p1108 autophosphorylation was addressed in vivo. CD28 stimulation of T cells 
increases phosphorylation of Ser1039 in p1105, which leads to a rapid decrease in 
p1108-associated lipid kinase activity (Vanhaesebroeck et al., 1999).
In addition to autophosphorylation and cross-phosphorylation of the regulatory 
subunit, evidence for the existence of exogenous class IA PI3K substrates is emerging 
(reviewed in (Foukas and Shepherd, 2004)).
1.3.4 Post-translational modifications of PI3K
Post-translational modifications modulate the activity, localisation and turnover of 
many eukaryotic enzymes. They are tightly regulated, and selectively control many 
aspects of cell growth, metabolism, division, motility and differentiation (Hunter, 1995; 
Posada and Cooper, 1992). Since protein phosphorylation is occurring in as many as a 
third of proteins in mammalian cells (Hubbard and Cohen, 1993), it is the most 
intensely studied post-translational modification. Other important protein modifications 
for cellular signalling are acetylation, methylation, acylation, glycosylation, and 
ubiquitylation due to their reversibility.
The regulatory and the catalytic subunit of class IA PI3Ks undergo reversible 
phosphorylation (summarised in Figure 1.6 and Figure 1.7). As discussed below, the 
biochemical properties and biological significance of these modifications are poorly 
understood. If possible, implications for the regulation of class IA PI3Ks are given.
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1.3.4.1 Post-translational m odifications of PI3K cata lytic subunits
Phosphorylation of the catalytic subunit on Ser, Thr and Tyr residues has been 
reported (Figure 1.6). While in vitro phosphorylation of Ser and Thr is inhibited by 
treatment of immunocomplexes with WM and LY294002, Tyr phosphorylation is not 
(Geltz and Augustine, 1998). It was subsequently shown that p110(3 and p1105 
autophosphorylate on Ser residues (see § 1.3.3). p110a is Ser/Thr phosphorylated by 
PKCa in vitro and this phosphorylation partially inhibits the in vitro lipid kinase activity 
of p110a (Sipeki et al., 2006). Phosphorylation of p110a by PKCa might therefore 
provide an alternative mechanism for PI3K activity regulation similar to 
autophosphorylation of p110(3 and p1108.
S1070 (p110p) 
S1039 (P1105)
ras bindinq kinare domain
Dcmair
B
Protein Residue Kinase Stimulation Biological implications Reference
p110« Ser PK Ca in vitro Lipid kinase activity i Sipeki e tal., 2006
p110a Tyr P D G F R in vivo Dissociation from R Roche etal., 1994
p110p S eri 070 pnop in vitro Lipid kinase activity * Czupalla et al., 2003
pnop Tyr P D G F R in vivo Dissociation from R Roche etal., 1994
p1106 S eri 039 p110o C D 28 - T  cells in vivo Lipid kinase activity I
Vanhaesebroeck et al., 
1999
p110 Tyr Lck CD4 - T  cells in vivo Mazerolles et al, 1998
p110 Tyr Syk BCR in vivo Craxton etal., 1999
p110 Tyr Syk, Lyn H20 2 - B cells in vivo Lipid kinase activity o Qin etal , 2003
Figure 1.6: Summary of class IA PI3K catalytic subunit phosphorylation
(A) Catalytic subunit phosphorylation sites were identified at the C-terminus of p110p and 
p1105. (B) Table of reported catalytic subunit phosphorylation events and their biological 
implications. 4 , decreased; <->, unchanged.
Tyr phosphorylation of the catalytic subunit is attributed to different Tyr kinases 
depending on cell type. In T cells, CD4 stimulation enhances Tyr phosphorylation of 
p110 maximally at 20 min after stimulation due to association of a p110-Lck complex 
with CD4 (Mazerolles and Fischer, 1998). In B cells, Tyr phosphorylation of p110 was 
shown to follow cellular stimulation by BCR crosslinking within minutes and is Syk-, but 
not Btk- or Lyn-dependent (Craxton et al., 1999). In line with this, H20 2 treatment of B 
cells increases Tyr phosphorylation of p110. This phosphorylation is decreased in Lyn-, 
BCAP- and Syk KO cells, but is unchanged in Btk- and Cbl KO cells. The Tyr
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phosphorylation of p110 in B cells does not impact on the intrinsic lipid kinase activity 
of p110 since in vitro PIP3 generation is the same with p110 from WT, Lyn-, Syk- and 
Btk KO cells (Qin and Chock, 2003).
Furthermore, p110a was shown to become Tyr phosphorylated following PDGF 
receptor stimulation in vivo, with maximal p110 phosphorylation between 30 and 60 
minutes of stimulation. Performing immunodepletion experiments, it was shown that 
p110 is released from the PDGF receptor in a Tyr phosphorylated form (Roche et al., 
1994). Also p110(3 becomes phosphorylated on Tyr residues following association with 
activated PDGF receptor (Roche et al., 1998).
Tyr phosphorylation of the catalytic subunit is underexplored. While early studies 
did not differentiate between the different p110 isoforms, later ones were not able to 
identify specific Tyr phosphorylation residues or Tyr kinases involved in 
phosphorylation.
1.3.4.2 Post-translational modifications of PI3K regulatory subunits
The regulatory subunit of class IA PI3K was discovered as an 85 kDa 
phosphoprotein associated with polyoma middle T antigen and Src (Cohen et al., 
1990). p85 phosphorylation of Ser, Thr and Tyr has been detected in several cell types 
following different stimuli (Figure 1.7).
Ser and Thr phosphorylation of p85 was reported in T cells. While p85a was 
shown to be Ser phosphorylated independent of TCR engagement, p85p becomes 
phosphorylated on Thr residue(s) following T cell stimulation (Reif et al., 1993). p85a 
was subsequently shown to be phosphorylated on Ser608 in vivo (Dhand et al., 1994), 
which leads to the downregulation of the p110 lipid kinase activity (§ 1.3.3). 
Phosphorylation of Ser608 was also observed in fibroblasts following PDGF stimulation 
(Foukas et al., 2004).
Also Tyr phosphorylation of the p85 subunit was observed in T cells. Following 
IL-2 stimulation, the Tyr kinase Fyn, but not Lck, was shown to phosphorylate the 
regulatory subunit and interaction with Fyn induces PI3K activity in unstimulated and 
even more so in stimulated T cells (Karnitz et al., 1994). Phosphorylation of p85 on Tyr 
residue(s) is also increased in lymphoblast cells containing a Bcr-Abl fusion protein 
(Gotoh et al., 1994; Varticovski et al., 1991). In line with this, irradiation of T cells 
induces Tyr phosphorylation of p85 by Abl which leads to a decrease in PI3K activity 
(Yuan et al., 1997). Residue Tyr688 in the N-terminal SH2 domain was identified as a 
p85a phosphorylation site following Bcr-Abl or constitutively active Lck overexpression 
in T cells. In contrast to previous results, the enzymatic activity of PI3K was unchanged 
upon Tyr phosphorylation by Abl. However, the interaction of p85a with binding 
partners was affected (von Willebrand et al., 1998). SHP1, an SH2 domain containing
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Tyr phosphatase expressed in cells of hematopoietic origin, was shown to decrease 
the Lck induced p85a Tyr phosphorylation (Cuevas et al., 1999). The same group 
subsequently showed that Cos7 cells transfected with a p85-Tyr688Ala construct have 
decreased Akt phosphorylation compared to WT cells while Cos7 cells transfected with 
a p85-Tyr688Asp construct show increased phosphorylation of Akt, suggesting that 
Tyr688 phosphorylation has an impact on the lipid kinase activity of PI3K (Cuevas et 
al., 2001). It therefore appears that the Tyr kinases Fyn, Lck and Abl do not 
phosphorylate the same (or at least not the same combination of) p85 Tyr residue(s) in 
T cells leading to differences in the intrinsic lipid kinase activity of PI3K. It is also 
possible that rather than the residue involved, the kinetics of Tyr phosphorylation are 
crucial for the PI3K lipid kinase activity.
Even though signalling cascades in B cells have been studied in depth, Tyr 
phosphorylation of class IA PI3K regulatory subunit has hardly been described. One 
report indicated that crosslinking of the BCR leads to Tyr phosphorylation of p85, 
however, this phosphorylation peaked at 20 min of stimulation (Beckwith et al., 1996). It 
is likely that Tyr phosphorylation of p85 in B cells occurs only at a later stage of 
stimulation, in contrast to what is observed in T cells.
Tyr phosphorylation of p85 has also been demonstrated in non-leukocyte cells. 
Following PDGF receptor engagement in NIH-3T3 cells, Tyr phosphorylation of the 
regulatory subunit was revealed (Kaplan et al., 1987). It was subsequently shown that 
Tyr phosphorylation of p85 inhibited the interaction of the N-terminal SH2 domain to the 
receptor while binding of the C-terminal SH2 domain was intact (Kavanaugh et al., 
1992). When recombinant p85a was subjected to in vitro protein kinase assays with 
recombinant PDGF receptor, Tyr508 was identified as a phosphorylation site. Tryptic 
phosphopeptide mapping demonstrated that p85a is also phosphorylated on Tyr508 in 
vivo (Kavanaugh et al., 1994). The homologous Tyr residue in p85p (Tyr458) was 
recently shown to become phosphorylated following pV stimulation of cells (Rush et al., 
2005).
Tyr368, Tyr580 and Tyr607 were identified as major p85 Tyr phosphorylation 
sites following overexpression of p85a and insulin receptor (IR) in Cos7 cells 
(Hayashi et al., 1993). It was previously shown that insulin stimulates the 
phosphorylation of the regulatory subunit in vitro and in vivo and that this modification 
does not change the lipid kinase activity of PI3K (Hayashi et al., 1992; Hayashi et al., 
1991; Hayashi et al., 1993). The homologous residue to Tyr607 in p55y is Tyr341. 
Tyr341 was shown to be phosphorylated by the insulin receptor in Sf9 and CHO-IR 
cells and this modification appears not to change the intrinsic lipid kinase activity of 













Protein Residue Kinase/Phosphatase Stimulation Biological implication References
p85o Tyr368. 580, 607 IR in vivo Lipid kinase activity Hayashi etal., 1993
p85o Tyr508 PDGF R In vivo Dissociation from R Kavanaugh et al.. 1994





Lipid kinase activity <-> 
(dissocation from Zap70/TCR) 
Lipid kinase activity i
Von Willebrand et al. 1998; 
Cuevas et al.. 1999; Cuevas 
et al.. 2001
p85p Y458 pV in vivo Rush et al.. 2005
p85p Thr T cells in vivo Reifetal., 1993
p85 Tyr Fyn IL-2 - T cells in vivo Lipid kinase activity T Kamitz et al.. 1994
p85 Tyr Abl Irradiation - T cells
in vivo Lipid kinase activity I Yuan etal.. 1997
p85 Tyr BCR in vivo Beckwith et al. 1996
p85 Tyr nitration Peroxynitrite,NONOate
in vivo p85 dissociation from p110 Hellberg et al.. 1998; E- Remessy et al.. 2005
Figure 1.7: Summary of class IA PI3K regulatory subunit phosphorylation
(A) p85a and p85p phosphorylation sites were identified in different cell types following various 
stimuli. (B) Table of reported phosphorylation on regulatory subunit and their implications. T 
increased; 1, decreased; <-», unchanged
In addition to protein phosphorylation, Tyr nitration of the regulatory subunit was 
reported. p85 was shown to be Tyr nitrated in macrophages following peroxynitrite and
NONOate treatment, two nitric oxide donors. Tyr nitration of p85 appears to abrogate
its interaction with p110 (Hellberg et al., 1998). In addition, high glucose and 
peroxynitrite treatment of endothelial cells also induces Tyr nitration of p85, which 
correlates with p85 dissociation from p110 and decreased phosphorylation of Akt. 
Dissociation of p85 from p110 is blocked by a peroxynitrite decomposition catalyst and 
by a Tyr nitration inhibitor (el-Remessy et al., 2005).
1.4 Downstream effectors of Class IA PI3K
Upon activation of class IA PI3K, the intracellular levels of PIP3 rapidly increase 
leading to the recruitment of PH domain containing proteins to the plasma membrane. 
PH domains are modular segments of about 100 amino acids found in many signalling 
molecules (Lemmon and Ferguson, 2000; Rameh et al., 1997), and the ability of PH 
domains to discriminate PIP3 from other Pis is a central basis for specificity in class IA
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PI3K signalling. Recruitment of PH domain containing proteins to the plasma 
membrane leads to protein-protein interactions and protein activation. Several 




















Figure 1.8: Class I PI3K signalling pathways
Generation of PIP3 at the plasma membrane by PI3Ks leads to the accumulation and activation 
of Tyr kinases, Ser/Thr kinases and guanine-nucieotide binding proteins amongst others. The 
signalling pathways originating from these molecules are described in detail below. The 
phosphatases PTEN and SHIP use PIP3 as substrates and are therefore involved in the 
feedback control of PI3K signalling (more detail in § 1.5).
1.4.1 Ser/Thr kinases
A key Ser/Thr kinase containing a PIP3 binding domain is protein kinase B (PKB, 
also known as Akt), a protein with fundamental roles in a multitude of cellular 
processes ranging from cell survival and proliferation to metabolism (Brazil and 
Hemmings, 2001; Burgering and Coffer, 1995; Datta et al., 1996; Vanhaesebroeck and 
Alessi, 2000).
Following recruitment to the plasma membrane by means of its PH domain, Akt is 
phosphorylated at Thr308 and Ser473 (Alessi and Cohen, 1998; Bellacosa et al., 
1998). Full enzymatic activation of Akt is only achieved when both residues are 
phosphorylated. The upstream kinase that targets Thr308 is PDK1, itself a PH domain 
containing protein (Alessi et al., 1997; Stephens et al., 1998). The protein kinase 
catalysing the phosphorylation of Ser473 is termed PDK2; its identity is controversial.
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In addition to Ser/Thr phosphorylation of Akt, also Tyr phosphorylation has been shown 
to influence the enzymatic activity of this protein (Conus et al., 2002).
The number of physiological Akt substrates is expanding rapidly (Brazil and 
Hemmings, 2001; Vanhaesebroeck and Alessi, 2000). The minimal consensus peptide 
sequence for Akt substrates was identified as Arg-Xaa-Arg-Xaa-Xaa-[Ser/Thr]-Hyd 
(where Xaa is any amino acid and Hyd is a bulky hydrophobic amino acid) (Andjelkovic 
et al., 1997; Meier et al., 1997). A study of the Swiss-Prot database in 2001 using 
Scansite identified this sequence 551 times in 446 protein entries (Nicholson and 
Anderson, 2002) underlining the potential abundance of Akt substrates. We 
summarised the more established routes of Akt signalling below.
Akt has been shown to regulate cell survival by phosphorylating a variety of 
proteins involved in the anti-apoptotic process. One target of Akt is BAD, a protein that 
binds Bcl-2 and Bcl-XL thus preventing their anti-apoptotic function (Downward, 1999). 
Another Akt target involved in the anti-apoptotic process is Caspase-9. Direct 
interaction, phosphorylation and thus inactivation of Caspase-9 by Akt inhibits the 
initiation step of apoptosis (Cardone et al., 1998). Furthermore, Akt has been 
implicated in the regulation of the transcription factor NF-kB by activating I-kB kinases 
(IKKs). Upon phosphorylation of the inhibitor of NF-kB by IKKs, NF-kB is released and 
moves to the nucleus where it induces the transcription of anti-apoptotic genes.
Similarily, Akt phosphorylates and induces translocation to the nucleus of the
transcription factor CREB that promotes transcription of anti-apoptotic/cell survival 
genes (Du and Montminy, 1998).
Another process in which Akt is involved is the regulation of metabolism. Akt has 
been shown to phosphorylate and inactivate glycogen synthase kinase 3 (GSK3). This 
results in the phosphorylation and consequent activation of metabolic and gene-
regulatory proteins. Furthermore, 6-phosphofructo-2-kinase (PFK-2), one of the key
players in glycolysis, is phosphorylated by Akt in vitro (Deprez et al., 1997) and 
activated as a phosphatase. Consistently, insulin-stimulated activation of PFK-2 is 
inhibited by WM (Lefebvre et al., 1996). PDB3B, an enzyme catalysing the hydrolysis 
of cAMP, was further shown to be an Akt target (Wijkander et al., 1998).
The Forkhead (FH) family of transcription factors regulates transcription of genes 
controlling cell cycle, cell death, and metabolism. FH transcription factors are 
inactivated by Akt phosphorylation due to prevention of nuclear entry (Burgering and 
Kops, 2002). This leads to a decrease in transcription of p27Kip, a protein involved in 
the inhibition of cell cycle progression (Dijkers et al., 2000) and of the Fas ligand, which 
is an inducer of apoptosis (Brunet et al., 1999).
The PH domain containing protein PDK1 is important in the regulation of not only 
Akt, but also many other AGC superfamily kinases (Williams et al., 2000). This enzyme
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catalyses the phosphorylation of the residue equivalent to Thr308 in PKC isoforms 
(Chou et al., 1998; Dutil et al., 1998), in p70S6K (Alessi and Cohen, 1998; Pullen et al., 
1998), in SGK (Kobayashi et al., 1999; Park et al., 1999) and in PKA (Cheng et al., 
1998; Toker and Newton, 2000; Vanhaesebroeck and Alessi, 2000). PDK1, itself 
member of the AGC family of kinases, requires phosphorylation for activation and 
appears to autophosphorylate (Casamayor et al., 1999). However, PDK1 is not 
regulated by extracellular signals. It seems more likely that its activation is modulated 
by interaction with its substrates (Biondi et al., 2001).
1.4.2 Tyrosine kinases
Tec kinases are non-receptor tyrosine kinases that contain N-terminal PH 
domains. This interaction controls their association with the plasma membrane and 
thus with Src kinases that catalyse the phosphorylation of Tec family members (Shan 
et al., 2000). Upon phosphorylation, these proteins are activated (Rawlings et al., 1996; 
Schaeffer and Schwartzberg, 2000). The importance of the PH domain is shown in one 
member of the Tec family called Bruton’s tyrosine kinase (Btk) which is essential in 
normal B cell development and function (more details in §1.7.1): mutations in the Btk 
PH domain cause X-linked agammagloblinaemia in humans and a similar X-linked 
immunodefiency (Xid) in mice (Li et al., 1995). The important function of Btk for B cell 
development stems from the essential role of this Tyr kinase in the control of PLCy 
(Scharenberg et al., 1998) whose activation is a crucial component for the regulation of 
intracellular Ca2+ levels. PLCy, itself a PH domain containing protein, hydrolyses 
Ptdlns(4,5)P2 to produce IP3 and diacylglycerol, which in turn mediate Ca2+ release 
from intracellular stores and activation of PKC (Rhee and Bae, 1997).
1.4.3 Guanine-nucieotide binding proteins
Important targets of the products of PI3Ks are the Rho family of GTPases 
including Rho, Rac and Cdc42. These proteins coordinate the dynamic organisation of 
the actin cytoskeleton and the assembly of associated integrin structures. Activation of 
Rac and Rho is regulated by guanine-nucieotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs) both containing PH domains (Cerione and Zheng,
1996). One well-studied Rac-GEF is Vav-1 whose catalytic activity depends on 
activation by Src kinases. In vitro models have suggested that binding of Vav-1 to PIP3 
potentiates Tyr kinase mediated Vav activation (Han et al., 1998). Furthermore, PI3K 
inhibitors block Rac activation by Vav-1.
There is also evidence of Rac regulation by Arfs (D'Souza-Schorey et al., 1997; 
Zhang and Xiong, 1999). Arfs are a family of small GTPases involved in the regulation 
of intracellular membrane trafficking. Arfs are regulated by Arf-GEFs, proteins
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containing a PH domain. There is a multitude of data showing that PI3K signalling is 
involved in Arf function via Arf-GEFs (Venkateswarlu et al., 1999) and Arf-GAPs (Kam 
et al., 2000; Krug man n et al., 2004).
Furthermore, activated small GTPases can stimulate PI3K activity, thus forming a 
positive feedback loop (Tolias et al., 1995; Zheng et al., 1994), reviewed in(Welch et 
al., 2003).
1.5 Feedback control of PI3K signalling
The effects of 3-phosphorylated Pis generated by PI3Ks are antagonised and/or 
diversified by PI phosphatases (Maehama et al., 2001; Vanhaesebroeck et al., 2001). 
Members of this group of enzymes can be divided into 3 families: 3-PI phosphatases, 
4-Pl phosphatases and 5-PI phosphatases. The two major routes for PIP3 degradation 
are mediated by PTEN and SHIPs.
1.5.1.1 PTEN
PTEN (Phosphatase and tensin homologue deleted on chromosome 10) is 
member of the 3-PI phosphatases family and converts PIP3 to Ptdlns(4,5)P2. PTEN 
was originally identified as a tumour suppressor and tyrosine phosphatase inactivated 
by loss of heterozygosity at chromosome 10 (Li et al., 1997; Myers and Tonks, 1997; 
Steck et al., 1997), but was later found to contain PI phosphatase activity (Maehama 
and Dixon, 1998). Several mutation and deletions in the PTEN gene are found in 
various human cancers (Cantley and Neel, 1999) and it was shown to be the lipid 
phosphatase activity that endows PTEN its tumour suppressor specificity by negative 
regulation of the PI3K pathway. Consistently, cells lacking PTEN have increased levels 
of PIP3 that correlates with activation of Akt (Stambolic et al., 1998).
While PTEN KO mice are embryonic lethal, information gained from PTEN KO 
heterozygous mice (Di Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 
1998) and mice containing tissue-specific deletions in the PTEN gene (Anzelon et al., 
2003; Li et al., 2002; Suzuki et al., 2001), confirmed the potency of PTEN tumour 
suppressor activity. Cells analysed in the various PTEN KO mice showed 
hyperproliferation, resistance to apoptosis, lower threshold to activation, and altered 
migration properties.
Little is known about the regulation of PTEN activity. The crystal structure of 
PTEN revealed that the protein consists of a phosphatase and C2 domain, which is 
involved in membrane recruitment of PTEN (Lee et al., 1999). A putative PDZ-binding 
motif at the C-terminus of the protein appears to mediate interaction with PDZ domain 
containing proteins. Furthermore, PTEN activity seems to be regulated by protein 




SHIP is an SH2 domain containing member of the 5-PI phosphatase family and 
dephosphorylates PIP3 to Ptdlns(3,4)P2. Two isoforms of SHIP have been identified in 
eukaryotes called SHIP1 and SHIP2. These enzymes contain similar substrate 
specifitiy but differ in their tissue distribution. SHIP1 is mainly found in cells of 
hematopoietic origin, where it takes part in cytokine signalling (Lioubin et al., 1996). In 
contrast, SHIP2 is broadly expressed, and participates in growth factor-stimulated 
signalling. In line with this, SHIP2 KO mice were originally reported to display severe 
hypoglycaemia and mortality (Clement et al., 2001; Habib et al., 1998; Rohrschneider 
et al., 2000). More recent data, however, revealed that SHIP2 KO mice are viable, 
have normal glucose and insulin levels, but display high resistance to weight gain when 
placed on a high-fat diet (Sleeman et al., 2005). The different KO mice were generated 
using different gene-targeting strategies likely explaining the different phenotypes.
SHIP proteins are controlled by inhibitory receptors such as FcyRllb (Liu et al., 
1998; Ono et al., 1997) by means of their SH2 domain. The SH2 domain of SHIP binds 
ITIM-motifs (l/V/L/S-x-Y-x-x-L/V) located in the cytosolic domain of inhibitory receptors. 
Due to its membrane localisation upon receptor binding, SHIP can dephosphorylate 
PIP3 (see also § 1.7.1).
1.6 Experimental inhibition of PI3K function
The analysis of class IA PI3Ks has been challenging for various reasons: stable 
overexpression of class IA regulatory subunits has a dominant-negative effect on the 
recruitment of endogenous protein to pYxxM-motif containing proteins. Stable 
overexpression of the catalytic subunit has not been reported probably due to the 
instability of monomeric p110. Thus, a variety of class IA PI3K gene-targeting 
approaches have been employed. However, deletion of either p110 or p85 subunits 
leads to compensationary expression of non-targeted class IA PI3K subunits 
hampering analysis (reviewed in (Vanhaesebroeck et al., 2005)).
Therefore, small molecule pharmalogical inhibitors of PI3Ks have been an 
indispensable tool for the elucidation of the physiological processes in which PI3Ks are 
involved. I C 5 0  values of different drugs against PI3Ks and related protein kinases are 
summarised in Table 1.3.
1.6.1.1 Broad-spectrum inhibitors
The two inhibitors that have been primarily used to study PI3K function are low 




Wortmannin (WM) is a fungal metabolite that irreversibly binds PI3K, resulting in 
covalent modification of the Lys residue in the catalytic domain of PI3K involved in ATP 
binding. This inhibitor is a very potent drug with IC50 values of 5 nM in vitro (Powis et 
al., 1994). All Class I, II and III PI3K members exert the same sensitivity to WM with the 
exception of PI3K-C2a, which is at least 10-fold less sensitive (Domin et al., 1997; 
Virbasius et al., 1996). However, also enzymes of class IV PI3K related kinases such 
as mTor (Brunn et al., 1996; Withers et al., 1997), DNA-PK (Hartley et al., 1995; 
Sarkaria et al., 1998), and ATM (Banin et al., 1998) are inhibited by WM although at 
concentration 10-100-fold higher than the dose required for class I, II and III PI3K. 
Although potent, WM has a short half-life in aqueous solutions (Woscholski et al.,
1994).
LY294002 is a flavonoid-based compound and a competitive inhibitor of ATP 
binding in the catalytic domain of PI3K (Vlahos et al., 1994). The in vitro sensitivity to 
LY294002 is similar for all class I, II, and III PI3Ks, apart from PI3K-C2a (Domin et al.,
1997). However, LY294002 also inhibits mTOR, DNA-PK and protein kinase CK2 with 
similar potency as PJ3K (Brunn et al., 1996; Izzard et al., 1999).
Table 1.3: IC50 values of PI3K inhibitors
Class IA PI3Ks can be inhibited by broad-range PI3K inhibitors WM or LY294002 that also 
target distantly related proteins, or by isoform-specific inhibitors. U: unknown.
IC50 (nM)
p110a p110p p1105 p110y PI3K-C2 DNA-PK References
Wortmannin 5 5 5 5 400 250 Powis et al.. 1994; Virbasius et al.,1996; Sarkaria etal., 1998
LY294002 1‘000 1*000 1*000 1*000 20*000 6*000 Vlahoe et al., 1994; Domin et 
al., 1997; Brunn et al., 1996
PI-103 1*000 U U U U U
TGX-221 10*000 5 100 1*000 >10*000 U Jackson et al., 2005
1C87114 100*000 75*000 500 29*000 >10*000 >100*000 Sadhu et al.. 2003
AS604850 450 >2*000 >2*000 250 u U Camps etal., 2005
1.6.1.2 Isoform-selective PI3K inhibitors
Comparison of the crystal structure of p110y with bioinformatic data of class IA 
PI3K revealed that the interior of the ATP binding pocket is highly conserved among 
class I PI3K, while the residues which line the entrance to the ATP binding pocket are
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divergent in their size and charge (Knight et al., 2004). These findings indicate a basis 
for isoform-specific ihhibitors interacting with the ATP-binding site of PI3K.
PI-103 is a p110a selevtive inhibitor with an IC50 for p110a of 1 pM.
TGX-221 is a p11 Op-specific inhibitor with similar chemical structure to 
LY294002. This inhibitor is 20-fold more selective for p110p than p1105 and shows 
more than 1000-fold selectivity for p110p over p110a, p110y and over a broad range of 
kinases tested. TGX-221 has minimal inhibitory effect on PI3K-C2a and PI4K. Since 
the concentration of ATP influenced the I C 5 0  value of TGX-221 against p110p, this 
inhibitor is likely acting as a competitive ATP antagonist (Jackson et al., 2005).
IC87114 is a p1105-selective inhibitor related to LY294002. IC50 values for 
p110a, p110p and p110y were more than 200-, 150- and 50-fold higher than for p1108. 
No significant inhbition of a variety of protein kinases was detected (Sadhu et al.,
2003).
AS604850 is a pHOy-selective inhibitor which is 10-fold more selective for p110y 
than for p110p and p1108. The I C 5 0  for p110a is 50 times higher than p110y. 
Furthermore, AS604850 is an ATP-competitive drug (Camps et al., 2005).
In summary, isoform-selective inhibitors are very helpful tools to analyse the non- 
redundant functions of class I PI3K. However, 2 important aspects of PI3K inhibitors 
need to be considered. First, I C 5 0  values are usually generated with recombinant 
protein performing in vitro activity assays. This may or may not reflect the inhibitory 
effect of a drug in vivo. Second, even though a panel of known proteins are normally 
scanned for their inhibition by a certain drug in order to determine its selectivity, it is 
likely that the chosen inhibitor decreases the activity of either uninvestigated or 
unknown proteins.
1.7 B lymphocytes and class IA PI3Ks
Most of the experiments discussed in this thesis were performed using B 
lymphocytes. We will therefore give an overview of B cell antigen receptor (BCR) 
signalling and the role of class IA PI3K downstream of the BCR.
1.7.1 B cell antigen receptor signalling
In immature and mature B cells, the BCR is composed of membrane 
immunoglobulin (Ig) associated with disulfide-linked heterodimers of immunoreceptor 
tyrosine based activation motif (ITAM)-containing CD79a and CD79P (also called Iga 
and Igp, respectively) (Cambier et al., 1994). BCR crosslinking by antigen or anti­
receptor Ab mediates clustering of associated Src family kinases which induce 
phosphorylation of ITAM-motifs (Yamanashi et al., 1991). An important Src kinase in
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this process is Lyn. Lyn is constitutively associated with the BCR via acetylation, which 
anchors the kinase to the membrane and via a unique N-terminal region that interacts 
with the non-phosphorylated BCR in unstimulated cells. Phosphorylation of ITAM- 
motifs by Lyn following BCR engagement leads to the recruitment of additional Src 
family kinases as well as the Tyr kinase Syk, which become Tyr phosphorylated and 
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Figure 1.9: BCR signalling cascade
Following BCR crosslinking, tyrosine kinases (in red) enable recruitment of PI3K (in yellow) and 
adaptor proteins (in white) to the plasma membrane. PI3K activity facilitates translocation of PH 
domain containing proteins, such as Akt, Btk, PLCy and Vav. Adaptor molecules function as 
nucleators of different signalling pathways through binding and activation of mainly SH2 domain 
containing proteins. Binding of Sos and Vav to adaptors induces Ras and Rac (in green) 
activity. BCR engagement ultimately leads to activation of PI3K and MAPK pathways and 
mobilisation of intracellular Ca2+ and activation of PKC (in blue).
In parallel, Tyr phosphorylation of B cell specific adaptor proteins such as B cell 
linker protein (BLNK/SLP-76) and B cell adaptor for PI3K (BCAP) by Lyn and Syk leads 
to membrane recruitment and subsequent generation of PIP3 (Li et al., 1999); (Buhl 
and Cambier, 1999). Btk and PLCy2 translocate to the plasma membrane by means of 
their PH domains but also through interaction of their SH2 domains with BLNK (Fu et 
al., 1998). Following membrane recruitment, Btk is phosphorylated and activated by 
Src family kinases (Li et al., 1997; Nisitani et al., 1999). Activated Btk and Syk 
phosphorylate and activate PLCy2 which mediates the hydrolysis of phosphoinositides, 
thereby generating inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Fluckiger 
et al., 1998). This leads to Ca2+ mobilisation from intracellular stores and activation of 
PKC. Furthermore, the guanine-nucieotide exchange factor Vav translocates to the
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plama membrane due to its PH and SH2 domains. In conjunction with Sos, which is 
recruited to the BCR complex via BLNK, activated Vav induces the MAPK pathway.
BCR-mediated signals are inhibited by co-engagement of BCR with the inhibitory 
receptor FcyRIIB (Ravetch, 1997). The FcyRIIB-mediated inhibition is dependent on the 
immunotyrosine based inhibitory motifs (ITIM) in the cytosolic domain of FcyRIIB 
(Amigorena et al., 1992; Muta et al., 1994) and its interaction with SH2 domain 
containing protein SHIP (Ono et al., 1996). Following membrane recruitment, SHIP 
dephosphorylates PIP3 to Ptdlns(3,4)P2 leading to changes in the membrane 
recruitment of PH domain containing proteins (Aman et al., 1998; Scharenberg et al.,
1998) and subsequent shut-down of the PI3K signalling pathway.
1.7.2 The role of class IA PI3K in BCR signalling
PI3Ks are important in the transduction of BCR signalling. Inhibitor studies using 
WM and LY294002 revealed that BRC-mediated proliferation of B cell lines (Beckwith 
et al., 1996; Buhl et al., 1997) and of primay B cells was inhibited in a PI3K-dependent 
manner (Fruman et al., 1999). The catalytic subunit p1105 and regulatory subunit p85a 
were subsequently shown to be the class IA PI3K isoforms predominantly involved in 
BCR signalling. B cells containing a catalytically inactive p1108 protein have a 60% 
reduction of total class I PI3K activity, abolished Akt phosphorylation and reduced Ca2+ 
mobilisation leading to completely abrogated in vitro proliferation in response to BCR 
engagement (Bilancio et al., 2006). While the B cell phenotype observed in cells 
depleted of p85a was similar to the one of p1105 Kl mice, no obvious B cell phenotype 
was detected in mice lacking p85p or p55y (Fruman et al., 1999; Suzuki et al., 1999). B 
cells were also not affected by deletion of p110y (p110y KO) which instead leads to 
altered signalling and function of T cells, macrophages, neutrophils and mast cells 
(Hirsch et al., 2000; Laffargue et al., 2002; Rodriguez-Borlado et al., 2003; Sasaki et 
al., 2000).
The mechanisms by which BCR crosslinking leads to activation of PI3Ks and its 
downstream effectors are complex. Class IA PI3Ks are recruited to the plasma 
membrane following BCR engagement by two mechanisms (Figure 1.10).
If BCR-CD19 crosslinking is induced (left panel of Figure 1.10), the regulatory 
subunit interacts with phosphorylated Tyr residues in the cytosolic domain of CD19 
leading to Akt activation (Buhl and Cambier, 1999; Tuveson et al., 1993). PI3K 
activation seems to be the primary signalling function of CD19. A CD19 transgene with 
mutations in the Tyr residues that interact with PI3K is unable to restore CD19 function 
when introduced into CD 19-deficient mice (Wang et al., 2002). Co-ligation of 
membrane Ig with CD19 was shown to require Vav function for PI3K activation and
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subsequent Ca2+ mobilisation (Vigorito et al., 2004). It is not clear how Vav proteins, 
which possess a PH domain and were traditionally considered to act downstream of 
PI3Ks, influence PI3K activity. One possibility is through activation of Rac proteins 
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Figure 1.10: PI3K signalling downstream of BCR
Two separate mechanisms for Ca2+ mobilisation downstream of the BCR have been suggested: 
BCR crosslinking to CD19 leads to Vav-dependent PI3K activation, whereas BCR only 
crosslinking induces Ca2+ mobilisation via 2 independent pathways.
In contrast, PI3K activation by BCR only crosslinking (right panel of Figure 1.10) 
is Vav-independent. However, Ca2+ mobilisation after BCR engagement is Vav- and 
PI3K-dependent, indicating two separate pathways leading to Ca2+ flux after BCR only 
engagement. These findings also explain the incomplete reduction in Ca2+ flux by 
inhibition of p1105 after BCR stimulation (Bilancio et al., 2006). PI3K activation by BCR 
crosslinking is believed to occur via the recruitment of adaptor/scaffolding molecules 
such as BLNK, BCAP, Cbl and Gab, which have all been shown to interact with class 
IA PI3K regulatory subunit through its SH2 domain. The key role of adaptor molecules 
in BCR signalling was shown in mice lacking BLNK, which exhibit similar defects in B 
cell function as observed in p85a, p1105 or CD19 KO mice (Jumaa et al., 1999; Pappu 
etal., 1999).
The Tyr kinase Btk has been implicated as a major down-stream effector of PI3K 
signalling in B cells. In line with this, membrane recruitment of Btk is blocked by PI3K 
inhibitors (Varnai et al., 1999). Btk may also stimulate PI3K activity and therefore act as 
an upstream effector. In Btk-deficient DT40 cells, Akt phosphorylation following BCR 
engagement is reduced compared to WT cells (Craxton et al., 1999).
Generation of DAG and activation of PKC have been suggested to be the crucial 
components for B cell proliferation following BCR signalling, since proliferation could be
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restored in Btk and p85a deficient cells by low levels of phorbol ester, a DAG analog 
(Deane and Fruman, 2004; Forssell et al., 1999). However, since mice lacking both 
p85a and Btk have more severe phenotypes than single KOs, it is likely that PI3K 
triggers important signals independent of Btk (Suzuki et al., 2003) (see § 1.4).
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A im  o f  t h is  s t u d y
While the biological activities of class IA PI3Ks have been investigated in great 
detail, the biochemical mechanism of their regulation is underexplored (Chapter 1). 
Mechanisms that have been implied in the modulation of PI3K lipid kinase activity 
include interaction with binding partners (such as Tyr kinases, Ras and G(3y subunits of 
trimeric G proteins), phosphorylation of the PI3K subunits on Ser residues, and the 
molar ratios of p85 to p110.
The aim of this research project was to explore the biochemical regulation of 
endogenous (i.e. not overexpressed) class IA PI3K following physiological stimulation. 
In particular, we strived to
1) identify post-translational modifications in the class IA PI3Ks and investigate 
their biological role. Our main focus was on the p110S isoform of PI3K, which is 
predominantly expressed in cells of hematopoietic origin. Therefore, the WEHI-231 B 
cell model system (Chapter 2) was used. As described in Chapter 4 and Chapter 5, 
post-translational modifications in p85 and p110 were assessed in unstimulated versus 
stimulated immature B cells by separation of class IA PI3Ks using 2D-gel 
electrophoresis and by mass spectrometry (MS). In order to analyse a protein of 
interest and its modifications by MS, pure and ample protein is a prerequisite. We 
therefore developed a novel class IA PI3K purification tool based on the interaction of 
p85 SH2 domains with Tyr phosphorylated residues in YxxM-motifs (Chapter 3). The 
biological relevance of the observed modifications was explored by comparison of PI3K 
lipid kinase activities, subcellular localisation and protein-protein binding partners in 
stimulated versus unstimulated conditions
2) analyse the molar equilibrium between regulatory and catalytic subunits 
(Chapter 6). Over the last couple of years, a vast literature on the existence of free p85 
has appeared, mainly in an attempt to explain the increase in PI3K signalling upon 
insulin stimulation observed in mice in which class IA regulatory subunits have been 
deleted. In the proposed model, free p85 in WT cells competes with heterodimeric p85- 
p110 for docking sites on Tyr phosphorylated IRS molecules. Thus, monomeric p85 
was put forward as a negative regulator in the PI3K signalling pathway. In order to 
address the relevance of these findings, we compared the p85 to p110 molar ratio in 
fibroblasts to those in B cells, in which no p85 excess has been reported. These 
investigations were employed by affinity and ion exchange chromatography and 
absolute quantitation (AQUA) MS.
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2 M a te r ia ls  &  M e t h o d s
2 .1 Buffers and Solutions
Company names and catalogue numbers are provided between brackets.
ACK lysis buffer 0.15 M NH4CI, 1 mM KHC03l 0.1 mM Na2EDTA, pH 7.3
mouse anti-chicken IgM
Mouse anti-chicken IgM, clone M4 (Cambridge Biosciences, 8300- 
0 1 )
goat anti-mouse IgM
AffiniPure F(ab')2 Fragment Goat Anti-Mouse IgM, mu Chain 
Specific (Jackson ImmunoResearch Laboratories, 115-006-075)
4x SEP buffer 1.5 M Tris-HCI pH 8 .8 , 0.4% w/v SDS, made up to 1 I with ddH20
4x SPAC buffer 0.5 M Tris-HCI pH 6 .8 , 0.4% w/v SDS, made up to 1 I with ddH20
5x SDS sample buffer
156.25 mM Tris-HCI pH 6 .8 , 5% w/v SDS, 25% v/v glycerol, 
0.0025% w/v bromophenol blue in 10 ml ddH20. Add 250 mM DTT 
just before use.
Protein Assay Dye 
Reagent Concentrate
Dilute according to manufacture’s protocol (BioRad, 500-0006)
Home-made ECL
Solution A: 20 mM Tris-HCI pH 8.5, 0.0192% H20 2
Solution B: 20 mM Tris-HCI pH 8 .6 , 13.2 mg cumaric acid (Sigma,
C9008), 0.868 mg luminol (3-Aminophtalhydrazide, Sigma, A8511)




0.05 TIU/mg aprotinin 10
fjM  leupeptin
0.7 mM pepstatin A
27 jjfA TLCK
1 mM PMSF
5 jjM fenvalerate 
5 //M bpVphen
1 jl/M okadaic acid
Phosphatase inhibitor (Bdh, 102464T)
Tyrosine phosphatase inhibitor (Sigma, S6508)
Serine protease inhibitor (Sigma, A6279)
Serine and cysteine protease inhibitor (Sigma, L2884)
Acid protease inhibitor (Sigma, P4265)
Serine protease inhibitor (Sigma, T7254)
Serine protease inhibitor, dissolved in isopropanol, (Sigma, P7626) 
PP2B inhibitor (Sigma, F1428)
Potassium Bisperoxo(1,10-phenanthroline)oxovanadate,
PTP inhibitor (Calbiochem, 203695)
PP1 and PP2A inhibitor, 0.5 mM in ethanol (100 jjg  in 248 j j \ )  
(Calbiochem, 495604)
Lysis buffer
50 mM Tris-HCI pH 7.4, 150 mM NaCI, 1 mM EDTA, 1% Triton X- 
1 0 0
PBS
137 mM NaCI, 2.7 mM KCI, 9.5 mM Na2P0 4H, 1.4 mM K2P04H2 
(Severn Biotech Ltd.)
Raft lysis buffer 25 mM Tris-HCI pH 7.4, 150 mM NaCI, 5 mM EDTA
SDS-PAGE running 
buffer
0.025 M Tris, 0.192 M glycine, 0.1% w/v SDS, pH 8.3
Stripping buffer 62 mM Tris pH 6 .8 , 2% SDS, 1M yff-mercaptoethanol
TAE buffer 50 mM Tris-Acetate, 1 mM EDTA, pH 8
TBE buffer 89 mM Tris-Borate, 2 mM EDTA
TBST 50 mM Tris-HCI pH 7.5, 150 mM NaCI, 0.1% v/v Tween 20








p1108-specific inhibitor (S e r o n o ) I  provided by Serono 
p110p-specific inhibitor (S e ro n o ) > scientists (Geneva) to 
p110y-specific inhibitor (S e ro n o ) Dr. Vanhaesebroeck 
PI3K inhibitor (T o c ris , 1130)
Chromatography buffer A
20 mM Tris, pH 7.6, 1 mM EGTA, 1 mM MgCI2, 10% glycerol, 0.1% 
octylglucoside
Pervanadate
1.84 g NaV04 was dissolved in 50 ml ddH20 , pH adjusted to 10, 
the solution boiled in the microwave until colourless, made up to 
100 ml with ddH20  (= sodium orthovanadate). 11 jj\ H20 2 (30%) 
was added to 1 ml sodium orthovanadate and incubated at RT for > 
15 min. 2 //I catalase (2 mg/ml) was added and incubated at RT for 
> 30 min.
2.2 Media
2.2.1 E. coli medium
LB medium
12.5 g LB Broth, Miller (Luria-Bertani) (B ec to n  D ickinson) in 500 
ml ddH20
LA plates
12.5 g LB Broth, Miller (Luria-Bertani) (B e c to n  D ickinson) and 7.5 
g Bacto™ Agar (B ec to n  D ickinson) in 500 ml ddH20
Antibiotics 100 //I Ampicillin (Amp)/ml for LB medium and LA plates
12.5 //I Tetracycline (Tet)/ml LB medium and LA plates
S.O.C. medium (In v itro g e n , 15544-034)
2.2.2 Mammalian cell culture medium
RPMI 1640 medium, 
complemented
Roswell Park Memorial Institute (RPMI) medium was purchased 
from (G ibco, 52400-025) supplemented with 10% FBS, 5 ml 
Pen/Strep
RPMI 1640 for WEHI- 
231 cell culture
supplemented with 10% FBS, 5 ml Pen/Strep, 
and 0.5 ml 5 x 10'2 8 -mercaptoethanol
DMEM
Dulbecco’s Modified Eagle Medium (G ibco, 41966-029) was 
supplemeted with 10% FBS, 5 ml Pen/Strep
Phosphate-free DMEM (G ibco, 11971-025)
2.2.3 Chicken cell culture medium
RPMI 1640
RPMI (G ibco, 52400-025) was supplemented with 10% FBS, 1% 
chicken serum, 5 ml Pen/Strep




The source of antibodies (Abs) generated by members of Dr. Vanhaesebroeck’s 
team is called BV laboratory.






Akt Akt Cell Signalling, 9272 Rabbit pAb 1:1000 (WB)
pS473 Akt Cell Signalling, 9271 Rabbit pAb 1:1000 (WB)
PT308-77 Akt Cell Signalling, 9275 Rabbit mAb 1:1000 (WB)
pT308-76 Akt Cell Signalling, 4056 Rabbit pAb 1:1000 (WB)
Akt-901 Akt Upstate, 05-901 Mouse mAb 1:1000 (WB)
P-actin p-actin Sigma, ac-15 Mouse mAb 1:10000 (WB)
BCAP BCAP Provided by Dr. Kurosaki, Riken Rabbit pAb
1:1000 (WB) 
1:1000 (IP)





Mouse mAb against 





Mouse mAb against 
cytoplasmic tail 1:1000 (WB)
IRS-1-526 IRS-1 Upstate, 06-526 Rabbit pAb 1:1000 (WB)
IRS-2-
S919 IRS-2
Provided by Dr. 
Foukas, LICR, 
S919
Goat pAb 0.55 mg/ml 1:1000 (IP)
IRS-2 IRS-2 Upstate, 06-506 Rabbit pAb 1:10000 (WB)
Itk Itk Pharmingen Rabbit mAb 0.5 mg/ml 1:1000 (WB)
Lck Lck TransductionLaboratories Mouse mAb 0.25 mg/ml 1:5000 (WB)
Lyn Lyn Santa Cruz, sc-15 Rabbit pAb 0 . 2  mg/ml 1:2000 (WB)
9E10 Myc Abeam Mouse mAb 1:1000 (WB)
9B11 Myc Cell Signalling Mouse mAb 1:1000 (WB) 1:1000 (IP)
p110a-15 p1 1 0 a BV laboratory Rabbit pAb against C-terminus 1:500 (WB)
p110a-16 p1 1 0 a BV laboratory Rabbit pAb 1:500 (WB)
sc-602 p1 1 0 p Santa Cruz Rabbit pAb against C-terminus 0 . 2  mg/ml 1:1000 (WB)
SK214/215 p1 1 0 a BV laboratory Rabbit pAb 0 . 0 1  mg/ml 1:100 (IP)
p1 1 0 a - 1 1 p1 1 0 a TransductionLaboratories Mouse mAb 0.25 mg/ml 1:1000 (WB)
p1 1 0 p-2 . 1 pnop BV laboratory Rabbit pAb against C-terminus 1:100 (IP)
P1108-CT P110P BV laboratory Rabbit pAb 1:300 (IP)
p1 1 0 y p1 1 0 y BV laboratory Mouse mAb 1:100 (WB)
p1108-CT p1105 BV laboratory Rabbit pAb against C-terminus 1 mg/ml
1:5000 (WB) 
1:1000 (IP)
pS1039 p1105 BV laboratory Rabbit pAb against pSerl 039
1 : 1 0 0 0  + 
competing 
peptide (WB)
p55y p55y Provided by Dr. Asano, Tokyo Rabbit pAb 0.33 mg/ml 1:1000 (WB)
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T15 p85p BV Laboratory/ Serotec Mouse mAb 0.35 mg/ml
1:1000 (WB) 
1:200 (IP)
T12 p85p BV laboratory/ Serotec Mouse mAb
1:1000 (WB) 
1:200 (IP)
U10 p85a BV laboratory/ Serotec
Mouse mAb against 
BH domain 0.5 mg/ml
1:1000 (WB) 
1:200 (IP)
pS608 p85a Provided by Dr. Foukas, LICR
Rabbit pAb against 
PS608 1:1000 (WB)
LazAB p85a,P85p
Provided by Dr. 
Foukas, LICR
Rabbit pAb against 
N-SH2 0.5 mg/ml 1:1000 (IP)
p85pan p85 aJ p85p Upstate, 06-195
Rabbit pAb against 




U2 p85cxl P85p BV laboratory
Mouse mAb against 
N- SH2 0.3 mg/ml
1:1000 (WB) 
1:100 (IP)
pThr phospho-Thr Cell Signaling Rabbit pAb 0 . 1  mg/ml 1:1000 (WB)
4G10 phospho-Tyr Upstate
Mouse mAb against 
phospho-tyramine 1 mg/ml 1:5000 (WB)
Src Src Provided by Dr. Gout, UCL Mouse mAb 1:1000 (WB)
Syk-1077 Syk Santa Cruz, sc1077 Mouse mAb 0 . 2  mg/ml 1:1000 (WB)
Syk-573 Syk Santa Cruz, sc- 573 Mouse mAb 0 . 2  mg/ml 1:1000 (WB)
Tubulin Tubulin Sigma, T5168 Mouse mAb 1:1000 (WB)
2.4 Cell lines
Cell line Species Additional information (including ATCC 
catalogue number if available)
A20 Mus musculus Mature B cell line
B16BL6 Mus musculus Melanoma cell line
CT26 Mus musculus Colon carcinoma cell line (CRL-2638)
DT40 Gallus gallus B lymphoma cell line (CRL-2111)
EL-4 Mus musculus T lymphoma cell line (TIB-39)
GIST-430 Homo sapiens Gastrointestinal stromal tumour cell line
HEK-293T Homo sapiens Kidney cell line
HMC-1 Homo sapiens Immature mast cell line
MDA-MB361 Homo sapiens Breast cancer cell line (HTB-27)
NALM- 6 Homo sapiens acute lymphoblastic pre-B cell line
NIH-3T3 Mus musculus Fibroblast cell line (CRL-165)
THP-1 Homo sapiens acute monocytic leukemia cell line
U937 Homo sapiens histiocytic lymphoma cell line (CRL-1593.2)
WEHI-231 Mus musculus Immature B cell line
2.5 DNA primers
Primers were ordered from Qiagen O p eron .
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2.6 Plasmids & bacterial strains





pGEX-4T-2 has a tac promoter followed by a 
multiple cloning site, thrombin recognition site 







pBG1 is a pGEX-4T-2 plasmid from Amersham 
with the single-small (ss) peptide inserted. 
pGEX-4T-2 is restriction digested with EcoRI 
and Sail
ss: 5' a att tat gtg ccg atg ctg ggc ggc gcc 3'
Amp N/A
pBG2
pBG2 is a pGEX-4T-2 plasmid from Amersham 
with the double-small (ds) peptide inserted. 
pGEX-4T-2 is restriction digested with EcoRI 
and Sail
ds: 5' a att ggt ggc tac atg gac atg age aag gac 
gag tct gtg gac tat gtg ccg atg ctg ggc gcc 3'
Amp N/A
pBG3
pBG3 is a pGEX-4T-2 plasmid from Amersham 
with the double-long (dl) peptide inserted. 
pGEX-4T-2 is restriction digested with EcoRI 
and Sail
dl: 5' aatt ggc gag age gac ggt ggc tac atg gac 
atg age aag gac gag tct gtg gac tat gtg ccg atg 
ctg gac atg ggc gcc 3*
Amp N/A




XL1-blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 




E. coll B F - dcm ompT hsdS(rB-m B~) gal 
A(DE3) [pTK Tetr] Lysogenic for lambda DE3, 
which carries the T7 polymerase gene under 
lacilV5  control.
Tet Stratagene(200134)
BG1 XL1-blue containing pBG1 Tet, Amp N/A
BG2 XL1-blue containing pBG2 Tet, Amp N/A
BG3 XL1-blue containing pBG3 Tet, Amp N/A
BG4 XL1-blue containing pGEX-4T-2 Tet, Amp N/A
BG6 TKB1 containing pBG1 Tet, Amp N/A
BG7 TKB1 containing pBG2 Tet, Amp N/A
BG8 TKB1 containing pBG3 Tet, Amp N/A
2.7 Cell culture techniques
All procedures were carried out in a flow hood using antiseptical techniques.
2.7.1 Cryopreservation of cells
Stocks of the various cell lines were kept in liquid nitrogen. To start cultures of 
frozen cells, aliquots were removed from storage and thawed quickly at 37°C in a water 
bath before transfer to a tissue culture flask containing the appropriate medium.
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To prepare for freezing, cells were harvested by centrifugation at 700 x g for 7 
min and resuspended in 100% fetal bovine serum to give a final cell density of 1 x 10® 
cells/ml. 0.5 ml of this cell solution was mixed with 0.5 ml of 20% DMSO, 80% FBS and 
immediately transferred to sterile cryovials, which were frozen slowly in a polystyrene 
box containing isopropanol at -80°C overnight. They were subsequently transferred to 
liquid nitrogen.
2.7.2 Mammalian cell culture
2.7.2.1 Maintenance of mammalian cells
In general, suspension cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium and adhesion cells in Dulbecco’s Modified Eagle’s Medium 
(DMEM) each supplemented with 10% Fetal Calf Serum and 1% antibiotic solution 
(Penicillin and Streptomycin). Cells were grown at 37°C in a humidified incubator with 
5% C02. For further propagation, when cells became confluent, they were either diluted 
in fresh, prewarmed medium in the case of suspension cells or washed with PBS and 
trypsin-treated in the case of adhesion cells.
2.7.2.2 Treatment of cells with PI3K inhibitors
WEHI-231 cells were incubated with 5 pM IC87114, 5 pM LY294002, 0.1 pM 
TGX-221, 1 pM AS604950 or an equivalent volume of DMSO only for 30 min at 37°C. 
Following treatment with PI3K inhibitors, the cells were either left untreated or 
stimulated with a-lgM.
2.7.2.3 Antigen stimulation of B cells
B cells were either stimulated with a-lgM (WEHI-231 cells) or a-IgG (A20 cells) in 
order to crosslink the B cell antigen receptor and to induce a signalling cascade leading 
to Akt phosphorylation. Cells were therefore split to 1-2 x 106 cells/ml and incubated 
with 10 //g/ml a-lgM or a-IgG for 1-10 min at 37°C. They were subsequently diluted 
with ice-cold PBS and harvested at 700 x g for 7 min in a cold centrifuge.
2.7.2.4 Treatment of cells with okadaic acid (OA)
OA treatment of cells leads to the accumulation of Ser and Thr phosphorylated 
proteins since this agent is a potent PP1 and PP2A phosphatase inhibitor. Mammalian 
cells were seeded at 1-2 x 10® cells/ml and incubated with 1 nM okadaic acid for 45 min 
at 37°C. They were subsequently diluted with ice-cold PBS and harvested at 700 x g 
for 7 min in a cold centrifuge.
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2.7.2.5 Transfection of mammalian cells
HEK-293T cells were transfected with plasmid DNA by calcium phosphate 
precipitation according to the manufacturer’s protocol ( In v it r o g e n , K2780-01).
2.7.3 Avian cell culture
2.7.3.1 Maintenance of DT40 cells
DT40 cells were cultured in RPMI containing 10% FBS, 1% chicken serum and 
1% antibiotic solution. The cells were grown at 39.5°C in a humidified incubator with 
5% C02. The cells were kept between 5 x 105 and 1 x 107 cells/ml. Stimulation of DT40 
cells with mouse anti-chicken IgM (clone M4, C a m b r id g e  B io s c ie n c e s ) or pervanadate 
was performed with 1x10® cells/ml.
2.8 Nucleic acid manipulation
Centrifugation steps were carried out in an Eppendorf microfuge at 14000 rpm 
unless otherwise stated. All DNA solutions were stored at -20°C.
2.8.1 DNA preparation methods
2.8.1.1 Small-scale preparations of plasmid DNA
Small-scale plasmid preparations were performed with the GenElute™ Plasmid 
Miniprep Kit (S ig m a ) according to the manufacturer’s protocol.
2.8.1.2 Determination of DNA concentration
DNA concentration was determined spectrophotometrically by measuring the 
optical density (OD) at 260 nm by a Nanodrop ND-1000 spectrophotometer (N a n o D ro p  
T e c h n o lo g ie s ). Concentrations were then calculated from the equation: OD260 =1= 50 
pg/ml double stranded DNA.
2.8.1.3 Agarose gel electrophoresis of DNA
Molecular biology grade agarose (H elen a  B io S c ie n c e s ) was dissolved in 1 x TAE 
buffer to a final concentration of 0.6-1.8%. The solution was boiled in a microwave 
oven until the agarose was completely melted. The solution was allowed to cool down 
to approximately 60°C, ethidium bromide was added to a final concentration of 10 
/yg/ml, and the agarose was poured into a horizontal gel apparatus. After solidification, 
the chamber was filled with 1 x TAE buffer to run the gel. The DNA samples were 
mixed with Mass Loading Dye Solution (MBI F er m e n ta s ), loaded into the slots and run 
at a constant voltage of 120 mV for 20-30 min. For the determination of the fragment 
size, either GeneRuler™ 100 bp DNA Ladder Plus or MassRuler™ DNA Ladder, High
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Range (both MBI Fermentas) were electrophoresed simultaneously. The bands were 
visualised under UV-light and photographed with Polaroid films.
In order to resolve DNA fragments of 200-300 bp, NuSieve® 3:1 agarose 
(Cambrex) was dissolved in 1 x TBE to a final concentration of 3%. The manufacturer’s 
protocol was followed. Briefly, the agarose was slowly added to 1 x TBE and soaked 
for 15 min, subsequently heated in the microwave oven and held at the boiling point 
until the agarose was completely melted. After cooling down and adding ethidium 
bromide, the same procedure was followed as describe for lower percentage agarose 
gels.
2.8.2 DNA cloning procedures
2.8.2.1 Restriction enzyme digestion of DNA
An appropriate amount of DNA was diluted in 1 x restriction enzyme buffer (MBI 
Fermentas or NEB) to a final volume of 20-100 /j\. If required, 1 //I of BSA (MBI 
Fermentas) was added. 5-10 units of the desired restriction enzyme(s) were added and 
the reaction mixture was incubated between 2 and 4 h at the temperature 
recommended by the manufacturers (usually 37°C). The reaction product was 
analysed by agarose gel electrophoresis.
2.8.2.2 Ligation of DNA fragments
In order to anneal synthesised oligonucleotides (provided by Qiagen), 100 pmol/pl 
each of an oligonucleotide and its complementary sequence were incubated with 1 x 
T4 ligase buffer at 100°C for 3 min. The samples were then switched to room 
temperature (RT) and left to cool down and the annealing reaction to proceed.
An appropriate amount of purified vector and insert DNA -  usually in a 3:10 
vector-to-insert molar ratio -  were diluted in 1 x T4 ligase buffer (MBI Fermentas) and 
400-800 units of T4 DNA ligase (MBI Fermentas) were added. Subsequently, the 
mixture was incubated at 4°C overnight.
2.8.3 Transformation of competent E. coli cells (XL1-blue)
In order to transform competent cells, an aliquot of 100 jj\ of cells was thawed on 
ice and mixed with 50 ng DNA of the ligation mix. Cells were kept on ice for 30 min and 
then heat-shocked (42°C) for 90 s. Upon storage on ice for 2 min, 0.9 ml of S.O.C. 
medium was added and the cells were recovered for 45 min at 37°C on a shaker. The 
cells were concentrated thereafter and plated on selective LA plates. Dilution series 




2.8.4 Polymerase chain reaction (PCR)
PCR experiments were routinely performed in a volume of 50 jj\ in 500 /vl PCR 
tubes. The thermocycler (P e l t ie r  T h e rm a l c y c le r ,  PTC-200) was equipped with heatable 
lids.
The reactions contained 1 x PCR reaction buffer without MgCI2 (S ig m a ), 200 pM 
of each dNTP (MBI F e r m e n t a s ), 2.5 mM MgCI2 (S ig m a ), 10 ng template DNA, 2.5 pmol 
primers and 0.5 units of Taq (S ig m a ).
The cycling programs for PCR were optimised for each template-primer 
combination. The program was started with a denaturation step (94°C, 1 min), followed 
by 30 cycles consisting of a denaturation step at 94°C for 30 s, an annealing step at 
60°C (in some cases slightly higher or lower) for 30 s and an elongation step at 72°C 
for 2-3 min depending on the length of the fragment amplified. The reaction was 
terminated by an additional extension at 72°C for 10 min to synthesise incomplete 
products.
For crude verification of transformation results, 100 //I LB containing the 
appropriate antibiotic were inoculated and grown for 3 h. 5 //I of the E. coli culture was 
added to 1 x PCR reaction buffer, 200 jjM of each dNTP, 2.5 mM MgCI2, 0.5 units of 
Taq, and 2.5 pmol primers. The PCR reaction was performed as described above.
2.8.5 Sequencing reactions
DNA sequencing reactions were performed by MWG (MWG-BIOTECH AG, 
Ebersberg, Germany). 1-2 jjg of plasmid DNA or PCR DNA sequences were supplied 
air-dried, in addition to primers at a concentration of 10 pmol/pl.
2.9 Protein analysis and detection
2.9.1 SDS polyacrylamide gel electrophoresis
Sodium Dodecyl Sulfate PolyAcryamid Gel-Electrophoresis (SDS-PAGE) was 
used for the separation of proteins according to their relative molecular weight (Mr).
The resolving gel (8%) was prepared in the following manner in a Hoefner gel 
apparatus: 10 ml 30% acrylamide solution , 10 ml 4 x SEP buffer, 18.8 ml water, 250 fj\ 
APS (10%) and 25 jj\ TEMED. After polymerization, the stacking gel was prepared as 
follows: 2.7 ml acrylamide solution, 5 ml 4 x SPAC buffer, 12.2 ml water, 90 jj\ APS and 
25 jj\ TEMED. The protein samples, dissolved in SDS sample buffer and boiled for 5 
min, and the marker were loaded. The gel was run at constant voltage of 150 V for 5 
hours or overnight at 50 V in 1 x SDS-PAGE running buffer.
57
Chapter 2
2.9.2 Two-dimensional gel electrophoresis
Two-dimensional (2D) gel electrophoresis sorts proteins according to two 
independent properties in two discrete steps: the first-dimension step, isoelectric 
focusing, separates proteins according to their isoelectric points (pi); the second- 
dimension, SDS-PAGE, separates proteins according to their molecular weights (Mr, 
relative molecular weight). Thus, complex mixtures or post-translationally modified 
proteins can be analysed in more detail than using 1D SDS-PAGE.
2D gel electrophoresis was first introduced by O’Farrell (O'Farrell, 1975) and 
Klose (Klose, 1975) in 1975. In the original technique, the first dimension separation 
was performed with ampholyte-containing polyacrylamide gels cast in narrow glas 
tubes. 2D gel electrophoresis has been more widespread used in the last few years 
due to a number of improvements, especially the introduction of immobilised pH 
gradients (IPG) in 2D gel electrophoresis which led to increased reproducibility and 
sample loading capacity (Gorg et al., 1985{Gorg, 1988 #214); (Gorg et al., 2000).
The work flow of 2D gel electrophoresis can be summarised as follows: after 
sample preparation, the IPG strips are rehydrated overnight by adding the protein 
sample. The next day, the first dimension isoelectric focusing is performed followed by 
IPG equilibration and second dimension SDS-PAGE. Furthermore, the gel is either 
stained with Coomassie or Silver or the protein transferred to PVDF membranes for 
immunoblotting analysis.
2.9.2.1 Sample preparation
The method of sample preparation is key to the success of the experiment. The 
protein fraction loaded on a 2D-PAGE gel must be in a low ionic strength denaturing 
buffer that maintains the native charges of proteins and keeps them soluble during all 
steps of 2D electrophoresis. We therefore used a 2D lysis buffer made of 2 M thiourea 
and 8 M urea (chaotropic agents, (Rabilloud, 1998)), 4% CHAPS (zwitterionic 
detergent, (Rabilloud, 1999)), 65 mM DTT (reducing agent) and 2% ampholytes (carrier 
ampholytes to reduce protein precipitation).
Cells were split the day before the experiment, then harvested by centrifuging at 
700 x g for 7 min at 4°C, and washed twice with ice-cold PBS. Lysis of 1 x 107 cells 
was performed in 0.8 ml 2D lysis buffer (8 M urea, 2 M thiourea, 4% CHAPS, 65 mM 
DTT, 2% ampholytes). The cells were incubated for 15 min at RT and passed three 
times through a 27-gauge needle. To separate the unbroken cells from the lysate, a 
centrifugation step at 10000 x g for 10 min at 16°C was performed. The protein 
concentration of the lysate was determined.
If immunoprecipitated protein was analysed by 2D gel electrophoresis, 
immunoprecipitation was performed as described in § 2.10, however, a low-salt/
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detergent free wash step (50 mM Tris-HCI pH 7.4, 10 mM NaCI, 5 mM EDTA) of the 
beads was incorporated after washing with lysis buffer. The beads were subsequently 
incubated with 2D lysis buffer for 15 min at RT and the supernatant loaded onto the 
first dimension of the gel.
2.9.2.2 First dimension isoelectric focusing (IEF)
The isoelectric point of a protein is the specific pH at which its net charge is zero. 
Proteins are positively charged at pH values below their pi and negatively charged at 
pH values above their pi. In IEF, proteins move under the influence of an electric field 
along a pH gradient until their net charge is zero.
For the first dimension isoelectric focusing, we used immobilised pH gradient 
(IPG) strips (A m e r s h a m  P h a r m a c ia  B io t e c h ). An IPG is created by covalently 
incorporating a gradient of acidic and basic buffering groups into a polyacrylamide gel 
at the time it is cast.
200 fjg total protein or immunoprecipitated protein in 350 //I 2D lysis buffer 
containing 0.001% bromophenol blue and 2% ampholytes was spread along the whole 
length of the IPG reswelling tray. A defrosted, 18 cm IPG strip (Immobiline DryStrip, pH 
3-10, A m e r s h a m  P h a r m a c ia  B io t e c h ) was labelled, the plastic backing removed and the 
strip layed gel-faced down. After 1 h of reswelling, 1 ml of PlusOne DryStrip cover fluid 
(Am e r s h a m  P h a r m a c ia  B io t e c h ) was added and the lid of the reswelling tray closed. The 
strip was rehydrated overnight at RT. Thereafter, the strip was transferred to a plastic 
strip aligner with the gel facing up and a 2 cm electrode strip, which was soaked in 100 
//I ddH20, placed on each side of the strip. The strip was connected to the Multiphor™ II 
Electrophoresis Unit (A m e r s h a m  P h a r m a c ia  B io t e c h ) and DryStrip cover fluid added. The 
focussing program was as follows: 300 V gradient for 30 min, 3500 V gradient for 6 h 
and 3500 V gradient for 20 h. The current and power was maintained at 5 mA and 10 
W, respectively for each step.
2.9.2.3 Equilibration of IPG strips
The equilibration step saturates the IPG strip with the SDS buffer system required 
for the second dimension separation. In addition, proteins are further reduced and 
alkylated in order to prevent protein streaking in the second dimension. To this end, the 
strips were emerged for 10 min in IPG equilibration buffer (50 mM Tris-HCI pH 8.8, 6 M 
urea, 30% glycerol, 2% SDS) containing 1% DTT, followed by 10 min incubation with 
IPG equilibration buffer containing 245 mM iodoacetamide.
2.9.2.4 Second dimension SDS-PAGE
For the analysis of PI3K proteins, 7-8% single percentage gels were cast in 20 x 
22 cm plates. The gel was made of 15 ml 1.5 M Tris-HCI pH 8.8, 12 ml 40%
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acrylamide, 33 ml HPLC ddH20, 0.6 ml 10% APS and 60 jj\ TEMED and poured until 
the gel solution reached 2-3 cm below the top of the lower glass plate.
After equilibration of the strip, melted second dimension overlay agarose solution 
(0.5% molecular biology grade agarose in SDS-PAGE running buffer containing 
0.001% bromophenol blue) was poured on top of the second dimension and the strip 
transferred. Once the agarose was set, the second dimension was run at 50 mA per 
gel with cooling in SDS-PAGE running buffer for 4-5 h until the dye front ran out 
(B io Ra d , Protean II xi Cell). Subsequently, the samples were analysed either by 
colloidal Coomassie blue (§ 2.9.3), Silver staining (§ 2.9.4) or by immunoblotting 
method (§ 2.9.5).
2.9.3 Colloidal Coomassie staining of acrylamide gel
Colloidal Coomassie staining of polyacrylamide gels was performed with the 
GelCode® Blue Stain Reagent according to the manufacturer’s protocol (P ie r c e , 
24592).
Briefly, polyacrylamide gels were fixed in 40% ethanol/10% acetic acid for 1 h to 
overnight. The gels were subsequently washed 3-5 times with excess ddH20 and 20 ml 
of GelCode® Blue were added for 1 h. After staining, the gels were incubated with 
ddH20 for another hour to decrease the background staining.
2.9.4 Silver staining of acrylamide gels
After SDS-PAGE, the gel was incubated in a 40% ethanol/10% acetic acid 
fixating solution for 1 h to overnight. Subsequently, the gel was washed in 50% ethanol 
and distilled water for 10 min each. The gel was further incubated with 0.02% sodium 
thiosulphate sensitising solution for 1 min, washed in water for 1 min and then stained 
in chilled 0.1% silver nitrate for 30 min at 4°C. Thereafter, the gel was washed 
generously in water for 1 minute and developed in 0.04% formalin, 2% sodium 
carbonate. The reaction was stopped with 1% acetic acid.
2.9.5 Electroblotting
After SDS-PAGE, proteins were transferred onto a PVDF membrane 
(lmmobilion™-P, M ill ip o r e ) by electroblotting.
The membrane cut to the same size as the gel was briefly soaked in methanol 
and rinsed in water. Both the gel and the membrane were pre-equilibrated in 1 x 
transfer buffer (48 mM Tris-HCI, 386 mM glycine, 1% SDS, 20% methanol), 
sandwiched between 2 sheets of Whatman 3MM paper and two sponges (both 
equilibrated in 1 x transfer buffer). The case was then placed in a blotting tank
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containing 1 x transfer buffer such that the gel was facing the cathode. Proteins were 
transferred for 100 Vh.
After the transfer, the membrane was blocked for 1 h to overnight in 5% milk, 1 x 
TBST. Subsequently, the membrane was incubated with the primary antibody (Ab) 
overnight at 4°C, washed thoroughly 3 times for 5 min in 1 x TBST and then incubated 
with the secondary Ab for 1 h at RT. The membrane was washed with 1 x TBST and 
incubated with ECL™ Western Blotting Detection Reagents (Amersham B iosciences) or 
home-made ECL for 2-3 min. The membrane was wrapped in saran foil and exposed to 
super RX Fuji medical X-ray films (F u ji) for different amounts of time.
Blots were stripped by immersing in stripping buffer (62 mM Tris-HCI pH 7.4, 20% 
SDS) supplemented with 700 //I p-mercaptoethanol per 100 ml stripping buffer for 30 
min at 55°C and then rinsed thoroughly in 1 x TBST.
2.9.6 Determination of protein concentration
The protein concentration of lysates was measured by comparing the 
spectrometrical absorbance of lysis buffer at 595 nm with the absorbance of the cell 
lysate. Therefore, 5 / j \ of the lysis buffer was added to 1 ml of BioRad solution (B ioR ad), 
mixed well and the absorbance measured with a spectrophotometer (Cary 50, V a ria n  
Inc.). This control absorbance was subtracted from the absorbance measured if 5 /j \ of 
cell lysate was added to 1 ml BioRad solution. The obtained value for the cell lysate 
was thereafter multiplied with a constant (24.75) and the dilution factor (200) to give the 
protein concentration in mg/ml.
2.10 Immunoprecipitation
Cells were harvested by centrifugation at 700 x g for 7 min and subsequently 
washed twice with ice-cold PBS. The pellet was resuspended in ice-cold lysis buffer (1 
ml lysis buffer/107 cells, 50 mM Tris-HCI pH 7.4, 150 mM NaCI, 1 mM EDTA, 1% Triton 
X-100) containing protease and phosphatase inhibitors and incubated for 20-30 min on 
ice. The lysate was centrifuged at 10000 x g for 10 min and the protein concentration of 
the supernatant determined. If mass spectrometry (MS) experiments were performed, 
the lysate was pre-cleared for 2 h with 10-100 pi packed, prewashed protein A/G 
sepharose beads (A m e r s h a m  B io s c ie n c e s ) followed by Ab addition. In all other 
experiments, this step was omitted and Ab was directly added to the lysate and 
incubated for two hours to overnight at 4°C. Subsequently, 10-100 pi packed, 
prewashed protein A/G sepharose beads were added and the lysate incubated at 4°C 
for two more hours. The beads were washed three times with lysis buffer, two times 
with lysis buffer containing 0.5 M NaCI and once with 10 mM Tris-HCI, pH 7.4. The
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beads were then incubated with 150 jxl 5 x SDS sample buffer and boiled for 5 min at 
100°C.
More detailed information to each Ab is provided in § 2.3.
2.11 Subcellular fractionation
2.11.1 Separation of cytosolic and membrane fraction
Analysis of the cytosolic and membrane fraction was performed using a protocol 
described by Susan Pierce (Stoddart et al., 2002).
Approximately 108 WEHI-231 or A20 cells were harvested by centrifugation at 
700 x g for 7 min and washed twice with ice-cold PBS. 3.5 ml of ice-cold Hypotonic 
buffer (10 mM Tris-HCI pH 7.4, 42 mM KCI, 5 mM MgCI2) was added to the cell pellet 
and incubated for 30 min on ice. Three rounds of freeze-thawing were performed. After 
this, protease and phosphatase inhibitors were added and the lysate subsequently 
centrifuged at 1000 x g for 10 min. The protein concentration of the supernatant was 
measured, a sample kept for immunoblotting analysis and the supernatant 
subsequently centrifuged at 150000 x g for 30 min. The high spin supernatant 
containing the cytosolic fraction and high spin pellet containing the membrane fraction 
were analysed by immunoblotting.
2.11.2 Raft fraction analysis
Lipid rafts were isolated by treatment of cell membranes with Triton X-100 and 
flotation on sucrose gradients.
3 x 107 WEHI-231 or A20 cells in 30 ml supplemented RPMI medium were 
harvested by centrifugation at 700 x g for 7 min, washed twice in ice-cold PBS and 
lysed in 3.5 ml Hypotonic buffer. The cells were incubated on ice for 30 min, followed 
by three rounds of freeze-thawing. The lysate was centrifuged at 1000 x g for 10 min. 
The post-nuclear supernatant was centrifuged for 30 min at 150000 x g. The high spin 
pellet containing the membrane fraction was resuspended in 1 ml 0.2% Triton X-100 in 
Raft lysis buffer (25 mM Tris-HCI pH 7.4, 150 mM NaCI, 5 mM EDTA) and incubated 
for 20 min on ice. 1.7 ml 65% sucrose in Raft lysis buffer was added to the membranes 
and overlayed with 5 ml 30% and 2 ml 5% sucrose solution in an ultracentrifuge tube. 
The discontinuous sucrose gradient was centrifuged at 200000 x g for 18 h, and eleven 




2.12 In vivo labelling with radioactive ATP
In order to perform a in vivo labelling experiment with WEHI-231 cells, 5x10® 
cells were washed twice in pre-warmed, phosphate-free DMEM and subsequently 
incubated with 50 ml phosphate-free DMEM containing 4% dialysed FCS and 10 mM 
HEPES, pH 7.4 (= Labelling medium) for 30 min at 37°C. After this incubation step, the 
cells were harvested and resuspended in 27 ml Labelling medium. 2 mCi [y-32P]ATP 
was added to 3 ml Labelling medium and added to the cells. The cells were incubated 
for 6 h at 37°C. Subsequently, the cells were harvested, washed twice with Labelling 
medium and resuspended in 40 ml fresh Labelling medium. The cells were split into 5 
flasks and either left unstimulated or stimulated with 10 /yg/ml a-lgM or 500 nM OA. 
The cells were then washed with ice-cold PBS and handled as described in § 2.10.
2.13 In v itro  PI3K lipid protein kinase assay
In vitro PI3K lipid protein kinase assays were performed with immunopurified 
protein after extensively washing the immunocomplex with lysis buffer and 2 x kinase 
buffer (40 mM Tris-HCI, pH 7.4, 200 mM NaCI, 1 mM EGTA). The reaction took place 
in a final volume of 80 //I reaction. 40 /yl 2 x Kinase buffer and 10 jj\ lipids 
(phosphatidylinositol or phosphatidylinositol 4,5-bisphosphate) were added to the 
beads. A mastermix of Mg/ATP/[y-32P]ATP (10 mM Mg, 100 jjM  ATP, 0.25 //I [y- 
32P]ATP) was prepared and added as well. The mix was incubated at 30°C for 15 min 
and the reaction stopped by addition of 100 //I 1 M HCI. The lipids were extracted by 
addition of 200 //I CHCI3:MeOH (1:1) followed by 80 /yl 1 M HCI:MeOH (1:1).
The lipids were separated by thin layer chromatography (TLC). To this end, the 
lipids were spotted onto a TLC plate pre-treated with Chelating solution (5 g oxalic acid, 
1 ml 0.5 M EDTA, 200 ml MeOH). The chromatography was performed using a solution 
made of propan-1-ol, 2 M acetic acid, 5 M phosphoric acid (65:35:1). The TLC plate 
was exposed to a phosphoimager plate for detection of radioactivity.
2.14 Liquid chromatography
Molecules can be separated by chromatography using differences in their 
biophysical properties, such as size, charge and hydrophobicity. Liquid 
chromatography was used in this work for sample fractionation and as front-end 
separation before MS analysis.
2.14.1 Ion exchange chromatography
Ion exchange chromatography (IEX) separates biomolecules based on 
differences in their charge. This separation technique depends upon the reversible
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adsorption of charged solute molecules to an immobilised ion exchange group of 
opposite charge. For the separation of class IA PI3K, we used anion exchange 
chromatography after a protocol by Shibasaki (Shibasaki et al., 1991). The chosen high 
performance anion exchange chromatography column (Tricorn Mono Q™ 4.6/100 PE 
column (Amersham Biosciences)) contained a strong anion exchanger (0-CH2-CH0H- 
CH2-0-CH2-CH0H-CH2-N+(CH3)3) covalently coupled to a polystyrene/di vinyl benzene 
matrix. The Tricorn Mono Q™ 4.6/100 PE column was chosen because of its high 
loading capacity, high resolution purification, reproducibility and durability. An Integral 
100Q system (Applied Biosystems, 5-1818-00, 203) was used for high pressure liquid 
chromatography.
After cell lysis as described in § 2.10, the lysate containing 30 mg total protein in 
10 ml lysis buffer was de-salted by applying the protein to 2 pre-cooled gel filtration 
columns (BioRad, Econo-Pac 10DG, 732-2010). Elution was performed with 2 x 4 ml 
cold Chromatography buffer A (20 mM Tris-HCI pH 7.6, 1 mM EGTA, 1 mM MgCI2, 
10% glycerol, 0.1% octylglucoside).
The anion exchange chromatography column was equilibrated with 10 column 
volumes of Chromatography buffer A before adding the lysate. After addition of protein 
solution, the column was washed with Chromatography buffer A until the baseline was 
reached, and the protein subsequently eluted using gradient elution (usually from 0 M 
NaCI to 0.5 M NaCI in 20 column volumes). The protein fractions were harvested and 
analysed by immunoblotting.
After usage, the column was routinely washed with 3 M NaCI, followed by ddH20. 
For more rigorous cleaning, 1 M NaCI, 1 M NaOH, 1 M HCI, 1 M NaCI were applied.
2.14.2 Reverse phase high pressure liquid chromatography
In reverse phase (RP) liquid chromatography, molecules are separated according 
to their hydrophobicity (Snyder, 1997). Sample mixtures in a hydrophilic mobile phase 
are introduced to a column containing a hydrophobic stationary phase. Elution occurs 
with applications of a hydrophobic phase applied in a fixed (isocratic) or variable 
(gradient) concentration. RP high pressure liquid chromatography (RP-HPLC) was 
used in conjunction with MS.
Depending on the hydrophobicity of the analyte, different stationary phases can 
be used. Small peptides are best separated with columns packed with beads 
derivatised with octadecyl groups (C18) containing relatively small pore sizes.
LC was performed using an Ultimate™ HPLC system (LC Packings, Amsterdam, 
Netherlands). The Ultimate system consisted of an auto-sampler (Famos™) that loaded 
5 jj\ sample at 20 /yl/min flow rate onto a peptide trap column (0.3 x 1 mm, PepMap, LC 
Packings) placed at a switching valve (Switchos™). Peptides in the peptide trap column
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were washed for 2 min at 20 /yl/min with 0.1% formic acid. Peptides were subsequently 
eluted onto a main analytical column (C18 PepMap, 75 pm x 15 cm) using an elution 
gradient of 300 nl/min. Solvent A was 0.1% formic acid and solvent B was 80% 
acetonitrile/0.1% formic acid. Elution was carried out from 5% B to 40% B in 20, 30, 40 
min depending on the application.
The eluents of the HPLC runs were analysed on-line by the MS described below.
2.15 Immobilised metal affinity chromatography
Immobilised metal affinity chromatography (IMAC) is a technique that can be 
used to selectively enrich phosphopeptides in protein digests, and can therefore 
increase the sensitivity of phosphopeptide detection by MS (Gronborg et al., 2002); 
(Bamouin et al., 2005).
In IMAC, a stationary phase made of nitrilotriacetic acid (NTA) is chelated to six- 
coordinate Fe(lll) or Ga(lll). The interaction between NTA and the metal ion occupies 4 
metal coordination bindig sites of Fe(lll) or Ga(lll), leaving 2 coordination sites free for 
interaction with phosphorylated amino acids. Although IMAC significantly decreases 
complex mixtures, some unphosphorylated peptides are retained by the chelating 
complex, particularly peptides rich in acidic residues (Ficarro et al., 2002; Schlosser et 
al., 2002).
We performed IMAC experiments following enrichment of PI3K by 
immunopurification and tryptic digestion of the protein. In a first step, the IMAC beads 
were prepared from Nickel-NTA-sepharose beads (Q iagen) by stripping off Ni2+ ions 
and replacing them by Fe3+ ions. To this end, 500 jj\ Ni(ll)-NTA-sepharose suspension 
was washed with 500 jj\ ddH20, treated 2 x with 500 //I 100 mM EDTA, washed 3 x 
with 500 fj\ 100 mM acetic acid and subsequently re-charged with 500 //I 100 mM 
Fe(lll)CI3. The beads were washed 6 x with 100 mM acetic acid and stored at 4°C until 
use.
In a second step, the digested protein (approximately 1 pmol//yl) was added to 1 
/yl IMAC beads and incubated for 15 min at RT. The supernatant was removed with an 
Eppendorf gel loader tip and the beads washed 3 times with 10 jj\ 10 mM acetic acid 
and 3 times with 10 jj\ ddH20. The bound peptides were eluted with 2 jj\ 100 mM 
ammonium phosphate and analysed by MS.
2.16 Mass spectrometry
2.16.1 Introduction to mass spectrometry
Mass spectrometry (MS) has become the technique of choice for protein 
identification and increasingly for the investigation of post-translational modifications.
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This is due to a number of instrumental advantages of MS over other techniques, such 
as sensitivity, low sample consumption, accuracy, and possibility to automate (Baldwin, 
2004).
Mass spectrometers generally consist of three functional elements: an ionisation 
source, a mass analyser and a detector.
2.16.1.1 Ionisation
In order to analyse molecules, they must first be ionised and converted into the 
gaseous phase. The most commonly used ion sources in biological MS are Matrix- 
Assisted Laser Desorption/Ionisation (MALDI) and Electrospray Ionisation (ESI).
2.16.1.1.1 Matrix-assisted laser desorption/ionisation
This method of soft ionisation was introduced in 1988 by Karas and Hillenkamp
(Karas and Hillenkamp, 1988) and Tanaka (Tanaka et al., 1988). In MALDI, the peptide 
sample is dissolved in a matrix (containing a chromophor), and irradiated with a pulsed 
nitrogen laser usually at 337 nm. The rapid energy absorption initiates a phase change 
of the absorbing material from solid to gas, while also inducing ionisation. However, the 
actual ionisation mechanism by MALDI is not well understood.
2.16.1.1.2 Electospray Ionisation
ESI was developed by Fenn in 1989 (Fenn et al., 1989). ESI allows for the
formation of ions from liquid phase samples. The analyte is introduced into a source 
and passes through an electrospray needle that has a high potential difference in 
comparison to the inlet of the mass spectrometer. The electric field generates charged 
droplets which decrease in size by solvent evaporation and Coulomb explosion until 
desolvated, single ions are formed.
2.16.1.2 Mass analysers
After production of ions in the source, the ions are separated according to their 
mass-to-charge (m/z) ratio by a mass analyser. The most commonly used mass 
analysers in biological MS can be divided into four general groups: (1) time-of-flight 
(TOF), (2) quadrupole, (3) ion trap, and (4) ion cyclotron resonance. In the experiments 
performed in this thesis, only TOF, quadrupole and ion trap analyser were used and 
therefore discussed.
2.16.1.2.1 TOF mass analyser
The time-of-flight (TOF) analyser is one of the simplest and most widely used
mass analysers. TOF analysers are instruments noted for their nearly unlimited mass 
range and sensitivity (Cotter, 1989; Roepstorff, 2000). Separation of ions is based on 
different flight times of ions in a field-free drift region after acceleration in an electric
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field. The ions travel the length of the flight tube at a velocity that can be calculated 
according to the classical equation of kinetic energy. The ions with greater mass will 
travel slower than the lighter ones and therefore reach the detector later.
2.16.1.2.2 Quadrupole mass analysers
Mass separation in a quadrupole analyser is achieved by establishing an electric
field in which ions of a certain m/z value have a stable trajectory through the field (Paul 
and Steinwedel, 1953). Quadrupole analysers consist of four parallel inert metal rods 
that are connected electrically. Ions travelling along the z-axis are subjected to the 
influence of a total electric field made up of a quadrupolar alternating field superposed 
on a constant field resulting from the application of the potential upon the rods.
Multiple quadrupoles can be applied successively in a mass spectrometer or 
quadrupoles can be combined with other mass analysers.
2.16.1.2.3 Ion trap mass analyser
Ion trap mass analysers are scanning devices which trap ions in a three-
dimensional electric field. Three hyperbolic electrodes consisting of a ring and two 
endcaps form the core of this instrument. Injected ions are trapped in a radio frequency 
quadrupole field and then sequentially ejected from the ion trap into an electron 
multiplier detector.
2.16.1.3 Detector
The ion beam passes through the mass analyser and is then detected and 
transformed into a usable signal by a detector. In the detector, ions are recorded when 
hitting a electron multiplier detector plate (multi channel plate, MCP). The signal is 
amplified by a cascade of electrons which are released if ions come in contact of the 
plate.
2.16.2 Sample preparation
In order to analyse proteins by MS, peptide fragments are needed. We therefore 
enzymatically digested protein using trypsin. Trypsin specifically hydrolyses peptide 
bonds at the carboxylic sides of Lys and Arg residues, unless Pro lies C-terminally of 
Lys or Arg.
In order to avoid protein contamination (mainly keratin), sample preparation was 
performed in either a ventilated hood (PCR workstation) or in a clean room (Proteomics 
Unit, LICR).
In-gel digestion was performed using in-house protocols (Benvenuti et al., 2002). 
In short, in-gel digestion consists of washing, reducing, alkylating, digesting and 
extracting the peptides from gel bands. Gel bands were cut into small pieces
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(approximately 1 mm3) and placed into 0.65 ml siliconised tubes. Gel plugs were 
washed and dehydrated several times by addition of 50% acetonitrile (ACN). The 
pieces were dried under vacuum and 10 mM DTT in 25 mM ammonium bicarbonate 
(AmBic) was added. The reaction was left at 50°C for 1 hour. After removing the 
supernatant, an equal volume of 55 mM iodoacetamide in 25 mM AmBic was added 
and the reaction was incubated in the dark for 60 min at RT. The supernatant was 
removed, the gel pieces washed 3 times with 50% ACN and fully dried under vacuum. 
50-100 ng trypsin (P ro m eg a , 608-274-4330) was added in enough volume to cover the 
gel pieces. The gel pieces were left rehydrating and more 25 mM AmBic was added to 
cover the gel pieces. The reaction was incubated at 37°C overnight. Peptides were 
extracted by removing excess liquid the following morning and adding 50 jj\ 50% ACN, 
5% trifluoroacetic acid 3 times with vigorous vortexing between the extraction steps. 
Samples were dried under vacuum and stored at -20°C until mass spectrometric 
analysis.
Samples for LC-ESI-MS were resuspended in 5-10 jj\ 0.1% formic acid and 
sonicated for 15 min. The liquid was transferred to 0.2 ml thin wall PCR tubes, which 
were placed in conical polypropylene vial and closed by addition of a polypropylene 
snap cap.
Samples for MALDI-TOF MS analysis were prepared using the dried droplet 
protocol. In short, the sample analyte was mixed with an excess of matrix. Frequently 
used matrices for MALDI experiments are 2,5-dihydroxybenzoic acid (DHB) and a- 
cyano-4-hydrocycinnamic acid (HCCA). Typically, 1 jj\ of sample was mixed with 1 //I of 
freshly prepared, saturated solution of DHB (Sigma) or HCCA (A g ile n t T e c h n o lo g ie s ). 
Since DHB is more tolerant to high salt concentrations compared to HCCA and is 
considered a “cool” matrix as the energy transfer is relatively low, it is more suitable for 
the analysis of labile modifications on peptides. HCCA on the contrary is a “hot” matrix. 
Because of the higher transfer of energy this matrix is more suitable to gain structural 
information of peptides. Samples mixed with matrix were dried under a stream of cold 
air.
2.16.3 Instrumentation and its operation
Mass spectrometry-based experiments were carried out using instruments 
located and maintained at the Proteomics Unit of the Ludwig Institute for Cancer 





Experiments were performed on an Ultraflex TOF/TOF™ (B r u k e r  D a l t o n ic s ). This 
is a low pressure MALDI-TOF instrument equipped with a nitrogen laser and with LIFT 
technology.
Samples were spotted onto a stainless steel MALDI plate as described in §
2.16.2 and placed into the Ultraflex TOF/TOF™. Analysis was performed using 
FlexControl (B r u k e r  D a l t o n ic s ) by averaging the spectra produced from 50 to 300 laser 
shots depending on the signal-to-noise ratio. Laser intensity was varied depending on 
the observed signal intensity such that peaks were not saturated. The instrument was 
externally calibrated using a standard mixture of peptides for the analysis of low 
molecular weight peptides such as those produced from protein digestion (Calmix, 
A p p l ie d  B io s y s t e m s ).
Spectra were analysed using FlexAnalysis (Compass software, Br u k e r  
D a l t o n ic s ). Background subtraction, smooting and centering were performed using 
FlexAnalysis. The peaklist was searched against the NCBInr databases using MSFit by 
Protein Prospector v3.4.1 or v4.0.4 (UCSF) run on a local server. The same search 
parameters as described in § 2.16.5.2 were used. Protein hits were accepted if the 
MOWSE score was above 250 and at least 30% of the protein sequence was covered.
2.16.3.2 LC-ESI-Q-TOF
Full-scan acquisitions and most of the multiple reaction monitoring experiments 
were performed on a Q-TOF™ instrument (M ic r o m a s s , Manchester) coupled to a 
Nanoflow LC (Ultimate™ HPLC system). The operations of the HPLC are described 
above (§ 2.14.2).
In the Q-TOF hybrid instrument (Morris et al., 1996); (Morris et al., 1997), two 
quadrupoles (Q1 and q2) are combined with a time-of-flight mass analyser. When 
scanning large mass ranges, Q1 operates in the so-called radio frequency (RF) mode 
allowing for transmission of ions with a wide m/z range to a push-pull region. From 
there, ions are accelerated orthogonally towards the field-free region of the TOF. In 
MS/MS experiments, Q1 is used in a static mode allowing for the isolation of desired 
ions and their transmission to the collision cell (q2) where their fragmentation due to 
collision induced dissociation (CID) occurs. Fragmented ions are subsequently 
separated by the TOF analyser.
The ESI mass spectrometers were equipped with nanoflow ion sources and 
fused silica ESI emitters with 50 urn I.D. tapered to 15 jim at the tip (PicoTip™, N ew  
O b je c t iv e ). Samples were introduced from the eluent of HPLC runs at flow rates of 300 
/yl/min. Operation parameters were determined empirically by infusing standard 
peptides. Typical spray tip potentials were 2000-3000 V depending on the tip of the
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emitter and the flow rate. Voltages at the orifice of the interface ranged from 40-150 V. 
The instrument was calibrated using the m/z values of the fragment ions generated 
from a MS/MS fragmentation of (Glul)-Fibrinopeptide B.
The instrument was controlled using the Masslynx software (Micromass, W a t e r s ). 
More detailed running parameters are provided in § 2.16.4.1.
2.16.3.3 LC-ESI-Q-STAR
Multiple reaction monitoring experiments were partially performed with a QSTAR 
instrument (PE Siex, A p p l ie d  B io s y s t e m s ) coupled to a Nanoflow LC (Ultimate™ HPLC 
system). This is another hybrid Q-TOF mass spectrometer with ion optics similar to 
those described above for the Q-TOF™ instrument.
2.16.3.4 LC-ESI-Q-TRAP
Precursor-ion scanning experiments were performed with the hybrid triple 
quadrupole linear ion trap 4000 Q-TRAP® system (Ap p l ie d B io s y s t e m s ) coupled to 
nanoflow chromatography. The Q-TRAP was equipped with a Flow NanoSpray® source 
controlled using Analyst 1.4 software (M D S -S c ie x ). The protein digests were separated 
using an LC Packings Integrated System (D io n e x ) consisting of a FAMOS™ micro 
autosampler, Switchos™ micro column switching module and UltiMate™ micro pump, a 
PepMap C18 column (75 pm x 15 cm, LC Pa c k in g s ), and a mobile phase of 
acetonitrile/0.1% formic acid, with a 45 minute gradient elution and a flow of 0.3 pl/min. 
Samples were loaded (20 pi injection of a digest reconstituted in 1% formic acid) onto a 
capillary trap (M ic h r o m  B io r e s o u r c e s ) and washed with 0.2% formic acid at a flow rate 
of 20 pl/min. After approximately 5 min, the capillary cartridge was switched in-line with 
the analytical column. Post column addition of 80% propan-2-ol was used at a flow rate 
of approximately 100 nl/min from a syringe pump (connected to a microtee (U p c h u r c h ) 
prior to the microionspray head), to improve stability of the spray in negative ion mode.
2.16.4 Peptide sequencing
The main objective of tandem mass spectrometry (MS/MS) is to gain structural 
information. Sequence information of a certain peptide is gained by its fragmentation 
into smaller peptides, which are subsequently analysed for their m/z. The 
fragmentation is achieved by exposing ionised peptides to an inert gas. Upon collision 
with the gas particles, the peptides undergo fragmentation, a process called collision 
induced fragmentation (CID). Figure 2.1 shows a schematic representation of the 
possible fragmentation of the peptide backbone. The nomenclature was proposed by 
Roepstorff (Roepstorff and Fohlman, 1984) and modified by (Biemann, 1990). Upon 
fragmentation of a peptide, the charge is retained either by the N- or the C-terminal
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side of the molecule. Fragments are named a, b, c in the first case and x, y, z in the 
latter case. In addition, amino acids such as Pro and carbamidomethylated Cys are 
prone to generate internal fragment ions. Internal fragments are the result of a double 
cleavage of the peptide backbone while the central part retains the charge.
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Figure 2.1: Labelling of fragment ions
Ion fragments formed through bond cleavages along the backbone of protonated linear 
peptides. The labelling of fragment ions in this study will be based upon the generally accepted 
nomenclature developed by (Biemann, 1990).
When phosphorylated peptides are fragmented under CID conditions, loss of 
phosphate is frequently the primary mode of fragmentation (Mann et al., 2002). This 
neutral loss of 80 (HP03) or 98 (H3P04) is due to a cleavage at either side of the 
phospho-ester bond. pSer and pThr readily loose phosphoric acid, H3P04, generating 
dehydroalanine and dehydroamino-2-butyric acid, respectively. pTyr cannot loose the 
phosphoric acid as that means disintegrating the aromatic ring, but it looses HP03. Due 
to the energy distribution of the aromatic ring, pTyr is more stable than pSer or pThr. 
Therefore, pTyr-peptide fragment ions are less abundant and more difficult to detect.
ESI precursor ions are multiply-charged with the distribution of charge states 
dependent upon both peptide structural properties and instrumentation parameters. 
Because MALDI ions are singly-charged for the most part, their fragmentation spectra 
are often dominated by signals arising from cleavage at the acidic residues and 
sometimes not enough information is present to establish the peptide sequence 
conclusively. For this reason, we mainly used ESI to perform MS/MS.
2.16.4.1 Data dependent acquisition
If unknown proteins were identified or primary analyses of post-translational 
modifications performed, data dependent acquisition using the Q-TOF was chosen. 
Data dependent acquisition allows for the automatic switching from MS to MS/MS 
experiments whenever an ion of pre-determined nature is detected. We usually set the 




2.16.4.2 Multiple reaction monitoring
By performing multiple reaction monitoring (MRM), the mass spectrometer is set 
to scan over a very small mass range, typically one mass unit. Only one or a few 
selected m/z (depending on the experimental set-up) are set for detection per run and 
subsequently chosen by the mass analyser for further fragmentation.
MRM was performed with the Q-TOF, Q-STAR or Q-TRAP. MRM was performed 
on potential phospho-peptide ions by calculating the precursor mass and daughter 
mass for the loss of HP04 (80 Da) from Tyr phosphorylated peptides. For the Q-TRAP 
instrument, the MRM builder script (MDS-Sciex) was used to calculate the precursor 
and daughter masses, along with the required collision energies. The 4000 Q-TRAP 
was run in positive ion mode with unit resolution in both Q1 and Q3 and the dwell time 
for each transition was set to 25 ms up to a total of 80 predicted Tyr phosphorylated 
peptide ions for a 2 s duty cycle.
MRM experiments were also performed for AQUA peptides and endogenous 
peptides. The required collision energy was determined empirically for the Q-TOF and 
Q-STAR, starting from 20 V for m/z = 300 up to 35 V for m/z = 1000. The scan time 
was set to 0.2 s and the interscan delay to 0.05 s.
2.16.4.3 Precursor-ion scanning on a 4000 Q-TRAP
In precursor-ion scanning, a parent ion that gives rise to the diagnostic fragment 
ions created by collisions in q2, is selectively detected in the third quadrupole (Q3) of a 
triple quadrupole instrument. For phosphopeptide analysis, scanning is performed in 
the negative ion mode. The first quadrupole is scanned over the full mass range and 
CID is induced in the second quadrupole filled with inert gas. The third quadrupole is 
set to detect the fragment ions of 79.
Precursor-ion scanning experiments are also possible with Q-TRAP instruments, 
in which Q3 is replaced by a linear ion trap. Precursor-ion scanning experiments in this 
thesis were performed on a 4000 Q-TRAP collaboration with Dr Nick Morrice, MRC 
Protein Phosphorylation unit, University of Dundee, Dundee. The following protocol 
was used:
Precursor-ion scanning was performed over a mass range of m/z 400-2000 at 
500 amu/s, with a ionspray voltage o f-2200 V applied to a Picotip FS360-50-15-N (N ew  
O b je c t iv e ) along with ionspray gas (nitrogen). Precursors were collided in q2 with a 
collision energy ramp of -65-110 V across the mass range. Once precursors of 79 were 
detected (with a minimum threshold of 2000 cps), the polarity was automatically 
switched to +2300V (after a 700 ms dwell at 0 V) with the same gas settings and a 
positive ion enhanced resolution scan was performed at 250 amu/s to determine the 
charge state of the ion. Enhanced product ion scans (MS/MS) were performed at 4000
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amu/s and collision voltages were calculated automatically. Once this duty cycle was 
completed, the polarity was switched back to negative (after a 700 ms dwell at 0 V) and 
the cycle repeated.
2.16.4.4 Absolute quantification
Absolute quantitation (AQUA) of endogenous protein by LC-MS can be achieved 
by comparing peak areas of endogenous peptide with those of known amounts of 
standard peptide possessing the same amino acid sequence (Barnidge et al., 2003; 
Barr et al., 1996; Gerber et al., 2003). In contrast to the endogenous peptide, the 
standard (=AQUA) peptide is synthesised using stable isotopes. While most 
biophysical properties of the endogenous and AQUA peptide are identical (e.g. the 
elution from RP-columns and ionisation potential), they differ in molecular weight and 
therefore in m/z. This difference is subsequently detected by MS and used to 
distinguish between the endogenous and the AQUA peptide. The work flow of a typical 
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Figure 2.2: Work flow of absolute quantitation (AQUA) MS
In a first step, endogenous peptides of the protein of interest detected by MS are selected for 
AQUA synthesis based on their detection frequency, amino acid sequence and non­
redundancy. In a second step, the isotopically labelled AQUA peptides are analysed for their 
elution profile from RP-columns, MS/MS-spectrum, detection limit and purity. In a third step, 
known amounts of AQUA peptides are spiked to protein samples. Endogenous and AQUA 
peptide are analysed by LC-MS or LC-MS/MS. Comparison of AQUA peptide peak areas with 




In a first step, suitable peptides of the protein of interest are selected. The 
selection is based on the frequency with which the peptide is detected in LC-MS/MS 
runs in different samples, on the quality of the MS/MS data, on the amino acid 
composition of the peptide (no Met, Cys and Try due to their chemical reactivity; no 
Asp-Gly, N-term Gin, N-term Asn due to their chemical instability), on its non­
redundancy and on the occurrence of the peptide in different species.
In a second step, the AQUA peptides are diluted in 0.1% formic acid to 10 
pmole/pl and subsequently analysed by MALDI and ESI for their molecular weight, 
purity, elution profile, and MS/MS spectrum.
In a third step, the AQUA peptides are spiked to the protein samples before 
trypsination (2.16.2) and analysed by LC-MS or LC-MRM. Integrated peak areas of 
endogenous and AQUA peptide were extracted by MassLynx (W a t e r s ) Quantify 
software.
2.16.5 Data mining
2.16.5.1 Peak list extraction of MS/MS data
The peak list was created by automatic extraction of all MS/MS data using 
ProteinLynx of Masslynx V4.0 software (M ic r o m a s s , W a t e r s ). The m/z peaks were 
centred using background subtraction (35% below the curve), smoothing (Savitzky 
Golay, 2 smoothings), and 80% percent of peak height for centroids. The output file 
was generated as a Micromass peaklist in a Mascot compatible file.
2.16.5.2 Database searches
All MS/MS spectra acquired in data-dependent acquisition, precursor-ion 
scanning or MRM mode were searched against public databases (NCBInr) using the 
Mascot search engine (M a t r ix s c ie n c e ) run on a local server. Sites of phosphorylation 
were assigned from manual interpretation of the MS/MS spectra viewed using 
Masslynx V4.0 software.
The following parameters were generally applied:
The chosen database was NCBInr, with the restriction of mus musculus as 
species. Up to 2 miss-cleavages were allowed after digestion with trypsin, adding 
carbamidomethylation of Cys as a fixed modification and N-acetylation of protein; 
oxidation of Met; phosphorylation of Ser, Thr, Tyr, and N-terminal pyro-glutamation as 
variable modifications. The precursor-ion mass and fragment ion mass accuracy were 
set to a tolerance of 100 ppm and 100 mmu, respectively.
If other modifications than phosphorylation were analysed, variable modifications 
were uploaded from the Mascot Webserver.
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2.16.5.3 Interpretation of MS/MS data output
Protein hits generated by MS/MS data were considered if the MOWSE score 
(Pappin et al., 1993) of a protein hit was above 40 and at least 2 peptides were 
identified.
Sites of phosphorylation were assigned from manual interpretation of the MS/MS 
spectra viewed using MassLynx V4.0 (M ic r o m a s s ).
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3 A  NEW TOOL TO PURIFY CLASS IA  P I3K
The aim of this study was to 1) investigate post-translational modifications of 
class IA PI3K and to 2) analyse the molar equilibrium between class IA PI3K regulatory 
and catalytic subunits using MS amongst other techniques. Protein identification by LC- 
MS/MS requires approximately 100 ng of protein following SDS-PAGE. Since the 
stoichiometry of protein phosphorylation is usually low, identification of post- 
translational modifications presupposes even more protein quantities. Therefore, 
efficient protein purification methods are required.
One possibility to enrich for proteins is the application of immunoprecipitation (IP) 
with protein-specific Abs. A variety of PI3K isoform-specific Abs was available at the 
host laboratory. However, protein purification by IP has disadvantages: first, large-scale 
IP can be limited by the restricted availability of Abs. And second, high purity of 
immunoprecipitates might not be ensured by using Abs due to Ab cross-reaction with 
unspecific proteins.
Another method to purify class IA PI3K is based on the interaction of the two SH2 
domains of the regulatory subunit of class IA PI3K with phosphorylated Tyr (pTyr) 
residues in the cytosolic domain of receptors. PI3Ks were first purified using 
immobilised full-length PDGF-receptor (Escobedo et al., 1991), which method was 
subsequently replaced by enrichment of the proteins with short, synthesised PDGF- 
receptor peptides containing pTyr residues known to be autophosphorylated in 
activated receptors and coupled to Actigel resin (Fry et al., 1992). Using restricted 
sequences of the PDGF-receptor instead of whole polypeptides allowed for a greater 
degree of specificity and higher density of affinity groups per unit volume of the column. 
The same study also showed that only peptides containing pTyr residues in YxxM- 
motifs were able to bind class IA PI3Ks. The potential binding sites of PI3K to the 
human PDGF-(3-receptor were further restricted to Y740 and Y751 (Klinghoffer et al., 
1996).
Because preliminary results obtained by incubation of cell lysate with synthesised 
PDGF-R-peptides of the sequence pYVPMLG coupled to Actigel did not reveal 
purification of pure and/or large quantities of class IA PI3Ks, we designed an 
alternative purification tool based on the interaction of the regulatory subunit with 
pYxxM-motifs. Three PDGF-receptor peptides of different lengths all containing at least 
Y751 of the human PDGF-p-receptor were generated (Figure 3.3; for general workflow 
see Figure 3.1). The constructs were cloned to the 3’ end of the glutathione S- 
transferase (GST) gene that was under the control of the tac promoter in the plasmid 
pGEX-4T-2 (A m e r s h a m  P h a r m a c ia  B io t e c h ). Plasmids containing the GST-tagged
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PDGF-p-receptor peptide were subsequently transformed into the E. coli strain TKB1 
( S t r a t a g e n e ) ,  which carries a plasmid-encoded, inducible Tyr kinase gene. Following 
induction of PDGF-receptor-peptide and Tyr kinase gene expression by IPTG, Tyr 
residues in the PDGF-receptor peptide were phosphorylated by the Tyr kinase. The 
phosphorylated GST-PDGF-receptor peptides were then affinity purified using 
glutathione sepharose beads. Murine cell extract was added to the GST-PDGF- 
receptor peptide-beads (further referred to as ‘pTyr-matrix’), and class IA PI3K was 
purified by interaction of the regulatory subunit with the pTyr residues of the GST- 
PDGF-receptor peptides in the pTyr-matrix. Below, we describe the cloning and 
biochemical assessment of the 3 GST-PDGF-receptor-peptides.
A Bacterial growth
Induction of gene 
expression by IPTG
Cell lysis and addition of 
glutathione sepharose beads
Addition of murine cell lysate 
containing class IA PI3Ks
IPTG
TKB1 chromosome containing T7 RNA  






Figure 3.1: Workflow of class IA PI3K purification
(A) Bacterial strains BG6, BG7, BG8 containing different PDGF-receptor peptide lengths were 
grown and (B) expression of GST-PDGF-peptide and Tyr kinase induced by addition of IPTG. 
(C) Glutathione sepharose beads were incubated with the bacterial cell lysate allowing for 
binding of the PDGF-receptor peptide to the beads via its GST-tag. (D) The pTyr-matrix was 
combined with cell lysate. Class IA PI3Ks were purified by binding of the regulatory subunit to 
the pTyr residues of the GST-PDGF-receptor peptides.
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3.1 Cloning the GST-PDGF-receptor peptides
Previous experiments with biotinylated, phosphorylated PDGF-receptor peptides 
have indicated that PDGF-receptor peptides of short length (6 amino acids) might not 
allow access of the regulatory subunit SH2 domains to the pTyr residue lying in 
proximity of the biotin-tag, and long PDGF-receptor peptides (24 amino acids) might 
cause peptide aggregation (G. Panayotou, unpublished work).
Therefore, we chose to generate constructs containing PDGF-receptor peptides 
with three different lengths, called prp1 (PDGF-receptor peptide 1), prp2, and prp3 
(peptide and nucleotide sequence provided in Table 3.1).
Nucleotide sequences corresponding to the peptide sequences were designed 
containing a Narl restriction site (which was later used to confirm correct insertion of 
the nucleotide sequence into the plasmid, see Figure 3.3) and a 5’ EcoRI and 3’ Sail 
overhang, respectively, to allow ligation with an EcoRI and Sail digested pGEX-4T-2 
plasmid. The respective oligonucleotides were annealed to their complementary 
sequences as described in § 2.8.2.2.
Table 3.1: Peptide/nucleotide sequences of the 3 PDGF-receptor peptide constructs
Tyr residues in the YxxM-motifs of the PDGF-receptor peptide are underlined. 5’ EcoRI 
overhang and 3’ Sail overhang of the nucleotide sequences are shown in italics. The Narl 
restriction site is drawn in bold. The resulting TKB1 strains were called BG6, BG7, and BG8.





a att tat gtg ccg atg ctg ggc ggc gcc





a att ggt ggc tac atg gac atg age aag gac gag tct 
cca ccg atg tac ctg tac teg ttc ctg etc aga 
gtg gac tat gtg ccg atg ctg ggc gcc 





a att ggt ggc tac atg gac atg age aag gac gag tct 
cca ccg atg tac ctg tac teg ttc ctg etc aga 
gtg gac tat gtg ccg atg ctg ggc gcc 
cac ctg ata cac ggc tac gac ccg egg age t
In parallel, the plasmid pGEX-4T-2 (Amersham Pharm acia B io te c h ) was restriction 
digested with EcoRI and Sail (1.8 pmol plasmid, 4 //I of each restriction enzyme, 10//I 
restriction buffer, made up in 100 jj\ ddH20) for 3 h at 37°C as described in § 2.8.2.1. 
pGEX-4T-2 contains the GST gene under the control of a tac promoter (a strong hybrid 
promoter composed of the -35 region of the trp promoter and the -10 region of the 
lacUV5 promoter/operator), a multiple cloning site at the 3’ end of the GST gene, the 
Amp resistance gene p-lactamase and the lacl repressor gene (see Figure 3.3). GST
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belongs to a family of multifunctional enzymes present in all living organisms whose 
main function is the detoxification of electrophilic compounds, but is used in molecular 
biology as a protein tag because of its ability to interact in a high-affinity binding with 
the glutathione tripeptide (ECG) coupled to sepharose (Smith and Johnson, 1988).
The digested plasmid DNA was resolved by electrophoresis in a 0.9% agarose 
gel and the desired plasmid fragments purified from the gel using the S ig m a  QIAquick 
Gel Extraction Kit. The annealed oligonucleotides prp1, prp2, and prp3 were 
subsequently ligated into the restricted vector pGEX-4T-2 using 3 different insert-to- 
vector ratios (350/1, 35/1, 3.5/1). One sample containing no insert was used as a 
negative control. Ligation was performed as described in § 2.8.2.2.
In order to confirm insertion of the oligonucleotides into pGEX-4T-2 (the resulting 
constructs were called gprpl, gprp2, and gprp3 on plasmid pBG1, pBG2, and pBG3), 
the ligation mix was transformed into 100 jj\ competent XL1-blue E. coli cells 
(S t r a ta g e n e )  using 10 //I of ligation mix (samples and negative control) and 1 //I of 
pGEX-4T-2 as a positive control as described in § 2.8.3 and plated onto Amp- 
containing LA-plates. 5 colonies of each construct were picked, dipped into 100 j j \ 
Amp-containing LB in eppendorf tubes and streaked out on Amp-containing LA-plates. 
The eppendorf tubes were incubated for 2 h at 37°C with shaking and then boiled at 
100°C for 5 min. 5 j j \ of the culture were added to a PCR mix containing the 5’- and 3’- 
pGEX sequencing primers (A m ersham  P h arm ac ia  B io te c h ) and the PCR reaction was 
performed as described in § 2.8.4. 10 //I of the samples was analysed by gel 
electrophoresis at 100 V for 5 h in a 4% NuSieve gel (§ 2.8.1.3). As shown in Figure 
3.2, the expected PCR products of 202 bp for pBG1, 238 bp for pBG2, and 256 bp for 





Figure 3.2: Confirmation of correct insertion of prp1, prp2, prp3 into pGEX-4T-2 by 
NuSieve gel electrophoresis
After transformation of pBG1, pBG2, pBG3 (the three pGEX-4T-2 plasmids containing prp1, 
prp2, prp3) into competent E. coli cells (XL1-blue), 5 colonies resulting from each transformation 
and 1 colony of the vector only positive control (sample #16) were subjected to PCR with 5’- and 
3’-pGEX sequencing primers. The PCR products were analysed after electrophoresis for 5 h at 
100 V on a 4% NuSieve agarose gel and corresponded to the expected sizes of 202 bp for 
sample #1-5 (pBG1), 238 bp for sample #6-10 (pBG2), and 256 bp for sample for #11-15 
(pBG3). A low range marker (M) was used to determine the relative size of the PCR products.
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Plasmids were extracted from two colonies of each construct containing the insert 
(colony #1 and #3 of the pBG1 construct, #6 and #8 of pBG2, and #13 and #15 of 
pBG3) by using the small-scale preparations of plasmid DNA method (§ 2.8.1.1). A 
restriction digest was performed with Narl to confirm correct insertion. The two Narl 
restriction sites of pBG1, pBG2, and pBG3 are shown in Figure 3.3. Two resulting 
nucleotide fragments of the expected sizes 3130 bp and 1870 bp were detected in all 
restricted plasmids after agarose gel electrophoresis (data not shown). Each of the two 
plasmids was subsequently sequenced using 5’- and 3-pGEX sequencing primers. 
Plasmids of colony #1, colony #6 and colony #15 contained perfect sequences (data 
not shown) and were further used. The three XL1-blue strains containing these 
plasmids were called BG1, BG2, and BG3.
pBG1, pBG2 and pBG3 were transformed into the competent E. coll TKB1 strain 
(S t r a t a g e n e ) according to the manufacturer’s protocol. TKB1 is a BL21 E. coli strain 
that harbours the gene for T7 RNA polymerase in the chromosome under the control of 
the lacUV5 promoter and also carries a plasmid-encoded, inducible Tyr kinase gene.
In order to verify correct transformation, the plasmids of the transformed colonies 
were analysed by PCR, Narl restriction digestion and DNA sequencing as described 
above (data not shown). The TKB1 strains containing perfect sequences of pBG1, 
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Figure 3.3: Schematic drawing of the cloning procedure leading to TKB1 strains BG6, 
BG7, and BG8
(1A) The nucleotide sequences of three different PDGF-receptor peptides all containing at least 
one YxxM-motif were annealed and (1B) the plasmid pGEX-4T-2 restriction digested with EcoRI 
and Sail. (2) The 3 constructs prp1, prp2 and prp3 were ligated to the 3’ end of the GST gene in 
pGEX-4T-2 leading to plasmids pBG1, pBG2 and pBG3. (3) The constructs were subsequently 
transformed into TKB1, an E. coli strain carrying an inducible Tyr kinase gene, leading to 
bacterial strains BG6, BG7, and BG8.
3.2 Assessment of optimal conditions to prepare pTyr- 
matrix
Before analysing the ability of the affinity system to purify class IA PI3K, we 
investigated the optimal conditions to prepare pTyr-matrix. First, induction of 
expression and phosphorylation of the GST-PDGF-receptor peptides (Figure 3.4) and
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in a second experiment binding of GST-PDGF-receptor peptides to glutathione 
sepharose beads (Figure 3.5) were assessed.
The expression of the GST-PDGF-receptor peptides as well as of the Tyr kinase 
was induced in BG6, BG7 and BG8 by addition of IPTG to the culture medium. 
Expression of T7 RNA polymerase in TKB1 strains containing GST-tagged PDGF-(3- 
receptor peptides was repressed under normal culture conditions by the Lacl protein 
that binds to the lac promoter. Upon addition of the (3-galactosidase isopropyl-beta-D- 
thiogalactopyranoside (IPTG) to the medium, IPTG binds to the Lacl repressor and 
inhibits its interaction with the lac promoter. T7 RNA polymerase expression occurs 
and controls protein expression of genes placed downstream of the T7 RNA 
polymerase binding sites, which was in TKB1 the plasmid-encoded Tyr kinase gene. 
Additionally, Lacl inactivation by IPTG led in our system to the expression of the 
transformed GST-PDGF-receptor peptide. Its Tyr residues were subsequently 
phosphorylated by the Tyr kinase.
The manufacturer’s protocol (S t r a t a g e n e ) was used as a guideline. Briefly, 3 ml 
Tet- and Amp-containing LB medium was inoculated with BG6, BG7, or BG8 and the 
cells were grown overnight at 37°C. The bacterial suspension was diluted 1:15 the 
following day. After 1 h of growth, a sample was removed as uninduced control and the 
expression and phosphorylation of the GST-PDGF-receptor peptides was induced by 
addition of IPTG (end concentration 0.4 mM). The culture was further incubated at 
37°C for 3-4 h.
Protein expression of all three GST-PDGF-receptor peptides was highly induced 
after 3 h of IPTG addition (Figure 3.4.A) as determined after resolving protein of BG6, 
BG7, and BG8 whole cell lysates minus or plus 0.4 mM IPTG on a 15% SDS 
polyacrylamide gel and staining the protein with Coomassie blue. The shift in protein 
motility of the different constructs in the 15% SDS polyacrylamide gel corresponds to 
the moderate difference in size between the 3 constructs with theoretical molecular 
weights of 27.7 kDa, 28.9 kDa and 29.7 kDa.
In order to analyse the induction of Tyr phosphorylation of the GST-PDGF- 
receptor peptides, proteins of whole cell lysates of BG6, BG7, and BG8 minus IPTG 
and 1, 2 and 3 h after IPTG stimulation were separated on a 15% SDS-polyacrylamide 
gel. The proteins were transferred to a PVDF membrane and analysed for Tyr 
phosphorylation by immunoblottig using pTyr Ab 4G10 (§ 2.3). As shown in Figure
3.4.B, induction of GST-PDGF-receptor peptide phosphorylation was very efficient. 
After 1 h, peptide phosphorylation, which was not completely abolished in uninduced 




We could not detect any major difference in the capacity to be expressed or 
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Immunoblot analysis with phospho-Tyr antibody
Figure 3.4: GST-PDGF-receptor peptide expression (A) and phosphorylation (B) are 
greatly induced after IPTG addition to bacterial cell culture medium
(A) Proteins of whole cell lysates of approximately 6x10® BG6, BG7, BG8 cells were analysed 
on a 15% SDS polyacrylamide gel before and after IPTG induction. Proteins were detected by 
Coomassie staining. (B) Proteins of BG6, BG7, and BG8 cell lysates treated without or with 
IPTG for the indicated times were resolved on a 15% SDS polyacrylamide gel, transferred to a 
PVDF membrane and subjected to immunoblotting with the pTyr Ab 4G10. Each sample 
contained approximately 6 x 107 cells.
In order to determine the binding capacity of the GST-PDGF-receptor peptides to 
glutathione sepharose beads, we performed a titration experiment. The three strains 
BG6, BG7, BG8 were grown and GST-PDGF-receptor peptide expression and 
phosphorylation induced as described above. After 4 h of IPTG induction, the cells 
were harvested, resuspended in PBS containing 1 mg/ml lysozyme and inhibitors 
(R o ch e , complete tablet) and sonicated in order to break open the cell walls. The cell 
lysate was centrifuged to clear it from debris, the protein concentration determined, and 
a sample of total cell lysate (TCL) removed for analysis. 0.4 mg of total bacterial protein 
of each strain was incubated with increasing volumes of glutathione sepharose beads 
(50, 100, 200 /j \ ) for 2 h at 4°C. After incubation, the glutathione sepharose beads were 
harvested by centrifugation and the same volume of unbound fraction (supernatant, 
SN) was compared to TLC by immunoblotting with pTyr Ab after the proteins in 
samples TCL and SN were resolved by SDS-PAGE and transferred to PVDF 
membrane. As shown in Figure 3.5, the phosphorylated GST-PDGF-receptor peptide 
amount contained in the unbound fractions decreased with increasing glutathione 
sepharose bead volumes for each strain. 50 jj\ of glutathione sepharose beads bound 
approximately 2/3 of phosphorylated GST-PDGF-receptor peptides in 0.4 mg total 
bacterial protein, whereas 200 /yl of glutathione sepharose beads was capable of 
interacting with at least 3/4 of phosphorylated GST-PDGF-receptor peptides. However,
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even 200 /yl sepharose beads did not bind all GST-PDGF-receptor peptides in 0.4 mg 
total bacterial protein. Since the aim of developing the pTyr-matrix was to enrich for as 
much class IA PI3K as possible, the ratio ensuring complete saturation of sepharose 
beads with GST-PDGF-receptor peptides (200 j j \ packed beads for 0.4 mg bacterial 
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Figure 3.5: Titration experiment assessing the binding capacity of sepharose beads to 
GST-PDGF-receptor peptides
BG6, BG7, BG8 treated with IPTG were lysed and the protein lysate corresponding to 0.4 mg 
total protein incubated with 50, 100, and 200 / j \ glutathione sepharose beads. The total cell 
lysate (TCL) and unbound fraction (SN) samples containing the same volume were resolved on 
a 15% SDS polyacrylamide gel, transferred to a PVDF membrane and analysed with the pTyr 
Ab 4G10. For BG8, only unbound fractions of 50 and 100 //I were analysed.
3.3 Optimal ratio of  pTyr-matrix to p110S protein
As demonstrated in the previous two experiments, the induction of expression, 
phosphorylation and the binding to glutathione sepharose beads were similar for the 
three different GST-PDGF-receptor peptide constructs. In order to reduce the 
complexity of the experiments, we decided to perform the assessments of how much 
pTyr-matrix was needed to deplete PI3K from murine lysate with BG7 alone. BG7 is the 
TKB1 strain possessing the medium sized PDGF-receptor peptide. Since we were 
mainly interested in p1105, we analysed the pull-down capacity of the pTyr-matrix 
towards this class IA PI3K isoform.
For this purpose, 5 mg total protein of WEHI-231 B cell lysate (§ 2.10) was 
incubated with 0.2 ml and 0.5 ml pTyr-matrix, respectively, for 3 h at 4°C. After 
incubation, the sepharose beads were harvested and washed four times with lysis 
buffer plus inhibitors. The proteins of total cell lysate (TCL), unbound fraction (SN), 
wash fraction (W) and bound fraction (PD) were separated by SDS-PAGE, transferred 
to a PVDF membrane and analysed with a C-terminal p1105 Ab by immunoblotting.
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A small amount of free p1105 could be observed in SN if 0.2 ml glutathione pTyr- 
matrix was added to 5 mg B cell lysate (Figure 3.6.A), whereas most p1105 bound to 
the glutathione sepharose beads if 0.5 ml pTyr-matrix was used (Figure 3.6.B). Equal 
amounts of cell lysate were loaded onto the SDS polyacrylamide gel in the TCL and SN 
sample, whereas three times more volume was loaded in the wash sample (W).
SN PDTCL
Figure 3.6: The majority of p1105 protein in 5 mg WEHI-231 cell lysate was bound by 0.5 
ml pTyr-matrix
5 mg total protein of WEHI-231 cell lysate was incubated with 0.2 ml (A) or 0.5 ml (B) pTyr- 
matrix. Proteins in total cell lysate (TCL), unbound fraction (SN), wash fraction (W), and bound 
fraction (PD) were separated on a 8% SDS polyacrylamide gel, transferred to a PVDF 
membrane and analysed by immunoblotting using CT-p1108 Ab. Same volumes of TLC and SN 
were loaded. Three times more W and 5 times more PD were loaded per lane.
3.4 Identification of proteins affinity purif ied by pTyr-  
matrix
After adaptation and improvement of the most important steps in the purification 
procedure, we separated the proteins bound to the pTyr-matrix by gel electrophoresis 
and analysed the protein content by colloidal Coomassie blue staining. 1 ml of pTyr- 
matrix was incubated with 4 mg induced bacterial protein and 12 mg WEHI-231 lysate 
was added. Two distinct bands at Mr 110 kDa and 85 kDa were detected. However, 
many additional protein bands were also observed (data not shown).
It has previously been shown that the interaction between endogenous p85 and 
phosphorylated PDGF-receptor is of high affinity (Escobedo et al., 1991) and that the 
interaction is resistant to treatment with solutions containing 2 M NaCI plus 0.5% Triton 
X-100, 5 M NaCI, 6 M urea, 50 mM pTyr or up to 1 mg of free Y751 phosphopeptide 
(Fry et al., 1992). We therefore incubated the pTyr-matrix binding p85/p110 with 1 x 
lysis buffer containing 5 M salt. This additional wash step reduced unspecific binding of 
proteins to the pTyr-matrix.
As shown in Figure 3.7.A, four major protein bands were detected on a SDS 
polyacrylamide gel after staining with colloidal Coomassie blue when class IA PI3Ks 
were purified using the pTyr-matrix generated in BG7. The proteins were cut from the 
gel, reduced, alkylated, subjected to tryptic in-gel digestion and analysed by LC-MS/MS 
(§ 2.14, § 2.16). Blasting the sequencing information gained from a full-scan acquisition
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against the NCBI database NCBInr using the Mascot program ( M a t r i x s c i e n c e )  led to 
the identification of the following proteins: The protein detected at Mr of 110 kDa was 
identified as p110(3 and p1105, the protein band labelled #2 contained p85a and p85p, 
protein band #3 was identified as member of the Hsp70 family (see also Table 5.1) and 
protein band #4 was elongation factor-1y (see also Table 5.1). In Figure 3.7.B, the 











Identified protein Probability Sequence
coverage
#1 p1105 2e-37 8%
p110(3 3e-5 1%
#2 p85a 1e-56 22%
p85p 1e-25 8%




Figure 3.7: Identification of class IA PI3Ks by LC-MS/MS after pTyr-matrix pulldown
(A) Proteins pulled down by the pTyr-matrix from WEHI-231 cell lysates were separated by 
SDS-PAGE and stained with colloidal Coomassie blue. The 4 major bands were cut from the gel 
and the proteins reduced, alkylated, tryptic in-gel digested and subjected to LC-MS/MS. 
Recombinant class IA PI3K was loaded onto the gel as a control. (B) The table lists the proteins 
identified by MS, the significance of the obtained MS results and the percentage of sequence 
coverage for each protein.
3.5 Discussion
Here we present a new class IA PI3K purification tool. It is based on the 
interaction of phosphorylated YxxM-motifs located in the cytosolic domain of the 
PDGF-receptor with the two SH2 domains of the regulatory subunit of PI3K. Instead of 
using synthesised, phosphorylated PDGF-receptor peptides, which were not successful 
for large-scale purification in our hands, we developed a bacterial system that is 
expressing and phosphorylating these PDGF-receptor peptides linked to GST protein. 
The construct can subsequently be purified with glutathione sepharose from bacterial 
lysate and be incubated with eukaryotic cell lysate to enrich for class IA PI3K.
Because it had previously been reported that short YxxM-containing peptides 
might be less able to recruit p85 and long YxxM-containing peptides seem to possess a 
low solubility, we generated three PDGF-receptor peptides of different lengths. These 
constructs were analysed in parallel for their protein expression level, their ability to
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become Tyr phosphorylated and their binding capacity to glutathione sepharose. The 
constructs performed equally in these experiments.
MS analysis of the four major protein bands pulled down by the pTyr-matrix led to 
the identification of class IA PI3K. However, p110a was not identified in the 110 kDa 
protein band and it was also not possible to detect a protein band at 50-55 kDa 
corresponding to p55a, p50a and p55y following Coomassie staining of protein gels. 
These results indicate that p110a and the small regulatory subunits do not occur in 
similar concentrations as p110p/p1108, and p85a/p85p, respectively in WEHI-231 cells 
or that the pTyr-matrix does not possess similar binding affinities towards the different 
class IA PI3K subunits. Since MS identification of p110a, p55y, p55a, and p50a was 
also less well achieved after IP experiments with different Abs raised against class IA 
subunits (see § 4.7.1), we conclude that these subunits might not be as highly 
expressed as p110p, p1108, p85a and p85(3 in WEHI-231 cells.
Two non-PI3K proteins were also identified by MS. Hsp70, member of the Hsp70 
chaperone family, was detected by LC-MS/MS as a protein band running at Mr 70 kDa 
in SDS polyacrylamide gels. However, this protein was also detected in anti-p1108 and 
anti-p85 immunoprecipitates, in immunopurifications performed with mixed anti-mouse 
immunoglobulin G from the IgG fraction of rabbit antiserum, and in pull-downs 
performed with the synthesised PDGF-receptor peptides coupled to actigel (data not 
shown). These findings suggest that rather than interacting with class IA PI3K, Hsp70 
most probably binds the agarose contained in the matrix used for IP and pull-downs. 
The second cross-contaminating band was identified as elongation factor-1 y. This 
protein was also identified by LC-MS/MS in an anti-p1108 IP experiment and in pull- 
downs with sepharose beads only (Table 5.1). This suggests that elongation factor-1y 
cross-reacts with the agarose, excluding specific binding to class IA PI3K.
The advantages of the new purification tool are manifold: it is cheaper than using 
synthesised, phosphorylated peptides, independent of outside resources for production 
and an infinite source compared to Abs. This purification tool can in theory enrich for all 
class IA PI3K. This attribute can be an advantage if an overall analysis is performed 
(as in absolute quantitation experiments, see chapter 6) or a disadvantage if single 
subunits are preferred for analysis (chapter 5). Further minor disadvantages of the new 
purification system over established class IA PI3K subunit enrichment methods are the 
increased volume of sepharose beads needed leading to increased working volume 
and cross-contaminating proteins and the increased expenditure of time compared to 
immunopurification (but not compared to enrichment by synthesised peptide which is 
also a two-day protocol).
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In summary, the pTyr-matrix provided an enrichment method independent of IP 
and we successfully applied it for the enrichment of class IA PI3K in several different 
projects of this thesis.
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4 In v e s tig a tio n  o f  p o s t -tr a n s l a t io n a l  m o d if ic a t io n s  in 
THE REGULATORY SUBUNITS OF CLASS IA PI3KS
Very few, if any, known proteins are merely the simple polymer of the basic 20 
primary amino acids but instead contain post-translational modifications. Such 
modifications have been shown to impact on the biophysical properties of proteins, 
such as enzymatic activity, protein-protein interaction, protein stability and subcellular 
localisation, leading amongst others to changes in their functions. In signalling 
pathways, reversible changes in protein modifications, and thus reversible changes in 
protein functions, allow for transmission and amplification of signals and subsequent 
return to basal state after a signal has passed through the cascade. Protein 
phosphorylation is one of a few post-translational modifications which are reversible 
due to the concerted action of protein kinases and phosphatases and therefore play an 
important role in the regulation of signalling molecules.
Phosphorylation of class IA PI3K regulatory subunits on Ser, Thr and Tyr 
residues upon different stimuli and in different cell types has been described (more 
information is provided in § 1.3.4.2). In order to gain insight into the regulation of class 
IA PI3K activity, we investigated post-translational modifications, in particular protein 
phosphorylation of the regulatory and catalytic subunit. In this chapter, we report on 
results obtained from analysis of p85 modifications and in chapter 5, post-translational 
modifications and their possible impact on PI3K function of the catalytic subunit p1108 
will be described.
Only six of many reported p85 phosphorylations have been assigned to specific 
residues in the regulatory subunit p85a (Tyr368, Tyr508, Tyr580, Tyr607, Ser608, 
Tyr688), and one each in the regulatory subunits p85p (Tyr458) and p55y (Tyr341). 
The biological relevance of these phosphorylation sites is often controversial or has not 
been investigated. Most of the work performed to gain insight into these 
phosphorylation events has been undertaken with recombinant p85a and not on 
endogenous protein. In addition, modifications other than phosphorylation have barely 
been investigated.
We set out to analyse post-translational modifications of endogenous regulatory 
subunit in the murine immature B cell line WEHI-231. Different electrophoretic and 
mass spectrometric methods were applied to investigate post-translational 
modifications in p85 in unstimulated and stimulated cells, the nature of these 
modifications and the amino acid residues involved. We observed that a variety of 
modifications existed in p85a of proliferating, but unstimulated WEHI-231 following 
separation of PI3K on 2D-gels, whereas p85(3 appeared not to be modified. Further
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analysis by immunoblotting and MS revealed that a fraction of these modifications was 
due to protein phosphorylation in general, and phosphorylation of Y688 in particular. 
Performing MS, we also detected p85a amino acid residues that underwent protein 
hydroxylation and amino acid substitutions. We could further demonstrate that the 
observed modifications in p85a were not restricted to B cells since a similar p85 
modification pattern could be observed in different cell types. Some of these 
modifications in p85a seemed to minor impact binding of p85 to the catalytic subunits. 
Interestingly, physiological stimulation of B cells leading to BCR crosslinking did not 
change the variety of modifications observed following 2D-analysis. Only treatment of 
cells with okadaic acid or pervanadate, two potent inhibitors of protein phosphatases 
increased protein phosphorylation. These findings indicate that p85a is extensively 
modified in proliferating cells, but these modifications do not seem to be crucial for 
changes in the lipid kinase activity observed following cellular stimulation of B cells.
4.1 2D-PAGE analysis reveals post-translational 
m odifications of the regulatory subunit in 
proliferating B cells
2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) is a powerful 
technique to (1) separate post-translationally modified proteins from their non-modified 
or differentially-modified counterparts allowing for the analysis of their stoichiometry, (2) 
compare their existence in different experimental set-ups, and (3) enrich for certain 
post-translationally modified protein forms (herein called ‘protein species’).
2D-PAGE of proliferating NIH-3T3 fibroblasts has revealed multiple p85 protein 
spots, indicative of post-translational modifications in the regulatory subunit (Cohen et 
al., 1990). We therefore investigated whether post-translational modifications could be 
detected by 2D-PAGE in proliferating WEHI-231 cells. For this purpose, total cell lysate 
of WEHI-231 cells was subjected to isoelectric focusing (IEF) using immobilised pH 
gradient (IPG) strips. After SDS-PAGE of lEF-separated proteins, electroblotting was 
performed and the proteins analysed by immunoblotting using different Abs against the 
regulatory subunits (Figure 4.1).
Multiple p85a spots were detected using a p85a mAb (U10), as well as 1 p85p 
spot using a combination of two p85(3 mAbs (T12 and T15) in two independent 
experiments. We also utilised 2 Abs that recognise both p85a and p85p (U2 mAb and 
p85pan polyclonal Ab (pAb)), which allowed for detection of 4 main protein spots and 
depending on the Ab for additional minor protein spots on 2D-immunoblots. A similar 
variety of p85 protein spots could be detected by p85pan Ab if the regulatory subunits 
were immunopurified using either p85 (data not shown) or p1108 Abs (Figure 4.2).
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These results suggested that differentially modified p85a and to a lesser extent 






U2 p85a ♦ U 10
T12/T15 41 p85(3 # T12/T15
p85pan * m p85pan m p85pan
PH 3 91 3 8
Figure 4.1: p85a protein is extensively modified in unstimulated WEHI-231 B cells
WEHI-231 total cell lysate was resolved by 2D-PAGE and p85 subsequently analysed by 
immunoblotting using p85-specific Abs. U10: mAb against p85a; T12 and T15: mAbs against 
p85(3; U2: mAb recognising p85a/p85p. p85pan: pAb against p85a/p85p. Sections of two 
independent 2D experiments are shown.
4.2 T re a tm e n t  w ith  o kada ic  acid a l te rs  the  
p h o s p h o ry la t io n  sta te  of c lass IA P I3K  re g u la to ry  
su b u n its ,  in c o n tra s t  to s t im u la t io n  w ith  a - Ig M
In order to investigate the nature of the p85 modifications observed following 20- 
PAGE from proliferating WEHI-231 cells, we compared the phosphorylation status of 
the regulatory subunit from unstimulated and stimulated B cells. Thus, WEHI-231 cells 
were treated with a-IgM or okadaic acid (OA).
Treatment of B cells with a-IgM leads to crosslinking of the B cell antigen 
receptor (BCR). This induces a complex signalling cascade in B cells, resulting in the 
phosphorylation of predominantly Tyr residues in proteins and activation/deactivation of 
many downstream targets, amongst others class IA PI3K (see § 1.7.1). OA is a potent 
inhibitor of protein phosphatase 1 (PP1) and PP2A, which account for the majority of 
phosphatase activity in the cytosol (Cohen, 1989). Treatment of cells with OA leads to 
the accumulation of pSer and pThr residues.
Analysis of the incorporation of phosphate groups into the class IA PI3K 
regulatory subunit was performed by immunoblotting using phospho-specific Abs 
following IP and separation of the proteins by 2D-PAGE. In order to monitor successful 
cellular stimulation, the increase in pSer473 and/or pThr308 of Akt, a key downstream 







Figure 4.2: The regulatory subunit becomes phosphorylated following OA treatment, but 
not upon a-IgM stimulation of B cells.
Class IA regulatory subunits were immunoprecipitated from control, a-lgM-stimulated or OA- 
treated WEHI-231 cells using p1105 Ab followed by analysis for pSer608, pThr and pTyr by 
immunoblotting.
As shown in Figure 4.2, p85 seemed to be phosphorylated on Thr residues in 
unstimulated cells. BCR crosslinking did not induce changes in the Thr phosphorylation 
of p85. These findings are in line with results from 1 D-experiments (data not shown). 
Following OA treatment of cells, an increase in Ser608 and a minor shift in Thr 
phosphorylation was detected by immunoblotting with phospho-specific Abs. The 
pattern of Ser608 phosphorylation following OA treatment indicates not only an 
increase in Ser608 phosphorylation, but possibly also in other modifications not 
detected with the phospho-specific Abs.
These findings indicate that BCR stimulation does not induce phosphorylation of 
the regulatory subunit in contrast to OA. Furthermore, residual Thr phosphorylation of 
p85 detected in unstimulated cells might possibly constitute some of the modifications 
detected by 2D-immunoblotting with p85 Abs.
4.3 Only a f ra c t io n  of the p o s t - t ra n s la t io n a l  
m o d if ica t io n s  o b s e rv e d  in c lass  IA P I3K  re g u la to ry  
su b un its  are due to pro te in  p h o s p h o ry la t io n
Since the analysis of protein phosphorylation by immuoblotting crucially depends 
on the quality and specificity of the phospho-specific Abs used for detection, we 
compared the regulatory subunit protein spot pattern detected by Abs to the regulatory 
subunit before and after in vitro dephosphorylation of immunoprecipitated proteins.
This was carried out by in vitro treatment of immunoprecipitated regulatory 
subunit with calf intestine alkaline phosphatase (CIAP). Ser608 phosphorylation of 
p85a was used as a positive control for the efficacy of CIAP, and cells were therefore
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first treated with OA. After cell lysis and IP, half of the immunopurified protein sample 
was subjected to CIAP treatment, whereas the other half was kept as untreated control. 
Two-thirds of the proteins of each sample (- and + CIAP) were subsequently separated 
by 2D-PAGE, transferred to a PVDF membrane and the protein spot analysed for the 
regulatory subunit by immunoblotting. The remaining one-third of each sample was 
used for the determination of the efficacy of dephosphorylation by analysis of Ser608 












Figure 4.3: p85 protein spots detected on 2D-immunoblots are only partially due to 
protein phosphorylation
The regulatory subunit was enriched from WEHI-231 cells by immunopurification using a 
mixture of 4 mAb to p85a and p85p, followed by in vitro dephosphorylation using calf intestine 
alkaline phosphatase (CIAP). (A) 2/3 of the immunocomplex was separated by 2D-PAGE, 
transferred to a PVDF membrane and analysed for the regulatory subunit by immunoblotting. 
Arrows are used to indicate p85 protein spots. Green arrows show a decrease, red arrows an 
increase and black arrow indicate similar p85 protein amounts in the + CIAP compared to the -  
CIAP sample. (B) 1/3 of the immunocomplex was separated by 1D-SDS-PAGE, transferred to 
PVDF membrane and analysed for pSer608 of p85a by immunoblotting.
As shown in Figure 4.3.A, dephosphorylation of some p85 spots occurred upon 
CIAP treatment. When the 4 main p85 protein spots are compared in both samples, a 
shift in protein spot distribution from acidic to basic pi can be detected in the 
dephosphorylated versus non-treated protein sample, leading to the most prominent 
spot being the most basic one. However, approximately half of the protein spots 
(indicated by black arrows in Figure 4.3.A) seemed to be only partially affected or 
unaffected by phosphatase treatment, suggesting that protein modifications other than 
phosphorylation exist in the regulatory subunit. As shown in Figure 4.3.B, 
dephosphorylation of Ser608 occurred under the chosen conditions, indicating 
successful in vitro protein dephosphorylation.
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We therefore conclude that the modifications observed in proliferating B cells are 
potentially due to protein phosphorylation, but also to other protein modifications.
4.4 Post-translational m odifications in class IA PI3K  
regulatory subunits  detected by 2D-PAGE are not 
subject to regulation by physiological stim ulation
Reversible protein modifications other than phosphorylation (such as 
hydroxylation, acetylation, carboxylation, sulfation, nitration) have been implicated in 
inducing changes in protein activity, interactions, localisation upon cellular stimulation. 
In order to analyse whether p85a modifications changed following cellular stimulation, 
we compared the p85 spot pattern detected by 2D-immunoblotting using p85 Abs of 
proliferating cells with a-IgM, OA and pervanadate treated WEHI-231 cells. 
Pervanadate (pV) is a potent Tyr phosphatase inhibitor (Fantus et al., 1989; Huyer et 
al., 1997).
Analysis of the regulatory subunit by Abs directed to p85a or p85(3 or both 
isoforms was performed on unstimulated and stimulated cells separated by 2D-PAGE. 
2 independent experiments were performed (Figure 4.4). p85(3 extracted from total cell 
lysate was analysed using the T12 and T15 mAbs. Cellular stimulation with a-IgM or 
treatment of WEHI-231 cells with OA did not alter the p85{3 protein spot pattern as 
compared to unstimulated samples. Only upon pV treatment, a second p85p protein 
spot became visible, suggesting modification of this regulatory subunit (Figure 4.4.A). 
However, since the protein shift was towards a more basic pH, modifications causing 
more acidic proteins such as phosphorylation, acetylation, carboxylation, hydroxylation, 
sulfation or nitration could be excluded as the cause for the occurrence of this protein 
spot.
Analysis of p85a from total cell lysate by 2D-PAGE using the U10 mAb indicated 
a minor increase of protein spots towards a more acidic pH in all stimulated samples 
versus the control sample, but mainly in OA treated cells. These results were confirmed 
when total cell lysate was analysed with a p85pan Ab.
Taken together, physiological stimulation of WEHI-231 cells with a-IgM did not 
induce major changes in the p85 protein spot pattern, suggesting that the modifications 
detected on 2D-immunoblots are insensitive to BCR crosslinking. When the cells were 
incubated with less physiological stimuli, such as OA and pV, a shift in the p85 protein 







Figure 4.4. Treatment of WEHI-231 cells with OA or pV, in contrast to stimulation with a- 
IgM, alters the protein spot pattern of the regulatory subunit on 2D-gels
WEHI-231 cells were stimulated with different chemicals (C, control; pV, pervanadate; a-IgM; 
and OA, okadaic acid) followed by separation of the protein spot pattern of the regulatory 
subunit by 2D-PAGE and analysis by immunoblotting. Total cell lysate of WEHI-231 cells was 
analysed using p85a or p85(3 Abs. a, b, c, d: 4 different experiments.
4.5  p85 m o d i f ic a t io n s  revea led  in u n s t im u la te d  cells  
are c o m m o n  in d i f fe ren t  cell  types
In order to detect whether the modifications observed in p85a were unique to B 
cells, we analysed in parallel the p85 protein spot pattern from total cell lysates of four 
different cell types by 2D-PAGE, focusing on cells of murine origin.
We compared the B cell line WEHI-231 with the T lymphoma cell line EL-4, the 
colon carcinoma cell line CT-26 and the fibroblast cell line NIH-3T3. 2D-immunoblots 
were analysed using different Abs directed against the regulatory subunits (Figure
4.5.A). This led to the detection of different p85 spot patterns depending on the Ab 
used. If the 2D-immunoblots were analysed for p85a using the U10 mAb, easily 
detectable differences were observed between cell types. However, analysis of the 
same membrane after protein stripping with the mAb U2 resulted in similar p85 protein 
spot pattern between the different cell lines with decreasing signal intensity toward the 
more acidic pH. If a pAb against all regulatory subunits was used for analysis 
(‘p85pan’), small differences between the different cell types were detected, which 
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Figure 4.5: p85 post-translational modifications in different murine cell types
(A) Total cell lysate of four different cell lines (WEHI-231, EL-4, CT-26 and NIH-3T3) were 
separated by 2D-PAGE and analysed for p85a (U10) and p85a/p85(3 (U2, p85pan). A 
schematic representation of the spot pattern is given. Sections of the 2D-immunoblots are 
shown. (B) Schematic drawing of class IA PI3K regulatory subunit (adapted from (Deane and 
Fruman, 2004)), indicating which domains the different Abs were raised against.
The observed differences may relate to the different epitopes recognised by the 
different Abs. The epitope recognised by U10 Ab lies within the Rac binding domain 
(also termed BH domain) and the epitope recognised by U2 lies within the N-terminal 
SH2 domain, respectively (End et al., 1993). It is thus possible that post-translational 
modifications in the amino acid sequences to which the Ab binds hampers recognition 
of these p85 species by the Abs used.
In summary, our data suggest that p85 protein modification in unstimulated cells 
is common in a variety of cell types. Small differences in the protein pattern seem to 
occur, suggesting modifications on different amino acid residues in different cell types.
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4.6 In te rac t ion  of c a ta ly t ic  and re g u la to ry  s u b u n i t  is 
affec ted  by p85 m o d if ic a t io n s
Post-translational modifications of proteins can affect protein-protein interactions. 
We therefore investigated whether recruitment of the catalytic subunits p110a, p110(3 
or p1105 to the regulatory subunits was affected by modifications in the regulatory 
subunits in unstimulated cells.
To this end, IPs of the regulatory subunit with Abs to either p110a, p110p or 
p1108 were performed, and the p85 protein pattern was analysed by 2D- 
immunoblotting using p85 Abs. The immunoprecipitated p85 proteins were also 
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Figure 4.6: Indications that differentially modified p85a subunits are not equally 
distributed over the 3 distinct p110 class IA catalytic subunits
(A) Total cell lysate (TCL) of WEHI-231 cells analysed by 2D-PAGE was compared to 
immunoprecipitations (IP) with Abs to p110a, p110p or p1105. Each sample (TCL and IP) was 
analysed for p85a, p85p and p85pan with specific Abs. (B) A schematic representation of the 
p85a protein spot pattern is shown, indicating the percentage of each of the four major protein 
spots in each of the four samples. Sections of the 2D-immunoblots are shown, representing 1 of 
2 independently performed experiments.
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As shown in Figure 4.6.A, p85(3 interacted with all catalytic subunits in a similar 
way. Since we did not investigate how successful the IP of each catalytic isoform was 
by analysing the depletion of each catalytic subunit after IP, no statement can be made 
on the strength of the interaction between p85p and the different catalytic subunits.
The p85a subunit also interacted with all catalytic subunits, but not identically. In 
Figure 4.6.B, a schematic representation and estimated percentage of each of the four 
main p85a protein spots of total cell lysate and after IP with different catalytic subunits 
is shown. This indicates that the p85a protein spot termed number 3 is the most 
prevalent, whereas protein spot number 4 is mainly found in p110a and p1105 
immunoprecipitates. Protein spot number 2 can be primarily observed in IPs of p1105. 
However, when the differentially modified p85 protein species are analysed using a 
p85pan Ab, the distinction between the associations of the regulatory subunits with the 
catalytic subunits was less obvious.
These findings suggest that there might be a minor preference of the different 
catalytic subunits towards the differentially modified p85 species, especially the less 
prevalent ones. However, the scale of such differences can not easily be determined 
because of conflicting results obtained with different Abs. Our observations are 
illustrative of the notion that the PI3K field as a whole has been hampered by the lack 
of good and fully characterised Ab reagents.
4.7 Identification  of post-translational m od ifications in 
the regulatory  subunit by MS
We aimed to find out more about the nature of the post-translational modifications 
in p85 and the specific p85 amino acid residues on which these occur. Thus, the main 
strategy to map these modifications was by mass spectrometry (MS). Different MS 
methods were applied, as described in more detail in § 2.16.
Briefly, matrix-assisted laser desorption/ionisation (MALDI) was used for peptide 
mass fingerprinting, an MS method which generates m/z that can subsequently be 
assigned to theoretical peptide fragments of proteins. Peptide mass fingerprinting was 
used as initial analysis of post-translational modifications of immunoprecipitated 
proteins. The advantages of this method are the speed of acquisition, the low 
consumption of sample, the large mass range of analysis and a simple identification of 
spectra due to predominantly singly-charged peptides. We also used electrospray 
ionisation (ESI) which, in contrast to MALDI, allows for easier generation of sequencing 
information. This is because high quality spectra and sequence specificity are 
generated due to low energy fragmentation. Furthermore, doubly- or triply-charged 
peptides occurring in ESI generate readily interpretable tandem mass spectra
98
Chapter 4
compared to singly charged peptides produced in MALDI. Another advantage of ESI is 
the ease with which it can be interfaced with chromatographic and electrophoretic liquid 
phase separation techniques. Full-scan acquisition by ESI was performed to determine 
the peptide sequences by assigning m/z of peptides (MS) and their fragments 
(MS/MS). Full-scan acquisition data were also used to perform error-tolerant searches, 
in which unexpected modifications, primary sequence variations and enzyme non­
specificities are increasing the probability of peptide identification. Once further 
information on a protein was available that suggested modifications of a specific 
residue, multiple reaction monitoring (MRM) was applied. In this approach, the mass 
spectrometer is set to scan over a very small mass range, typically one mass unit. Only 
one or a few selected m/z (depending on the experimental set-up) are set for detection 
per run and subsequently chosen by the mass analyser for further fragmentation. The 
advantage of this method over full-scan monitoring is increased sensitivity. Instead of 
scanning the most prominent m/z in a complex peptide mixture, in MRM only a small 
fraction of all m/z will be analysed allowing for detection of less abundant peptides.
4.7.1 Testing the tools: identification of class IA PI3K 
isoforms by MS
Analysis of post-translational modifications of proteins by MS requires enrichment 
tools that are specific for the protein of interest only and allow for the purification of 
large amounts of protein.
As described in § 3.4, the regulatory subunit p85a and p85f3 and the catalytic 
subunit p110p and p1105 could be identified by tandem mass spectrometry (MS/MS) 
from protein samples enriched for class IA PI3K by a pull-down using the pTyr-matrix. 
However, the described pulldown method does not discriminate between different class 
IA PI3K isoforms. We therefore tested whether a mAb which recognises p85a and 
p85(3 (U2) and a pAb to the p1108 catalytic subunit could be used to purify these 
specific subunits from WEH1-231 cell lysates.
After incubation of cell lysate with the indicated Abs and protein A or protein G 
sepharose beads, the protein complexes were vigorously washed, separated by SDS- 
PAGE and the proteins visualised by colloidal Coomassie staining. As shown in Figure 
4.7, two dominant protein bands could be detected at relative molecular weight (Mr) of 
110 kDa and 85 kDa using either enrichment method. No such proteins were found in 
immunoprecipitates of a control Ab (anti-mouse immunoglobulin G from the IgG 
fraction of rabbit antiserum). Following tryptic in-gel digestion, the peptides were 
subjected to full-scan acquisition using an ESI-Q-TOF coupled to an HPLC instrument. 
The sequencing data were extracted with Masslynx ( M i c r o m a s s )  and searched against
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the NCBInr (non redundant) database using Mascot ( M a t r i x s c i e n c e ) .  Details and 
parameter values for data interpretation can be found in § 2.16.5.
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Figure 4.7: Enrichment of class IA PI3K by IP
The regulatory and catalytic subunits were immunoprecipitated from WEH1-231 cell lysate with 
Abs to either p85a/p85p (p85) or p1105. The enriched proteins were separated by SDS-PAGE 
and subsequently visualised by colloidal Coomassie. A mix of anti-mouse IgG immunoglobulins 
was used as a negative control. The protein bands were extracted and subjected to LC-MS/MS 
(see Table 4.1).
IP with U2 (p85a/p85(3) led to the identification of p110(3, p1105 and p85a (Table
4.1). Protein identification with a probability-based MOWSE score (Pappin et al., 1993) 
above 40 was considered significant. p85(3 and p110a could not be identified by 
MS/MS following IP, but could be detected by immunoblotting (data not shown), 
suggesting that the U2 mAb does not equally enrich for p85a and p85f3 and/or that 
p85p and p110a are present at lower levels in WEHI-231 cells compared to the other 
class IA subunits.
IP with the p1108 Ab resulted in the identification of p1108, p85a and p85(3 (Table
4.2). MS analysis also revealed the presence of thymopoietin, a protein with the same 
Mr as p85a/p85(3. Since thymopoietin is not detected in p85 IPs, it is most likely a 
p1108 Ab crossreacting protein and not part of the p110-p85 protein complex.
Since p85(3 could be identified when immunoprecipitated with the p110S Ab and 
also when pulled down with the pTyr-matrix (§ 3.4), it is likely that the mAb U2 
preferentially binds p85a, rather than p85(3 being available in much minor protein 
amounts in vivo. The abundance of p110a on the other hand seems to be lower than 
that of p110p and p110S in WEHI-231 cells, since this subunit could neither be 
identified by MS after IP using U2 nor after a pulldown with the pTyr-matrix. In fact,
100
Chapter 4
p110a could only be identified by MS analysis if the protein was immunopurified using 
a p110a Ab (data not shown). Preliminary data obtained by subjecting class IA PI3K to 
AQUA analysis revealed that p110a is indeed expressed at lower protein levels than 
p1108 and p110(3 in WEHI-231 cells (§ 6.6).
Taken together, any of the 3 methods presented (pTyr-matrix, IP using the U2 
mAb, or p1105 pAb) is capable of enriching class IA PI3K subunits; however, not all of 
them are equally powerful. We conclude that for the scope of this investigation, which 
was focused on the analysis of the regulatory subunits, the use of the pTyr-matrix or IP 
using p1105 Ab represent the best approach, since both methods enrich for p85a and 
p85(3.
Table 4.1: ESI-Q-TOF analysis of U2 IP reveals the presence of p110|3, p1105 and p85a
WEHI-231 cells were used for IP of regulatory subunit with the p85 U2 mAb. The proteins were 
separated by SDS-PAGE (Figure 4.7), subjected to in-gel tryptic digestion and LC-MS/MS using 
an ESI-Q-TOF mass spectrometer. Data mining was performed by extraction of the peaklist 
using MassLynx ( M ic r o m a s s ) and automated database searches using Mascot demon 
(M a t r ix s c ie n c e ) , with MS/MS ion search parameters as detailed in § 2.16.5. Each identified 
peptide is given a score according to the MOWSE scoring algorithm, resulting in a total score for 
each identified protein, mox indicates oxidation of methionine residues.
P11O0 peptide sequences experimental m/z exp/ calc delta score
DSLALGK 352.19 -0.03 20
LNTEETVK 467.22 -0.05 31
DALLNWLK 486.75 -0.06 41
TWSSEISGK 503.75 -0.05 55
EYNSGDDLDR 592.22 -0.05 40
AAELASGDSANVSSR 717.80 -0.09 43
p1108 peptide sequences experimental m/z exp/ calc delta score
DSLALGK 352.19 -0.03 20
AYTILR 368.70 -0.04 28
FNEALR 375.18 -0.04 39
ALLVNVK 378.73 -0.04 33
SEMHVPSVALR + m0x 414.53 -0.06 58
QVLWHR 419.72 -0.03 26
NANLSTIK 430.72 -0.04 39
NPGEALDR 436.20 -0.03 32
DALLNWLK 486.75 -0.06 41
HSDNIMIR + m0x 501.23 -0.03 17
SKNPGEALDR 543.75 -0.05 38
GELLNPAGTVR 563.79 -0.06 38
SNMAATAAFNK + m0x 571.24 -0.06 74
ITEEEQLQLR 629.80 -0.07 89
FGLIMEAYCR + m0x 638.27 -0.06 41
LINSQISLLIGK 649.87 -0.08 78
MTPYGCLPT GDR 692.27 -0.08 26
YESYLDCELTK 710.78 -0.08 45
LCDIQPFLPVLR 735.87 -0.09 59
p85a peptide sequences experimental m/z exp/ calc delta score
NLLNAR 350.69 -0.03 25
AENLLR 358.19 -0.03 42
ALYDYK 386.68 -0.04 22
DGTFLVR 404.23 -0.05 24
LLEAIEK 408.23 -0.04 5
LEEDLKK 437.73 -0.04 32
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ALYDYKK 450.75 -0.03 17
RLEEDLK 451.75 -0.02 16
ISEIIDSR 466.73 -0.04 59
LLEAIEKK 472.26 -0.07 24
NKAENLLR 479.25 -0.06 14
LYEEYTR 487.2 -0.06 8
EDNIEAVGK 487.73 -0.03 30
YQQDQWK 504.23 -0.05 29
DTADGTFLVR 547.75 -0.05 55
GLECSTLYR 549.74 -0.06 33
NESLAQYNPK 582.25 -0.07 11
TQSSSNPAELR 595.26 -0.08 16
TAIEAFNETIK 618.80 -0.06 44
YQQDQWKEDNIEAVGK 654.96 -0.10 15
LRDTADGTFLVR 682.34 -0.06 20
VLSEIFSPVLRF 703.85 -0.12 16
MNSIKPDLIQLR + m0x 722.37 -0.07 8
IFEEQCQTCER 734.27 -0.11 54
Table 4.2: ESI-Q-TOF analysis of p1105 IPs reveals the presence of p1105, p85a and p85p 
See Table 4.1 for methodical details.
p1108 peptide sequences experimental m/z exp/ calc delta score
ALNDFVK 403.70 -0.05 7
QFCEEAAAHR 406.81 -0.08 24
SEMHVPSVALR + m0x 414.51 -0.07 11
QVLWHR 419.71 -0.06 14
SEMHVPSVALR 428.20 -0.08 22
NANLSTIK 430.72 -0.06 11
NPGEALDR 436.18 -0.06 12
AYTILRR 446.76 -0.02 9
AKPPPIPAK 459.75 -0.06 24
KLINSQISLLIGK 476.28 -0.07 13
VKFNEALR 488.75 -0.07 15
GRITEEEQLQLR 491.24 -0.09 31
FRGYCER 494.20 -0.06 8
HSDNIMIR + m0x 501.21 -0.08 5
HEVQEHFPEALAR 521.56 -0.09 1
LKALNDFVK 524.28 -0.07 7
DEQSNPAPQVQKPR 531.89 -0.10 25
SKNPGEALDR 543.74 -0.08 17
TNNSEKFER 562.73 -0.07 7
AAGLPELSCSK 566.74 -0.04 24
SNMAATAAFNK + m0x 571.23 -0.08 3
QRLEFDISVDCLPR 583.23 -0.09 46
VNWLAHNVSK 584.28 -0.07 18
ITEEEQLQLR 629.79 -0.07 26
FGLIMEAYCR 630.26 -0.07 35
LINSQISLLIGK 649.88 -0.06 54
LCFALYAWEK 656.82 -0.07 29
VPFILTYDFVHVIQQGK 668.66 -0.12 13
GLHEFDSLRDPEVNDFR 682.62 -0.11 4
MTPYGCLPTGDR 684.27 -0.08 10
MTPYGCLPTGDR + m0x 692.28 -0.05 26
KLINSQISLLIGK 713.92 -0.06 32
DIQYLKDSLALGK 732.36 -0.1 13
LCDIQPFLPVLR 735.86 -0.08 28
GRITEEEQLQLR 736.35 -0.09 11
DSLALGKTEEEALK 752.36 -0.07 20
ERVPFILTYDFVHVIQQGK 763.72 -0.11 5
DEQSNPAPQVQKPR 797.34 -0.12 10
KPSSVSLWSLEQPFSIELIEGR 834.73 -0.16 23
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p85a peptide sequences experimental m/z exp/ calc delta score
DGTFLVR 404.19 -0.05 24
LLEAIEK 408.20 -0.04 5
LRDTADGTFLVR 455.23 -0.07 31
ISEIIDSR 466.72 -0.07 33
LLEAIEKK 472.26 -0.07 24
NKAENLLR 479.23 -0.06 14
LHEYNTQFQEK 479.53 -0.10 10
MNSIKPDLIQLR + m0x 481.92 -0.07 28
LYEEYTR 487.18 -0.08 8
FPAASSDNTEHLIK 510.56 -0.09 27
TWNVGSSNR 510.72 -0.06 5
YSKEYIEK 530.23 -0.08 17
ISEIIDSRR 544.78 -0.06 17
GLECSTLYR 549.71 -0.06 33
NESLAQYNPK 582.24 -0.07 11
TQSSSNPAELR 595.26 -0.08 16
MHGDYTLTLR + m0x 611.73 -0.06 19
KGLECSTLYR 613.77 -0.08 9
TAIEAFNETIK 618.77 -0.06 44
YQQDQWKEDNIEAVGK 654.96 -0.10 15
LRDTADGTFLVR 682.34 -0.06 20
LHEYNTQFQEK 718.80 -0.09 7
MNSIKPDLIQLR + m0x 722.37 -0.07 8
IFEEQVQTQER 734.27 -0.11 54
FPAASSDNTEHLIK 765.30 -0.09 33
QGCYACSVWDGEVK 835.82 -0.12 12
TEADTEQQALPLPDLAEQFAPPDVAPPLIK 1109.79 -0.38 1
p858 peptide sequences experimental m/z exp/ calc delta score
HCVIYR 424.19 -0.06 4
TALYDAVK 440.70 -0.03 8
LRDTPDGTFLVR 463.90 -0.08 19
APGPGPPSAAR 489.22 -0.08 2
FLLQHLGR 492.26 -0.06 37
HESLAQYNAK 580.75 -0.07 16
TAIEAFNETIK 618.77 -0.12 35
IFEEQGQTQEK 668.76 -0.13 38
ERPEDLELLPGDLLWSR 684.00 -0.12 7
LVEAIEQAELDSECYSKPELPATR 916.71 -0.22 16
4.7.2 MS did not allow for identification of post-translational 
modifications of class IA PI3K regulatory subunits after 
2D-PAGE purification
A single 2D-gel protein spot is enriched specifically for a differentially modified 
residue, due to the isoelectric focusing of proteins in the first dimension. In order to 
identify post-translational modifications of class IA regulatory subunit by MS, we 
purified the regulatory subunit from large amounts of starting material (up to 40 mg total 
cell lysate, compared to 1 mg total cell lysate if the regulatory subunit was analysed by 
immunoblotting) by using either an p1105 Ab, p85 Ab (data not shown) or the pTyr- 
matrix (data not shown). The protein complex was separated by 2D-PAGE and the 










Figure 4.8: 2D-PAGE of regulatory subunit separates p85a from p85p
The regulatory subunit of class IA PI3K was immunoprecipitated using an Ab to p1105 and 
subjected to 2D-PAGE. Proteins were visualised by colloidal Coomassie staining. The most 
abundant protein spots with a Mr of 85 kDa were cut from the gel. After tryptic in-gel digestion, 
the resulting peptides were analysed by MALDI-TOF and identified as p85a, p85[3 and HSP70 
(see Table 4.3).
The protein spot pattern detected with Coomassie (Figure 4.8) did not entirely 
correspond to the one seen in experiments performed by immunoblotting. Instead of 
revealing a multitude of protein spots at the Mr of 85 kDa, we could only discover 3 
protein spots. This might be due to high specificities of the p85 Abs to low 
stoichiometry p85 species or to differential binding of the p85 species to the PVDF 
membrane.
Nevertheless, the different protein spots were cut from the gel and subjected to 
reduction, alkylation and in-gel tryptic digestion. The peptides were analysed by 
peptide mass fingerprinting using MALDI-TOF or MS/MS using ESI-Q-TOF (data not 
shown). p85a and p85p were identified (Table 4.3). However, even though we could 
detect more than one p85a spot in certain experiments, and potentially phosphorylated 
peptides were identified using peptide mass fingerprinting (Table 4.3), no regulatory 
subunit phospho-peptide could be sequenced using LC-MS/MS.
Table 4.3: Identification of p85a and p85p by MALDI-TOF after 2D-PAGE
Peptide mass fingerprinting was used to identify class IA PI3K regulatory subunit. The peptide 
sequences corresponding to the experimental m/z are indicated on the left, followed by the error 
between experimental and theoretical m/z. Delta values >0.1 indicate low significance of 
identification, but were listed if the peptides were identified in other experiments by MALDI-TOF 




p85a peptide sequences experimental m/z exp/ calc delta modification
EYDR 662.24 0.03 1P04
DGTFLVR 807.43 -0.02
LYEEYTR 973.45 -0.01
SAEGYQYR + Nacetvi 1015.46 0.01
TWNVGSSNR 1020.5 0.01
DTADGTFLVR 1094.56 0.01





LHEYNTQFQEKSR 1759.96 0.1 IPO4
LYEEYTRTSQEIQMK 2239.12 0.15 IPO4




AVYPFR 832.34 -0.04 IPO4
DGTFLIR 901.41 -0.01 IPO4
RDGTFLIR 977.46 -0.09
FLLQHLGR 983.57 -0.01
YQQ DQ W K 1007.49 -0.03
AGAEGFQYR + Nacetvi 1040.45 -0.02
KINEWLGIK 1100.55 -0.09




SRIAEIHESR 1277.68 0.07 IPO4
TQAEEMLSGKR 1329.68 0.07 IPO4
VALQALGVADGGER 1355.74 0.01
DQYLVWLTQK 1373.63 -0.02 IPO4
EYDQLYEEYTR 1508.65 -0.01
GCYACSVWDGDTK 1638.89 0.15 IPO4
EREPEDLELLPGDLLWSR 2050.10 -0.01
EREPEDLELLPGDLLWSR 2130.16 0.04 IPO4
IPPSGGEGDGSEPVPDFPVLLLER 2477.16 -0.04
EVAGPVGLEVLEPPTLPLHQALTLR 2520.44 -0.01
DGHYGFSEPLTFCSWELISHYR 2807.23 -0.01 IPO4
4.7.3 Similar post-translational modifications are revealed in 
endogenous and overexpressed p85a protein
In order to increase the probability to detect and identify post-translationally 
modified p85 proteins by MS, we transiently overexpressed bovine p85a in HEK-293T 
cells, a cell line known for its ability to be readily transfected by calcium phosphate 
precipitation transfection (see § 2.7.2.5 and § 6.4.1).
Total lysates from WEHI-231 cells and p85a overexpressing HEK-293T cells 
were subjected to 2D-PAGE, followed by transfer of proteins to PVDF membranes. 
Overexpression of p85a in HEK-293T cells was successful as determined by 
immunoblotting using p85pan Abs (Figure 4.9), leading to a 10-fold increase in p85a 
level compared to WEHI-231 cells. If a longer exposure time was chosen for the 
membrane containing WEHI-231 cell sample (endogenous p85a) and shorter exposure
105
Chapter 4
time for the membrane containing p85a overexpressing HEK-293T cell sample, the 
similarity of the protein spot pattern of the two samples was revealed (right panel of 
Figure 4.9), confirming similar p85a protein modification patterns even if the protein 
was highly overexpressed.
protein amount comparison: protein pattern comparison:







_  85 kDa
 85 kDa
pH 3
Figure 4.9: Endogenous and overexpressed p85a have a similar 2D-PAGE spot pattern
Total cell lysates of WEHI-231 and p85a overexpressing HEK-293T cells were subjected to 2D- 
PAGE. Analysis of the regulatory subunit spot pattern was performed by immunoblotting using a 
p85pan Ab. Two different exposure times are shown in order to demonstrate successful 
overexpression of p85a in HEK-293T cells (left) and pattern similarity between the 2 samples 
(right). Sections of the 2D-immunoblots are shown.
4.7.4 MS did not allow for identification of overexpressed 
p85 protein after 2D-PAGE
p85a overexpressed in HEK-293T cells was purified by Abs (data not shown) or 
by using the pTyr-matrix and resolved by 2D-PAGE. Following staining by colloidal 
Coomassie, protein bands were excised and analysed by MS/MS. Unfortunately, we 
could not identify p85a using this procedure, despite the observation that the 
Coomassie-stained gel closely resembled the p85 immunoblotting pattern (Figure 
4.10). The 9 spots shown in Figure 4.10 could either not be assigned to a specific 
protein (spot 1; data not shown) or were identified as the Hsp70 chaperone protein 
(spot 2, 3, 4, 5, 6, 7, 8, 9; data not shown).
We have observed that Hsp70 can bind to the agarose used for IP or pull-down 
(data not shown). As shown in Figure 4.8, Hsp70 runs at a similar Mr as the class IA 
regulatory subunit if separated by gel electrophoresis, accounting for the incorrect 
assessment on 2D gels. Several potential explanations can be given for the presence 
of Hsp70 in these experiments. Compared to IP, we used higher amounts of sepharose 
beads in the pTyr-matrix approach, possibly leading to increased Hsp70 
‘contamination’. In addition, it is possible that Hsp70 is complexed to the
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overexpressed p85 subunit. Indeed, heat shock protein expression is often induced by 
transfection or overexpression of proteins, possibly as a cellular reaction to expression 
of ‘higher than normal’ levels of a protein. Induction of Hsp70 has also been found 
when only one subunit of a multimeric protein is expressed.
It is of interest to note that no changes in post-translational modifications of 
Hsp70 were detected that could account for its spot pattern on a 2D gel, despite the 
identification of multiple Hsp70 spots by MS/MS. This suggests that the chosen 
strategy could have been challenging to map sites of post-translational modifications in 
p85, should we have managed to isolate sufficient p85 protein from 2D gels.
We conclude that 2D-PAGE is a valuable method to analyse analytical amounts 
of class IA PI3K regulatory subunits. Large amounts of p85, however, were not 
successfully separated. In addition, visualisation of protein trains on 2D-gels does not 
necessary allow for identification of post-translational modifications by MS, as 
illustrated by our observations on the Hsp70 protein. This may amongst other be due to 
incomplete sequence coverage and ionisation suppression of acidic peptides, such as 
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Figure 4.10: Similarities in the spot pattern of overexpressed, immunoprecipitated p85a 
between immunoblot and Coomassie-stained gel
Bovine p85a was overexpressed in HEK-293T cells and purified using the pTyr-matrix. 1/50 of 
the sample was used for immunoblotting; the remainder was used for visualisation of proteins 
by colloidal Coomassie blue on 2D-gels. The numbered boxes indicate gel pieces subjected to 
tryptic in-gel digestion and LC-MS/MS. Spot number 2-8 were identified as Hsp70, number 1 
could not be assigned to a protein. Sections of the 2D-gel/-immunoblot are shown.
4.7.5 MALDI-TOF analysis of the regulatory subunit after 1D- 
PAGE reveals a variety of potentially phosphorylated 
p85a and p85(5 species
Since the 2D-PAGE approach to identify post-translational modifications by MS 
was not successful, we next performed MS analysis on p85 isolated from 1D- 
polyacrylamide gels following IP using Abs to p85 or p1105, or using the pTyr-matrix
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(Figure 3.7, Figure 4.7). The protein bands were cut from the gel, reduced, alkylated, 
subjected to in-gel tryptic digestion followed by identification of the peptides by peptide 
mass fingerprinting using MALDI-TOF, in order to gain broad insight into the possible 
modification sites occurring in the regulatory subunit. Once potentially modified 
residues were determined, the aim was to sequence the relevant peptides by ESI- 
MS/MS. In order to decrease the complexity of the database searches, peptide mass 
fingerprinting data were only searched against NCBInr using pSer, pThr, pTyr as 
variable post-translational modifications, even though previous experiments suggested 
that other modifications than phosphorylation were likely occurring in p85a (see § 4.3) 
In contrast, when database searches with MS/MS data were performed, a variety of 
additional potential modifications were included in the analysis.
Trypsinised peptides were either spotted directly onto MALDI metal plates 
containing a saturated solution of the matrix chemical 2,5-DHB or first purified over a 
zip-tip to remove salt and other small molecules interfering with the ionisation process.
As can be seen in Table 4.4, peptide mass fingerprinting of 6 independent 
experiments identified 51 peptides of p85a (sequence coverage of 63%) and 24 
peptides of p85p (35% sequence coverage). 19 potentially phosphorylated peptides 
were detected in p85a and p85p (marked in bold). In Figure 4.11, an example of one of 
the MALDI-TOF experiments is shown. The most promising of the potentially 
phosphorylated peptides (marked • in Table 4.4) were
(1) those detected in both their unphosphorylated (m=x) and phosphorylated 
state (m =(x+80)). Peptides marked with * met this criterion.
(2) those phospho-peptides which could be detected with different m/z because 
of modifications or miscleavages (marked with °).
(3) those peptide sequences whose potentially phosphorylated residues could be 
found in p85a and p85|3 in their equivalent sequences (marked with ♦).
Amongst the potentially phosphorylated peptides detected by MALDI-TOF was 
the peptide containing Y368 of p85a (MHGDYTLTLRK), whose phosphorylation was 
identified in insulin-stimulated cells. Furthermore, Y499 of p85p (EYLERFR) was 
detected as a potentially phosphorylated peptide, whose equivalent Tyr residue in p85a 
(Y508) was shown to be phosphorylated in PDGF-stimulated cells. We also identified 
the peptide containing Y688 of p85a and Y458 of p85p, but only in their 
unphosphorylated state. Y508, Y607, S608 of p85a, amino acid residues that had also 




Table 4.4: Identification of potentially phosphorylated p85 peptides by MALDI-TOF 
analysis of immunopurified regulatory subunits.
Potentially phosphorylated peptides are in bold, peptides detected in their unphosphorylated 
and phosphorylated state are marked with *, phospho-peptides identified with different m/z are 
marked with °, phospho-peptides found in p85a and p85p are marked with \  m0x indicates 
oxidation of methionine.












KQAAEYR 945.50 0.08 1P04
NKAENLLR 957.65 0.11
LYEEYTR 973.44 -0.02





i MHGDYTLTLRK 1206.66 0.07
TAIEAFNETIK* 1236.67 0.02
• TAIEAFNETIK* 1316.79 0.17 IPO4
LRDTADGTFLVR 1363.84 0.08
RTAEAFNETIK 1392.79 0.04
• KGLECSTLYR 0 1400.68 -0.08 2P04
VLSEIFSPVLFR 1406.95 0.1
MNSIKPDLIQLR 1427.85 0.05
MHGDYTLTLRK + m0x 1430.69 0.03 IPO4
EIQRIMHNHDK + mox 1436.77 0.07
! IFEEQCQTQER 1467.74 0.09
! GDFPGTYVEYIGR * 1473.86 0.11





(•GDFPGTYVEYIGR* 1633.63 0.01 2P04 :
YQQDQWKEDNIEAVGK 1963.05 0.04 j
TAT GYGFAEPYN LYSSLK S 1982.15 0.1
' EREEDIDLHLGDILTVNK 2109.37 0.14
| ESSKQGCYACSVWDGEVK * 2130.27 0.13
! ISPPTPKPRPPRPLPVAPGSSK * 2276.47 0.06
• ESSKQGCYACSVWDGEVK * 0 2290.09 0.08 2P04
• ISPPTPKPRPPRPLPVAPGSSK * 2356.34 0.02 IPO4
YGFSDPLTFNSWELINHYR 2371.24 0.03
• GLECSTLYRTQSSSNPAELR 0 2443.16 0.05 2P04
• QGCYACSVWDGEVKHCVINK 0 2544.19 0.02 IPO4
TAIEAFNETIKIFEEQCQTQER 2685.34 0.02
TEADTEQQALPLPDLAEQFAPPDVAPPLLIK 3327.6 -0.04
GSLVALGFSDGPEARPEDIGWLNGYNETTGER 3567.54 -0.03 2P04
YLADLPNPVIPVAVYNEMMSLAQELQSPEDCIQLLK 4277.82 -0.04 2P04
p853 peptide sequences experimental m/z exp/ calc delta modification!
AVYPFR* 752.41 -0.02
LLYPVSK * 819.47 -0.02
DGTFLIR * 821.45 -0.02
• AVYPFR* 832.31 -0.08 IPO4
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• DGTFLIR * 9 0 1 .4 1 -0 .01 1P 04
L Y E E Y T R 9 7 3 .4 4 -0 .0 2
• LLYPVSK * 979.56 0.13 2P 04
F L L Q H L G R 9 8 3 .6 9 0.11
EYLERFR 1092.57 0.07 IP O 4
T A IE A F N E T IK * 1 2 3 6 .6 2 -0 .0 2
• TAIEAFNETIK * 1316.79 0.17 IP O 4
E Y D Q L Y E E Y T R 1 5 0 8 .6 6 0 .0 3
G C Y A C S V W D G D T K 1 5 3 0 .7 7 0 .0 7
M N S L K P D L M Q L R K 1 5 7 4 .0 1 0.1
R M N S L K P D L M Q L R K  +  2  m 0x 1 6 3 3 .7 9 -0 .0 4
• RMNSLKPDLMQLR * + m 0x 1697.87 0.03 IP O 4
E R P E D L E L L P G D L L W S R  * 2 0 5 0 .2 3 0 .0 8
G F L L A L P A A W T P E A A A E A Y R 2 1 3 0 .3 2 0 .0 8
• ERPEDLELLPGDLLW SR* 2130.38 0.08 IP O 4
R A P S P D T A V H A L A S A F G P L L L R  * 2 2 6 0 .3 7 0 .0 5
•  RAPSPDTAVHALASAFGPLLLR * 2290.09 -0.02 2P 04
L V Q E H V E E Q D A A P P A L P P K P S K 2 3 8 0 .3 9 0 .0 6
IP P S G G E G D G S E P V P D F P V L L L E R 2 4 7 7 .3 4 0 .0 3
E V A G P V G L V L E P P R L P L G Q A L T L R 2 5 2 0 .4 4 -0 .0 8
T A IE A F N E T IK IF E E Q G Q T Q E K 2 5 5 4 .4 0 0 .0 5
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Figure 4.11: MALDI-TOF peptide mass fingerprinting spectrum of immunoprecipitated 
class IA PI3K regulatory subunit
The regulatory subunit was enriched by IP of p1105, followed by SDS-PAGE separation and 
Coomassie brilliant blue staining. Protein bands were cut from the gel, reduced, alkylated and 
subjected to in-gel tryptic digestion. The peptides and DHB were spotted onto a MALDI metal 
plate and analysed by MALDI-TOF. m/z peaks corresponding to p85a, p85(3 and thymopoietin 
are shown in red, pink and orange, respectively. Underlined m/z correspond to trypsin peptides.
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4.7.6 IMAC enrichment increased the detection of 
phosphorylated p85 residues
Immobilised metal ion affinity chromatography (IMAC) can be used for the 
enrichment of phosphorylated proteins and peptides ((Andersson and Porath, 1986; 
Cutillas et al., 2005). The separation principle of IMAC is based on electronic 
interaction of analyte molecules with metal ions immobilised to a stationary phase. 
Because of the composition of the metal chelate affinity chromatography column, 
phosphorylated peptides and acidic peptides preferentially bind to the column and can 
therefore be separated from non-phosphorylated peptides.
In order to enrich for phosphorylated peptides from tryptic digests of class IA 
PI3K regulatory subunits, we performed IMAC prior to MALDI-TOF analysis. Table 4.5 
lists the peptides detected by peptide mass fingerprinting after IMAC enrichment of 2 
independent experiments. Two peptides (TATGYGFAEPYNLYSSLK of p85a 
containing the previously mapped pY688 phosphorylation site, and 
EVAGPVGLVLEPPRLPLGQALTLR of p85p, marked with ®) were detected in their 
phosphorylated state in samples subjected to IMAC, which were only found in their 
non-phosphorylated state in non-enriched samples. Furthermore, 2 potentially 
phosphorylated peptides identified after IMAC were not detected in the non-enriched 
samples (LYEEYTRTSQEIQMK of p85a, EYDQLYEEYTRTSQELQMK of p85p, 
marked with V). Interestingly, these peptides contain equivalent sequences to the 
previously mapped Y458 phosphorylation site of p85(3. One potentially phosphorylated 
peptide detected in the sample applied to IMAC (LLYPVSKYQQDQWK of p85a and 
p85(3, marked with * )  containing a miscleavage, was found in the non-enriched sample 
in its cleaved form. Furthermore, two potentially phosphorylated peptides of p85a 
detected after IMAC were also detected in non-enriched samples (KGLECSTLYR, 
MHGDYTLTLRK), the latter containing the previously mapped Y368 phosphorylation 
site.
Because IMAC also enriches for acidic peptides, we analysed the peptides 
detected by peptide mass fingerprinting after IMAC for their theoretical pi with a 
computational tool that calculates the estimated pi of an amino acid sequence using pK 
values of amino acids described in (Bjellqvist et al., 1982). The majority of all non- 
phosphorylated peptides shown in Table 4.5 contain a theoretical pl<5 (excluding 
peptide RMNSLKPDLMQLR for calculations) compared to an average pi » 7 for 
randomly picked peptides from Table 4.3. However, the majority of potentially 
phosphorylated peptides enriched by IMAC contain a pi >5, suggesting IMAC binding 
is due to phosphorylation. Only the potentially phosphorylated peptides 
LYEEYTRTSQEIQMK of p85a and EYDQLYEEYTRTSQELQMK of p85f3 have a pi <5,
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suggesting IMAC enrichment because of both the acidity of the peptide and protein 
phosphorylation.
Table 4.5: Potentially phosphorylated p85 peptides identified by MALDI-TOF after IMAC 
enrichment
Potentially phosphorylated peptides are in bold, peptides found in IMAC sample that were found 
non-phosphorylated in non-IMAC samples are marked with ®, phospho-peptides only found in 
IMAC samples are marked with v, phospho-peptides also found in non-enriched samples are 
marked with *.
p85a sequences experimental m/z exp/ calc delta modification Pi
EDNIEAVGK 974.46 -0.03 4.14
EGNEKEIQR 1102.53 -0.02 4.79
EDNIEAVGKK 1102.53 -0.04 4.68
KGLECSTLYR 1400.66 0.07 2P 8.2
MHGDYTLTLRK + m0x 1430.69 0.03 1P 8.36
IFEEQCQTQER 1467.61 -0.03 4.09
YQQDQWKEDNIEAVGK 1962.97 -0.02 4.32
LLYPVSKYQQDQWK * 1967.84 -0.04 2P 8.43
TATGYGFAEPYNLYSSLK ® 2061.80 -0.06 1P 5.66
EREEDIDLHLGDILTVNK 2109.07 -0.06 4.29
LYEEYTRTSQEIQMK v 2158.93 0.05 3P 4.79
QGCYACSVWDGEVKHCVINK 2544.19 0.02 1P 6.72
p853 sequences experimental m/z exp/ calc delta modification Pi
TQAEEMLSGK + m0x 1109.50 -0.01 4.53
EGNEKEMQR + m0x 1136.46 -0.04 4.79
IFEEQGQTQEK 1336.64 -0.01 4.25
EYDQLYEEYTR 1508.64 -0.09 4.00
RMNSLKPDLMQLR+ 1 m0x 1617.81 -0.03 10.84
RMNSLKPDLMQLR+ 2 m0x 1633.83 -0.02 10.84
LLYPVSKYQQDQWK * 1967.84 -0.04 2P 8.43
YQQDQWKEDSVEAVGAQLK 2234.18 0.02 4.32
EVAGPVGLVLEPPRLPLGQALTLR ® 2602.01 -0.04 1P 6.24
EYDQLYEEYTRTSQELQMK V 2694.27 0.10 3P 4.25
LVEAIEQAELDSECYSKPELPATR 2748.36 0.08 4.14
4.7.7 Confirmation of phosphorylated Tyr688 of p85a in 
proliferating WEHI-231 cells by multiple reaction 
monitoring
As shown in Table 4.1 and Table 4.2, LC-MS/MS analysis of the regulatory 
subunit did not reveal phosphorylated residues although we identified a variety of 
potentially phosphorylated peptides by MALDI-TOF. We therefore applied LC-MRM.
Before analysing the regulatory subunit for novel phosphorylation sites by MRM 
using potentially phosphorylated residues detected by MALDI, we were interested in 
the identification of previously mapped p85 phosphorylation sites. The mass 
spectrometric data gained by peptide mass fingerprinting and MS/MS experiments 
revealed that MS analysis allowed for the identification of unphosphorylated Y368, 
Y508, Y580 and Y588, whereas identification of Y607 and S608 was not possible. 
Therefore, LC-MRM was only performed with m/z of peptide sequence containing
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phosphorylated Y368, Y508, Y580 and Y688. The MS/MS data for each total ion 
chromatogram (TIC) peak were extracted and compared to in silico MS-product data of 
the chosen peptide (Protein Prospector, UCSF). As shown in Figure 4.12.A, a doubly- 
charged peptide containing phosphorylated Y688 was identified from WEHI-231 cells if 
MRM was performed with [M+2H]2+=687.9. Most of the m/z peaks of the MS/MS 
spectrum shown could be assigned to fragment ions of the TATGYGFAEPYNLYSSLK 
peptide. Fragment ions are generated if a peptide bond undergoes two or more 
fragmentation events (Aebersold and Goodlett, 2001). Empirical observations showed 
that internal fragments often occur if either proline or aspartic acid residues are 
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Figure 4.12: Identification of pY688 in WEHI-231 cells by MRM
(A) MRM was performed with tryptic digests of immunopurified regulatory subunit producing the 
MS/MS spectra of m/z = 687.9. The MS/MS data of each peak in the total ion chromatogram 
(TIC) were compared to in silico collision induced dissociation (CID) and the m/z peaks were 
labelled accordingly. Unassigned m/z peaks are marked with an arrow. (B) The majority of the 
unassigned m/z peaks were also found in a second TIC peak of the same MRM run, indicative 
of contaminating ions (B).
m/z peaks depicted with an arrow in the MS/MS spectrum of [M+2H]2+=687.9, 
which represented most of the unassigned m/z in the spectrum, were also found in a 
closely eluting peptide TIC peak of this LC-MS/MS run shown in Figure 4.12.B, 
indicative for contaminating ions. Y688 has been previously identified as a 
phosphorylation site in overexpressed p85a and its identification here in endogenous,
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not overexpressed condition using MS techniques indicates that our MS approach is, in 
principle, capable of identifying phosphorylation sites.
Performing the same experiment with the m/z of phospho-peptides containing 
Y368, Y508 and Y580, respectively, did not lead to identification of these 
phosphorylated residues.
4.7.8 Analysis of protein phosphorylation by MRM MS did 
not uncover novel phosphorylation sites
After successful identification of phosphorylated Tyr688 in p85a, we performed 
MRM experiments with p85 samples enriched by immunopurification or pTyr-matrix 
pull-down and selected for different m/z corresponding to potentially phosphorylated 
p85a or p85{3 peptides identified by MALDI-TOF. For every run, the total ion 
chromatogram (TIC) of each selected ion was extracted using MassLynx V4.0, the 
sequencing information within each peak accumulated, centred and smoothed and the 
sequencing data scanned against the NCBI nr using Mascot. Unfortunately, none of 
the investigated m/z led to the identification of a predicted phospho-peptide.
4.7.9 Error-tolerant searches reveal hydroxylation and amino 
acid substitutions of p85a
When the results of an MS/MS search are reviewed, there are often a number of 
spectra that remain unmatched. If that given spectrum contains adequate information 
(reasonable number of fragment ion peaks at usable signal to noise ratio) causes for 
failure to find a peptide match are underestimated mass measurement errors, incorrect 
determination of precursor charges, non-specificity of the enzyme used for digestion, 
unsuspected chemical and post-translational modifications, and unreported peptide 
sequences. Error-tolerant searches by Mascot allow for addressing the latter three 
challenges.
We performed error-tolerant searches on the complete p85 dataset gained from 
various experiments in order to reveal post-translational modifications other than 
phosphorylation that could account for the modifications of class IA PI3K regulatory 
subunit detected on 2D-PAGE in unstimulated cells (see § 4.1). Table 4.6 lists the 
modifications occurring in class IA PI3K regulatory subunit revealed by error-tolerant 
searches. The output data of the error-tolerant searches were assigned from manual 
interpretation of the MS/MS spectra viewed using MassLynx V4.0 (Figure 4.13).
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Table 4.6: Identification of post-translational modifications and primary sequence 
alterations performing error-tolerant searches
LC-MS/MS data were analysed in error-tolerant searches for enzyme non-specificity, chemical 
and post-translational modifications, and amino acid alterations. Output data of error-tolerant 
searches were assigned from manual interpretation of the MS/MS spectra using MassLynx 
V4.0.
p85a peptide sequences experimental m/z exp/ calc delta modification
VLSEIFSPVLFR 703.86 0.05
VLSEIFSpVLfR A 727.86 0.04 POH, F(OH)2
LLEAIEK 408.22 0.03
LVEAIEKK B 465.28 0.02 L136V
FPAASSDNTEHLIK 765.36 0.02
FPAASSENTEHLIK C 772.40 -0.01 D281E
ISEIIDSR 466.76 0.01
ISEIVDSR D 459.74 0.01 I539V
A Hydroxylation of Pro270 and Phe273
nov06bgtb 246 (51 025) Cm (248:249) VLSEIFSPVLFR
631.43 666.49
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D Amino acid variation of Ile539
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Figure 4.13: Mass spectra of modifications in p85a identified by error-tolerant searches
Output data of error-tolerant searches were assigned from manual interpretation of the MS/MS 
spectra using M as sL yn x  V4.0. (A ) MS/MS spectra of unmodified and hydroxylated Pro270 and 
Pro273; (B, C, D), amino acid variations in the primary sequence of p85a.
The modified residues cluster in the Rac-binding domain of p85a, with one amino 
acid substitution detected in the inter-SH2 domain, also termed p110 binding domain 
(Figure 4.14). The Rac-binding domain, a 200-residue region also named breakpoint 
cluster region-homology (BH) domain, is responsible for the GAP activity of p85. It has 
been shown to interact with a variety of GTPases, such as Rac1 and Cdc42 (Tolias et 
al., 1995; Zheng etal., 1994).
OH
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Figure 4.14: Schematic representation of the identified amino acid modifications in p85
Performing error-tolerant searches by MS, 5 amino acid modifications of p85a were identified in 




It has previously been documented that the regulatory subunit of class IA PI3K 
becomes phosphorylated on several residues upon cellular stimulation (§ 1.3.4.2).
4.8.1 Class IA PI3K regulatory subunit modifications in 
proliferating WEHI-231 cells
Here, we report that the regulatory subunit is also modified in the established 
murine WEHI-231 B lymphoma cell line under basal culture conditions, in agreement 
with investigations made in murine fibroblast cells (Cohen et al., 1990). Analysis by 20- 
PAGE revealed that these modifications mainly occur on p85a. However, the fact that 
modifications were not observed in p85(3 may be related to a possible lower relative 
abundance of this p85 isoform. In vitro dephosphorylation assays demonstrated that 
approximately half of the modifications in p85 from proliferating WEHI-231 cells are due 
to protein phosphorylation as revealed by 2D-gel analysis. This finding is in agreement 
with indications for Thr phosphorylation of p85 in unstimulated WEHI-231 cells as 
revealed by immunoblotting using pThr Abs and with our MS identification of Y688 
phosphorylation site in p85a from WEHI-231 cells cultured under basal conditions. 
Unfortunately, detailed MS analysis of peptides derived from the regulatory subunit 
only provided indications for potentially phosphorylated amino acid residues without the 
capacity to confirm this by sequencing of the peptides of interest.
The remaining other half of the post-translational modifications in p85 from 
unstimulated WEHI-231 cells are most likely due to modifications other than 
phosphorylation. Since the pi values of the p85 species that are resistant to 
phosphatase treatment are more acidic than the main p85 protein 2D gel spot, we 
speculate that the changes in pi could be due to hydroxylation, acetylation, sulfation/ 
nitration, specific proteolysis of the N- and/ or C-terminus or amino acid alterations. 
Many other post-translational modifications are known (Krishna and Wold, 1993), but 
these do not have a major impact on the pi of proteins.
Analysis of p85 sequencing data revealed 3 amino acid substitutions and 2 
protein hydroxylations in p85a. Since the substituted amino acid residues contained 
similar chemical properties as the original amino acids, e.g. L->V or D->E, significant 
changes in the isoelectric point of p85a are not expected. However, unless mutant 
protein was to be expressed and analysed by 2D-PAGE, these modifications can not 
be excluded from being part of the observed p85a spot pattern. The substituted 
residues of L136, D281 and I539, which were found in their non-modified and modified 
form in WEHI-231 cells, are also found in p85a sequences of other mammalian 
species, for example V136 is present in homo sapiens. The frequency with which these
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amino acids are mutated gives reason to believe that their specificity is not crucial for 
p85 function. Analysis of the p85a nucleotide sequence revealed that the amino acid 
substitutions are likely due to single nucleotide polymorphisms (SNPs). SNP could 
either occur in a subpopulation of WEHI-231 cells or exist on one p85a allele only. SNP 
analysis of class IA PI3K regulatory subunit genes revealed mutation of amino acid 
M326 to lie in p85a (Hansen et al., 1997). This SNP is associated with reduced binding 
affinity of p85a to IRS-1, but not IRS-2 (Algenstaedt et al., 2004). Further SNPs have 
been detected in the intronic sequence of the p85a gene, and have therefore no impact 
on p85a amino acid sequence (Barroso et al., 2003); (Suzuki et al., 2004). In contrast 
to amino acid substitutions detected by MS, protein hydroxylation is likely to reduce the 
pi of a protein thereby influencing the protein spot pattern detected on 2D gels. 
However, hydroxylation of proteins during sample preparation for MS analysis due to 
oxidative conditions can not be excluded as the cause for the identified hydroxylated 
amino acids in p85a even though reducing agents are added to the sample in each 
step in order to prevent oxidation.
The modifications detected in unstimulated cells are mainly found in the BH 
domain of p85a, with one amino acid alteration in the inter-SH2 domain and one in the 
C-terminal SH2-domain. Since class IA PI3K regulatory subunits are adaptor proteins, 
it is likely that the modifications identified here are involved in the regulation of protein- 
protein interactions. This is at least true for pY688 in the C-terminal SH2-domain, which 
has been implicated in the reduction of p85a interaction with tyrosine phosphorylated 
proteins (von Willebrand et al., 1998).
4.8.2 Class IA PI3K regulatory subunit modifications in a-IgM 
stimulated WEHI-231 cells
In order to gain insight into the biological significance of these modifications, p85 
post-translational modifications were analysed in WEHI-231 cells activated with 
physiologically relevant stimuli. No increase in p85 protein phosphorylation was 
detected by immunoblotting analysis after BCR triggering, even though the 
downstream effector PKB showed increased phosphorylation, indicative for effective 
cellular stimulation. In addition, the overall 2D gel spot pattern did only change very 
marginally upon stimulation. Only when cells were treated with okadaic acid or 
pervanadate, two powerful inhibitors of phosphatases, S608 and global Thr 
phosphorylation were increased and the 2D gel spot pattern of p85 significantly 
changed. We were surprised not to find any changes in protein phosphorylation, 
especially Tyr phosphorylation, of p85 upon physiological stimulation of B cells. Tyr 
phosphorylation of p85 on different p85 residues in different cell types upon
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physiological stimulation has been reported by various research teams (for more 
information see § 1.3.4.2). In addition, we documented phosphorylation of Y688 by MS 
in unstimulated B cells and this phosphorylation was previously shown to be increased 
upon cellular stimulation of T cells. However, it is possible that BCR crosslinking 
undergoes different signalling pathways than TCR crosslinking or stimulation of cells 
with growth factors/hormones. In line with this, stimulation of B cells induces Tyr 
phosphorylation of the regulatory subunit only after 20 minutes of BCR crosslinking 
(Beckwith et al., 1996), while other stimuli induce modification of p85 much earlier. We 
conclude that under the conditions used for cellular stimulation of WEHI-231 cells, the 
class IA PI3K regulatory subunit does not undergo significant protein phosphorylation 
or, in fact, any post-translational modifications that would lead to changes in the 
isoelectric point of the protein.
4.8.3 Biochemical role of class IA PI3K regulatory subunit 
modifications
In order to gain knowledge of the biochemical roles of these modifications, we 
analysed the protein spot pattern in different cell types, and following p110 IP in B cells. 
Minor differences in the 2D gel spot pattern of p85 were found in 4 different murine cell 
systems using a p85 Ab whose epitope lied within the Rac-binding domain. However, 
no differences could be detected if p85 Abs were used whose epitopes lied within the 
N-terminal SH-2 domain. It is therefore possible that the same type of modification (e.g. 
protein phosphorylation) occurs on different amino acid residues in the regulatory 
subunit in different cell types. Thus, if one of the amino acids within the Rac-binding 
domain was modified, one would expect the Rac-Ab to bind this sequence with lower 
affinity. If the same modification occurred on another residue in a different cell line, 
differences in the Ab signal using the Rac-Ab, but not using the N-SH2 Ab should be 
detectable between the cell types. Observations made in stimulated cells, where 
different p85a amino acid residues have been implicated in phosphorylation in different 
cell types, e.g. pY508 in PDGF-responsive, pY580 in insulin-responsive and pY688 in 
immune-responsive cells (see § 1.3.4.2) are in line with this hypothesis.
We also investigated whether the modifications observed in p85 were related to 
its interaction with the distinct p110 catalytic subunits. Therefore, the 3 class IA 
catalytic subunits were immunopurified with p110 isoform-specific Abs. Modest 
differences in the protein spot pattern of the regulatory subunit could be detected after 
IP with different p110 Abs, suggesting that the interaction of the regulatory and catalytic 
subunits was partially dependent on the observed modifications. These findings also 
suggest that some of the modifications of p85a detected in unstimulated cells may 
occur on amino acid residues located in the p110-binding domain of the regulatory
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subunit, such as Ile539 residue which was modified to Val as detected by MS. An 
alternative explanation for these observations could be that the p110-specific 
modifications are catalysed by the catalytic subunits.
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5 B io c h e m ic a l  a n a l y s is  o f  p 1108 in b c e l l  a n t ig e n  
RECEPTOR STIMULATED IMMATURE B CELLS
Signal transduction through the BCR changes dramatically during B cell 
development resulting in growth arrest and apoptosis in immature B cells and leading 
to proliferation in mature B cells. Apoptosis in immature B cells serves to remove 
overreactive or unresponsive lymphocytes. The initial response in immature and 
mature B cells to BCR engagement seems to be similar, leading to a transient increase 
in Akt and Erk phosphorylation (Bilancio et al., 2006) followed by a decrease in PI3K- 
dependent PI levels within 1 h of stimulation (Carey and Scott, 2001). However, the 
PIP3 concentration in a-lgD stimulated B cells (which do not undergo growth arrest or 
apoptosis) returns to basal levels after 4-8 h of BCR engagement, while PIP3 levels 
remain low in a-IgM stimulated immature B cells. BCR crosslinking of immature B cells 
leads to a concomitant long-term decrease in the phosphorylation of the PI3K effector 
S6K, downregulation of c-myc expression and upregulation of p27K,p1 inducing G1 
growth arrest (Carey and Scott, 2001).
BCR engagement induces a complex signalling cascade described in § 1.7. 
Briefly, following B cell stimulation by antigen, the Tyr kinases Lyn and Syk are 
recruited to the BCR and activated, and increase phosphorylation of adaptor 
molecules. PI3Ks are subsequently recruited to the plasma membrane by association 
of their SH2 domains with pTyr residues in adaptor molecules. Membrane recruitment 
leads to PI3K activation and PIP3 generation. This induces the accumulation of proteins 
into a signalosome ultimately increasing MAP kinase and PI3K signalling pathway 
activation and Ca2+ flux. Mouse-gene targeting and inhibitor studies have documented 
an important role for p85a and p1108 in B cell development and function (Beckwith et 
al., 1996; Bilancio et al., 2006; Clayton et al., 2002; Fruman et al., 1999; Jou et al., 
2002; Okkenhaug et al., 2002; Suzuki et al., 1999). Inactivation of PI3K impairs BCR- 
mediated proliferation as a consequence of reduced PIP3 generation and Ca2+ 
mobilisation.
In order to gain insight into the molecular mechanism of p1105 activation and 
subsequent de-activation following BCR engagement in immature B cells, we analysed 
post-translational modifications, lipid kinase activity, subcellular localisation and binding 
partners of p1105 following a-IgM stimulation. Our results confirm the dependence of 
PI3K signalling on p1105 following BCR crosslinking, and indicate that the increase in 
PI3K activity is not due to enhanced intrinsic lipid kinase activity, but to alterations in 
p1108 binding partners, which likely influences p1108 subcellular localisation. These 
changes might be due to enhanced Tyr phosphorylation of p1108, which is primarily
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found in the p110S isoform of class IA PI3Ks and mainly detected in B cells. 
Furthermore, we present a panel of novel, potential PI3K interaction partners -  in 
unstimulated and stimulated immature B cells.
5.1 Time-course of Akt phosphorylation following BCR  
engagement
In order to investigate the time course of BCR-induced PI3K activation, we 
analysed the phosphorylation state of the PI3K downstream effector Akt following BCR 
engagement of the immature B cell line WEHI-231. As shown in Figure 5.1, in 
unstimulated cells little Akt was phosphorylated compared to a-IgM stimulated cells. 
The phosphorylation of Akt increased steadily over a period of 10 min of stimulation. 
Analysis of Akt phosphorylation beyond 10 min of stimulation indicates a slow decrease 







Figure 5.1: BCR engagement of WEHI-231 cells induces phosphorylation of Akt
WEHI-231 cells were treated for the indicated time points with a-IgM leading to crosslinking of 
BCR. The phosphorylation state of the PI3K downstream effector Akt following stimulation was 
analysed by immunoblotting. Immunoblotting analysis of tubulin protein amounts was used to 
confirm equal gel loading. Relative quantitation of immunoblot signals is shown in the lower 
panel of Figure 5.1.
5.2 p110S lipid kinase activity is critical for Akt  
phosphorylation following BCR engagement in 
WEHI-231
In order to dissect which class IA PI3K catalytic subunit was responsible for the 
increase in PI3K activity following BCR engagement in WEHI-231 cells, the a-IgM 
induced phosphorylation of Akt was analysed following pretreatment of cells with PI3K 
pharmacological inhibitors. To this end, WEHI-231 cells were pre-treated for 30 min 












Figure 5.2: p1105 is the critical class IA PI3K subunit following BCR engagement
Phosphorylation of Akt on Thr308 and Ser473 in unstimulated cells was compared by 
immunoblotting to cells stimulated with a-IgM and cells pretreated with PI3K inhibitors before 
BCR crosslinking. Concentrations of the isoform-specific inhibitors IC87114 (to p1105), TGX- 
221 (to p110p) and AS604950 (to p110y) were chosen which ensured isoform-selective 
inhibition. LY294002 is a broad-spectrum PI3K inhibitor. Immunoblot analysis of a-Actin was 
used to ensure equal sample loading.
Phosphorylation of Akt at Thr308 and Ser473 was increased following BCR 
engagement of untreated WEHI-231 cells in line with previous results (Figure 5.1). 
However, when the lipid kinase activity of the catalytic subunit p1105 was inhibited by 
the p1105-selective inhibitor IC87114, phosphorylation of Akt was abolished. Similarly, 
the broad-spectrum inhibitor LY294002 blocked Akt phosphorylation following BCR 
engagement. In contrast, inhibition of p110p or p110y activity by TGX-221 and 
AS604950, isoform-selective inihibitors to p110p and p110y, did not lead to a reduction 
in Akt phosphorylation. On the contrary, inhibition of p110p and p110y activity led to an 
increase in Akt phosphorylation compared to a-IgM stimulated, untreated cells. 
Analysis of p110a contribution to Akt phosphorylation was not possible at the time, 
because no p110a isoform-specific inhibitor was available to us.
These results suggest that p1105 is primarily responsible for the increase in Akt 
phosphorylation in WEHI-231 cells following BCR crosslinking. Since phosphorylation 
of Akt is a direct cause of PIP3 generation, we conclude that p1105 is the main 
producer of PIP3 under the chosen conditions. These results confirm previous 
observations in our laboratory (Bilancio et al., 2006).
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5.3 p1105  in v i t ro  lipid kinase activity is unchanged  
following BCR stimulation
An increase in PIP3 concentration following cellular stimulation of WEHI-231 cells 
could be due to an increase in the intrinsic lipid kinase activity of p1105, to a shift in the 
subcellular localisation or to a change in the interaction partners of this protein. In order 
to investigate the cause for the observed increase in PI3K signalling following BCR 
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Figure 5.3: The intrinsic lipid kinase activity of p1105 does not increase following BCR 
engagement
WEHI-231 cells were stimulated with a-IgM for the indicated time points and in vitro lipid kinase 
activity assays were subsequently performed. (A) Immunoprecipitated p1105 was subjected to 
in vitro lipid kinase assays using PI (left panel) or Ptdlns(4,5)P2 (right panel) as substrates. The 
incorporation of radioactive phosphate into Ptdlns was measured by autoradiography. 
Immunoprecipitated p85 was used as a positive control for the in vitro lipid kinase activity assay. 
A fraction of the p1106-IP was used to determine equal p1105 enrichment after each time point 
of stimulation by immunoblotting with p1105-specific Ab. (B) Total cell lysate of each time point 
of stimulation was analysed by immunoblotting for phosphorylation of Akt. Immunoblot analysis 
of total Akt or tubulin was used to ensure equal sample application.
To this end, WEHI-231 cells were left untreated or stimulated with a-IgM for 
different lengths of time. Following cell lysis, p1105 was immunoprecipitated using a 
p1105-specific Ab and subjected to in vitro lipid kinase activity assays using 
phosphoinositides as substrates as described in § 2.13. As shown in Figure 5.3, equal 
amounts of 3’-phosphorylated phosphoinositides were detected by autoradiography 
following separation of lipids by thin layer chromatography independent of cellular 
stimulation, suggesting that p1105 activity was unaltered upon cellular stimulation of 
WEHI-231 cells. Neither the choice of PI3K substrate (PI or Ptdlns(4,5)P2) nor the time 
of stimulation seemed to have an effect on p1105 in vitro lipid kinase activity. These
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results indicated that the increase in Akt phosphorylation observed following BCR 
engagement was most likely not due to an increase in intrinsic p1105 lipid kinase 
activity.
5.4 BCR engagement results
pH O SSer 1039 phosphory la t ion
Autophosphorylation of Ser1039 located in the C-terminus of p1108 has been 
implicated in the downregulation of its intrinsic lipid kinase activity (Vanhaesebroeck et 
al., 1999). In T cells, CD28 stimulation leads to an increase in Ser1039 phosphorylation 
and concomitant decrease in p1105 lipid kinase activity (Vanhaesebroeck et al., 1999).
In order to address phosphorylation of p1108 Ser1039 following BCR 
engagement, WEHI-231 cells were stimulated with a-IgM for the indicated time points, 
followed by IP of p1105 from cell lysates. The protein complex was resolved by SDS- 
PAGE and phosphorylation of Ser1039 analysed by immunoblotting using a phospho- 
Ser1039-specific Ab. The filter was subsequently stripped of Abs and reprobed for 
p1105 by a p1105 isoform-specific Ab in order to determine the amount of protein in 
each gel lane.
experiment A experiment B





Figure 5.4: BCR engagement induces a small decrease in p1105 Ser1039 phosphorylation
p1105 was immunoprecipitated from total cell lysate of unstimulated or a-IgM stimulated WEHI- 
231 cells. The immunocomplex was separated by SDS-PAGE, the proteins transferred to a 
PVDF membrane and p1105 analysed for Ser1039 phosphorylation using a pSerl 039-specific 
Ab. After stripping of proteins from the filter, total p1105 protein was analysed as a loading 
control.
BCR stimulation of WEHI-231 cells led to a small decrease in Ser1039 
phosphorylation compared to the basal state and this decrease in phosphorylation was 
dependent on the time of stimulation (Figure 5.4). In contrast to the observations made 
from in vitro lipid kinase activity assays, which indicated unaltered intrinsic lipid kinase 
activity of p1105 following cellular stimulation of WEHI-231 cells (§ 5.3), this result 
suggests that p1105 lipid kinase activity is increased following B cell stimulation pre­
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supposing that the phosphorylation state of Ser1039 can be used as a readout for 
instrinsic lipid kinase activity.
The changes observed in Ser1039 phosphorylation following B cell stimulation 
could potentially be due to decreased autophosphorylation or increased protein 
phosphatase activity. We therefore compared p1105 protein interaction partners from 
unstimulated and a-IgM stimulated B cells by MS following co-IP experiments using a 
p1108-Ab (see § 5.6), but did not detect any protein phosphatase interacting with 
p1108. Furthermore, we analysed the protein interaction partners of peptide sequences 
containing non-phosphorylated versus phosphorylated Ser1039. To this end, a peptide 
made of the p1108 C-terminal amino acid sequence KVNWLAHNVSKDNRQ containing 
Ser1039 (in bold) and a second peptide made of the same amino acid sequence, but 
containing phosphorylated Ser1039 were coupled to Actigel beads. These constructs 
were used to pull-down potential p1108 interacting partners from 20 mg WEHI-231 cell 
lysates. Beads uncoupled to peptides were also incubated with WEHI-231 cell lysate in 
order to determine which proteins unspecifically interacted with the Actigel beads 
(Control). The pulled-down proteins were resolved by SDS-PAGE. The protein gel was 
subsequently fixed and proteins stained with colloidal Coomassie blue (Figure 5.5.A). 
Gel lanes were cut into sections of equal size and molecular weight. Proteins were 
reduced, alkylated and subjected to tryptic in-gel digestion and LC-MS/MS was 
performed using the peptide content of each gel section (described in § 2.16).
This experimental approach did not lead to the identification of a protein 
phosphatase. However, the interaction between substrate and enzyme may not be 
strong enough to pull-down the phosphatase. A protein called Acrogranin was identified 
in the pull-down of Actigel beads coupled to the C-terminal peptide containing 
unphosphorylated and phosphorylated Ser1039, but not in the control sample 
containing beads only (Figure 5.5.B/C). Acrogranin, also known as proepithelin and 
PC-cell-derived growth factor (PCDGF), is the largest member (67 kDa) of a family of 
growth modulators and has been implicated in the contribution to tumorigenesis in 
diverse cancers (He et al., 2002; Matsumura et al., 2006; Ong and Bateman, 2003). 
These findings implicate that Acrogranin might interact with the C-terminal domain of 

















Sample Protein Matchingpeptides Score MW
C Hsp70 23 427 72.5
DEAD/H 10 225 73.4
Glycyl-tRNA synthetase 13 215 82.2
moesin 13 187 66.6
Ser Acrogranin 8 180 68.3
Hsp70 3 22 72.5
aSer Hsp70 15 212 72.5
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Figure 5.5: Identification of Acrogranin as potential p1105 interacting partner by LC- 
MS/MS
(A) Pull-downs of beads only (Control), beads coupled to a peptide made of the p1105 C- 
terminal amino acid sequence containing Ser1039 (Ser) and beads coupled to a peptide made 
of the same amino acid sequence, but containing phosphorylated Ser1039 (pSer) were 
separated by SDS-PAGE and the protein gels stained with colloidal Coomassie blue. (B) 
Identification of Acrogranin by LC-MS/MS from the gel piece of Ser and pSer sample indicated 
in (A). (C) Comparison of LC-MS data of one peptide of Acrogranin (m/z = 876.53) in the LC-MS 
run of the control sample (C) and pSer sample (pSer).
5.5 p110S is not recruited to the plasma membrane  
following B cell stimulation
The subcellular localisation of class IA PI3K subunits was analysed from 
unstimulated and stimulated B cells in order to determine whether membrane 
recruitment of class IA PI3K isoforms could contribute to increased PI3K signalling 
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Figure 5.6: Membrane recruitment of class IA PI3K subunits is not increased following 
BCR engagement
WEHI-231 cells were left unstimulated (control) or were stimulated with a-IgM or OA. Following 
stimulation, the cells were lysed under hypotonic conditions and the cytosolic fraction separated 
from the membrane fraction by ultra-high centrifugation. 40 pg of cell lysate (L), cytosolic (C) 
and membrane (M) fraction were resolved by SDS-PAGE, followed by electroblotting. Class IA 
PI3K isoforms were analysed by immunoblotting using isoform-specific Abs. Immunoblotting 
analysis of the membrane marker Lyn was performed to control for successful membrane 
fractionation.
To this end, WEHI-231 cells were left unstimulated, stimulated for 5 min with a- 
IgM or for 30 min with the Ser/Thr phosphatase inhibitor okadaic acid (OA). The cells 
were subsequently lysed under hypotonic conditions and the membrane and cytosolic 
fraction separated by ultra-high centrifugation (§ 2.11). As shown in Figure 5.6, the 
majority of class IA PI3K protein from unstimulated, a-IgM stimulated and OA treated 
WEHI-231 cells was detected in the cytosolic fraction after cellular fractionation. The 
membrane-coupled protein kinase Lyn was used as a control for successful cellular 
fractionation.
These results suggest that class IA PI3Ks are not targeted to the plasma 
membrane following BCR stimulation in WEHI-231 cells. This finding implies that the 
increase in PI3K signalling observed following a-IgM stimulation of WEHI-231 cells is 
not due to membrane recruitment of p1106.
5.6 PI3K interaction partners change following BCR  
engagement
The binding partners of p1108 in basal state and after a-IgM stimulation of WEHI- 
231 cells were analysed by MS in order to identify potential protein interaction partners 




Thus, WEHI-231 cells were left unstimulated or were stimulated with a-IgM for 5 
min. p1105 was subsequently immunoprecipitated from cell lysate using a p1106- 
specific Ab. The immunocomplexes were vigorously washed using lysis buffer and the 
proteins of each sample resolved by SDS-PAGE. The protein gel was subsequently 
fixed and protein stained with colloidal Coomassie blue (Figure 5.7).
BCR engagement
Figure 5.7: Differences in the potential interaction partners of p1106 immunoprecipitated 
from unstimulated and a-IgM stimulated WEHI-231 cells
WEHI-231 cells were left unstimulated or stimulated with a-IgM for 5 min. p110S was 
immunoprecipitated from total cell lysate and resolved by SDS-PAGE. The protein gel was 
subsequently stained with colloidal Coomassie blue leading to the detection of small differences 
(marked with red line) in protein content between sample of unstimulated and stimulated cells.
In order to analyse the potential interaction partners of p1105 (and its regulatory 
subunit) in an unbiased manner, gel lanes were cut into sections of equal size and 
molecular weight as depicted in Figure 5.7, and gel pieces of unstimulated and 
stimulated sample were stored in separate tubes. Proteins in each sample were 
reduced, alkylated and subjected to tryptic in-gel digestion. LC-MS/MS was performed 
of the peptide content of each gel section.
LC-MS/MS analysis of two independent experiments performed as described 
above led to the identification of the proteins listed in Table 5.1 and Table 5.2. Proteins 
marked in grey were also identified by MS in pull-downs of WEHI-231 cells using plain 
beads only and are therefore likely enriched in p1105 IPs due to their binding capacity 
to agarose and/or protein A/G.
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Table 5.1: Potential interaction partners of p1105 from untreated and a-IgM stimulated 
WEHI-231 cells
p110S was immunopurified using a p1105 Ab from unstimulated and a-IgM stimulated WEHI- 
231 cells and the immunocomplexes were resolved by SDS-PAGE. The Coomassie stained gel 
was cut into pieces of equal size and molecular weight and the proteins reduced, alkylated and 
in-gel digested with trypsin. The peptides were analysed by LC-MS/MS. The experiment was 
performed twice and each sample was analysed two times by MS (4 MS runs in total). Peptide 
numbers and scores were taken from the first LC-MS/MS run of the first experiment. Proteins 
indicated in italics were only detected in 1 of the 2 experiments. Numbers in brackets indicate 
the highest peptide number and score for a certain protein. Listings in grey indicate that the 
protein was also found in plain bead-only (negative) control. Listings in black indicate that the 
protein was only detected by LC-MS/MS in the IP of stimulated cells.
Unstimulated sample Stimulated sample
MW protein name g»-number
peptide





200 P200 Arf-GEF 51704830 1 21 p200 Arf-GEF 51704830 3 60
IRS-2 3024044 1(9) 25(125)
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Damage-specific DNA 




binding protein 1 
(DDB1)
7 85
PARP-1 20806109 3 83
P1105 22758919 11 149 p1108 22758919 27 802
nucleolin 70844 4 87
100 Y-tubulin complex component 2 (GPC2) 19526968 4 64
Y-tubulin complex 




component 3 (GPC3) 39930567 4 42
Y-tubulin complex 
component 3 39930567 (13) (406)
90 H S P 90 * •23681 y 117 H S P 9 0 ‘ 12368’ 15 388
Gd 96* 6755863 1 40 G o9 6 ' 6755363 £. 95
p850 3379321 NA NA p858 3379321 14 243
85 p85a 91175 4 457 p85a 91175 14 392
Thymopoietin 6755817 18 497 Thymopoietin 6755817 17 403
75 HSP70’ '661134 c. 52 HSP7CT 1661134 6 103
Immunoglobulin NA NA NA Immunoglobulin NA NA NA
50 Gi28175231 28175231 2 84 Gi28175231 28175231 1 49
Y-tubulin 19527246 2 45 Y-tubulin 19527246 2 15
eEF-1a* 72870 1 56 eE F -1a ' 2 32
35 P0 6671569 3 42 P0 6671569 37
Proliferin 2-precursor 91201 1 36 Proliferin 2-precursor 91201 1 29
25 Hist1h4i, h 51311 3 50 Hist1h4i, h 51311 2 27
Immunoglobulin NA NA NA Immunoglobulin NA NA NA
We identified p200 Arf-GEF, damage-specific DNA binding protein 1 (DDB1), y- 
tubulin complex component 2/3 (GPC2, GPC3), y-tubulin, histone 1h4i, thymopoietin 
and p85a/p85(3 in p1105 IPs independent of B cell stimulation. Of these proteins, y- 
tubulin has previously been implicated in constitutively binding p85a, p55a and p55y 
(Inukai et al., 2000; Kapeller et al., 1995). Furthermore, GPC2 and GPC3 have been 
shown to constitutively interact with y-tubulin (Murphy et al., 1998). Thymopoietin was 
identified as a cross-contaminating protein of the p1105 Ab (§ 4.7.1). Arf-GEF, DDB1 
and histone are to the best of our knowledge novel potential PI3K interaction partners.
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BCAP, caprin-1, NEDD1 and Ras-GTPase-activating protein SH3-domain binding 
protein (G3BP) were also identified by MS in p1105 IPs (Table 5.2). BCAP has been 
reported to interact with the regulatory subunit of class IA PI3K (Okada et al., 2000) 
and NEDD1 was recently shown to bind to the y-tubulin ring complex (Haren et al., 
2006). However, caprin-1 and G3BP are novel potential PI3K interaction partners.
Proteins marked in bold in Table 5.1, were only detected by LC-MS/MS in the 
p1105 IP following BCR engagement of WEHI-231 cells. These are IRS-2, PARP-1 and 
nucleolin. IRS-2 is known to interact with the regulatory subunit of PI3K (although not 
downstream of BCR); PARP-1 and nucleolin are novel potential PI3K interaction 
partners.
Table 5.2: Potential p1105 binding partners
This table includes p1106 binding partners which were detected in the IP after a-IgM stimulation 
of WEHI-231 cells from the first experiment. However, because the LC-MS/MS run of the control 
cells was not as efficient as the one of the stimulated cells, it is possible that the indicated 
proteins also bind p1105 in unstimulated cells.
MW protein name gi-number
peptide
number score
90 BCAP 13878195 4 82
80 caprin-1 42558248 2 71
70 NEDD1 82592513 4 76
50 Ras-GTPase-activating protein SH3-domain binding protein (G3BP) 7305075 5 76
Data-dependent acquisition allows for automatic switching from MS to MS/MS 
experiments whenever an ion of pre-determined nature is detected. If, however, the 
count of a certain ion is below the set threshold for automatic switching or if more than 
3 ions are detected simultaneously, the ion will not be chosen for fragmentation. In 
order to verify that the absence of proteins in unstimulated samples is not due to the 
settings of the automatic switching, we manually analysed selected LC-MS and LC- 
MS/MS spectra of peptides derived from unstimulated and stimulated samples (Figure 
5.8, Figure 5.9).
Peak integrated areas of peptides related to proteins listed in Table 5.1 and Table 
5.2 were compared with peak integrated areas of unrelated (control) peptides. This 
analysis revealed similar protein amounts of p1105, p85a and p200 Arf-GEF in the 
p1105 IP of unstimulated and stimulated WEHI-231 cells (Figure 5.8). Analysing 
integrated peak areas of nucleolin and BCAP peptides exposed 2 times higher base 
peak intensity (BPI) values in samples derived from stimulated WEHI-231 cells 
compared to samples derived from control cells, suggesting that twice as much 
nucleolin and BCAP was pulled down in p1108 IPs from cell lysates of stimulated cells 
(Figure 5.9). 3-, 5- and 100-fold more PARP-1, IRS-2 and caprin-1 peptides were 
detected by MS in p1105-IP samples of stimulated WEHI-231 cells compared to control
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cells (Figure 5.9). The increase in BPI values following peak integration of peptides 
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Figure 5.8: Comparison of LC-MS spectra depicting integrated peak areas of peptides 
derived from control versus a-IgM stimulated WEHI-231 cells
LC-MS runs of p1106 IP samples derived from unstimulated and stimulated cells were analysed 
for protonated peptides of proteins listed in Table 5.1 and Table 5.2. The peptide peak 
containing the respective m/z is marked with an arrow. The integrated peak area of independent 
ions are shown for comparison. On the right, the MS/MS spectra are shown belonging to the 
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Figure 5.9: Comparison of LC-MS spectra depicting integrated peak areas of peptides 
derived from control versus a-IgM stimulated WEHI-231 cells
LC-MS runs of p1106 IP samples derived from unstimulated and stimulated cells were analysed 
for protonated peptides of proteins listed in Table 5.1 and Table 5.2. The peptide peak 
containing the respective m/z is marked with an arrow. The integrated peak area of independent 
ions are shown for comparison. On the right, the MS/MS spectra are shown belonging to the 
parent ions marked with an arrow in the MS spectra (left).
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Analysis of IRS-2 by LC-MS/MS following p1105 IP of a-IgM stimulated WEHI- 
231 cells revealed Ser573 as a novel phosphorylation site in IRS-2 (Figure 5.10). This 
residue has to the best of our knowledge not been identified as a phosphorylation site 
in murine or human IRS-2, and its equivalent Ser residue in IRS-1 has not been 
determined as a phosphorylation site.
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Figure 5.10: Ser573 identified as novel phosphorylation site in IRS-2 by LC-MS/MS
LC-MS/MS analysis of IRS-2, which was pulled down in a p1105-IP from a-IgM stimulated 
WEHI-231 cells, revealed phosphorylation of Ser573 in murine IRS-2. The MS/MS spectrum of 
the peptide TYpSLTTPAR is shown on the right, and fragment ion m/z are listed on the left.
In order to corroborate the interaction between p85-p1108 and BCAP or IRS-2, 
we analysed immunoprecipitates of p1105, p110a, IRS-2 and BCAP by immunoblotting 
for class IA PI3K isoforms and IRS-1, IRS-2 and BCAP (Figure 5.11). To this end, 
WEHI-231 cells were left unstimulated or stimulated with a-IgM. Following cell lysis, 
proteins were immunoprecipitated with respective Abs and the immunocomplexes 
resolved by SDS-PAGE. The immunoblots were incubated with the indicated Abs after 
electroblotting. Between Ab incubations, the filter was stripped of proteins if different 
primary Abs were used for analysis. Total cell lysate of unstimulated and stimulated 
WEHI-231 cells was analysed for Akt phosphorylation by immunoblotting (Figure 
5.11 .A) in order to control for successful stimulation conditions.
Immunoblotting results shown in Figure 5.11.B and Figure 5.11.C confirm the 
interaction of p85-p1108 with BCAP and IRS-2. While interaction of IRS-2 with all class 
IA PI3K isoforms increased following BCR engagement, analysis of BCAP interaction 
with class IA PI3Ks was more variable. Furthermore, IRS-1 was also shown to interact 
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Figure 5.11: Co-IP analysis of class IA PI3K with IRS and BCAP
(A) Total cell lysate (TCL) of control and a-IgM stimulated WEHI-231 cells was analysed by 
immunoblotting for Akt phosphorylation and tubulin. (B) IPs using Abs to p1105 and to p110a 
from unstimulated and stimulated WEHI-231 cell lysates were resolved by SDS-PAGE and 
subjected to electroblotting. Immunoblot sections are shown. (C) IPs using Abs to IRS-2 and 
BCAP from unstimulated and stimulated WEHI-231 cells were resolved by SDS-PAGE and 
subjected to elelctroblotting. Immunoblot sections are shown.
5.7 Net phosphorylation of p110S is increased  
following BCR engagement
Changes in the protein-protein binding affinities following cellular stimulation are 
often due to alterations in protein phosphorylation of the interacting proteins. Protein 
domains interacting specifically with phosphorylated residues have been revealed. 
SH2-, PTB-, and C2-domains can interact with pTyr (Benes et al., 2005; Kavanaugh 
and Williams, 1994; Sadowski et al., 1986), while BRCT-, and FHA-domains were 
shown to bind pSer/Thr (Durocher et al., 1999; Manke et al., 2003). Since IRS-2 
contains a PTB domain and an additional, uncategorised amino acid sequence shown 
to interact with pTyr and PARP-1 contains a BRCT domain, we analysed the 
phosphorylation state of p1105 following BCR engagement by in vivo labelling 
experiments with radioactive ATP (§ 2.12).
For this purpose, WEHI-231 cells were incubated with 0.4 mCi [y-32P]ATP for 6 h 
and were subsequently stimulated with a-IgM or OA (Ser/Thr phosphatase inhibitor, 
positive control). Following cell lysis, p1105 was immunoprecipitated and the complex 
resolved by SDS-PAGE. Incorporation of [y-32P]ATP into proteins was measured by 
exposure of the dried gel to phospho-imager plates.
As shown in Figure 5.12, incorporation of radioactive phosphate into p1105 was 
increased following a-IgM and OA stimulation of WEHI-231 cells. Surprisingly, 
phosphorylation of p1105 upon BCR engagement was higher than in OA treated cells
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even though OA treatment of cells has been shown to greatly induce phosphorylation 
of Ser1039 as detected by immunoblotting (Vanhaesebroeck et al., 1999). These 
results suggest that p1105 becomes phosphorylated in a-IgM stimulated WEHI-231 
cells. Furthermore, the increase in p1105 phosphorylation outweighs the decrease in 
Ser1039 phosphorylation observed following BRC engagement (Figure 5.4) leading to 




Figure 5.12: BCR engagement of immature B cells induces net phosphorylation of p1105
In vivo labelling of WEHI-231 cells with [y-32P]ATP was followed by stimulation of B cells with a- 
IgM or OA. p1105 was immunoprecipitated with an Ab raised against its C-terminus and the 
immunocomplex resolved by SDS-PAGE. The gel was stained with colloidal Coomassie blue 
and dried. [y-32P]ATP incorporation was measured by exposure of the dried gel to phospho- 
imager plates.
5.8 B cell stimulation induces Tyr phosphorylation of  
p110S
Tyr phosphorylation of class IA PI3K catalytic subunit has been demonstrated in 
chicken DT40 B cells following BCR engagement (Craxton et al., 1999) or H20 2 
treatment (Qin and Chock, 2003). We therefore analysed whether the increase in net 
phosphorylation detected following BCR engagement of WEHI-231 cells could be due 
to an increase in Tyr phosphorylation of p1105.
WEHI-231 cells were stimulated for the indicated times with a-IgM or pV 
(pervanadate, Tyr phosphatase inhibitor). Following cell lysis, p1105 was 
immunoprecipitated and the immunocomplex resolved by SDS-PAGE. Phosphorylation 




As shown in Figure 5.13.A, Tyr phosphorylation of p1105 was induced and 
peaked shortly after BCR crosslinking in WEHI-231 cells. pV treatment also enhanced 
Tyr phosphorylation of p1105 (Figure 5.13.B). In contrast, treatment of cells with the 
























Figure 5.13: Tyr phosphorylation of p1105 is induced following BCR stimulation or pV 
treatment of WEHI-231 cells
WEHI-231 cells were stimulated for the indicated time points with a-IgM or pV and p1105 
immunoprecipitated from cell lysates. Tyr phosphorylation of p1105 was analysed by 
immunoblotting with anti-pTyr Abs. Following stripping of proteins off the PVDF membrane, 
p1105 was analysed by immunoblotting with p1105-specific Abs.
5.9 p110S, but not p110a  or p110fi, becomes Tyr 
phosphorylated following BCR crosslinking
In order to address whether Tyr phosphorylation was common in all 3 class IA 
PI3K catalytic subunits under the chosen stimulation conditions, p110a, p110p and 
p1105 were immunoprecipitated from unstimulated and a-IgM stimulated WEHI-231 
cells. The immunoprecipitated proteins were resolved by SDS-PAGE and Tyr 
phosphorylation analysed by immunoblotting. Following stripping of proteins off the 
filter, the amount of regulatory subunit detected by immunoblotting in each IP was used 
as a control for equal p85 immunoprecipitation and equal gel loading.
As shown in Figure 5.14, it was mainly p1105 that became Tyr phosphorylated 






Figure 5.14: Comparison of Tyr phosphorylation between class IA PI3K catalytic subunits
The 3 class IA PI3K catalytic subunits were immunoprecipitated from unstimulated (control) and 
a-IgM stimulated WEHI-231 cells with isoform-specific Abs and analysed by immunoblotting for 
Tyr phosphorylation. The regulatory subunit was detected in each IP by immunoblotting using a 
p85pan Ab.
5.10 Tyr phosphorylation of p110S occurs mainly in B 
cells
p1105 is mainly expressed in cells of hematopoietic origin, but is also found in 
other cell types (§ 1.2.1.1.1.3). In order to investigate whether Tyr phosphorylation of 
p1105 occurs in cell types other than immature B cells, we tested a panel of p1105 
expressing cell lines: murine mature B cells (A20); human immature B cells (NALM-6); 
murine T cells (EL-4); human gastrointestinal stromal sarcoma cells (GIST); human 
mastocytoma cells (HMC-1); murine melanoma cells (B16BL6) and breast cancer cells 
(MDA-MB361). Since results described in § 5.8 indicated that pV treatment of WEHI- 
231 cells induced Tyr phosphorylation of p1105, pV was used as a stimulus.
In order to determine whether pV stimulation induced overall protein Tyr 
phosphorylation, total cell lysates of the indicated cell lines were first analysed by pTyr 
immunoblotting. As shown in Figure 5.15.A, induction of Tyr phosphorylation following 
pV treatment was successful in all cell types, even though least effective in EL-4 cells. 
After stripping of proteins of the filter, p1105 protein expression levels in total cell lysate 
were compared in each cell type by immunoblotting using an anti-p1105 Ab. This 
analysis revealed variable p1105 protein amounts in different cell types and 
undetectable levels of p1105 in the breast cancer cell line MDA-MB361.
Nevertheless, all cell types were subsequently treated with pV for 30 min and 
p1105 was immunoprecipitated following cell lysis. The proteins were resolved by SDS- 
PAGE, electroblotted to PVDF filters and the immunoblot was incubated with pTyr- 
specific Abs. As shown in Figure 5.15.B, Tyr phosphorylation of p1105 following pV 
treatment of cells mainly occurred in B cells (immature, mature, murine, human).
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Figure 5.15: p1105 is phosphorylated on Tyr residue(s) mainly in B cells
(A) Total cell lysate of various cell lines separated by SDS-PAGE and electroblotted to PVDF 
filter was analysed by immunoblotting for Tyr phosphorylation following pV treatment. The filter 
was reprobed with a p1105 Ab after stripping of proteins (lower panel). (B) Immunoprecipitated 
p1105 was analysed by immunoblotting with a pTyr-specific Ab for Tyr phosphorylation following 
pV treatment of various cell lines. The filter was reprobed with a p1105 Ab after stripping of 
proteins.
5.11 pV  stimulation of HEK-293T cells overexpressing  
p110S did not induce Tyr phosphorylation of p11 OS
Overexpression of p1105 was desirable in order to identify phosphorylated Tyr 
residues by MS. Since transfection of leukocytes by electroporation or calcium 
phosphate precipitation was not successful (data not shown), we used HEK-293T cells, 
a cell line that can easily be transfected.
106 HEK-293T cells were transiently transfected with 10 /yg plasmid DNA 
containing murine or human p1105 cDNA in combination with 10 /yg plasmid DNA 
containing bovine p85a or p85p cDNA using the calcium phosphate precipitation 
protocol (§ 2.7.2.5). Following cell lysis, total cell lysate was resolved by SDS-PAGE 
and analysed by immunoblotting for PI3K isoforms. Endogenous p1105 and p85 
protein amounts expressed in WEHI-231 or HEK-293T transfected with vector only (-) 
were compared to overexpressed p1105/p85 from HEK-293T cells. Overexpression of 
human and murine p1105 was successful following calcium phosphate precipitation 
transfection compared to HEK-293T cells transfected with vector only. Higher p1105 




However, when HEK-293T cells transfected with murine p1108 and bovine p85a 
(or p85p, data not shown) were treated with pV, Tyr phosphorylation of 
immunoprecipitated p1105 was not observed by pTyr immunoblotting (Figure 5.16.B). 
We therefore did not perform MS experiments with overexpressed p1108.
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Figure 5.16: pV stimulation of HEK-293T cells does not induce Tyr phosphorylation of 
overexpressed p1108
(A) HEK-293T cells were transfected with vector only (-), a DNA plasmid containing human or 
murine p1105, and a combination of plasmid containing p110S and bovine p85a or p85(3. PI3K 
isoform expression in HEK-293T cells was compared to endogenous protein expression in 
WEHI-231 cells. Cell lysates were analysed by immunoblotting with Abs to p1105 and p85pan.
(B) p1105 was immunoprecipitated from pV stimulated HEK-293T cells, which were previously 
transfected with p1105 and p85a cDNA. Phosphorylation of p1105 was analysed by pTyr 
immunoblotting (right panel). Following stripping of proteins, the filter was incubated with Abs to 
p1105 and p85pan.
5.12 MS analysis of p110S did not reveal  
phosphorylated Tyr residue(s)
In order to determine the site(s) of Tyr phosphorylation of endogenous p1108, MS 
analysis was performed. To this end, the catalytic subunit was immunoprecipitated 
from WEHI-231 cell lysate and the proteins resolved by 2D-PAGE in order to enrich for 
phosphorylated species. However, as shown in Figure 5.17.A, 2D-PAGE analysis of 
p1108 was not feasible due to the incapability of the catalytic subunit to enter the first 
dimension of 2D-gels (IPG strips (shown below) and tube gels (data not shown)). We 
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Figure 5.17: Separation of p110 by 2D-PAGE is not feasible, therefore
immunoprecipitated p1108 was resolved by 1D-SDS-PAGE
(A) WEHI-231 total cell lysate (TCL) was applied to IPG strips and left to rehydrate overnight. 
The following day, the strips were removed from the strip aligner and the 1 D-gels scrapped from 
the plastic support and boiled for 5 min in 5 x SDS-sample buffer (IN fraction). The remaining 
liquid in the strip aligner was also diluted with 5 x SDS-sample buffer and boiled (OUT fraction). 
The fractions were separated by 1D-SDS-PAGE and analysed for PI3K isoforms by 
immunoblotting. (B) p1105 was immunoprecipitated from WEHI-231 cell lysate and resolved by 
1D-SDS-PAGE. The gel was fixed and stained with colloidal Coomassie blue. Recombinant 
p110/p85 protein was resolved in the same gel.
p1105 immunoprecipitated from a-IgM stimulated WEHI-231 cells was analysed 
by MS following SDS-PAGE and in-gel protein digestion.
For preliminary analysis, MALDI mass fingerprinting was applied (detailed 
information to MALDI mass fingerprinting is provided in § 4.7.5). This led to the 
identification of 5 p1105 peptides that could potentially be phosphorylated on Tyr 
residues (Figure 5.18). The amino acid sequence surrounding these Tyr residues were 
analysed in silico for their conservation between class IA catalytic subunits using 
ClustalW, for their probability to become phosphorylated (NetPhos and Proscan) and to 
be part of a SH2-binding motif (Motifscan). We also analysed the probablity of these 
Tyr residues to become phosphorylated by a panel of protein kinases (Motifscan, 
NetPhosK, GPS). Using Swiss PDB viewer, we investigated the exposure to the 
surface of the 5 Tyr residues in order to estimate the accessibility of this amino acid to 
protein kinases. This analysis was performed by overlaying the primary structure of 
p1105 with the solved crystal structure of p110y.
Further analysis of the 5 potentially phosphorylated Tyr residues by LC-MS/MS, 
LC-MRM and error-tolerant searches of MS-data did not allow for identification of 
phosphorylated residues (more detailed information to each method is provided in § 
4.7). Moreover, IMAC enrichment or precursor-ion scanning (in collaboration with Dr. 
N. Morrice, MRC Phosphorylation Unit, University of Dundee, UK) of p1105 did also not 
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Figure 5.18: Potential p1105 phospho-peptides identified by MALDI mass fingerprinting
MALDI analysis of trypsinised p1105 revealed 5 potentially phosphorylated peptides. These 
peptides were analysed for their conservation between class IA PI3K (ClustalW) and for their 
probability to become phosphorylated using prediction programs NetPhos and Proscan. 
Furthermore, the Tyr residues were analysed for their probability to be part of a SH2 binding 
motif (Motifscan) and to be phosphorylated by kinases (Motifscan, NetPhosK, GPS). The Swiss 
PDB viewer was used to investigate the position of the Tyr residue in the catalytic subunit 
tertiary structure using the p110y structure as a template.
5.13 Discussion
5.13.1 Critical role for p1105 in BCR sigalling
Stimulation of B cells by BCR crosslinking leads to PI3K activation. The critical 
component in PI3K signalling following BCR engagement seems to be p1105. This was 
confirmed by pharmacological studies using PI3K-isoform specific inhibitors to p110p, 
p1105, and p110y to analyse Akt phosphorylation following BCR engagement, which 
was decreased by inhibition of p1105, but not p110(3 or p110y. Interestingly, inhibition 
of p110|3 and p110y by isoform-specific inhibitors led to enhanced Akt phosphorylation 
following BCR crosslinking, indicative for a negative feedback loop on PI3K signalling 
exerted by these isoforms in B cells.
In order to gain insight into the regulation of p1105 activity in B cells following 
cellular stimulation, we performed diverse biochemical analyses.
5.13.2 In vitro lipid kinase activity of p1106 is unchanged 
following BCR engagement
BCR engagement did not impact on the intrinsic lipid kinase activity of p1105 as 
determined by in vitro lipid kinase activity assays. The generation of 3-phosphorylated
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Pis by p1105 was similar if cells were unstimulated or stimulated with a-IgM prior to the 
assay. This result was independent of the lipid substrate used (Ptdlns/Ptdlns(4,5)P2). 
Our findings are in line with previous reports which have shown that the in vitro lipid 
kinase activity of immunoprecipitated PI3K did not increase in stimulated DT40 cells 
compared to unstimulated control (Qin and Chock, 2003). However, the p1108 fraction 
which becomes activated following BCR engagement might be too small in order to 
measure a difference in the in vitro lipid kinase activity of the whole p1105 population 
immunoprecipitated with p1108-specific Abs.
In contrast, p1108 Ser1039 phosphorylation decreased modestly following BCR 
crosslinking. The Ser1039 residue of p1108 has previously been shown to be important 
in the regulation of the p1108 lipid kinase activity in vitro, since the lipid kinase activity 
of Ser1039 mutants (Ser1039Asp, Ser1039Glu) is reduced compared to WT p1108. 
Furthermore, phosphorylation of this site correlates with a decrease in PI3K lipid kinase 
activity in human T cells upon CD28 stimulation (Vanhaesebroeck et al., 1999). Thus, if 
CD28 stimulation of T cells was comparable to a-IgM stimulation of B cells, a decrease 
in pSer1039 following a-IgM stimulation of WEHI-231 cells would indicate an increase 
in p1108 lipid kinase activity. However, the impact of Ser1039 phosphorylation on 
p1108 lipid kinase activity in T cells might be distinct from B cells due to differences in 
concomitant p1108 phosphorylation which control the lipid kinase activity. It is further 
possible that the decrease in Ser1039 phosphorylation was too minor to measure a 
difference in the in vitro lipid kinase activity assay.
5.13.3 BCR stimulation of WEHI-231 cells does not lead to 
p1105 membrane recruitment
Fractionation experiments to separate cytosolic from membrane fraction of 
unstimulated and a-IgM stimulated WEHI-231 cells (and mature A20 B cells, data not 
shown) revealed cytosolic localisation of all class IA PI3Ks, while the membrane 
marker Lyn was detected in the membrane fraction. This finding indicates that the 
increase in PI3K signalling following BCR engagement is also not due to recruitment of 
the catalytic subunit to the membrane. However, it is possible that the lysis conditions 
used in this experimental set-up were chosen too stringently to reveal membrane 
localisation of class IA PI3Ks. Furthermore, the number of PI3K molecules recruited to 
the membrane following cellular stimulation might be very small compared to the 
cytosolic pool, not allowing for its detection by immunoblotting.
Another possibility is that not membrane recruitment but changes in the nuclear 
localisation of p110S is the decisive factor in BCR signalling of immature B cells. As will
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be described in more detail below, p1108 appears to be found in close contact with a 
variety of nuclear proteins.
5.13.4 p1105 is Tyr phosphorylated upon BCR crosslinking
In vivo labelling experiments revealed increased phosphorylation of p1105 
following BCR engagement of WEHI-231. This increase was at least partially due to 
enhanced phosphorylation of Tyr residues. Tyr phosphorylation of p1108 rose quickly 
following cellular stimulation and decreased to its half-maximum within 10 min of 
stimulation. We further provide evidence that mainly p1105 is Tyr phosphorylated in B 
cells, since only a modest increase in Tyr phosphorylation of p110(3, but no significant 
Tyr phosphorylation of p110a was detected upon BCR engagement. Comparative 
analysis of murine p1108, with p110a and p110(3 amino acid sequences disclosed 8 
Tyr residues in p1108 whose equivalent Tyr residue was only present in p110(3. 
Tyr395, which was identified as a potential phospho-acceptor by MS, was one of these 
8 Tyr residues.
We could further demonstrate that Tyr phosphorylation of p1108 preferentially 
occurred in B cells. For this purpose, Tyr phosphorylation of p1108 was compared by 
immunoblotting in a panel of p1108-expressing cell lines that were treated with the Tyr 
phosphatase inhibitor pV. Only immature and mature B cells of murine and human 
origin showed a significant increase in p110S Tyr phosphorylation following pV 
treatment. Furthermore, pV treatment of HEK-293T cells in which p1108 was 
transiently overexpressed did also not induce p1108 Tyr phosphorylation. These 
findings indicate that a B-cell specific Tyr kinase might be involved in p1108 
phosphorylation. Studies performed in DT40 cells have shown that the catalytic subunit 
of class IA PI3K is Tyr phosphorylated following BCR engagement (Craxton et al., 
1999). Tyr phosphorylation of p110 following BCR engagement was unchanged in Btk- 
and PLCy-deficient cells compared to wild-type cells, decreased in Syk-deficient DT40 
cells, and increased in Lyn-deficient cells. Also DT40 cells treated with H20 2 had 
enhanced Tyr phosphorylation of p110, and Syk- and Lyn-deficient cells showed 
dampened phosphorylation (Qin and Chock, 2003). These findings indicated that Syk, 
Lyn or an effector of these kinases is likely to be responsible for p110S 
phosphorylation. Applying the GPS prediction algorithm to p1108, Syk is predicted to 
phosphorylate Tyr55 and Tyr523 in p1108, which are not part of the potentially 
phosphorylated Tyr residues revealed by MS. In contrast, Lyn is predicted to 
phosphorylate Tyr239, Tyr523 and Tyr723. Tyr239 was identified as a potential p1108 
Tyr phosphorylation site by MALDI mass fingerprinting.
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Even though it was not possible to identify a phosphorylated Tyr residue in 
p1105 by LC-MS/MS, we could detect 5 p1108 peptides with potentially phosphorylated 
Tyr residues by MALDI mass fingerprinting (Tyr239, Tyr395, Tyr670, Tyr812, and 
Tyr963). These residues and their surrounding sequences were analysed by several 
biocomputational tools. Tyr670 is not exposed to the protein surface and is also not 
predicted to become phosphorylated by a Tyr kinase or to encompass a SH2 binding 
motif, and is therefore an unlikely candidate for Tyr phosphorylation. Also Tyr963 is not 
well exposed to the protein surface and therefore less likely to be phosphorylated. In 
contrast, Tyr239 is exposed, predicted to be phosphorylated by Lyn and could 
potentially constitute an Itk binding site. Also Tyr395 is exposed to the protein surface 
and phosphorylation of Tyr395 seems probable due to the sequence homology of the 
Tyr395 flanking region of p1108 to p110(3, but not p110a. Furthermore, phosphorylated 
Tyr812 could constitute a binding site for SHIP.
Following a-IgM stimulation of WEHI-231 cells, IRS-2, PARP-1 and caprin-1 
interacted with p1108. Some of these interaction partners might bind to p1108 due to its 
Tyr phosphorylation. This will be discussed in more detail below.
5.13.5 Interaction partners of p1105 in unstimulated B cells
By performing co-IP experiments from proliferating, but not a-IgM stimulated 
WEHI-231 cells, known and novel PI3K interaction partners were detected by MS. 
Figure 5.19 shows a hypothetical model of the PI3K interaction partners and the 
subcellular localisation of p85-p1108 due to the respective interaction. The potential 
PI3K interaction partners were compared to information obtained from the yeast 2- 
hybrid database available at Afcs gateway, from pSTIING and BIND database in 
conjunction with literature data. Although the associations of the novel potential PI3K 
interaction partners detected in unstimulated cells were unlikely due to unspecific 
interaction with matrix because we compared these data with a bead-only control, it is 
possible that purification of these proteins occurred because of unspecific Ab 
association. The interaction partners and nature of the complex will be discussed 
below.
The interaction between BCAP and PI3K is likely due to binding of class IA 
PI3K regulatory subunit to pTyr residues in YxxM-motifs of BCAP. BCAP is a B cell- 
specific adaptor molecule containing 4 YxxM p85-binding motifs (Okada et al., 2000) 
and has been shown to become Tyr phosphorylated within minutes of BCR 
engagement (Inabe and Kurosaki, 2002). p85 association with BCAP was observed in 
unstimulated B cells, and rapidly increased and subsequently decreased following 
cellular stimulation (Okada et al., 2000). Comparison of our MS/MS data gained from
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unstimulated versus stimulated WEHI-231 cells indicated a small increase in BCAP 
association with PI3K following cellular stimulation. In contrast, immunoblotting data 
revealed a large decrease in binding of p1105 to BCAP upon a-IgM stimulation of 
WEHI-231 cells. The discrepancy between these findings might be due to small 
differences in the length of stimulation. However, it seems that in proliferating WEHI- 
231 cells a fraction of BCAP is constitutively phosphorylated thereby providing docking 
sites for p85.
The interaction between y-tubulin and PI3K has previously been reported, y- 
tubulin was shown to bind p55a and p55y constitutively, while binding to p85 following 
cellular stimulation (Inukai et al., 2000; Kapeller et al., 1995). y-tubulin is part of the 
centrosome and other microtubule-organising centres and stabilises the minus-end of 
microtubules. It has been suggested that PI3Ks could be involved in the regulation of 
microtubule stability or in the regulation of vesicle budding/fusion located at 
microtubules.
GPC2, GPC3 and NEDD1 interact with y-tubulin to form a so-called y-tubulin 
ring complex (Haren et al., 2006; Murphy et al., 1998). Thus, their identification in 






Figure 5.19: Hypothetical model of potential PI3K interaction partners and subcellular 
localisation in unstimulated WEHI-231 cells
Co-IP experiments using p1105-specific Abs revealed a variety of potential PI3K interaction 
partners in unstimulated cells. Data gained from the literature allowed drawing some 
conclusions about the nature of their interaction with class IA PI3Ks. Details to each interaction 
partner can be found below.
p200 Arf-GEF is a novel potential PI3K interaction partner. This protein does 
not contain any known domain or motif which could explain binding to p85 or p110.
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p200 Arf-GEF is a Brefeldin A-sensitive guanine nucleotide exchange factor for small 
GTPases of the ADP ribosylation factor (Arf) family (Mansour et al., 1999) and is 
localised at the Golgi. Vesicle transport from the Golgi to the plasma membrane is 
regulated by Arf and occurs along microtubules. Therefore, regulation of vesicle 
transport could possibly link the interaction of PI3K to p200 Arf-GEF with PI3K to the y- 
tubulin ring complex. However, interaction between p200 Arf-GEF and PI3K has to be 
verified using independent Abs or techniques.
The 4 potential PI3K interaction partners G3BP, nucleolin, DDB1 and histone 
H4 are proteins detected in the nucleus in proliferating and/or stimulated cells. Since 
class IA PI3Ks have been shown to translocate to the nucleus following cellular 
stimulation (Neri et al., 1994), it is possible that a fraction of class IA PI3Ks reside in 
the nucleus in proliferating WEH1-231 cells.
Ras GTPase activating protein SH3 domain binding protein (G3BP) is a novel 
potential PI3K interaction partner and its interaction with PI3K can not easily be 
deduced from primary sequence analysis or literature data. G3BP is a RasGAP 
interacting endonuclease that cleaves AU-rich regions in mRNA, thereby targeting 
mRNA for rapid degradation. Following growth factor stimulation, G3BP is 
phosphorylated on Ser residues and translocates to the nucleus (Barnes et al., 2002). 
Since proliferating WEH 1-231 cells can be compared to stimulated cells, G3BP is likely 
localised in the nucleus in WEHI-231 cells. In contrast, unphosphorylated G3BP 
assembles in so-called stress granules in the cytoplasm in response to cytotoxic stress 
(Tourriere et al., 2001); (Tourriere et al., 2003). Interestingly, G3BP KO mice exhibit 
increased apoptotic cell death suggesting that G3BP is involved in the regulation of 
apoptosis (Zekri et al., 2005). On the basis of these findings, we speculate that a-IgM 
stimulation of immature B cells, which induces apoptosis, leads to translocation of the 
G3BP-PI3K complex to the cytoplasm. Furthermore, G3BP was shown to interact with 
caprin-1 (Katsafanas and Moss, 2004), a novel potential cytoplasmic PI3K interaction- 
partner of p85-p1108 in a-IgM stimulated WEHI-231 cells.
Tyr phosphorylated residues of Nucleolin were shown to interact with the SH2 
domain of the regulatory subunit (Barel et al., 2001). A recent study has further 
revealed that interaction of nucleolin with the class IA PI3K regulatory subunit was 
increased in endothelial cells following induction of fluid flow (Huddleson et al., 2006). 
Qualitative MS analysis revealed a small increase of nucleolin associated with PI3K in 
a-IgM stimulated WEHI-231 cells compared to control samples. Nucleolin is a 
multifunctional protein that plays a key role in ribosome biogenesis and in nuclear 
organisation (Ginisty et al., 1999). Although generally considered a nuclear protein, 
nucleolin can also be present in the cytoplasm and cell surface (Borer et al., 1989). In 
fact, translocation from the nucleus to the cytosol was observed in apoptotic B cells (Mi
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et al., 2003). This suggests that the nucleolin-PI3K complex, residing in the nucleus in
proliferating WEHI-231 cells, might translocate to the cytosol following a-IgM
stimulation of WEHI-231 cells. Nucleolin also interacts with the PH domain of IRS-1
and IRS-2 (Burks et al., 1998), and with PARP-1 (Borggrefe et al., 1998). However,
since IRS-2 and PARP-1 were only detected in association with PI3K in stimulated 
cells, whereas nucleolin was found in co-IPs of unstimulated and stimulated WEHI-231 
cells, we conclude that the interaction between PI3K and nucleolin is probably not via 
IRS-2 or PARP-1
No information is available about the interaction between PI3K and damage 
DNA binding protein 1 (DDB1) and no known PI3K interaction domain or motif in DDB1 
could be detected. DDB1 forms a heterodimeric complex with DDB2. DDB expression 
and activity increase following UV irradiation of cells leading to increased nucleotide 
excision repair. Furthermore, DDB1 was recently shown to interact with Cul4 to form an 
ubiquitin E3 ligase complex which ubiquinates histones in response to UV irradiation 
(Groisman et al., 2003). Since we also detected histone H4 in the p1105 IPs by MS, 
we speculate that the interaction between PI3K, DDB1 and histone H4 occurs in 
proximity of DNA.
In addition to co-IP experiments, we also performed pull-down assays of WEHI- 
231 cell lysates using peptides corresponding to the C-terminal sequence of p1105. 
These peptides contained non-phosphorylated or phosphorylated Ser1039. Analysis of 
pulled-down proteins by MS led to the identification of Acrogranin. Acrogranin is an 
epithelial tissue growth factor that has been implicated in the progression of many 
cancers. It has been shown to stimulate MAPK, PI3K and FAK kinase pathways. We 
speculate that the potential interaction of Acrogranin to p1105 might have a role in the 
regulation of p1108 activity.
In summary, in unstimulated, but proliferating immature B cells p1105 likely 
exists in the cytoplasm associated with BCAP, p200 Arf-GEF and the y-tubulin ring 
complex. Association with the latter two proteins might suggest involvement of p1105 in 
vesicular traffic. A fraction of p1108 might also be found in the nucleus, where it seems 
to bind proteins involved in DNA and RNA metabolism.
5.13.6 Interaction partners of p1105 following BCR 
engagement
In order to further determine the impact of p1108 Tyr phosphorylation on PI3K 
signalling and of BCR crosslinking in immature B cells, we analysed by MS proteins 
immunoprecipitated by p1108 Abs from a-IgM stimulated WEHI-231 cells. IRS-2, 
PAPR-1 and caprin-1 were identified as novel potential p85-p1108 interaction partners
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downstream of the BCR. A hypothetical model of PI3K interactions and subcellular 
localisation following BCR engagement is shown in Figure 5.20.
The interaction between p85-p1105 and insulin receptor substrate (IRS)-2 
increased by more than 5-fold following BCR engagement as determined by qualitative 
MS analysis and immunoblotting of co-IP experiments. This interaction is likely due to 
binding of the regulatory subunit SH2 domains to phosphorylated Tyr residues in YxxM 
motifs of IRS-2. IRS contains multiple YxxM motifs to which p85 can bind (Backer et 
al., 1992). Since also the interaction of p110a with IRS-2 was increased upon cellular 
stimulation, binding of PI3K to IRS-2 via p85 is emphasised. Two further domains of 
IRS-2 could be involved in p85-p1108 binding. First, a pTyr binding (PTB) domain 
which interacts with pTyr residues located in NPxY sequences (He et al., 1996). p1105 
contains two Tyr residues with similar flanking sequences: Tyr474 is part of YxPE and 
Tyr484 lies within HPxYxPA. Second, amino acid sequence 591-733 of IRS-2, but not 
IRS-1 was shown to interact with IR and IGF-R in a pTyr-dependent, but NPxY- 
independent manner (He et al., 1996). We therefore hypothesise that IRS-2 might bind 
p1105 via pTyr residue(s).
Involvement of IRS-2 downstream of the BCR has not been reported and it is 
therefore not evident how IRS-2 is coupled to the BCR. Unlike the IL-4 receptor, which 
has been implicated in IRS-2 signalling in B cells (Johnston et al., 1995), the 
immunoglobulin-associated CD79a/p do not possess Tyr residues in NPxY motifs in 
their cytosolic domains which could provide docking sites for IRS-2. However, the IRS- 
2-specific amino acids sequence 591-733 binding to phosphorylated Tyr residues might 
provide this interaction. Furthermore, IRS-2 contains a PH domain implicated in the 
binding to Pis (Razzini et al., 2000), which might induce interaction with the BCR. 
Interestingly, nucleolin, a potential novel p85-p1108 protein partner in proliferating 
WEHI-231 cells, was shown to bind to the PH domain of IRS-2, thereby inhibiting 
insulin-stimulated Tyr phosphorylation of IRS-2 (Burks et al., 1998). Interaction 
between the nucleolin-PI3K complex and IRS-2 might therefore provide a negative 
feedback loop in BCR signalling. In addition, it is not clear how phosphorylation of IRS- 
2 downstream of the BCR might be achieved. IRS-2 cannot be phosphorylated on 
YxxM motifs by the BCR complex, since BCR does not contain kinase activity. Janus 
kinases have been implicated in IRS-2 phosphorylation downstream of receptors 
lacking kinase activity (Johnston et al., 1995; Kellerer et al., 1997) and those kinases 
might possibly phosphorylated IRS-2 downstream of the BCR. However, it has also 
been suggested that the IRS pathway is independent of the JAK pathway in 
hematopoietic cells (Uddin et al., 1997).
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A novel IRS-2 phosphorylation site on Ser573 was determined by LC-MS/MS. 
Ser phosphorylation of IRS seems to regulate insulin signal transduction by blocking 
IRS interaction with IR (Tanti et al., 1994) or by inducing IRS degradation (Pederson et 
al., 2001). Ser phosphorylation was shown to be catalysed by different Ser kinases, 
amongst other class IA PI3K (Lam et al., 1994; Tanti et al., 1994) and Akt (Guo et al., 
1999; Paz et al., 1999). Indeed, Ser573 lies within an acceptor sequence for Akt 
phosphorylation. Ser phosphorylation of IRS-2 by Akt might therefore provide a 
regulatory feedback loop in WEHI-231 cells.
Plasma membrane




Figure 5.20: Hypothetical model of PI3K interaction partners and subcellular localisation 
following BCR engagement of WEHI-231 cells
Co-IP experiments using p1105-specific Abs revealed a variety of potential PI3K interaction 
partners in unstimulated cells. Data gained from the literature allowed drawing some 
conclusions about the nature of their interaction with class IA PI3K. Details to each interaction 
partners can be found below.
A potential novel PI3K interaction partner in a-IgM stimulated WEHI-231 cells is 
PARP-1. The interaction between PARP-1 and p85-p1105 was increased by 4-fold 
following BCR engagement of WEHI-231 cells. In addition to the identification of PARP- 
1 in p1105 co-IPs, p1105 and p110p were also identified in PARP-1 IPs (T. Helleday, 
Institute for Cancer Studies, University of Sheffield, personal communication). 
Interaction between PARP-1 and PI3K could be mediated by dimerisation of the basic 
leucine zipper regions (bZIP) of p1108/p110(3 and PARP-1. PARP-1 also contains a 
BRCT domain which can bind phosphorylated Ser/Thr residues; however, since p1105
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Ser1039 phosphorylation is decreased following BCR stimulation, this is unlikely to 
happen unless unidentified pSer/pThr residues exist in p1105. PARP-1 is activated by 
broken DNA and catalyses the reversible modification of proteins with ADP-ribose. 
Poly(ADP-ribosyl)ation of histones and other nuclear proteins contributes to the 
survival of proliferating cells following DNA damage (reviewed in (Ame et al., 2004)). 
During apoptosis, PARP-1 is one of the first proteins cleaved by caspases (Kaufmann 
et al., 1993). Interestingly, PARP-1 has also been shown to interact with nucleolin. We 
therefore speculate that translocation of PARP-1 by PI3K-nucleolin complex to the 
cytosol following BCR engagement of WEHI-231 cells might inhibit DNA repair in the 
nucleus leading to the onset of apoptosis.
Furthermore, we could identify Cytoplasmic Activation/Proliferation-Associated 
Protein-1 (caprin-1) as a novel potential PI3K interaction protein. Interaction beween 
caprin-1 and PI3K increased by more than 100-fold following cellular stimulation as 
determined by qualitative MS. As its name suggests, caprin-1 is a cytosolic protein 
involved in cellular proliferation (Grill et al., 2004). It contains 2 SH3 domains which 
might mediate interaction with the proline-rich regions of p85 or p1108. Interestingly, 
caprin-1 was shown to interact with G3BP (Katsafanas and Moss, 2004). We 
hypothesise that translocation of G3BP-PI3K from the nucleus to the cytosol following 
cellular stimulation leads to interaction of the complex with caprin-1.
In summary, following a-IgM stimulation of immature B cells, p1108 seems to 
be recruited to the membrane by interaction with IRS-2 and possibly BCAP leading to 
increased phosphorylation of Akt. Furthermore, p85-p1108 might translocate from the 
nucleus to the cytosol due to interaction with G3BP and nucleolin, which were shown to 
become cytosolic following cellular stress. This might lead to interaction of G3BP-PI3K 
with caprin-1 and of nucleolin-PI3K with IRS-2.
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6 In ves tig a tio n  o f  th e  p85  t o  p 110 expression r a t io  in
MAMMALIAN CELLS
The role of the regulatory subunit of class IA PI3K in resting cells appears to be 
stabilisation of the catalytic subunit and inhibition of its lipid kinase activity. Following 
cellular stimulation, p85 was shown to recruit p110 to the plasma membrane and to 
release inhibition on the lipid kinase activity by interaction of p85 SH2 domains with Tyr 
phosphorylated proteins (Rordorf-Nikolic et al., 1995; Yu et al., 1998; Yu et al., 1998).
It was therefore surprising that mice with targeted deletion of one or more p85 
genes, which leads to p85 and p110 protein reduction, exhibit enhanced PI3K 
signalling in insulin responsive cells (Chen et al., 2004; Fruman et al., 2000; Terauchi 
et al., 1999; Ueki et al., 2002). Subsequent analysis revealed that forced 
overexpression of class IA PI3K regulatory subunits in skeletal muscle cells leads to a 
decrease in Akt phosphorylation (Ueki et al., 2000), indicating that excess p85 might 
compete with p85-p110 for pTyr-binding sites. Furthermore, a 30% excess of p85 over 
p110 in WT mouse embryonic fibroblasts (Ueki et al., 2002) and in liver cells (Mauvais- 
Jarvis et al., 2002) was reported. Based on this information, a model attributing a 
negative role of p85 to PI3K signalling was proposed: in WT cells, surplus, thus free 
p85 competes with heterodimeric p85-p110 for pTyr binding sites in receptor tyrosine 
kinases or adaptor molecules thereby dampening PI3K signalling. In p85 KO cells, 
expression of monomeric p85 is preferentially reduced leading to enhanced access of 
heterodimeric p85-p110 to pTyr binding sites and to increased PI3K signalling.
In insulin-responsive tissue of p85 KO mice, however, the PI3K signalling 
pathway is skewed due to “knock-on” effects of regulatory subunit gene deletion. 
Analysis of class IA PI3K isoform expression in p85a KO cells revealed decreased 
levels of p110 protein and increased protein expression of p55a, p50a or p85|3. 
Furthermore, PTEN protein expression is increased in heterozygous p85a KO mouse 
embyronic fibroblasts (Ueki et al., 2002) and IRS-2 phosphorylation is increased in 
cells gene-targeted for p55a/p50a and p85(3 (Chen et al., 2004; Ueki et al., 2002). A 
further challenge to the model described above arises from the quality of the Abs used 
in immunodepletion experiments to demonstrate excess of p85 over p110 in insulin- 
responsive cells (Mauvais-Jarvis et al., 2002; Ueki et al., 2002).
In order to address whether monomeric p85 exists in vivo or whether class IA 
PI3Ks are obligate heterodimers, knowledge of binding affinities of the monomers to 
each other and in vivo molarities of the subunits is crucial. Interaction between the 
regulatory and catalytic subunit was shown to be very tight, withstanding high 
concentrations of salt, urea or detergent (Fry et al., 1992; Kazlauskas and Cooper,
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1990). These data indicate that dissociation of p85 and p110 is unlikely. Free 
regulatory subunit could also exist if p85 was expressed in excess of p110 provided 
that monomeric p85 is stable. Pulse-chase experiments of cells overexpressing p110a 
and p85a compared to overexpression of p85a on its own, revealed that the half-life of 
monomeric p85a is more than 3 times shorter than that of p85a associated with p110a 
(Brachmann et al., 2005). These data indicate that the existence of monomeric p85 in 
vivo is not likely.
We aimed at investigating the p85 to p110 ratio in mammalian cells. 
Immunoprecipitation, immunodepletion and ion exchange chromatography experiments 
were performed to analyse the presence of monomeric and dimeric class IA PI3K 
subunits in vivo. Furthermore, we set out to analyse the absolute protein amounts of 
each subunit by absolute quantitation (AQUA) mass spectrometry. Analysis of these 
experiments did not reveal any evidence of free p85 indicating that class IA PI3Ks are 
obligate heterodimers. We provide an alternative model to monomeric p85 for the 
observed increase in PI3K activity in insulin-responsive cells of p85 KO mice.
6.1 Class IA PI3K isoform expression in fibroblasts and 
leukocytes
We compared the p85 to p110 ratio in murine fibroblasts and in leukocytes given 
that different phenotypes of PI3K signalling were observed in these cell types of p85a 
KO mice. While studies in p85a KO mice revealed that PI3K signalling is upregulated in 
insulin-responsive cells following insulin stimulation leading to enhanced insulin 
sensitivity (Fruman et al., 2000; Terauchi et al., 1999), downregulation of PI3K 
signalling in p85a KO B cells following BCR engagement was believed to dampen B 
cell proliferation and development (Fruman et al., 1999; Suzuki et al., 1999).
We first analysed the PI3K protein amounts by immunoblotting using various 
class IA PI3K Abs in cell extracts of NIH-3T3, A20 and WEHI-231 cells (Figure 6.1). 
This analysis revealed that relative expression levels of p110a were similar in each cell 
line tested, but p110(3 and p1108 protein expression followed an inverse correlation: 
p110{3 protein levels were high in fibroblasts and low in leukocytes; in contrast, p1105 
protein expression was low in fibroblasts and high in leukocytes. Variation in the protein 
expression of class IA isoforms in different cell types has been reported (Hu et al., 
1993; Vanhaesebroeck et al., 1997). Remarkably, depending on the Ab used for 
immunoblotting, the relative p85 protein expression in fibroblast and leukocytes was 
variable. Using Abs whose epitopes lie within the BH/Rac binding domain of p85, the 
p85 expression levels were higher in leukocytes compared to fibroblasts (U10, 
T12/T15). In contrast, if Abs were used whose epitopes lie within the N-terminal SH2
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domain, similar protein expression levels were noted in all cell types (U2, p85pan). It is 
possible that p85 modifications occurring within the recognition site of the Ab might 
interfere with Ab binding (see § 4.5).
p 1 1 0 a
p 8 5 a  (U10) 
p8 5p  (T12/15) 
p 8 5 a /p  (U2) 
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Figure 6.1: Relative protein expression of class IA PI3K isoforms in fibroblasts and 
leukocytes
The same amount of total cell lysate of the indicated cell lines was analysed for class IA PI3K 
subunit protein expression. (A) Immunoblot using Abs to the different class IA PI3K isoforms.
(B) Relative quantitation of class IA PI3K isoforms based on immunoblot signals in A. The 
protein expression levels of each subunit are standardised against the lowest protein amount 
detected in any of the 3 cell types analysed.
6.2 Purification o f  class IA PI3K by various methods  
mediates equal amounts of p85 and p110 protein
In order to address whether class IA PI3K regulatory and catalytic subunits exist 
in equimolar amounts or whether one subunit prevails over the other, we performed 
class IA PI3K enrichment experiments. By comparing protein amounts visualised by 
colloidal Coomassie blue of p110-IP with p85-IP, an excess of one subunit over the 
other should be detectable.
Therefore, class IA PI3Ks were immunoprecipitated from leukocytes with Abs to 
catalytic subunits (p110a and p1105) or to regulatory subunits. In addition, class IA 
PI3Ks were purified using the pTyr-matrix, which interacts with the SH2 domain of p85 
(§ 3). The enriched protein were separated by SDS-PAGE and visualised by colloidal 
Coomassie blue (Figure 6.2). Densitometric analysis of the protein bands at Mr of 110 
and 85 kDa revealed equal amounts of catalytic and regulatory subunits in the purified 
fractions of the various enrichment methods. These data argue against the existence of 
molar excess of one subunit over the other.
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Figure 6.2: Enrichment of class IA PI3K isoforms does not reveal excess of regulatory 
over catalytic subunit.
Class IA PI3K subunits were immunoprecipitated from leukocytes either with Abs to the catalytic 
or regulatory subunit or enriched with the pTyr-matrix (pYxxM). The proteins were separated by 
SDS-PAGE and stained with colloidal Coomassie blue. Relative protein quantitation of 
densitometric data from 3 independent pull-downs performed with pYxxM-matrix is shown in the 
right panel.
6.3 Immunodepletion of one subunit does not give rise 
to free remaining subunits
We next performed sequential IP experiments of class IA PI3K subunits and 
compared the protein amount of catalytic and regulatory subunits in total cell lysate 
(TCL) with supernatant (SN) by immunoblotting. A schematic drawing of 
immunodepletion experiment is shown in Figure 6.3. If class IA PI3Ks were obligate 
heterodimers, immunodepletion of the catalytic subunit would lead to equal amounts of 
regulatory and catalytic subunits in the third supernatant (SN3) (Figure 6.3.A). In 
contrast, immunodepletion of the catalytic subunit from cell lysates containing a 30% 
molar excess of the regulatory subunit (non-obligate heterodimers) would reveal a 
300% excess of the regulatory subunit in SN3 (Figure 6.3.B) if 85% of all class IA PI3K 
protein was depleted. Since class IA PI3Ks were immunodepleted with an Ab-mix 
against the regulatory and in a separate experiment against the catalytic subunit, a 
molar excess of any subunit should be detectable using this method.
Conditions to perform immunodepletion experiments were established using 
WEHI-321 cell extracts (§ 6.3.1). These experiments were followed by analysis of 3 
different methods of regulatory subunit depletion (§ 6.3.2) and by determination of PI3K 
immunodepletion from NIH-3T3 and A20 cell lysates. In § 6.3.4, we present a summary 
of immunodepletion experiments performed with WEHI-231, A20 and NIH-3T3 lysates.
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Unless otherwise stated, 1 mg of total cell lysate was subjected to sequential IP 
with a mix of p110 Abs (0.2 /yg p110a (SK214+215), 0.3 ug p110(3 (2.1) and 1 jjq  
p1105 (CT) Ab) or with a mix of p85 Abs (0.8 /yg of U2, 1 /yg U10, 3 jj \ T12 and 1 /yg 
T15). The protein amount of class IA PI3K subunits in total cell lysate (TCL) was 
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Figure 6.3: Schematic representation of immunodepletion experiments
Immunodepletion experiments are performed by 3 rounds of IP with an Ab-mix to the regulatory 
or catalytic class IA subunits. In each round, more class IA PI3Ks are being depleted from total 
cell lysate (TCL). Immunodepletion with Abs raised against the catalytic subunit is shown. If 
class IA PI3Ks were obligate heterodimers (A), one would expect similar depletion of p85 and 
p110 in the third supernatant (SN3). If class IA PI3Ks were non-obligate heterodimers (B), one 
would expect to detect an excess of the regulatory over catalytic subunit in SN3.
6.3.1 Immunodepletion of WEHI-231 cell extracts
Sequential immunodepletion as described in § 6.3 was performed with WEHI-231 
cell extracts. In Figure 6.4.A, immunoblots of total cell lysate and SN3 after depletion 
with p85 or p110 Ab-mix of 3 independent immunodepletion experiments are shown. 
Relative quantitation of chemiluminescence signals after incubation of the filter with 
Abs to p110a, p1105, p85a and p85pan are summarised in Figure 6.4.B. In the latter 
figure, the signal obtained for total cell lysate of each isoform in each experiment 
(minus background signal) was set as 100% and the signal values for SN3 were 
calculated relative to this amount. The average and standard deviation (SD) of the 3 
experiments are shown.
More than 80% of the regulatory and catalytic subunit were found to be depleted 
after 3 sequential IP of class IA PI3K IP. A small excess of p110 following p85 IP and a 















Figure 6.4: Sequential IP using Abs to class IA PI3K leads to equal depletion of the 
catalytic and regulatory subunit
3 independent IPs on WEHI-231 total cell lysate (TCL) with an Ab-mix against the catalytic or 
regulatory class IA subunits were performed. (A) Immunoblots of TCL and the third 
supernantant (SN3) following depletion of regulatory or catalytic subunit depletion. Note that 
twice the amount was loaded for SN3 compared to TCL. (B) The chemiluminescence signal of 
the immunoblots was quantified and the average depletion including SD is shown for each 
subunit analysed.
6.3.2 Comparison of 3 different regulatory subunit enrichment 
methods
In order to further examine the efficacy of immunodepletion experiments, we 
compared 3 depletion approaches, which differentially enrich for the regulatory subunit. 
p85 was depleted from 1 mg WEHI-231 cell extract by 3 rounds of IP with either 0.8 pg 
p85pan pAb or 0.8 p.g U2 mAb, or by 3 rounds of p85 pull-down with 100 / y I of pTyr- 
matrix. Figure 6.5 shows immunoblots of p110a, p110p, p1108, and p85a/p detected in 
TCL and SN3 samples (A) and relative quantitation of the chemiluminescence signal 
after incubation of the filter with PI3K Abs (B) as described in § 6.3.1. The average 
relative protein amount of p110 and p85 in TCL is compared to SN3 (C).
The data revealed similar depletion efficiencies of class IA PI3K with the different 
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Figure 6.5: Depletion of class IA PI3K from WEHI-231 cells using different p85 enrichment 
methods
The regulatory subunit was depleted from total cell lysate (TCL) by 3 sequential IPs with p85pan 
pAb or U2 mAb or by 3 rounds of pull-down with the pTyr-matrix (pYxxM). (A) Immunoblotting of 
class IA PI3K isoforms in samples of TCL and SN3 derived from the 3 different depletion 
methods. (B) Relative quantitation of the chemiluminescence signal after immunoblotting with 
class IA PI3K Abs by comparing the protein amount in TCL and SN3. (C) Relative quantitation 
of the average p110 and p85 protein amount detected in TCL and SN3.
6.3.3 Immunodepletion in NIH-3T3 and A20 cell extracts
In order to compare the results obtained for WEHI-231 cells with the two cell lines 
used in § 6.1, we performed immunodepletion experiments with A20 and NIH-3T3 cell 
extracts. As shown in Figure 6.6.A, relative quantitation of class IA PI3K isoforms after 
p85 immunodepletion (SN3-p85) revealed more than 80% depletion of regulatory and 
catalytic class IA PI3K subunits in NIH-3T3 and A20 cells. In contrast, immunodepletion 
using a p110 Ab-mix mediated only 40-60% depletion of p110p, while depletion of 
p110a and p1105 was similar to previous experiments. Since significantly more p110(3 
was found in NIH-3T3 and slightly more p110(3 seems to exist in A20 compared to 
WEHI-231 (Figure 6.1), we probably did not use enough p110p Ab to deplete the 
protein. However, average depletion of the regulatory subunit correlated with average 
depletion of the catalytic subunit in SN3-p110 (Figure 6.6.B). These data indicate that 











Figure 6.6: Immunodepletion of NIH-3T3 or A20 using PI3K Abs to class IA PI3K does not 
expose excess of one class IA PI3K subunit over the other
Class IA PI3K subunits were depleted from NIH-3T3 and A20 total cell lysate (TCL) by 3 rounds 
of IP with a mix of Abs to p85 or p110. The class IA PI3K protein amount detected by PI3K Abs 
in SN3 was compared to the TCL sample by immunoblotting. (A) Relative quantitation of 
depleted fraction compared to TCL for each PI3K subunit. (B) Quantitation of p110 and p85 
protein levels shown in A.
6.3.4 Summary of immunodepletion experiments
In Figure 6.7, a summary of the average relative quantitation and SD of the 
immunoblot signals of all immunodepletion experiments performed with the different 
cell lines is shown.
No significant excess of one class IA PI3K subunit over the other could be 
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Figure 6.7: Summary of immunodepletion experiments performed with NIH-3T3, A20 and 
WEHI-231 cells
The average relative protein amount detected in SN3 compared to TCL gathered from various 
immunodepletion experiments is shown in this graph including standard deviations. Each data­
set includes at least two independent experiments.
6.4 Ion exchange chromatography of class IA PI3K 
subunits indicates that p85/p110 are obligate 
heterodimers
Ion exchange chromatography separates biomolecules based on differences in 
their charge characteristics. In anion exchange chromatography, a strong anion 
exchanger is coupled to an inert resin. Application of negatively charged proteins to 
anion exchange chromatography columns leads to binding of the protein to the 
stationary phase, while increasing the ionic strength in the mobile phase subsequently 
elutes the protein from the column.
Since monomeric class IA PI3Ks likely possess different charge characteristics 
than heterodimeric PI3K, ion exchange chromatography was expected to separate 
monomeric and heterodimeric class IA PI3K isoforms. We therefore used anion 
exchange chromatography to analyse the p85 to p110 ratio of class IA PI3K subunits in 
vivo.
6.4.1 Ion exchange chromatography of overexpressed p85a 
and p85a/p110a
In order to investigate whether the elution profiles of monomeric regulatory 
subunit could be discriminated from elution profiles of heterodimeric regulatory subunits 
by anion exchange chromatography, p85a was overexpressed in HEK-293T cells with 
or without p110a and subjected to anion exchange chromatography. To this end, 20 pg 
pSG5 plasmid DNA (Stratagene) containing the cDNA sequence of bovine p85a or
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bovine p110a under the control of SV40 early promoter were transiently transfected 
into HEK-293T cells by calcium phosphate precipitation (§ 2.7.2.5). Following cell lysis, 
the lysate was desalted by gel filtration and proteins subsequently subjected to anion 
exchange chromatography as described in § 2.14.1. 1 ml eluate fractions were 
collected and analysed for p85a and p110a by immunoblotting (Figure 6.8).
p85a was found to elute at higher salt concentrations than endogenous p110a in 
cells overexpressing p85a, suggesting that the p85a protein detected by 
immunoblotting in Figure 6.8.A is overexpressed, i.e. monomeric p85 protein. A longer 
exposure of the same filter revealed additional p85a, which presumably includes 
endogenous p85a, co-eluted with endogenous p110a. When bovine p85a was co­
expressed with bovine p110a in HEK-293T cells (Figure 6.8.B), the proteins eluted at 
the same ionic strength. Furthermore, the elution profile of overexpressed p85a/p110a 
matched the elution profile of endogenous p110a. These data indicate that monomeric 
p85 can be separated from heterodimeric p85-p110 by anion exchange 
chromatography.
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Figure 6.8: Anion exchange chromatography analysis of overexpressed p85a +/- p110a
HEK-293T cells were transiently transfected with bovine p85a without (A) or with (B) bovine 
p110a using the calcium phosphate transfection method ( I n v it r o g e n ) .  Total cell lysate was 
subsequently subjected to anion exchange chromatography. The fractions were analysed for 
class IA PI3K subunits by immunoblotting with Abs to p85a and p110a (left panel). The elution 




6.4.2 Endogenous class IA PI3K subunits co-elute from anion 
exchange chromatography columns
Total cell lysate of WEHI-231 cells was subjected to anion exchange 
chromatography under the same conditions as used for HEK-293T cells described in § 
2.14.1. Eluate fractions were analysed by immunoblotting using Abs to the class IA 
PI3K isoforms (Figure 6.9.A, only fractions 8-15 of 50 are shown since only modest 
PI3K signals were detected in other fractions) followed by quantitation (Figure 6.9.B). 
The results shown in Figure 6.9 are a representative example of 3 independent 
experiments.
From Figure 6.9 it is clear that all PI3K subunits co-elute within a few 
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Figure 6.9: Ion exchange chromatography experiments do not expose monomeric class 
IA PI3K subunits
Total cell lysate of WEHI-231 cells was fractionated by anion exchange chromatography. Each 
fraction was analysed by immunoblotting for class IA PI3K. (A) Immunoblotting of different class 




6.5 AQUA analysis allows for quantitative class IA PI3K 
protein determination
In order to quantify the protein concentration of each class IA PI3K isoform in 
different cell types, we applied absolute quantification MS. This method is described in 
more details in 2.16.4.4. Briefly, an internal standard (IS) peptide containing the same 
sequence as an endogenous peptide following proteolysis is spiked to the cell sample 
at known concentrations. MS is subsequently used to quantify the endogenous peptide 
by comparison of peak integrated areas of endogenous and IS peptides.
In a first step, class IA PI3K isoforms were analysed by LC-MS/MS and suitable 
peptides for AQUA selected as described in 2.16.4.4. Some of their biophysical 
properties are listed in Table 6.1.
Table 6.1: Class IA PI3K peptides selected for AQUA synthesis.
AQUA peptides sequences, m/z for endogenous and isotopically labelled IS peptides and 
elution times for all class IA PI3K subunits are shown. Isotopically labelled residues are 
underlined. Elution times correspond to a 30 min gradient from 5% to 40% of an 80% (v/v) 
acetonitrile/0.1% (v/v) formic acid solution on a C18 PepMap column. B, Bos bovis; C, 













1 DPEVQDFR pi 10a 503.24 508.24 28 B. C. G. H, Mu. R
2 EYNSGDDLDR pi 103 592.25 597.25 23 C. H. Ma. Mu, R
3 TLNSLEK pi 108 394.75 398.25 26 G. C, H. Ma. Mu. R
4 NANLSTDC pllOS 430.75 434.25 21 B. H. Mu
5 ALLVNVK pi 106 378.75 382.25 26 H. Mu
6 NESLAQYNPK p85a 582.27 585.77 20 B. a  Mu, R
12 ISEHDSR p85a 466.76 471.76 31 H. Mu, R
7 FLLQHLGR p85P 492.28 497.28 27 B, H. Ma. Mu, R
8 IQGEYTLTLR p858 597.33 602.33 32 B, R  Ma. Mu, R
9 HCVIYSTAR p55y 525.62 530.62 24 B. H, Mu
10 TWFVEDINR p55y 590.29 595.29 32 B. H. Mu
In a second step, the IS peptides were tested for their biophysical properties as 
described in 2.16.4.4. The IS peptides were also analysed for correlation between 
peptide abundance and integrated peak areas and for their detection limit (Figure 
6.10). These experiments revealed that the integrated peak areas obtained by LC-ESI- 
MS of IS peptides are linear with respect to the amount of peptide analysed and that 
the detection limit of the IS peptides analysed by LC-ESI-Qtof is below 50 fmole.
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Figure 6.10: Integrated peak areas obtained by LC-ESI-MS of IS peptides are linear with 
respect to the amount of peptide analysed
(A) Detection of increasing ion counts by analysis of increasing amounts IS peptide amounts for 
IS peptide nr. 1 (p110a). (B) Average standard curve constructed by plotting the amount of IS 
peptide against the respective integrated peak areas.
Absolute quantitation of endogenous class IA PI3K subunits (step 3) is described 
in more detail below. In summary, the IS peptides were spiked to the protein samples 
(e.g. peptide number 1-4 in p110 samples) before trypsination and analysed by LC-MS 
or LC-MRM.
6.5.1 Class IA PI3K cannot be detected by MS when isolated 
from total cell lysate separated by SDS-PAGE
Absolute quantitation of proteins is most exact if least purification steps are 
involved during which the protein can be lost. We therefore aimed to perform AQUA 
MS with total cell lysate. To this end, total cell lysate of WEHI-231 cells was separated 
by SDS-PAGE, the protein stained by colloidal Coomassie blue, protein of Mr 110, 85, 
55, and 50 kDa cut from the gel, reduced, spiked with IS peptides and trypsinised.
Since the sample capacity of the nanoLC column was less than 1 ng, saturation 
of the column was reached if digested protein from 2 mg total protein was applied to 
RP-LC. 2 mg total protein, however, did not allow for the detection of endogenous class 
IA PI3K peptide either by LC-MS or LC-MRM (data not shown).
6.5.2 IP of class IA PI3Ks prior to AQUA analysis allows for 
the sensitivity required for absolute protein quantitation 
by AQUA
Because PI3K quantitation by MS following SDS-PAGE separation of total cell 
lysate was not feasible with our instrumentation, we performed two different IP 
approaches to enrich for class IA PI3K isoforms by IP using either an Ab-mix to p85, or 
an Ab-mix to p85 and p110. Each IP was divided into 2 fractions containing 2/3 or 1/3
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of the sample in order to assess for MS ionisation suppression effects (see below). The 
immunocomplexes were resolved by SDS-PAGE and the protein gel stained by 
colloidal Coomassie (Figure 6.11.A). In parallel, samples of TCL and SN were analysed 
for class IA PI3K isoforms by immunoblotting. This revealed that the majority of class 
IA PI3K was depleted from total cell lysate after each IP (Figure 6.11.B).
p85/p110 
p85-IP -IP











Figure 6.11: Enrichment of class IA PI3K subunits using 2 different approaches
Class IA PI3Ks were immunoprecipitated with an Ab-mix either to p85 (U2, U10, T12, T15) or to 
p85/p110 (U2, anti-p110a and -p1105 Ab). (A) Coomassie-stained gel of the IPs and Mr of class 
IA PI3K subunits. (B) TCL and IP-SN samples were analysed for class IA PI3K subunits by 
immunoblotting using isoform-specific Abs.
Peptide quantitation of endogenous p1105 after LC-MS is shown in Figure 6.12. 
The integrated peak areas of IS peptides nr. 4 and nr. 5 were compared to integrated 
peak areas of endogenous peptide for sample 2/3 and 1/3 of both IPs (Figure 6.12.A). 
In order to obtain mean values, the endogenous p1105 amounts in sample 2/3 and 1/3 
calculated from known amounts of IS peptide were extrapolated to 1 (by multiplying 
with 1.5 and 3, respectively), and the average and SD of each experiment calculated 
(Figure 6.12.B). The endogenous, average p1105 amount was 2.9 +/- 0.37 pmole if 
Abs to p85 were used versus 3.6 +/- 0.44 pmole if Abs to p85/p110 were used. The 
lower p1105 amount detected in the p85-IP correlates with inferior depletion efficiency 
of p1105 as observed by immunoblotting (Figure 6.11.B).
Signals generated by ESI could possibly be suppressed by co-elution of several 
species from the LC column, thereby competing for ionisation. However, the integrated 
peak areas of 2 pmole IS peptide compared with endogenous peptide were similar in 
sample 2/3 and sample 1/3 (containing 66% and 33% of the IP, respectively). This
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revealed that ionic intensities were not significantly affected by differences in protein 
amounts suggesting that signal suppression effects are negligible. Furthermore, 
calculated protein amounts of endogenous p1105 were similar if integrated peak areas 
of IS peptides nr. 4 and nr. 5 were compared. This suggests that the choice of p1105 
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Figure 6.12: Absolute quantitation of p1108 from WEHI-231 cells
p110 protein samples of p85- or p85/p110-IP (Figure 6.11) were spiked with 2 pmole of all p110 
IS peptides and analysed by LC-MS. (A) The LC-MS spectra and corresponding base peak 
intensities (BPI) of endogenous (m/zNANLSTiK=430.75, m/zAi_LVNVK=378.75) and IS peptides nr. 4 
and nr. 5 (m/zNANLSTiK=:434.25, m/zALLVNVK=382.25) were extracted by MassLynx Quantify 
software. (B) BPI values of endogenous p1105 peptide were compared to BPI values of IS 
peptides. This allowed for calculations of respective endogenous p1105 protein amounts in each 
sample. Extrapolation to 1 revealed the amount of endogenous p1105 protein in the IP before 
sample separation into 2/3 and 1/3. (C) The average amount of endogenous p1105 (plus SD) 
immunoprecipitated from WEHI-231 cells using p85-Abs or p85/p110-Abs is shown.
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6.5.3 Absolute quantitation of class IA PI3K isoforms 
enriched from WEHI-231 and NIH-3T3 cells
We used two different affinity matrices for the isolation of class IA PI3K isoforms 
in order to eliminate artefacts in protein quantification due to protein enrichment. PI3Ks 
were either immunoprecipitated with a mix of isoform-specific Abs to the regulatory and 
catalytic subunits or pulled-down with the pTyr-matrix. We used two independent pTyr- 
matrices to perform these experiments: one which consist of the YVPMLG peptide 
coupled to Actigel matrix (containing a single Tyr; further referred to as pY-matrix) and 
a second GST-tagged peptide (GST-GGYMDMSKDESVDYVPML) absorbed to 
glutathione-S-sepharose matrix (further referred to as pYpY-matrix; described in detail 
in chapter 3). These purification tools were used to enrich class IA PI3K proteins from 
7-15 mg TCL, resolved by SDS-PAGE followed by visualisation of proteins by colloidal 
Coomassie blue staining (Figure 6.13.A). Additionally, TCL and supernatant (SN) of the 
IP/pull-downs were analysed by immunoblotting using Abs to class IA PI3K isoforms 
(Figure 6.13.B). This analysis allowed assessing whether class IA PI3K depletion from 
TCL was achieved and whether all isoforms were depleted equally.





















Figure 6.13: Enrichment of class IA PI3K isoforms by 3 different approaches from WEHI- 
231 and NIH-3T3 cells
(A) Class IA PI3Ks were purified from WEHI-231 or NIH-3T3 cells by affinity chromatography (IP 
using a mix of isoform-specific Abs or pull-down using pTyr-matrix containing 1 (pY) or 2 (pYpY) 
phosphorylated Tyr residues in a YxxM-motif). The complex was separated by SDS-PAGE and 
proteins visualized by colloidal Coomassie blue. Gel sections excised for further analysis are 
indicated by grey boxes. (B) Protein depletion was assessed by immunoblotting for class IA 
PI3K isoforms of total cell lysate (TCL) compared to supernatant (SN) following IP or pull-down.
Figure 6.14 shows integrated peak areas of 2 pmole IS peptides (dotted line) and 
endogenous peptides (solid line) immunoprecipitated from WEHI-231 or NIH-3T3 cells. 
While the protein amount of p110a was low in both leukocytes and fibroblasts, p110/5 
protein levels were high in fibroblast and low in leukocytes. As expected, p1105 protein
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expression was low in fibroblasts compared to leukocytes. The overall level of class IA 
PI3K regulatory subunit protein expression was similar in leukocytes and fibroblasts, 
with protein expression of p55a and p50a being undetectable (data not shown). 
Remarkably, p85/3 protein expression was higher than that of p85a, previously 
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Figure 6.14: Extracted ion chromatograms (XIC) of class IA PI3K isoforms
Graphs depict XICs of endogenous (ENDO) and IS (IS, 2 pmole) peptides for all class IA PI3K 
isoforms immunoprecipitated from WEHI-231 and NIH-3T3 cells.
The integrated peak areas obtained from the 3 affinity chromatography 
experiments (IP, pY, pYpY) were processes and the concentration of each endogenous 
protein calculated in pmole/mg TCL (Figure 6.15). These analyses revealed that similar 
protein amounts were detected following IP and pull-down of WEHI-231 cells for 
p110a, p110£, p85a and p85/3 each, but the amounts differed for p1105 between IP 
and pull-down. This finding is in line with immunoblotting data shown in Figure 6.13.B
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indicating that p1105 is not entirely depleted from WEHI-231 cells following pull-down 
using pTyr-matrices. In NIH-3T3 cells, similar protein amounts for each class IA PI3K 
isoform were detected following IP or pull-down, apart from p110a, which was 3 times 
more abundant following pYpY pull-down than following IP or pY pull-down (marked 
with an arrow in Figure 6.15). Since immunoblotting data shown in Figure 6.13.B do not 
reveal differences in p110a protein amounts in the SN following enrichment between 
the different enrichment methods, we suspect that the p110a protein amount detected 
in pYpY pull-down is an artefact.
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Figure 6.15: Determination of class IA PI3K protein amounts
XICs of 2 independent LC-MS runs for all class IA PI3K isoforms isolated from WEHI-231 and 
NIH-3T3 cells were analysed following IP using class IA PI3K specific Abs and pull-down using 
pTyr-matrix. Endogenous amounts of each isoform are given in pmole/mg TCL.
Table 6.2 shows the amount of molecules of class IA PI3K isoforms per cell. 
These numbers were calculated by using average protein amounts minus the outliers 
for p110a and p1105 obtained following the 3 enrichment methods. A standard curve of 
WEHI-231/NIH-3T3 cells per volume lysis buffer was used to determine how much TCL 
(in mg) was obtained from a certain number of cells (data not shown). This analysis 
revealed that WEHI-231 and NIH-3T3 cells overall express very similar numbers of 
class IA PI3K isoform, namely approximately 25,000 molecules of p110 and p85/cell. In 
addition, the total of all catalytic subunits matches the total of all regulatory subunits, 
indicating that there is no excess of p85 in the cell lines used here. p110a protein 
expression was low in both cell lines (below 2,000 molecules/cell), compared to p110/? 
(12,300 and 1,700 molecules/cell in NIH-3T3 and WEHI-231, respectively) and p1105 
(800 and 7,900 molecules/cell in NIH-3T3 and WEHI-231, respectively). The amount of
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p85£ (approximately 9,000 molecules/cell) was more than double that of p85a (4,000 
molecules/cell), while p55y, p55a, p50a protein expression is below 500 molecules/cell 
in these cell lines.
Table 6.2: Average class IA PI3K protein amounts in WEHI-231 and NIH-3T3 cells
An average amount of class IA PI3K molecules/cell was calculated by using the values of each 
enrichment method shown in Figure 6.16. The sum of all catalytic and regulatory subunit protein 
amounts are shown at the bottom.
PI3K Molecules/cell
isoform WEHI-231 NIH-3T3
p110a 620 ±20 1900 ±500
pnop 1700 ±300 12300 ±1200
p1106 7900 ±2900 800 ±300
p85a 3900 ±600 5000 ±700
p85(3 8000 ±1200 9500 ±100
p55y 530 ±60 100 ±50
p55a 100 ±50 10 ±10
p50a 300 ±300 30 ±20
p110 10300 ±3220 15000 ±2000
p85 12900 ±2210 14000 ±880
6.6 Discussion
Over the last couple of years, a vast literature on the existence of free p85 has 
appeared, mainly in an attempt to explain the increase in PI3K signalling upon insulin 
stimulation observed in mice in which class IA regulatory subunits have been deleted. 
In the proposed model, free p85 in WT cells competes with heterodimeric p85-p110 for 
docking sites on Tyr phosphorylated IRS molecules. Thus, monomeric p85 was put 
forward as a negative regulator in the PI3K signalling pathway.
Various data have cast doubts on this model:
1) Monomeric p85 seems to be unstable. A recent study addressing the 
phenotype of p110a+/7p110p+/‘ mice revealed that heterozygous loss of p110a and 
p110p leads to a decrease in the protein expression of the regulatory subunit 
(Brachmann et al., 2005). These findings were confirmed by RNAi experiments, in 
which a loss of p110 protein caused instability of the p85 protein. In addition, pulse- 
chase experiments of cells transfected with p85 or p85-p110 revealed a 3-fold higher
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degradation rate of free p85 compared to its heterodimeric counterpart (Brachmann et 
al., 2005).
2) Monomeric p85 does not necessarily compete with p85-p110 for pTyr docking 
sites. p85a overexpression in muscle cells correlates with a decrease in in vitro lipid 
kinase activity compared to non-transfected cells (Ueki et al., 2000). This experiment 
helped to establish the hypothesis that free p85 might oust p85-p110 heterodimer from 
pTyr binding sites. However, further investigations have shown that an excess of p85 
over p110 does not always impact on PI3K lipid kinase activity. Thus, in p85a-deficient 
brown adipose cells reconstituted with p85a, a 4-fold excess of p85 over p110 does not 
reduce the in vitro lipid kinase activity in pTyr-IPs, compared to p85a KO cells 
reconstituted with similar p85a to p110 protein levels (Ueki et al., 2003). Furthermore, 
the in vitro lipid kinase activity of pTyr immunoprecipitated PI3K was similar in WT and 
p85a+/' MEF cells, despite an allegedly 40% excess of p85 over p110 in WT cells (Ueki 
et al., 2002). Also no difference in the in vitro lipid kinase activity of pTyr 
immunoprecipitated PI3K was observed when WT brown adipose cells were compared 
to p85p'/‘ cells, which were shown to contain a 30% decrease in monomeric p85 
compared to WT cells (Ueki et al., 2002). Unfortunately, the experiment which would 
resolve matters has not been presented yet: Comparison of the p110 and p85 protein 
amount in pTyr immunoprecipitates of WT versus p85+/' cells. This should result in 
reduced levels of p110 protein in pull-downs of WT compared to p85a+/' cells if 
monomeric p85a exists and competes for pTyr docking sites.
3) The PI3K signalling pathway is skewed in p85 gene-targeted mice. Analysis of 
PI3K protein expression levels revealed that homozygous or heterozygous loss of the 
regulatory subunit leads to concomitant distortion of the p110 and untargeted p85 
protein expression (Fruman et al., 2000; Fruman et al., 1999; Suzuki et al., 1999; 
Terauchi et al., 1999). Furthermore, PTEN expression is increased in murine cells of 
p85a+/’ origin (Ueki et al., 2002), and IRS-2 phosphorylation is enhanced in cells 
deficient of p55a/p50a and p85p (Chen et al., 2004; Ueki et al., 2003). These finding 
indicate that in insulin-responsive cells, deletion of p85 leads to many “knock-on” 
effects which likely impact on PI3K signalling.
Despite the challenges described above to the hypothetical model of free p85 in 
insulin-responsive cells, it is emerging that p85a protein expression can be increased 
by several chemical agents in these cells, correlating with a reduction in PI3K activity. 
Thus, the corticosteroid dexamethasone induces p85a protein expression due to an 
increase in p85a mRNA in cultured muscle cells (Giorgino et al., 1997). Treatment of 
these cells with dexamethasone concomitantly reduces IRS-1 protein expression and 
PI3K lipid kinase activity. Similar observations were made when WT skeletal muscle
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cells were compared to skeletal muscle cells of p85a KO mice following growth 
hormone (GH) treatment (Barbour et al., 2005). GH treatment induces p85a protein 
expression levels in WT cells compared to untreated control, while p85a protein levels 
remain low in p85a+/' cells. In this system ([p85a]wT+GH> [p85a]wT > [p 85(x]h e t), the in 
vitro lipid kinase activity of PI3K associated with IRS-1 decreases in WT cells 
stimulated with growth hormones compared to unstimulated WT cells, but increases in 
p85a+/' cells. Furthermore, overexpression of the cellular retinol-binding protein-1 
(CRBP-1) appears to decrease PI3K activity by inducing dissociation of p85 and p110 
(Farias et al., 2005). However, in order to draw conclusions about the existence of free 
p85, the expression levels of all catalytic subunits and IRS/adaptor molecules have to 
be analysed.
Because of the controversial data published on the p85 to p110 ratio, we 
performed different biochemical analyses in order to investigate whether monomeric 
p85 exists in murine WT fibroblasts and leukocytes.
Since the concept of monomeric p85 in WT cells of insulin-responsive tissue is 
primarily based on immunodepletion experiments (Ueki et al., 2002), we analysed by 
immunoblotting PI3K protein amounts of fibroblasts and leukocytes before and after 
sequential IP. This analysis did not reveal an excess of one subunit over the other. We 
frequently observed minor differences between depletion of catalytic subunit and 
regulatory subunit, however, these laid within the coefficient of variation of the method.
Under native conditions, monomeric p85 is expected to have different biophysical 
characteristics than p110-bound p85. In ion exchange chromatography, separation of 
molecules is based on differences in their charge characteristics. Thus, monomeric p85 
is expected to elute at different ionic strength than p110-bound p85 from ion exchange 
chromatography. To formerly address this assumption, the protein lysates of HEK-293T 
cells overexpressing p85a or p85a-p110a were analysed by ion exchange 
chromatography. Indeed, p85a overexpressed in HEK-293T cells eluted from the 
column at higher salt concentrations than p85a co-expressed with p110a. Subsequent 
analysis of endogenous class IA PI3K isoforms from WEHI-231 cells revealed that all 
PI3K isoforms elute in the same fractions suggesting that they do not possess 
monomeric p85. We have not addressed by ion exchange chromatography whether 
monomeric p110 exists for two reasons. First, monomeric catalytic subunit is believed 
to be thermally labile (Yu et al., 1998) and therefore non-existent. Second, transient 
overexpression of p110 in HEK-293T cells was not successful (§ 5.11), probably due to 




A variety of MS strategies for the quantitation of protein expression levels in cells 
have been developed. However, the majority of these methods only allow for relative 
quantitation of expressed protein. The stable isotope labelling by amino acids in cell 
culture (SILAC) approach allows for in vivo incorporation of isotopically labelled amino 
acids into proteins. This method enables large-scale relative protein and post- 
translational modifications quantitation of cell culture cells, but not primary tissues (Ong 
et al., 2002). Another variation of the stable isotope quantitation methods, which can 
also be employed for primary tissue samples, is the isotope coded affinity tag (ICAT) 
method (Gygi et al., 1999). In this post-harvesting approach, proteins are isotopically 
labelled with chemicals that covalently bind to cysteine residues. Peak area 
measurements with an internal standard (PAIS) allows for protein quantitation between 
different samples without metabolic labelling by comparison of endogenous peptides 
with an internal standard added to the samples before protein digestion (Cutillas et al.,
2005). However, all these methods only allow for relative quantitation of expressed 
proteins. In order to quantify the absolute protein amounts of class IA PI3K isoforms, 
we used the absolute quantification (AQUA) MS strategy (Gerber et al., 2003; 
Kirkpatrick et al., 2005). The AQUA method is based on the use of an isotope labelled 
IS that is spiked at known concentrations to cell samples. This IS peptide mimics an 
endogenous peptide of the target protein, except that it is enriched in stable isotopes. 
Analysis of the proteolysed sample by MS results in the detection and quantitation of 
both the endogenous peptide and isotope-labelled IS peptide.
11 IS peptides with equivalent sequences to class IA PI3K isoform peptides were 
validated using different MS approaches. We determined the detection limit of the 
peptides in our instrumentation, their elution times from RP chromatography columns, 
and ruled out ionisation suppression by endogenous peptides. Furthermore, equal 
endogenous protein amounts were compared with different IS peptides to the 
respective protein (if applicable). This confirmed the independence of the IS peptide 
sequence for absolute quantitation of endogenous protein.
AQUA analysis of class IA PI3Ks was not feasible with protein of whole cell lysate 
due to the low abundance of these proteins. We therefore investigated the absolute 
PI3K protein amounts following IP and pull-down using pTyr-matrices. Although not 
ideal because of protein loss during enrichment, the depletion of each isoform was 
monitored by immunoblotting and optimal conditions for protein enrichment established 
in order to ensure that all class IA PI3K are equally enriched.
The analysis of endogenous class IA PI3K isoforms by AQUA revealed similar 
amounts of class IA PI3K in NIH-3T3 and WEHI-231 cells, amounting to approximately 
25,000 molecules/cell. In addition, the total of all catalytic subunits matches the total of 
all regulatory subunits, indicating that there is no excess of p85 in the cell lines used
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here. p110a protein expression was surprisingly low in both cell lines (below 2,000 
molecules/cell), compared to p110p (12,300 and 1,700 molecules/cell in NIH-3T3 and 
WEHI-231, respectively) and p1108 (800 and 7,900 molecules/cell in NIH-3T3 and 
WEHI-231, respectively). Remarkably, the amount of p85(3 (approximately 9,000 
molecules/cell) was more than double that of p85a (4,000 molecules/cell), indicate that 
p85p is the most prevailing regulatory subunit in the two cell lines tested, contrary to 
previous reports in MEFs (Ueki et al., 2002). p55y, p55a, p50a protein expression is 
below 500 molecules/cell in these cell lines.
Since our data presented in this chapter do not support the existence of an 
excess of p85 over p110, we would like to present an alternative model to the 
existence of monomeric p85 that could explain an increase in PI3K activity of insulin- 
responsive cells in p85-KO mice. First, we discuss how PI3K activity might be modified 
in vivo. An increase in endogenous PIP3 concentration as observed in p85 KO cells 
could be mediated by an increase in class IA PI3K activity or a decrease in the activity 
of PTEN/SHIP. Changes in the net activity of these molecules could be due to
1) alterations in the protein concentration of class IA PI3K or PTEN/SHIP. Indeed, 
the protein expression levels of the different class IA PI3K (Chen et al., 2004; Fruman 
et al., 2000; Terauchi et al., 1999; Ueki et al., 2002) and PTEN (Ueki et al., 2002) are 
modulated in p85 KO cells. In p85a-KO mice, p110 protein levels are decreased 
suggesting a decrease in PI3K activity. In addition, non-targeted p85 protein 
expression levels are increased. However, this rise in p85 protein does not seem to 
compensate for the loss of p85 protein due to gene manipulation as determined by 
immunoblotting using p85pan Abs (Ueki et al., 2002). Furthermore, PTEN protein 
expression was shown to be increased in p85a+/" cells, while SHIP expression was 
unchanged (Ueki et al., 2002). These findings would also indicate a decrease in PI3K 
signalling. Furthermore, in p85-KO mice PI3K activity in cells of insulin-sensitive tissue 
increases following insulin stimulation, whereas PI3K activity decreases in B and T 
cells following stimulation of B- and T cell receptor, respectively (Fruman et al., 1999; 
Suzuki et al., 1999). These findings suggest that it is not the concentration of total p85 
which is crucial for the observed changes in PI3K activity.
2) modulations in the intrinsic activity of class IA PI3K or PTEN/SHIP, e.g. PI3K 
activity could be enhanced by a decrease in Ser phosphorylation or an increase in Ras 
binding or SHIP activity could be decreased by Tyr phosphorylation (Habib et al., 
1998). The intrinsic PI3K lipid kinase activity measured following IP using either Abs to 
pTyr or p110 are decreased in P85CX''' and p55aJp50a,' cells (Chen et al., 2004; 
Terauchi et al., 1999; Ueki et al., 2002). PTEN or SHIP activity has not been studied.
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3) changes in the subcellular localisation of the lipid kinase or phosphatase, e.g. 
by an increase in IRS phosphorylation or membrane recruitment of monomeric p110 or 
of PTEN/SHIP. Indeed, Tyr phosphorylation of IRS-2 seems to be enhanced by 
deletion of p85 (Chen et al., 2004; Ueki et al., 2002), possibly allowing for increased 
amounts of PI3K to be recruited to the plasma membrane and to be activated. Although 
in vitro lipid kinase assays following IRS-2 IP revealed enhanced PI3K activity, the 
increase is not enough to impact on total lipid kinase activity following pTyr IP.
In summary, these findings indicate that the phenotypes observed in p85- 
deficient cells of insulin-sensitive tissue are probably not mediated by changes in 
protein concentrations of PI3K or PTEN/SHIP or by changes in the intrinsic PI3K 
activity. Thus, the increase in PIP3 production in p85 KO cells could be due to an 
increase in PTEN/SHIP activity or to membrane recruitment of monomeric p110 or 
PTEN/SHIP. Since monomeric p110 seems to be unstable (Yu et al., 1998), we 
present a hypothetical model explaining an increase in PIP3 concentration in p85 KO 
cells independent of class IA PI3K.
In p85-KO mice, IRS phosphorylation in cells of insulin-sensitive tissues is 
unchanged or mildly increased (Chen et al., 2004; Ueki et al., 2002). It is likely that less 
regulatory and catalytic subunit binds to phosphorylated IRS following cellular 
stimulation in p85 KO cells, because less p85 exists. Thus, other molecules, which 
usually do not associate with IRS due to lower binding affinities compared to p85, might 
engage with IRS. The janus kinase JAK and lipid phosphatase SHIP are such 
candidates, since they both possess SH2 domains (Al/lazikani, 2001). JAKs have been 
shown to interact with and phosphorylate IRS-1 (Wang et al., 1997) and SHIP 
(Giallourakis et al., 2000). Interaction of JAK with IRS might therefore lead to the 
observed increase in IRS phosphorylation in p85-KO mice. Interaction of JAK with 
SHIP could further lead to phosphorylation and inactivation of SHIP (Habib et al., 1998) 
mediating an increase in PIP3 concentration.
In hematopoietic cells, JAK activation seems to be independent of IRS (Uddin et 
al., 1997), possibly explaining why p85 deletion in insulin-responsive cells leads to an 







Figure 6.16. Hypothetical model explaining increased PI3K signalling in p85 KO cells
Following insulin receptor stimulation, IRS molecules are phosphorylated on Tyr residues. This 
allows for recruitment of p85-p110 to the plasma membrane in WT cells, but also of She, which 
can further recruit SHIP. While PI3Ks generate PIP3 leading to Akt recruitment and activation, 
SHIP reduces PIP3 levels. In p85 KO cells, less p85-p110 will bind to phosphorylated IRS 
molecules, leaving access for JAK and SHIP. JAK possibly phosphorylates SHIP, thereby 
inactivating its catalytic activity leading to an increase in PIP3.
In summary, we have thoroughly investigated the molecular ratio between the 
regulatory and catalytic subunit of class IA PI3K using different biochemical 
approaches. Performing these analyses, we did not find any evidence for monomeric 
p85 therefore concluding that class IA PI3K activity is not regulated by free p85. 




7 D is c u s s io n
Class IA PI3Ks play critical roles in the regulation of cellular proliferation, survival, 
metabolism and migration. Aberrant activation of the PI3K pathway contributes to 
pathological conditions such as cancer, diabetes and inflammation. A key subset of 
PI3Ks are the so-called class IA enzymes which consist of a p85 regulatory and p110 
catalytic subunit (reviewed in (Vanhaesebroeck et al., 1997)). These lipid kinases act 
downstream of tyrosine kinases and Ras. Following cellular stimulation, class IA PI3Ks 
catalyse the phosphorylation of Ptdlns(4,5)P2 leading to the generation of the lipid 
second messenger PIP3 (Hawkins et al., 1992). A variety of proteins can bind to PIP3 
and membrane association of these proteins often leads to changes in their catalytic 
activity (Musacchio et al., 1993). One important downstream effector of class IA PI3K is 
the protein kinase Akt (reviewed in (Brazil and Hemmings, 2001)).
The regulation of class IA PI3Ks is complex. In unstimulated cells, class IA PI3K 
heterodimers appear to reside in the cytosol. The regulatory subunit stabilises the 
thermally labile p110 protein, but also inhibits PI3K lipid kinase activity (Yu et al., 1998). 
The activity of class IA PI3Ks can be enhanced by
1) membrane recruitment of the catalytic subunit. Genetic modifications of p110 
with membrane-targeting domains that induce constitutive membrane association leads 
to constitutively enhanced PIP3 levels in transfected cells (Aoki et al., 2000; Auger et 
al., 2000; Didichenko et al., 1996; Reif etal., 1996).
2) interaction of the p85 SH2 domains with pTyr residues in YxxM-containing 
proteins such as receptor tyrosine kinases or adaptor molecules (Rordorf-Nikolic et al., 
1995). Evidence has been presented that binding of the N-terminal SH2 domain of 
p85a to pYxxM-motifs, but not the binding of the C-terminal SH2 domain, is responsible 
for the rise in PI3K activity (Yu et al., 1998).
3) interaction of the catalytic subunit with Ras or nuclear protein PIKE, and 
interaction of p110p with G(3y subunits of trimeric G proteins (Kurosu et al., 1997; 
Rodriguez-Viciana etal., 1994; Rodriguez-Viciana etal., 1996; Rong et al., 2003).
4) dissociation of the catalytic from the regulatory subunit. The lipid kinase activity 
of monomeric p110 purified from bovine thymi is increased compared to the activity of 
heterodimeric p85-p110 (Shibasaki et al., 1991). Similarly, the lipid kinase activity of 
recombinant p110a is decreased by in vitro reconstitution with recombinant p85a (Yu 
et al., 1998).
The enzymatic activity of class IA PI3K can be decreased by autophosphorylation 
of p110p or p1108 on Ser residues located in the C-terminus of the catalytic domain 
(Czupalla et al., 2003; Vanhaesebroeck et al., 1999). Furthermore,
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transphosphorylation of Ser608 in p85a by p110a leads to the downregulation of 
p110a lipid kinase activity (Dhand et al., 1994; Foukas et al., 2004). Interaction of the 
regulatory subunit p85a with the adaptor protein Ruk also seems to reduce the intrinsic 
lipid kinase activity of PI3K (Gout et al., 2000). In addition, monomeric p85 has been 
implicated as a negative regulator in PI3K signalling (Luo and Cantley, 2005).
In this study, we focused on two aspects of PI3K regulation:
1) the role of known and novel post-translational modifications in the regulation of 
endogenous class IA PI3K activity, especially of the p1105 subunit. The established 
immature B cell line WEHI-231, which expresses all class IA PI3K isoforms, was used 
as a main model system. The aim was to separate extracts of these B cells by 2D-gel 
electrophoresis and to subsequently identify the modifications in class IA PI3K isoforms 
by MS. The biological relevance of the identified modifications would then be analysed 
using biochemical approaches. We used a cell-based assay, in-house Abs as well as a 
new class IA PI3K purification tool (‘pTyr-matrix’) to obtain sufficient amounts of PI3K 
for MS analysis.
2) the molar ratio between the regulatory and catalytic subunit. The ratio between 
class IA PI3K catalytic and regulatory subunit was analysed using affinity and ion 
exchange chromatography and absolute quantitation (AQUA) MS. The assessment of 
the molarity of class IA PI3K regulatory and catalytic subunit is relevant since an 
excess of p85 protein has been implicated in the negative regulation of PI3K activity 
(Luo and Cantley, 2005; Ueki et al., 2002).
Below, we first discuss the generation of the pTyr-matrix (§ 7.1), followed by an 
examination of post-translational modifications in the class IA PI3K p85 regulatory 
subunit (§ 7.2) and p1108 catalytic isoform (§ 7.3). Potential novel interaction partners 
of p85-p1105 detected in the course of these investigations are discussed in § 7.4. In § 
7.5, we discuss our findings of equimolarity between class IA PI3K regulatory and 
catalytic subunit and finally in § 7.6, we provide conclusions and discuss potential 
future experiments.
7.1 Generation of a novel pTyr-matrix to enrich for 
class IA PI3K proteins
In order to identify proteins and post-translational modifications by peptide 
sequencing using MS, more than 100 ng target protein is required. This prerequisite 
not only necessitates cellular systems producing large amounts of proteins, but also 
efficient protein purification tools.
In our laboratory, a variety of home-made Abs to PI3K and synthetic PDGF- 
receptor peptides coupled to Actigel (Fry et al., 1992) were available for the enrichment
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of class IA PI3K. While the use of some of these Abs was restricted by availability, 
others did not allow for high purity of immunocomplexes due to the association of the 
Ab with several proteins. Furthermore, preliminary results obtained by incubation of cell 
lysate with the synthetic PDGF-receptor matrix that is made of 6 amino acids 
(pYVPMLG, containing Y571) linked to Actigel did not reveal enrichment of pure or 
large quantities of class IA PI3K.
We therefore designed three PDGF-receptor peptides of different lengths, all 
containing Y751 with or without Y740. Residues Y751 and Y740 are both located in 
YxxM-motifs of the human PDGF-(3-receptor (Klinghoffer et al., 1996). DNA constructs 
encoding these peptides were cloned into pGEX-4T-2 (Amersham Pharmacia Biotech), a 
plasmid containing the GST gene under the control of an inducible promoter (Figure
3.2). These plasmids were subsequently transformed into E. coli strain TKB1 that 
contains an inducible Tyr kinase gene (Stratagene). Following gene induction and 
phosphorylation of Tyr residues in the constructs by incubation of E. coli with the 
inducer IPTG, bacterial extracts were incubated with glutathione-bound sepharose in 
order to immobilise the GST-peptide complex. Class IA PI3Ks present in eukaryotic cell 
lysate was expected to be enriched by interaction of its SH2 domains with pY751 
and/or pY740 of this so-called pTyr-matrix.
Successful cloning of the GST-PDGF-receptor peptide constructs and 
transformation into E. coli was confirmed by gel electrophoresis of PCR products 
(Figure 3.2), restriction digestion and DNA sequencing of purified plasmids. Expression 
of the GST-PDGF-receptor peptide constructs in TKB1 following promoter induction 
was assessed by SDS-PAGE and protein detection by colloidal Coomassie. This 
analysis revealed that expression of all 3 GST-PDGF-receptor peptides was highly 
induced (Figure 3.4). Immunoblotting of bacterial extract using pTyr Abs revealed a 
more than 5-fold increase in Tyr phosphorylation of the GST-PDGF-receptor peptides 
following gene induction (Figure 3.4). We further assessed the binding capacity of 
sepharose beads to the GST-PDGF-receptor peptides by titration experiments (Figure 
3.5) and analysed the amount of pTyr-matrix required to bind p1105 (Figure 3.6). 
These analyses revealed that GST-PDGF-receptor peptides contained in 1 mg 
bacterial lysate was sufficient to saturate 500 j j \ glutathione sepharose matrix and that 
this amount of pTyr-matrix could bind the majority of p1105 present in 5 mg WEHI-231 
cell extract.
Assessment of eukaryotic proteins pulled-down by the pTyr-matrix using SDS- 
PAGE and Coomassie staining revealed 4 major protein bands. Analysis of these 
bands by LC-MS/MS revealed enrichment of p110p, p1105 at Mr of 110 kDa, and p85a 
and p85p at Mr of 85 kDa (Figure 3.7). p110a, p55y, p55a, and p50a could not be
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detected by MS probably due to low protein expression levels in WEHI-231 cells (see 
also § 4.7.1). However, p110a could be detected by p110a-specific Abs in pull-downs 
using the pTyr-matrix (data not shown, Figure 6.5). Furthermore, Hsp70 and Elongation 
factor-1 y were identified by MS as the protein bands resolved at Mr of 70 and 45 kDa. 
The latter proteins were also detected in pull-downs with sepharose matrix only, 
indicating that these proteins bound non-specifically to the matrix.
In our hands, this pTyr-matrix proved to be more efficient than the synthetic 
PDGF-receptor peptide coupled to Actigel. This might be due to the different lengths of 
constructs or to the different characteristic of the linker region between PDGF-receptor 
peptide and glutathione sepharose (GST-protein) and synthetic PDGF-receptor peptide 
and Actigel (5-atom spacer). Furthermore, pTyr-matrix is cheaper than synthetic 
peptides plus Actigel. The advantage of this class IA PI3K purification tool over Abs lies 
in its potential capacity to interact with all regulatory subunits similarily and thus to 
enrich for all class IA PI3K isoforms simultanously.
In summary, the pTyr-matrix provided an enrichment method independent of IP 
and we successfully applied it for the enrichment of class IA PI3Ks in several projects 
of this thesis.
7.2 Class I A PI3K activity is not controlled by
modifications of p85a following BCR stimulation of 
WEHI-231 cells
The five class IA PI3K regulatory subunits (p85a, p85p, p55y, p55a, p50a) are 
generated by 3 independent genes (PIK3R1, PIK3R2, PIK3R3) and alternative splicing 
or differential promoter usage of PIK3R1 (Abell et al., 2005). These proteins contain 
various protein-protein interaction domains, such as SH2, p110-binding and proline-rich 
domains and in case of p85a and p85|3 also a BH/Rac-binding and SH3 domain. The 
biological role of p85 likely lies in the modulation of PI3K activity by altering protein 
partner associations. Modifications of class IA PI3K regulatory subunit are therefore 
expected to impact on binding affinities between the regulatory subunit and protein 
partners and thus to impact on p110 catalytic activity.
Indeed, phosphorylation of Y508 of p85a in fibroblasts following PDGF receptor 
engagement leads to the dissociation of p85a from the receptor (Kavanaugh et al., 
1994). Phosphorylation of Y688 by Lck or Abl does not induce changes in the in vitro 
lipid kinase activity of PI3K, but leads to alterations in the interaction of p85 with 
binding partners (von Willebrand et al., 1998). This likely enhances total PI3K lipid 
kinase activity as determined by an increase in Akt phosphorylation of Cos-7 cells 
transfected with p85a Y688D mutant compared to WT p85a (Cuevas et al., 2001). In
181
Chapter 7
addition, nitration of Tyr residues in p85a following peroxynitrite treatment of 
macrophages seems to abrogate the interaction of p85 with the catalytic subunit 
(Hellberg et al., 1998). Treatment of endothelial cells with high doses of glucose and 
peroxynitrite has also been shown to induce Tyr nitration of p85, correlating with p85 
dissociation from p110 (al-Shami et al., 1997).
As described in Chapter 4 and discussed below, the analysis of modifications in 
class IA PI3K regulatory subunits by 2D-gel electrophoresis and MS revealed that p85a 
is extensively modified in non-BCR stimulated, but proliferating WEHI-231 B cells. The 
observed modifications on 2D-gels might be due to protein phosphorylation, 
hydroxylation and amino acid substitutions as identified by MS. These modifications do 
not seem to be dynamic or of high stoichiometry since stimulation of WEHI-231 cells 
via BCR did not induce significant changes in these modifications.
7.2.1 Class IA PI3K regulatory subunit modifications in 
unstimulated immature B cells
Analysis of WEHI-231 cell extracts by 2D-gel electrophoresis revealed that the 
p85 regulatory subunit is extensively modified in unstimulated, but proliferating WEHI- 
231 cells, in agreement with investigations in murine fibroblasts (Cohen et al., 1990) 
(modifications identified by us using MS are shown in Figure 7.1). Evidence for 
modifications were primarily observed in p85a following immunoblotting using p85a 
isoform-specific Abs or following MS analysis (Figure 4.1, Figure 4.12, Figure 4.13). 
Due to a lack of good Abs to p85p, no conclusions on modifications in this regulatory 
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Figure 7.1: Summary of modifications identified by LC-MS/MS in p85a and their potential 
effect on protein-protein interactions
Immunoprecipitated p85a was analysed by LC-MS/MS for protein modifications. Identified 
modifications are depticted and potential effects on protein-protein interactions indicated.
The modifications detected following 2D-PAGE of WEHI-231 cells are partially 
due to phosphorylation. This was determined by immunoblotting analysis of in vitro
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dephosphorylated (using alkaline phosphatase) p85 immunoprecipitates. Indeed, some 
basic p85 spots appeared following dephosphorylation (Figure 4.3). This finding is in 
agreement with indications of Thr phosphorylation of immunoprecipitated p85 by 
immunoblotting using phospho-specific Abs (Figure 4.2) and with the identification of 
the known p85a Tyr688 phosphorylation site by LC-MRM in unstimulated WEHI-231 B 
cells (Figure 4.12). Unfortunately, detailed MS analysis of peptides derived from the 
regulatory subunit only provided indications for novel potentially phosphorylated amino 
acid residues (Table 4.4, Table 4.5, Figure 4.13) without the capacity to confirm these 
by sequencing of the peptides of interest.
The remaining post-translational modifications of p85 identified by 2D-PAGE of 
unstimulated WEHI-231 cell extracts are likely due to modifications other than 
phosphorylation. Hydroxylation of P270 and F273 in p85a was identified by error- 
tolerant searches of LC-MS/MS data (Figure 4.13). Hydroxylation of Pro residues has 
been shown to occur in collagen and elastin, resulting in changes in their interaction 
with protein partners (Mazzorana et al., 1996; Perret et al., 2003; Urry et al., 1979) and 
in hypoxia-inducible factor (HIF) leading to HIF degradation (reviewed in (Safran and 
Kaelin, 2003)). Hydroxylation of Phe residues seems to be less abundant in vivo. 
Reducing agents are added to the sample in each step in order to prevent oxidation, 
but hydroxylation of proteins during sample preparation due to oxidative conditions 
cannot be excluded as the cause for the identified hydroxylated amino acids in p85a. 
Thus, it is possible that some of the p85 protein spots detected on 2D gels are due to 
protein hydroxylation, however, it is not known whether this hydroxylation might be an 
artefact.
In addition, amino acid substitutions in L136, D281 and I539 of p85a were 
detected by error-tolerant searches of LC-MS/MS data (Figure 4.13). These 
substitutions but also the WT sequences were identified in p85a from unstimulated 
WEHI-231 cells. The observed amino acid substitutions could be due to heterogeneity 
of the WEHI-231 population (i.e. certain cells contain L136 and others V136) or to 
differences in the maternal and paternal p85a genomic sequence. Since the 
substituted amino acids contained similar chemical properties as the WT amino acids, 
significant changes in the isoelectric point of p85a are not expected. Thus, the 
separation of p85a species by 2D-gel electrophoresis is probably not affected by these 
modifications. However, unless mutant protein was to be expressed and analysed by 




7.2.2 p85 does not undergo significant post-transiational 
modifications upon cellular stimulation of WEHI-231 
cells
In order to address whether physiologically relevant stimuli would impact on p85a 
post-translational modifications, WEHI-231 B cells were treated with a-IgM to induce 
BCR signalling. However, this treatment did not seem to alter p85 phosphorylation as 
assessed by immunoblotting of immunoprecipitated p85 using phospho-specific Abs 
following IP (Figure 4.2), even though the PI3K downstream effector Akt showed 
increased phosphorylation indicative for effective cellular stimulation. In addition, the 
p85 2D-gel spot pattern did only change marginally following cellular stimulation as 
assessed by immunoblotting using Abs to p85, suggesting that changes in the 
stoichiometry of p85 modifications, it they occurred, were very low. Only upon 
treatment with OA or pV, two potent inhibitors of protein phosphatases, could changes 
in p85 modifications be observed following 2D-PAGE of cell lysate (Figure 4.4).
Given that BCR engagement did not appear to induced p85 modifications, 
despite the increase in cellular PI3K lipid kinase activity, we speculate that PI3K activity 
is not modulated by p85a modifications in the chosen cell system. Alternatively, 
stoichiometry of modifications could be too low for detection.
7.2.3 Speculation on role of class IA PI3K regulatory subunit 
modifications
In order to gain insight into the potential biochemical role of the basal p85 
modifications detected in unstimulated B cells, we compared the p85 2D-gel spot 
patterns of murine B cells to that of murine colon carcinoma, fibroblast and T cells. This 
analysis revealed only minor differences in the p85a spot pattern in these 4 different 
cell systems, suggesting that the observed modifications are not cell type-specific 
(Figure 4.5).
Since one of the amino acid substitutions (I539V) detected following LC-MS/MS 
is located in the p110-binding (iSH2) domain of p85a, we addressed whether the 
modifications detected by 2D-PAGE could have an impact on the interaction of p85 
with the catalytic subunits. 2D-gel electrophoresis of p85 co-immunoprecipitated with 
Abs to p110a, p110p or p1105 revealed modest differences in the protein spot pattern 
of the regulatory subunit (Figure 4.6). This finding might indicate that the interaction of 
the regulatory and catalytic subunit could partially be dependent on the observed 
modifications, e.g. a certain p85 modification increases association with p110a. It is 
therefore possible that amino acid substitution of Ile539 might have an impact on the 
binding affinity of p85 to p110. Another possibility is that the observed changes in p85
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pattern between p110 IPs are not consequences of modifications but their causes. 
Thus, the catalytic subunits might be responsible for phosphorylation of the regulatory 
subunit (Dhand et al., 1994) leading to the observed differences in the p85 2D gel spot 
pattern.
Furthermore, two potential amino acid substitutions and two protein 
hydroxylations (Leu136, P270, F273, D281; identified by error-tolerant searches of LC- 
MS/MS data) are located within the BH/Rac-binding domain of p85a. Since Rac and 
Cdc42 were shown to bind p85 via this domain (Zheng et al., 1994), it is possible that 
the modifications in this domain affect interaction of p85 with small GTPases. However, 
due to time constrictions, the analysis of p85a species associated with Rac or Cdc42 
was not undertaken.
The p85a Y688 phosphorylation site identified by LC-MRM in WEHI-231 cells lies 
within the C-terminal SH2 domain. Y688 was previously identified in T cells where it 
seems to modulate the interaction with protein partners (von Willebrand et al., 1998) 
leading to enhanced PI3K lipid kinase activity (Cuevas et al., 2001). Since WEHI-231 
cells proliferate independently of a-IgM stimulation, we speculate that Y688 might be 
phosphorylated at low stoichiometry in basal culture conditions leading to low level 
PI3K activity and contributing to cell proliferation.
7.3 Possible role of Tyr phosphorylation of p110S in 
protein-protein interactions following BCR 
engagement of WEHI-231 cells
Activation of the BCR induces a complex signalling cascade also leading to an 
increase in PI3K activity and hence Akt phosphorylation (Figure 5.1; reviewed in (Dal 
Porto et al., 2004)). The rise in PI3K activity following BCR engagement of WEHI-231 
cells is primarily mediated by an increase in p1105 activity as determined by a-IgM 
stimulation with or without p1108 isoform-specific inhibitors (Figure 5.2; (Bilancio et al.,
2006)).
7.3.1 p1105 is phosphorylated on Tyr residue(s) following 
BCR engagement of WEHI-231 cells
In order to gain insight into the regulation of p1105 activity following BCR 
stimulation, post-translational modifications of p1105 were analysed. The analysis of in 
vivo labelling experiments using [y-32P]ATP (Figure 5.12) revealed that net 
phosphorylation of p1105 in WEHI-231 cells increased following BCR engagement. 
This increase was at least partially due to a rise in p1105 Tyr phosphorylation as 
determined by immunoblotting using pTyr-specific Abs (Figure 5.13). Since Tyr
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phosphorylation of p1105 has not been reported, we further analysed the biological 
significance of this modification. A panel of p1108-expressing cell lines were tested for 
p1105 Tyr phosphorylation following cellular stimulation with the Tyr phosphatase 
inhibitor pV. This analysis revealed that p1105 Tyr phosphorylation mainly occurred in 
B cells of murine and human origin, and could not be detected in mastocytoma, 
melanoma, gastrointestinal stromal sarcoma, breast cancer and T cells (Figure 5.15). 
Furthermore, IP of class IA PI3K catalytic subunits followed by immunoblotting with 
pTyr Abs revealed that primarily p1108, and not p110a or p110(3, was phosphorylated 
on Tyr residues (Figure 5.14). These data suggest that Tyr phosphorylation of p1105 
might be implicated in the critical role that p1105 plays in B cells.
B cell-specific p1108 phosphorylation also indicates that the Tyr kinase catalysing 
this reaction might only exist in B cells. However, analysis of proteins co- 
immunoprecipitating with p1108 by MS (Table 5.1, Table 5.2) or by immunoblotting 
using a variety of Abs to Src-, Syk- and Tec-family kinases (data not shown) did not 
provide indications as to which Tyr kinase might phosphorylate p1108. Studies 
performed in the chicken B cell line DT40 have revealed that Tyr phosphorylation of 
class IA PI3K catalytic subunit is dependent on Syk and Lyn following stimulation with 
either a-IgM or H20 2 (Craxton et al., 1999); (Qin and Chock, 2003). We therefore 
speculate that Syk or Lyn might constitute the p1108 Tyr kinase in B cells. This 
assumption is supported by our own observations that p1108 phosphorylation peaks 
within a very short time of stimulation (Figure 5.12), suggesting that its Tyr kinase is 
quickly activated upon BCR engagement.
7.3.2 Potential p110S Tyr phosphorylation sites identified by 
MS
In order to identify the phosphorylated Tyr residue(s) in p1108, 2D-gel 
electrophoresis was applied to enrich for the modified p1108 protein species. However, 
for reasons unknown to us, the class IA PI3K catalytic subunits did not enter the first 
dimension of 2D-PAGE (Figure 5.17). We therefore resolved immunoprecipitated 
p1108 by 1D-PAGE. Extensive mass spectrometric analysis was performed in order to 
determine phosphorylated Tyr residue(s) in p110S peptides. However, these could not 
be identified by conventional LC-MS/MS, precursor-ion scanning (in collaboration with 
Dr. Morris of the MRC Phosphorylation Unit, University of Dundee), or multiple reaction 
monitoring of suspected phospho-peptides or error-tolerant searches of LC-MS/MS 
data. This might be due to low stoichiometry of p1108 phosphorylation or to incomplete 
p1108 sequence coverage. LC-MS/MS analysis usually generates incomplete 
sequence coverage because either the protease used to digest the protein produces
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peptides of unsuitable length or hydrophobicity, which are lost during LC or MS, or 
because the peptide is not readily ionised at the ion source. Sequence coverage of 
immunoprecipitated p1108 was between 30-60%.
Analysis of p1108 peptides by MALDI mass fingerprinting allowed for the 
identification of m/z corresponding to peptides potentially containing non- 
phosphorylated (m=x) and phosphorylated (m=x+80) Tyr residues. A shift in 80 Da 
corresponds to the loss/addition of HP03. Thus, we found some evidence for 5 
potentially phosphorylated Tyr residues in p1108 (Tyr239, Tyr395, Tyr670, Tyr812, 
Tyr963; Figure 5.18). Comparison of the p1105 amino acid sequence with the crystal 
structure of p110y suggested that Tyr670 and Tyr963 are unlikely to be phospho- 
acceptors due to their shielded position within the molecule. Biocomputational analysis 
of the potentially phosphorylated Tyr in p1108 revealed that Tyr239, which is located in 
the Ras-binding domain, could be phosphorylated by Lyn (Figure 5.18), whereas Tyr 
395 (within the C2-/lipid binding-domain) might be phosphorylated by the Tec-family 
kinase Itk. No potential Tyr kinase was identified for Tyr812 (located in the kinase 
domain).
7.3.3 Potential biological relevance of p1105 Tyr 
phosphorylation
In order to investigate the biological relevance of p1105 Tyr phosphorylation, we 
compared the intrinsic lipid kinase activity, membrane localisation and protein 
interaction partners of p1108 from unstimulated and a-IgM stimulated WEHI-231 cells. 
In vitro lipid kinase activity assays performed with immunoprecipitated p1108 did not 
show time- or substrate-dependent changes in p1105 lipid kinase activity following 
BCR stimulation (Figure 5.3). Thus, Tyr phosphorylation does not seem to have an 
impact on the intrinsic lipid kinase activity of p1108. However, if only a small fraction of 
p1108 molecules became Tyr phosphorylated and activated following BCR 
engagement, the increase in PIP3 due to these modified p1108 molecules compared to 
non-activated p110S might not be detectable.
In contrast to its non-apparent role in the regulation of the intrinsic lipid kinase 
activity, p1108 Tyr phosphorylation might have a role in the subcellular localisation of 
p1108 and/or its interaction with protein partners. Enhanced interaction of p85-p1108 
with membrane-bound BCAP and IRS-2 (Table 5.1, Table 5.2) could lead to an 
increase in p1108 membrane association following BCR engagement, i.e. when p1108 
is Tyr-phosphorylated. Indeed, recruitment of p85 to the plasma membrane has been 
shown to be partially BCAP-dependent, since BCAP-deficient chicken DT40 cells have 
reduced PI3K membrane association following BCR engagement (Okada et al., 2000).
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Also IRS can contribute to association of p1105 with the plasma membrane. Indeed, 
IRS-2 has been shown to accumulate at the plasma membrane following cellular 
stimulation, leading to a concomitant increase in recruitment of PI3K to the membrane 
(reviewed in (Whitehead et al., 2000)). Enhanced membrane association of p1105 
could explain the observed increase in Akt phosphorylation upon cellular stimulation 
(Figure 5.1). Subcellular fractionation experiments did not indicate a shift of the 
predominantly cytosolic p1105 to the membrane post BCR engagement (Figure 5.6). 
However, the experimental conditions in the analysis of PI3K subcellular localisation 
might disrupt weak p1108 association with the membrane. It is also possible that the 
fraction of the p1108 protein translocated to the plasma membrane following B cell 
stimulation is too small to be detected by immunoblotting following cellular 
fractionation.
We also performed p1108 co-IP experiments and investigated potential p1105 
interaction partners from unstimulated and a-IgM stimulated WEHI-231 cells by MS. 
This analysis revealed that p85-p1108 likely interacts with IRS-2, PARP-1 and caprin-1 
following B cell stimulation, i.e. when p1105 is Tyr-phosphorylated (Table 5.1, Table
5.2). The biochemical aspects of these interactions are discussed in this paragraph, for 
the potential biological relevance of these interactions see § 7.4.
Interaction between p85-p1108 and IRS-2 was increased more than 5-fold 
following BCR engagement, as assessed by qualitative MS (Figure 5.9). This 
interaction was confirmed by immunoblotting of co-immunoprecipitating partners 
following enrichment of p1108 or IRS-2 (Figure 5.11). Association of p85-p1108 with 
IRS-2 is likely due to Tyr phosphorylation of YxxM-motifs in IRS-2. However, IRS-2 
also contains 2 phospho-Tyr-interacting domains that might mediate binding to 
phosphorylated Tyr residues in p1108. One is an N-terminal PTB domain implicated in 
the interaction with NPxpY-containing proteins. p1108 possesses 2 NPxpY- 
homologous amino acid sequences. A second non-categorised domain in the central 
region of IRS-2 allows for interaction with pTyr residues, independent of NPxpY 
sequences (He et al., 1996).
Interaction of p85-p1108 with PARP-1 was increased 3-times following BCR 
engagement (Figure 5.9). This association was reinforced by analysis of PARP-1 
interaction partners, which revealed p110p and p110S as binding partners of PARP-1 
(T. Helleday, Institute for Cancer Studies, University of Sheffield; personal 
communication). PARP-1 contains a basic region leucine zipper (bZIP), which might 
dimerise with the bZIP of p110p/p110S. Tyr395, one of the potentially phosphorylated 
amino acids in p1108 identified by MALDI-MS (Figure 5.18), is located next to the bZIP 
of p1108 and its phosphorylation might therefore enhance binding of p1108 to PARP-1.
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In addition to dimerisation via bZIP, PARP-1 might also associate with p85-p1108 by 
complex formation via nucleolin (Borggrefe et al., 1998), a potential p85-p1108 
interaction partner identified by us (Table 5.1, Figure 5.9) and others (Barel et al., 2001; 
Huddleson et al., 2006).
Interaction between p85-p1108 and caprin-1 increased by more than 100-fold as 
assessed by qualitative MS (Figure 5.9). The potential association between p85-p1108 
and caprin-1 remains to be confirmed by alternative techniques. This association might 
be mediated by SH3 domains of caprin-1 and the proline-rich domains of p85 or p1108. 
It is also possible that p85-p1108 and caprin-1 interact via complex formation with 
G3BP, a novel potential interaction partner of p85-p1108 (Table 5.2, Figure 5.9). 
Interaction between G3BP and caprin-1 has been shown in HeLa cells transfected with 
Vaccinia virus intermediate transcription factor (Katsafanas and Moss, 2004).
Thus, while interaction between IRS-2 and PARP-1 with p85-p1108 might be 
mediated by Tyr phosphorylation of p1108, it is not clear if such modification could 
have a role in the interaction between caprin-1 and PI3K.
7.4 Novel potential PI3K interaction partners identified 
in WEHI-231 cells
Signal transduction via the BCR is known to change during B cell development 
depending on the B cell maturation stage. In immature B cells, BCR engagement 
induces growth arrest or apoptosis, while BCR crosslinking in mature B cells leads to 
proliferation. In a primary phase of BCR signalling, PI3K activity is induced resulting in 
an increase in Akt phosphorylation (Bilancio et al., 2006). PI3K-dependent phospholipid 
levels drop within a short time following BCR engagement in B cells (Figure 7.2). While 
phosphoinositide concentrations return to the basal state in mature B cells following 
sustained BCR engagement, PIP3 levels remain low in immature B cells. In the latter 
cells, a concomitant decrease is observed in the phosphorylation of S6K, upregulation 
of p27KIP1 protein expression, and down-regulation of c-Myc expression (Carey and 
Scott, 2001; Donjerkovic and Scott, 2000). It has further been shown that 
downregulation of the PI3K pathway by LY294002 in B cells mimics the effects of BCR 
engagement in that these cells undergo growth arrest and apoptosis (Carey and Scott, 
2001). Thus, downregulation of PI3K activity following BCR stimulation of immature B 
cells seems necessary for the induction of apoptosis. In addition, it is emerging that not 
only the level of PI3K activity at the plasma membrane might be critical for the switch 
between cell survival and apoptosis, but also the rate of PI3K activity at the nuclear 
membrane. Thus, the generation of nuclear PIP3 by class IA PI3K has been shown to 
mediate anti-apoptotic effects in neuron-like cells following cellular stimulation (Ahn et
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al., 2005). However, nuclear localisation of class IA PI3K is controversial due to 
experimental challenges in the fractionation of nucleus and cytosol.
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Adapted from Carey and Scott, 2001
Figure 7.2: Differences in the regulation of the PI3K pathway between B cells stimulated 
with a-IgM or a-lgD
The B cell lymphoma cell line ECH408 was treated with either a-IgM (Anti-p) leading to growth 
arrest and apoptosis or with a-lgD (Anti-6). PI3K-dependent phospholipids dropped sharply 
following BCR engagement and returned to the basal state in a-lgD stimulated cells, but not in 
a-IgM stimulated cells. A concomitant increase in phosphorylation of S6K could be observed in 
a-lgD stimulated cells that is not noticeable in a-IgM treated cells. Figure adapted from (Carey 
and Scott, 2001).
How a decrease in PI3K activity following BCR engagement of immature B cells 
is achieved is unknown. Possibilities include PI3K degradation, changes in post- 
translational modifications, protein-protein interactions or subcellular localisation.
Our analysis of novel potential p85-p1108 interaction partners in the WEHI-231 
cells by MS points at a possible sequestration of PI3K from the plasma and nuclear 
membrane to the cytosol following BCR engagement (Table 7.1, Figure 7.3). Proteins 
that co-immunoprecipitated in unstimulated and a-IgM stimulated cells were analysed 
by MS (Table 5.1, Table 5.2, § 5.13.5, § 5.13.6). While we are confident that the novel 
potential interaction partners do not result from aspecific binding to the matrix, we can 
not eliminate the possibility that these proteins cross-react with Ab. We therefore 
performed literature and database searches (such as PI3K yeast two-hybrid data 
available at Alliance for Cellular Signaling (http://www.signaling- 
gateway.org/data/Y2H/cgi-bin/y2h.cgi)) to independently confirm interaction of some of 
these binding partners with PI3K. However, none of the novel potential interaction p85- 
p1105 partners we identified by MS had previously been observed.
Below, we discuss the identified potential p85-p110S interaction partners in 
WEHI-231 cells according to their potential role in the sequestration of PI3K from
190
Chapter 7
membranes. We realise that this is speculative at this point in time but this provides a 
framework for discussion.
Table 7.1: Potential novel interaction partners of p85-p1105 in immature B cells
Binding partners of p85-p110S were identified by LC-MS/MS following p1108 IP from 
unstimulated (-) or a-IgM stimulated (+) WEHI-231 cells. Analysis of integrated peak areas of 
LC-MS data allowed for refined assessment of interactions (in brackets). Biocomputational 
analysis and literature data of binding partners revealed potential interaction domains with PI3K 
and potential roles in the sequestration of p1105 from the plasma and nuclear membrane by 
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Figure 7.3: Potential role of p85-p1108 and interaction partners in the induction of 
apoptosis
In proliferating cells, p1105 is possibly found both at the plasma membrane and in the nucleus 
where its activity supports proliferation. In apoptotic cells, p1106 might be sequestered in the 
cytoplasm in complex with G3BP and caprin-1, or with nucleolin, IRS-2 and PARP-1 thereby 
possibly decreasing PI3K activity.
7.4.1 p85-p1108 interaction partners with diverse functions
Using p1105 co-IP and MS analysis, we identified the cytosolic proteins y- 
tubulin, GPC2, GPC3, NEDD1 and p200 Arf-GEF and the nuclear proteins histone 
H4 and DDB1 as potential p85-p1108 interaction partners by (Table 5.1, Table 5.2). 
These proteins have to the best of our knowledge not been implicated in apoptosis.
Interaction of p85-p1108 with y-tubulin has been previously reported (Kapeller et 
al., 1995). y-tubulin is part of microtubule-organising centres and stabilises the minus- 
end of microtubules. GPC2, GPC3 and NEDD1 have been shown to associate with y- 
tubulin to form the so-called y-tubulin ring complex (Murphy et al., 1998). Thus, their 
interaction with PI3K likely occurs via y-tubulin. We speculate that interaction between 
PI3K and the y-tubulin ring complex might be involved in the regulation of microtubule 
stability or vesicle transport along microtubules.
p200 Arf-GEF is a nucleotide exchange factor for small GTPases of the ADP 
ribosylation factor family (Mansour et al., 1999). The protein does not contain any 
known domain or motif which could explain its binding to PI3K. p200 Arf-GEF is 
localised at the Golgi and might therefore be involved in vesicle transport from the 
Golgi to the plasma membrane along microtubules in cooperation with y-tubulin.
192
Chapter 7
DDB1 and histone H4 have been shown to interact with DNA. While DDB1 has a 
role in nucleotide excision repair, histones are proteins involved in the packaging of 
DNA. Their interaction with p85-p1108 can not be deduced from known protein-protein 
binding domains or motifs.
7.4.2 p85-p1105 interaction partners potentially linked to the 
onset of apoptosis
LC-MS/MS analysis of proteins immunoprecipitated with p1108 Ab revealed 
various proteins that might have a role in the onset of apoptosis by sequestering p1108 
to the cytoplasm. These include BCAP, G3BP, caprin-1, nucleolin, PARP-1 and IRS- 
2.
Binding of p85-p1108 to the adaptor protein BCAP detected by LC-MS/MS in 
WEHI-231 cells independent of cellular stimulation was confirmed by reciprocal IP 
experiments using Abs to BCAP and p1108 followed by immunoblotting (Figure 5.11). 
This interaction is likely due to binding of p85 SH2 domains to phosphorylated YxxM- 
motifs in BCAP (Okada et al., 2000). The interaction between PI3K and BCAP has 
been observed in unstimulated B cells, and seems to rapidly fluctuate following BCR 
engagement (Okada et al., 2000). BCAP has the potential to modulate PI3K subcellular 
localisation since it is a scaffolding protein for PI3K and BCR-associated kinases 
(Okada et al., 2000). It might therefore be involved in the sequestration of PI3K from 
the membrane to the cytoplasm at the onset of apoptosis.
G3BP is an endonuclease interacting with RasGAP and has a role in the 
regulation of mRNA stability. In growth factor-stimulated cells, G3BP is localised in the 
nucleus (Barnes et al., 2002) and translocates in response to cytotoxic stress to so- 
called cytosolic stress granules, where mRNA is stored in an abortive translation 
initiation complex (Tourriere et al., 2003; Tourriere et al., 2001). Even though G3BP 
association with PI3K can not easily be deduced from primary sequence analysis or 
literature data, on the basis of the described findings we speculate that G3BP might 
interact with PI3K in the nucleus of proliferating B cells and the complex might be 
exported to the cytoplasm at the onset of apoptosis. G3BP has also been shown to 
interact with caprin-1 (Katsafanas and Moss, 2004), a novel potential p85-p1108 
interaction partner.
Caprin-1 is a cytosolic protein upregulated in proliferating B and T cells (Grill et 
al., 2004). DT40 cells deficient in caprin-1 show defects in proliferation (Wang et al.,
2005). Due to its association with G3BP, we speculate that following BCR engagement 




The association between nucleolin and p85-p1108 might be due to interaction of 
the p85 SH2 domains with Tyr phosphorylated residues in nucleolin (Barel et al., 2001) 
and has been shown to occur in endothelial cells subjected to fluid flow (Huddleson et 
al., 2006). Nucleolin is a multifunctional protein that plays a role in the nuclear 
organisation (reviewed in (Ginisty et al., 1999)). Although generally considered to be a 
nuclear protein, translocation of nucleolin from the nucleus to the cytosol has been 
observed in apoptotic B cells (Mi et al., 2003). We therefore hypothesise that the 
complex of p85-p1108 and nucleolin might be exported from the nucleus to the 
cytoplasm following apoptosis. Nucleolin has been observed in association with the 
p85-p1105 potential interaction partners IRS-2 and PARP-1.
PARP-1 is a novel potential interaction partner of p85-p1108 whose association 
with PI3K has been confirmed by reciprocal IP (see § 7.3.3). PARP-1 is activated 
following DNA damage and catalyses the reversible modification of proteins with ADP- 
ribose. This modification contributes to the survival of proliferating cells following DNA 
damage (reviewed in (Arne et al., 2004)). PARP-1 has been shown to interact with 
nucleolin (Borggrefe et al., 1998) and we therefore speculate that complex formation of 
PARP-1 with nucleolin and PI3K leads to the export of PI3K and PAPR-1 from the 
nucleus to the cytosol.
While interaction of PI3K with the adaptor molecule IRS-2 has been reported in B 
cells downstream of cytokine receptors (Johnston et al., 1995), IRS-2 recruitment has 
not been implicated following BCR engagement. It is thus not clear how IRS-2 couples 
to the membrane and becomes Tyr phosphorylated upon BCR engagement. However, 
sequestration of PI3K from the plasma membrane could be achieved by interaction of 
PI3K with IRS-2 and nucleolin. Nucleolin has been shown to interact with the PH 
domain of IRS molecules, which was shown to interact with phosphoinositides (Burks 
et al., 1998). This interaction might lead to a decrease in membrane association of IRS- 
2. We therefore speculate that export of nucleolin from the nucleus to the cytoplasm 
following induction of apoptosis might lead to its association with IRS-2, to removal of 
IRS-2 complexed to PI3K from the plasma membrane and therefore to down-regulation 
of PI3K activity.
It is likely that not only the translocation of PI3K from the nuclear and plasma 
membrane to the cytosol has an impact on the induction of apoptosis but also the 
nuclear export of nucleolin, G3BP, and PARP-1. These molecules are involved in the 
regulation of nuclear organisation, RNA stability and DNA damage repair and 
disruption of their function most likely induces aberration of cellular proliferation.
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7.5 Class IA PI3K activity is not regulated by 
monomeric p85
In the traditional model of class IA PI3K regulation, it is suggested that p110 and 
p85 form obligate heterodimers and that regulation of lipid kinase activity of the 
heterodimer is mainly steered by interaction with non-PI3K binding partners and 
membrane recruitment (Fry et al., 1992; Yu et al., 1998). Various reports have 
challenged this view. For example, purification of endogenous class IA PI3K from 
bovine thymi presented evidence for two catalytically active p110 subunits: p110 in 
complex with p85, and a p110 in what was considered to be a monomeric form 
(Shibasaki et al., 1991). Over the last couple of years, also a vast literature on the 
existence of free p85 has appeared, mainly in an attempt to explain the increase in 
PI3K signalling upon insulin stimulation in mice in which class IA regulatory subunits 
have been deleted. Thus, data gained from analysis of p85 KO mice compared to WT 
mice presented evidence for a greater than 30% molar excess of p85 over p110 in WT 
MEFs (Ueki et al., 2002) and WT murine liver cells (Mauvais-Jarvis et al., 2002) 
compared to p85-KO cells. Furthermore, evidence has been presented that this 
monomeric p85 can compete with heterodimeric p85-p110 for pTyr-binding motifs on 
IRS molecules since forced overexpression of p85a in muscle cells leads to a decrease 
in in vitro lipid kinase activity of PI3K following pTyr IP and to a decrease in Akt 
phosphorylation (Ueki et al., 2000). Based on this information, a model attributing a 
negative role of p85 to PI3K signalling was proposed: in WT cells, surplus, thus free 
p85 competes with heterodimeric p85-p110 for pTyr binding sites in receptor tyrosine 
kinases or adaptor molecules thereby dampening PI3K signalling. In p85 KO cells, 
expression of monomeric p85 is preferentially reduced leading to enhanced access of 
heterodimeric p85-p110 to pTyr binding sites and to increased PI3K signalling.
Arguments based on literature data that cast doubts on the existence of 
monomeric p85 in WT cells, and the role of p85 as a negative regulator are presented 
in § 6.6. Briefly, monomeric p85 seems to be unstable (Brachmann et al., 2005) and 
does not necessarily compete with p85-p110 for pTyr binding places (Ueki et al., 2002; 
Ueki et al., 2003; Ueki et al., 2002). In addition, several proteins other than the deleted 
p85 were found to be deregulated in p85 KO cells. This includes a decrease in p110 
protein expression and increases in PTEN protein expression and IRS-2 
phosphorylation have been observed (Fruman et al., 2000; Fruman et al., 1999; Suzuki 
et al., 1999; Terauchi et al., 1999).
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7.5.1 Experimental evidence supporting the notion that class 
IA PI3Ks are obligate heterodimers
In Chapter 6, we present biochemical data demonstrating that class IA PI3Ks are 
obligate heterodimers. No excess of one subunit over the other was observed after 
affinity chromatography of fibroblast (data not shown) and leukocyte cell lysates using 
Abs to class IA PI3K regulatory and catalytic subunits or using pTyr-matrix (Figure 6.2). 
In addition, depletion of one class IA PI3K subunit from TCL by sequential IP using 
isoform-specific Abs led to the concomitant depletion of the other class IA PI3K subunit 
(Figure 6.7). Ion exchange chromatography of leukocyte cell lysate did also not reveal 
any evidence for the existence of free p85 in vivo (Figure 6.8). Thus, these data do not 
support a role of monomeric p85 in the regulation of PI3K activity.
We also employed a technique called AQUA (absolute quantitation) MS (Gerber 
et al., 2003) in order to determine the absolute amounts of class IA PI3K isoforms in 
WEHI-231 and NIH-3T3 cells. The AQUA method is based on the use of a synthetic 
internal standard (IS) peptide that is added to the cell sample at known concentrations 
before MS analysis. This IS mimicks an endogenous peptide produced during 
proteolysis of the target protein expect that it is enriched in stable isotopes. LC-MS or 
LC-MS/MS analysis of the cell sample spiked with the IS peptide results in the 
detection and quantitation of both the endogenous and AQUA peptide.
We used 11 IS peptides with equivalent sequences to stretches of class IA PI3K 
isoforms (Table 6.1). These IS peptides were added to regulatory and catalytic 
subunits following PI3K enrichment from cells. Absolute quantitation MS revealed 
similar protein amounts of class IA PI3K in NIH-3T3 and WEHI-231 cells, amounting to 
25,000 molecules/cell (Table 6.2). Importantly, the total of all regulatory subunits 
matched the total of all catalytic subunits, indicating that class IA PI3K are obligate 
heterodimers. Furthermore, p110a protein expression was low in both cell lines 
compared to p110(3, which seems highly expressed in NIH-3T3 cells, and p1108, which 
is highly expressed in WEHI-231 cells. The amount of p85p was more than double that 
of p85a in both cell lines, while p557, p55a, p50a protein expression was low.
Thus, the use of this AQUA method did not only allow for the determination of the 
absolute amounts of regulatory and catalytic class IA PI3K subunits, but also for the 
determination of which class IA PI3K isoforms is the most prevalent, and thus probably 
most critical in different cell types.
196
Chapter 7
7.5.2 Alternative model for the observed increase in PI3K 
signalling in p85 KO cells
Our findings that class IA PI3Ks are obligate heterodimers i.e. no monomeric 
p110 or p85 exists in vivo, necessitates an alternative model for the observed increase 
in PI3K activity in insulin-responsive cells of p85-KO mice. As discussed in more detail 
in § 6.6, changes in the protein concentrations of PI3K and PTEN/SHIP or in the 
intrinsic PI3K activity unlikely enhance the total lipid kinase activity of PI3K. Although 
p110, p85 and PTEN protein levels are affected in p85-KO cells, the observed 
variations in protein expression compared to WT cells are in fact expected to decrease 
PI3K signalling. Furthermore, the in vitro lipid kinase activity of p110 or pTyr 
immunoprecipitates is also decreased in p85-KO cells.
We therefore present a model that could explain an increase in PIP3 levels 
independent of class IA PI3K (Figure 6.16). This model is based on the “interaction 
vacuum” of phosphorylated IRS molecules in cells with diminished levels of p85 
molecules. Since phosphorylation of IRS is unchanged or slightly increased (Chen et 
al., 2004; Ueki et al., 2002), molecules usually not associated with IRS due to a 
stronger interaction between IRS and the p85 subunit of PI3K, might engage with IRS 
instead of p85. JAKs and SHIP are such molecules since they both possess SH2 
domains (Al-Lazikani et al., 2001; Damen et al., 1996). Interaction of the Tyr kinase 
JAK with IRS might lead to the observed increase in IRS phosphorylation (Wang et al., 
1997). JAK might also phosphorylate and inactivate the phosphoinositide phosphatase 
SHIP (Habib et al., 1998), which might be concomitantly associated with IRS. 
Inactivation of SHIP would subsequently lead to the observed increase in PIP3 levels. 
In hematopoietic cells, JAK activation does not seem to be dependent on IRS 
molecules (Uddin et al., 1997), possibly explaining why p85 deletion in insulin- 
responsive cells leads to an increase in PI3K activation while p85-deficient B and T 
cells have decreased PI3K signalling.
7.6 Conclusions and future experiments
In this study, we used biochemical approaches to analyse the regulation of class 
IA PI3K activity in immature B cells. We thereby focused on the investigation of post- 
translational modifications of endogenous (i.e. non overexpressed) p85 and p1105 and 
of the molar ratio between the regulatory and catalytic subunits of PI3K.
A variety of modifications in the regulatory subunit were detected by 2D-PAGE, 
which might be due to protein phosphorylation, hydroxylation or amino acid 
substitutions, as identified by MS and in vitro dephosphorylation. These modifications 
do not seem to be dynamic, since BCR stimulation of WEHI-231 cells did not lead to
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significant changes in the p85 spot pattern resolved by 2D-gel electrophoresis. Given 
that PI3K activity was found to be increased following BCR stimulation, the p85 
modifications unlikely impact on the class IA PI3K activity. However, the stoichiometry 
of p85 modifications that affect PI3K activity might be too low to be detected by 
immunoblotting. If not involved in the regulation of intrinsic PI3K lipid kinase activity, the 
question arises therefore what role, if any, these modifications have. We presented 
some evidence to suggest that the interaction between p85 and p110 might be 
modestly affected by these modifications. Since the regulatory subunit contains various 
protein-protein interaction domains, it would be interesting to analyse whether these 
modifications impact on the association with other known protein partners. In order to 
address this question, these interaction partners (e.g. a-/p-tubulin, Rac/Cdc42, 
Shc/Ezrin/Syk) would have to be purified by IP using Abs to each of them and the 
modifications in the co-purified regulatory subunit analysed by 2D-PAGE (as performed 
for interactions between p110a/(3/8 and p85; Figure 4.6). Furthermore, investigation of 
the biological relevance of p85a modifications identified by LC-MS/MS would be of 
interest. In order to do this, site-directed mutagenesis of p85a cDNA could be 
performed such that the amino acids identified by MS (Leu136, Pro270, Phe273, 
Asp281, Ile539, Tyr688) would be mutated to either the identified substitutions (Val136, 
Glu281, Val539), or to an amino acid residue mimicking the modification (Asp688). The 
p85a cDNA would subsequently be cloned to a tag. These mutant p85a proteins could 
then be analysed for association with interaction partners, including p110, by 
transfection of the mutated cDNA into cells and IP of the p85a protein using its tag. Co- 
immunoprecipitating proteins could be identified by LC-MS/MS.
Analysis of the p1108 catalytic subunit for post-translational modifications 
revealed dynamic changes following BCR engagement of WEHI-231 cells. We showed 
that p1108 becomes phosphorylated on Tyr residues upon B cell stimulation. 
Unfortunately, identification of phosphorylated Tyr residue(s) by MS was not 
successful. It was furthermore not feasible to determine the protein kinase or 
phosphatase involved in the modification. Based on literature data, we speculate that it 
might be Lyn or Syk. Further investigations into the biological relevance of p1105 Tyr 
phosphorylation revealed that this modification mainly occurs in B cells, in p1105 and 
not p110a or p110(3 and does not seem to impact on the intrinsic lipid kinase activity. 
The subcellular localisation of p1105 and its interaction with IRS-2, PARP-1 and caprin- 
1 might however be affected by Tyr phosphorylation of p1105. In order to investigate 
whether interactions between p85-p1108 and PARP-1, caprin-1 or IRS-2 are mediated 
by p110S Tyr phosphorylation, the phosphorylated Tyr residue would have to be 
determined. In order to do this, in vitro protein kinase assays using recombinant
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Syk/Lyn or other Tyr kinases and p1105 could be performed to 1) determine the Tyr 
kinase which phosphorylates p1105 and 2) increase the stoichiometry of Tyr 
phosphorylation to enhance the probability of MS identification of phosphorylated 
residues. This Tyr residue could subsequently be mutated to a phospho-mimicking 
residue (Y-^D/E) or a residue which can no longer be phosphorylated (Y->A). 
Following transfection, p1108-WT and -mutant protein could be analysed for 
interaction with IRS-2, PARP-1 and caprin-1 by co-IP experiments and LC-MS/MS.
MS analysis of p1105 co-IP protein partners revealed novel potential p85-p1108 
interaction partners in unstimulated and a-IgM stimulated WEHI-231 cells. The 
potential interaction with these proteins raises some interesting questions:
1) Does p1105 activity have a role in the onset of apoptosis? This question can 
be addressed by inhibiting PI3K activity in general and p1108 activity in particular by 
pharmacological inhibitors following BCR engagement of immature B cells and 
subsequently investigating the rate of apoptosis by MTS assays or PI staining. Pre­
treatment of B cells with LY294002 followed by BCR crosslinking (a-IgM and a-lgD) 
has revealed increased p27KIP expression and decreased c-myc expression compared 
to non-inhibitor treated cells, indicating that a decrease in PI3K activity mimicks the 
effects of BCR stimulation in immature B cells (Banerji et al., 2001; Carey and Scott, 
2001).
2) Do the associations between p85-p110S and the indicated proteins exist in 
vivo? The interactions could be confirmed by IP of interaction partners with a different 
p1108-specific Ab in order to eliminate the possibility that the association is due to Ab 
cross-reaction. Furthermore, we could perform reciprocal IP experiments with Abs to 
PI3K and the potential protein partners followed by immunoblotting as done in this 
study for confirmation of IRS-2 and BCAP as p85-p1108 binding partners. It would also 
be interesting to investigate interaction partners of p110(3 and p110a by IP and MS in 
order to identify PI3K isoform-specific binding partners.
3) Is p110S translocated from the nucleus to the cytosol following BCR 
engagement? Preliminary fractionation experiments performed to analyse p85-p1108 
subcellular localisation revealed that p1108 nuclear localisation indeed decreases 
following BCR engagement of immature B cells (data not shown). These fractionation 
experiments could be complemented by immunohistochemistry of WEHI-231 cells 
using Abs to p1108 and p85. It would furthermore be interesting to investigate whether 
the potential interaction partners change their subcellular localisation following a-IgM 
stimulation of B cells.
4) Which of the novel potential PI3K interaction partners is the most important 
one? We speculate that interaction of PI3K with caprin-1 will turn out to be crucial since
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this association increased by more than 100-fold following BCR engagement. The 
important role of caprin-1 in the proliferation of leukocytes might link this protein to
p1108.
In order to investigate the potential role of monomeric regulatory subunit in the 
regulation of class IA PI3K activity, we analysed the molar ratio between p85 and p110. 
Extensive biochemical analysis of class IA PI3K protein levels by affinity and ion 
exchange chromatography did not reveal an excess of one subunit over the other. 
Furthermore, absolute quantitation MS allowed for the determination of precise protein 
amounts of each class IA PI3K isoform in cell lines, indicating that class IA PI3Ks are 
obligate heterodimers. Thus, our data do not support a role of monomeric p85 in the 
negative regulation of PI3K. We speculate that recruitment of JAK and SHIP to the 
plasma membrane by interaction with phosphorylated IRS might lead to the observed 
increase in PIP3 generation following insulin stimulation in p85 KO cells.
The AQUA method could also be expanded to analyse molar ratios between 
PI3Ks and interaction partners, such as receptor molecules. Furthermore, it will be of 
interest to investigate how much class IA PI3K protein exists in more physiological 
material, such as murine tissues.
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